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Abstract: N-methyl D-aspartate (NMDA) receptor is a nonselective cation channel formed four out of
seven known subunits capable of binding glutamate or glycine. These amino acids are the agonists of
the NMDA receptors in the brain where this receptor is involved in neurotransmission and intracellular
signaling. Recently NMDA receptor expression and function were shown in several non-neuronal tis-
sues. NMDA receptors were found in human bone marrow in osteoclasts, osteoblasts and hematopoietic
precursor lineages. Expression of several of the NMDA receptor subunits was reported in mammalian
myocardial tissue, however, the NMDA receptor function in the heart was never investigated. The aim
of the present study was to characterize NMDA receptor expression and its physiological and pathophys-
iological roles in the heart, and in red blood cells (RBC) as well as in erythroid precursor cells (EPCs).
We were the first to report the presence of NMDA receptors in RBCs of rats and humans and in human
and rat EPCs. Subunit composition of the erythroid receptors varied depending on the differentiation
stage in human EPCs and differed substantially from that in the brain with NR2D and NR3B were
the dominating over the neuronal NR1 and NR2B common in neurons. Erythroid receptors could be
activated by the NMDA and glutamate. Stimulation of the NMDA receptors in humans EPCs as well as
in human and rat RBCs resulted in massive transient Ca2+ uptake. Plasma-born glutamate and glycine
were sufficient to maintain basal receptor activity which was controlled by the plasma agonists levels and,
most likely, other humoral factors. We have demonstrated that abnormally high numbers of receptor
copies in RBCs of sickle cell disease patients translate into excessive permeability of RBC membranes
for Ca2+. As calcium is a master regulator of various processes in RBCs, its uptake upon stimulation
of the erythroid NMDA receptors resulted in the alterations of cytoskeletal structure and cell volume,
modulation of oxidative state, intracellular pH, and RBC half-life in the circulation. In the EPCs NMDA
receptors are required for survival of precursor cells, particular at the earlier differentiation stages. Our
motivation to investigate the expression and function of the NMDA receptors in the heart was based on
the fact that elevation of the plasma levels of the agonist of these receptors, homocysteine, was reported
to be associated with several heart diseases including heart failure. We have characterized expression of
the NMDA receptor subunits in different parts of rat myocardium and elaborated on the relation be-
tween the subunit composition of cardiac NMDA receptors and their pharmacology using “brainless rat
heart model” (isolated blood-perfused heart) and sarcolemmal membrane preparations. Similar to that
in RBCs, subunit composition of cardiac NMDA receptors differed substantially from that in the brain
and showed remarkable chamber-dependent heterogeneity with NR3A and NR2D dominating. Expres-
sion of the NR2B subunit was age-dependent and most likely associated with hypertrophic remodeling.
Expression of the subunits NR2A and 2C was restricted to atria. We found that NMDA receptor ago-
nists and antagonists regulated autonomous heart rate and rhythmicity. Myocardial repolarization and
depolarization rate were prolonged by the NMDA receptor antagonists. Our data indicate that cardiac
NMDA receptors are an attractive target for pharmacological interventions to treat arrhythmias and
other cardiovascular disorders.
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1. Abbreviations AMPA – α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ARC – adult rat cardiomyocytes ATD – amino-terminal domain CTD – carboxyl-terminal domain  D-APV – (2R)-amino-5-phosphonovaleric acid EPC – erythroid precursor cells Glu – L-glutamate Gly – L-glycine GSH – γ-L-Glutamyl-L-cysteinylglycine, glutathione reduced GSSG – glutathione oxidized iGluR – ionotropic glutamate receptor LBD – ligand binding domain NMDA – N-Methyl-D-aspartate NO – nitric oxide NOX – NADPH oxidase NR – NMDA receptor subunit (NR1, NR2A etc.) NRC – neonatal rat cardiomyocytes NTD – N-terminal domain (of the protein) PFK – phosphofructokinase PLC – phospholipase C PKC – protein kinase C RBC – red blood cells SCD – sickle cell disease        
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2. Summary N-methyl D-aspartate (NMDA) receptor is a nonselective cation channel formed four out of seven known subunits capable of binding glutamate or glycine. These amino acids are the agonists of the NMDA receptors in the brain where this receptor is involved in neurotransmission and intracellular signaling. Recently NMDA receptor expression and function were shown in several non-neuronal tissues. NMDA receptors were found in human bone marrow in osteoclasts, osteoblasts and hematopoietic precursor lineages. Expression of several of the NMDA receptor subunits was reported in mammalian myocardial tissue, however, the NMDA receptor function in the heart was never investigated.  The aim of the present study was to characterize NMDA receptor expression and its physiological and pathophysiological roles in the heart, and in red blood cells (RBC) as well as in erythroid precursor cells (EPCs). We were the first to report the presence of NMDA receptors in RBCs of rats and humans and in human and rat EPCs. Subunit composition of the erythroid receptors varied depending on the differentiation stage in human EPCs and differed substantially from that in the brain with NR2D and NR3B were the dominating over the neuronal NR1 and NR2B common in neurons. Erythroid receptors could be activated by the NMDA and glutamate. Stimulation of the NMDA receptors in humans EPCs as well as in human and rat RBCs resulted in massive transient Ca2+ uptake. Plasma-born glutamate and glycine were sufficient to maintain basal receptor activity which was controlled by the plasma agonists levels and, most likely, other humoral factors. We have demonstrated that abnormally high numbers of receptor copies in RBCs of sickle cell disease patients translate into excessive permeability of RBC membranes for Ca2+. As calcium is a master regulator of various processes in RBCs, its uptake upon stimulation of the erythroid NMDA receptors resulted in the alterations of cytoskeletal structure and cell volume, modulation of oxidative state, intracellular pH, and RBC half-life in the circulation. In the EPCs NMDA receptors are required for survival of precursor cells, particular at the earlier differentiation stages.  Our motivation to investigate the expression and function of the NMDA receptors in the heart was based on the fact that elevation of the plasma levels of the 
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agonist of these receptors, homocysteine, was reported to be associated with several heart diseases including heart failure. We have characterized expression of the NMDA receptor subunits in different parts of rat myocardium and elaborated on the relation between the subunit composition of cardiac NMDA receptors and their pharmacology using “brainless rat heart model” (isolated blood-perfused heart) and sarcolemmal membrane preparations. Similar to that in RBCs, subunit composition of cardiac NMDA receptors differed substantially from that in the brain and showed remarkable chamber-dependent heterogeneity with NR3A and NR2D dominating. Expression of the NR2B subunit was age-dependent and most likely associated with hypertrophic remodeling. Expression of the subunits NR2A and 2C was restricted to atria. We found that NMDA receptor agonists and antagonists regulated autonomous heart rate and rhythmicity. Myocardial repolarization and depolarization rate were prolonged by the NMDA receptor antagonists. Our data indicate that cardiac NMDA receptors are an attractive target for pharmacological interventions to treat arrhythmias and other cardiovascular disorders.              7  
3. Zusammenfassung Die N-methyl D-aspartate (NMDA) Rezeptoren sind nicht-selektive Kationenkanäle, die sich aus 4 von 7 möglichen Untereinheiten zusammensetzen und Bindungsstellen für Glutamat und Glycin besitzen. Beide Aminosäuren fungieren als NMDA Rezeptoragonisten im Gehirn, wo der Rezeptor Neurotransmission und intrazelluläre Signalwege reguliert. Interessanterweise wurde Expression und Funktionalität der NMDA Rezeptoren auch in verschiedenen nicht-neuronalen Geweben, unter anderem in Osteoklasten, Osteoblaten und hämatopoetischen Vorläuferzellen des menschlichen Knochenmarks, nachgewiesen. Auch im Myokardgewebe von Säugetieren wurden verschiedene NMDA Rezeptoruntereinheiten entdeckt, wobei deren Funktion allerdings noch nicht bekannt ist. Das Ziel dieser Studie war es die NMDA Rezeptorexpression und die physiologische und pathophysiologische Rolle im Herzen, in roten Blutkörperchen (RBK) und in erythroiden Vorläuferzellen (EVZ) zu charakterisieren. In dieser Studie zeigen wir erstmalig, dass NMDA Rezeptoren in EVZ und RBK bei Ratten sowie Menschen exprimiert werden können. Die Rezeptorzusammensetzung aus den verschiedenen Untereinheiten variiert dabei in Abhängigkeit des Reifungs- und Differenzierungsgrades der EVZ und unterscheidet sich generell von der Zusammensetzung im Gehirn. Während Neurone primär NR1 und NR2B Untereinheiten exprimieren, fanden wir in EVZ hauptsächlich NR2D und NR3B Untereinheiten. Diese Rezeptoren liessen sich durch NMDA und Glutamat aktivieren und die daraus resultierende Stimulation führte zu einer massiven, transienten Ca2+ Aufnahme in human EVZ sowie humanen und Ratten RBK. Die Konzentrationen von Glutamat und Glycin im Plasma reichen aus, um eine basale NMDA Rezeptoraktivität zu erzeugen und aufrecht zu erhalten. Zusätzlich zu den im Plasma enthaltenen Agonisten Glutamat und Glycin wird diese Rezeptoraktivität jedoch sehr wahrscheinlich durch weitere humorale Faktoren kontrolliert. Interessanterweise exprimieren rote Blutzellen von Sichelzellanämie Patienten eine ausserordentlich hohe Anzahl von NMDA Rezeptoren, was zu einer zu einer stark erhöhten Aufnahme von Ca2+ führt. Kalzium ist ein Schlüsselregulator verschiedenster Prozessen in 
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EVZ und RBK. NMDA Rezeptoren sind dabei besonders in frühen Differenzierungsstadien essentiell für das Überleben der EVZ. Aktivierung vom NMDA Rezeptoren in RBK führt weiterhin zu Veränderungen des Zytoskeletts und des Zellvolumens, zu einer Modulation des oxidativen Status und des intrazellulären pH, sowie zu einer Anpassung der Lebensdauer zirkulierender RBK.  Erhöhte Plasmakonzentrationen von NMDA Rezeptorantagonisten (wie z.B. Homocystein) sind mit verschiedenen Herzkrankheiten, inklusive Herzversagen, assoziiert. Daher war die genaue Charakterisierung von Expression und Funktion der NMDA Rezeptoren im Herz ein wesentlicher Bestandteil dieser Studie. Wir haben die Expression der NMDA Rezeptor Untereinheiten in verschiedenen Bereichen des Rattenmyokards analysiert und konnten einen Zusammenhang zwischen der Zusammensetzung der Herz NMDA Rezeptoren und deren Pharmakologie herausgearbeitet. Dabei haben wir ein ex vivo Model (isoliertes blut-perfundiertes Rattenherz) sowie Sarkolemma Membranpräparationen verwendet, mit dem wir den NMDA Metabolismus im Herz unabhängig von dem im Gehirn analysieren konnten. Wie bei RBK unterschied sich die Zusammensetzung der NMDA Rezeptoren im Herz (hauptsächlich NR3A und NR2D Untereinheiten) von denen im Gehirn und zeigte ausserdem eine ausserordentliche Heterogenität zwischen beiden Herzammern. Die Expression der NR2B Untereinheiten war altersabhängig und ist sehr wahrscheinlich mit einer hypertrophen Remodellierung assoziiert. Die Expression der Untereinheiten NR2A und 2C beschränkte sich hauptsächlich auf die Vorhöfe. Wir fanden heraus, dass  NMDA Rezeptor Agonisten und Antagonisten die Herzrate und den Herzrhythmus autonom regulieren. Dabei zeigte sich, dass die myokardiale Repolarisierungs- und Depolarisierungsrate durch NMDA Rezeptorantagonisten verlängert wurde. Unsere Daten verdeutlichen, dass Herz NMDA Rezeptoren sehr geeignete Ziele für pharmakologische Interventionen sind, um Arrhythmien und andere kardiovaskuläre Krankheiten zu behandeln.   
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4. Introduction Chapter 1 NMDA receptor properties and pharmacology 
Ionotropic glutamate receptors (iGluR) iGluR belongs to group of ligand-gated ion channels (GABA receptors, ATP-gated channels, nicotinic acetylcholine receptors etc). These channels are capable of coupling the ligand binding to the opening of an electrical pore. Thus, they convert chemical signals into appropriate electrical responses. Ionotropic glutamate receptors are integral membrane proteins composed of four large subunits that form a central ion channel pore. iGluRs subunits  have a module-based structure and contain four discrete domains: the extracellular amino-terminal regulatory domain (R or ATD), the extracellular ligand-binding domain (LBD or S1/S2), four transmembrane helices (M1, M2, M3, M4), and an intracellular carboxyl-terminal domain (CTD) (Fig 1).   
 
Figure 1.1. Domain organization and structure of iGluR. A. A linear representation of the subunit polypeptide chain and schematic illustration of the subunit topology. B. Crystal structure of the tetrameric iGluR (here the AMPA receptor) 1.   The mammalian iGluR superfamily consists of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), kainate, N-methyl D-aspartate 10otentia (NMDAR) and delta receptor families. Most of these receptors require 10  
glutamate (Glu) binding to their ligand-binding domain for the receptor activation, with three exceptions: NMDARs formed by the NR1 and NR3A or B subunits due to the structural properties of their LBS are activated by glycine (Gly) or D-serine, and delta receptor subunit 2 can only bind D-serine 2. Ligand binding induces subsequent conformational changes first in LBD and then in position of trance-membrane helices which are directly coupled to LBD (see Fig 1 A upper panel). The channel pore opens and allows cations to pass through the pore down their chemical gradients.  Unlike phylogenetically related K+-channels (see Chapter 2), iGluR have larger channel pore (0.17 nm in diameter for K+-channel in frog nerve vs 0.55-0.78 nm for different types of iGluR 3). Thus, interactions between the ions and the pore walls are weaker and pore selectivity is reduced 4. The iGluR channel pore is permeable for alkali metal ions (Li+, Na+, K+, Rb+, Cs+). Moreover, large size of the channel pore allows Ca2+ permeabilization (mostly in NMDA and LBD-mutated delta receptors 2) and Mg2+ binding to the channel pore (as well as binding or permeability for other divalent cations like Zn2+, Ba2+, Fe2+  5, 6 and probably Cd2+, Hg2+ and Ni2+ 7.   Activity of iGluR can be efficiently modified by various regulatory molecules, interacting with ATD, LBD and channel pore.  Cytoplasmic C-terminal domain has multiple sites of phosphorylation, S-nitrosylation and palmitoylation 1. The diversity and complexity of iGluR in mammalian CNS produces broad spectrum of receptor types mediating and regulating synaptic transmission. In the present study we focused on the NMDA receptor family proteins.   
NMDA receptor: general properties The NMDA receptor was named after the specific agonist N-methyl D-aspartate 8 which was used to differentiate between this class of receptor and other classes of ionotropic glutamate receptors. Most of the studied subtypes of neuronal NMDA receptors from rodents (containing NR1/NR2 subunits) have four important properties unique for this family of iGluR: 1) Binding of both agonist L-glutamate and  co-agonist L-glycine is required for the complete activation of the receptor 9; 
11  
2) Voltage-dependent channel blockade by Mg2+ 10 (Fig 2) as well as by other channel-binding divalent cations. Mg2+ blocks from both extracellular and intracellular sides, therefore, the NMDA receptor works as a bidirectional rectifier. It passes ions in a voltage range around 0 mV and progressively reduces the current as membrane potential is increased or decreased 11. 3) High permeability for Ca2+ 12. 4) Slow activation and deactivation kinetics13.   
 
Figure 1.2.  Openings of the NMDA receptor channel requires both, receptor activation by agonists and membrane depolarization. A. A scheme of the NMDA receptor activation in the synaptic cleft. Glutamate released from presynaptic neuron binds to the NMDA and non-NMDA iGlu receptors permeable for Na+ and K+ ions. Following the depolarization of postsynaptic membrane Mg2+ ion is released from the NMDA receptor channel pore.  That makes NMDA receptor ion channel permeable for the extracellular Ca2+ and monovalent cations (14, p 655). 
B. Voltage-dependent Mg2+ block of activated NMDA receptor channels during synaptic transmission 15.  In mammalian brain NMDARs are not critical for the basal synaptic transmission. Though NMDARs have high affinity for glutamate, ion fluxes are blocked by internal Mg2+ bound within the opened channel pore at the negative membrane potentials (Fig 2). As a result, the NMDAR channel activation requires both glutamate binding and membrane depolarization. Since NMDARs have much slower activation kinetics than AMPA receptors (AMPAR τdeactivation < 1 ms, NMDAR activation time ~5 ms 1), only a strong membrane depolarization (or a sequence of depolarization events) lasting for more than 5 ms will result in NMDAR-related ion fluxes.  Thus, NMDARs in the brain act as a molecular coincidence detectors (glutamate release and long-lasting strong depolarization) 
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and thereby regulate functional plasticity of individual synapses by Ca2+-dependent signaling cascades 16.  The ability of NMDAR to discriminate frequency of synaptic impulses (single depolarization event or low frequency events versus multiple high frequency events) is used by neuronal networks for memory formation 17.  
NMDA receptor: molecular organization The NMDA receptor is a homo- or heteromeric complex composed of four subunits. Each subunit may belong to one of three types (in mammals): NR1, NR2 (subtypes A-D) and NR3 (subtypes A and B) 18. Properties of NMDA receptor are defined by the domain structure of the receptor subunits. As with all iGlu receptors, each subunit is composed of an extracellular amino terminal, four hydrophobic channel forming domains and intracellular carboxyl terminal. The extracellular part of the receptor contains amino terminal domain (ATD) that binds allosteric modulators like Zn2+ (NR2A) or polyamines (NR2B) (Fig 2A). The amino acid binding domain is formed by S1 segment located between ATD and first transmembrane domain (M1) and S2 segment located on extracellular loop between M3 and M4. The S1 and S2 segments form bilobed structure with the cavity for glutamate (NR2 subunits) of glycine (NR1 and NR3 subunits) binding.  Different expression systems used for detailed investigation of the NMDA receptor properties have introduced substantial variability in the obtained data. For example, when HEK293 cells was used as a model expression system for the NR1 and NR2A subunits, channel pore opening was achieved only if  both Gly and Glu were present for binding NR1 and NR2A subunits respectively (Figure 3B), 19.  Similar NR1/NR2A-containing receptors expressed in Xenopus oocyte produced high amplitude but slow deactivation current when stimulated with glycine alone.  Experiments with Glu-site antagonist APV showed that Gly was probably binding to Glu site and therefore causing receptor activation 20. Receptors built exclusively by NR1 and NR3 subunits unlike “classical” NR1/NR2 containing receptors have an intermediate opening state when only one type of subunits interacts with agonist (NR3 on Fig 2C).    13  
Figure 1.3. A. Domain organization of the NMDA receptor NR1 and NR2 subunits. Glycine and glutamate bind to the shell-like structure formed by S1/S2 compartments of ligand binding domains (LBD). External ATD I domain binds various allosteric modulators. pH-sensitive residues were identified in M3 and M4 regions of both NR1 and NR2 subunits 21. B.  Proposed mechanism of agonist-dependent channel opening in NR1/NR2 heterotetramer 19. C. Model for the intermediate activation state of NR1/NR3 receptors 22.  
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The M2 and M3 transmembrane regions are participating in channel pore formation. Point mutations in the M2 region of NR1 subunit may significantly alter the channel selectivity for mono and bivalent cations 23. A single residue within the M3 segment of the NR2 subunit define the single-channel conductance, selectivity for cations, in particular to Ca2+ ions, and affinity to Mg2+. Mutation of a Ser-632 to Leu in this segment of the NR2A subunit makes the NR2A/NR1-receptor acquire the properties of the channel formed by the NR2D and NR1 subunits 24. Receptors, containing NR3 subunits are resistant to Mg2+ block under physiological conditions. NR1/NR2/NR3 heteromeres cannot be blocked by 1 mM of Mg2+ at negative membrane potentials 25.  Site-directed mutagenesis of the NR1 and NR2 subunits within the channel pore region revealed that Mg2+ ion is coordinated four Asn residues, one from each NR1 and NR2 subunits. In rodents NR3 subunits have Gly residue instead of Asn in these positions. Voltage-dependent Mg2+ block could be recovered in NR1/NR3 receptors by replacement of Gly or nearby amino acid residues with Asn in NR3 subunit 26. Thus, incorporation of NR3 subunit dramatically changes NMDA receptor channel properties. In human NR3B subunit same position is occupied by arginine residue 27. Properties of human NR3B-containing receptors were not studied so far.  At present “the existence” of functional NR3/NR2 channels remains a matter of discussion. Smothers et al have recorded the Glu-Gly-depended currents in HEK293 cells expressing NR3 and NR2 cDNA 28. Earlier on  it was claimed that, when expressed in HEK293 cell line, NR3/NR2 oligomers can assemble in the endoplasmic reticulum, but their trafficking to the plasma membrane is not possible in the absence of NR1 subunit 29. The reason of this controversy could be related to the various culturing conditions and cell type. For example, functional NR1/NR3 receptors were successfully expressed in Xenopus oocytes 30, 22. In HEK293 cell line only one group obtained electrophysiological recordings from native and mutant NR1-NR3 receptors 28, whereas the other group failed to express functionally active NR1-NR3 receptors in that cell line 31. So far it is not clear if NR3 subunit may replace NR1 for the receptor assembly and trafficking. Under the current paradigm NR1 subunit is necessary for the 15 
NMDA receptor translocation to the cytoplasmic membrane and function. Based on this assumption, many researchers concentrate on the NR1 abundance when looking for NMDA receptor in non-neuronal tissues. That approach can be fruitless.  
NMDA receptor: channel properties Depending on the subunit composition the properties of the NMDARs are very diverse. Based on the knowledge obtained using various expression systems the following structural-functional interactions are revealed linking the receptor subunit composition, the channel cation selectivity, amplitude of currents, inactivation time, and sensitivity to Mg2+ block and synthetic antagonists. NR1-NR2 receptors are 4-8-fold more permeable for Ca2+ than for alkali cations. Receptors containing NR3 subunits have about 2-4-fold higher permeability for alkali ions compared to that for Ca2+ (see Table 1). The cation selectivity is believed to be determined by a single amino acid residue at the tip of the reentrant pore loop in the region called QRN (framed in Fig 4). In iGluR the residue in the apex of M2 region is either Gln (Q) in AMPA receptors, or Arg I in kainite, and Asn (N) in NMDA receptors. Notably, this position in NR3 is occupied by Gly (Figure 4) leaving more space for the cations to pass through the pore and opting for poor selectivity of the channel filter to cations 26, 32. 
Figure 1.4. Amino acid sequence alignment of M2 region in human NMDA receptor subunits. Fully conserved residues are orange, conserved residues are blue, and less conserved residues are shown in green. QRN residue marked in the 
16 
black frame. The NR3A and B amino acid sequences in this region are highly different from both NR1 and NR2 subunits. Modified from 33. 
In contrast to Ca2+-permeable NR1-NR2 receptors with pronounced Mg2+ block, NR1-NR3 receptors are resistant to Mg2+ inhibition, but can be blocked by other divalent cations such as Ca2+ and Ba2+ at negative membrane potentials 5, 34. Notably,  NR1-NR3A receptor expressed in Xenopus oocytes was blocked by extracellular Ca2+ ions at negative membrane potentials within the physiological range (1.8 mM of CaCl2 is present in the blood plasma).  For Mg2+ block to occur  NR2 subunit should be present in the NMDAR in which Asn (N) is conserved in the QRN domain 35. Whereas NR2 is replaced by NR3, blocking by Mg2+ does not occur at negative membrane potentials as it lacks N in the QRN region (Fig 4). Moreover, even the slight differences in M2 sequence between NR2A/B and NR2C/D subunit types are sufficient to produce high variety in sensitivity of the receptors to Mg2+ block (see Table 1 and Fig 4).  The QRN region in NR1 subunit is responsible for Ca2+ selectivity, the replacement of Asn (N) to Gln (Q) or Arg I substantially decreases channel permeability for Ca2+.  The following structural/functional interactions may be postulated for the NMDA receptors: 1) NR1 + NR2  high Ca2+ permeability, Mg2+ block2) NR1 + NR3  low Ca2+ permeability, no Mg2+ block, but potential-dependent Ca2+ block, altered I/V curve3) NR1 + NR2 + NR3  reduced Ca2+ permeability, reduced Mg2+ block4) NR2 + NR3  (predicted) low Ca2+ permeability, normal Mg2+ block, veryslow deactivation kinetics, altered I/V curve.
Deactivation time of the receptor (τ) is controlled by the type of NR2 subunit and by the splice variant of NR1 subunit (Table 1). NMDA receptors demonstrate great variability in the time of current decay depending on the subunit composition. Slow decay kinetics of the ion currents is produced in presence of NR2D subunit due to the slow dissociation of glutamate from this receptor subtype. A point mutation in glutamate binding site of the NR2D subunit 
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produced up to a 60-fold faster deactivation of the ion current 36. Thereby, properties of the LBD (or ligands with the different affinity to the receptor) may influence the kinetics of ion currents. Exon 5 splicing in NR1 combined with NR2 results in prolongation of the deactivation time (see NR1a, NR1e splice variants in Table 1). The presence of exon 5 is associated with much shorter channel opening time interval (NR1b, NR1g) 37. Two other NR1 exons, 21 and 22, can also undergo alternative splicing, however, they are present in carboxyl-terminal domain and have much smaller influence on channel properties (for example, both NR1a and NR1b consist of 21 and 22 exons but both NR1e and NR1g do not, see Table 1).  
In neuronal cells NMDA receptors exist within the multi-protein complex consisting of several dozens of proteins involved in signal transduction 38. Many of them are calcium-sensitive kinases and phosphatases that can be directly activated by Ca2+ within the micro-domain around NMDA receptor ion channel. But, despite the local increase in Ca2+ concentration, NMDA receptors may affect cellular concentration of Ca2+ due to high single channel conductance (around 40-50 pS) 39. This value exceeds conductance of L-type calcium channels by ~20-fold 40).  Even a single opening of the NR1/NR2 containing NMDA receptor channel is sufficient to raise Ca2+ concentration within 1 µm3 volume (for example, in a spine head of dendrite) by 1 μM 39. The exact amount of Ca2+ passing through the NMDAR channel can be efficiently adjusted by altering the subunit composition of the receptor, duration and frequency of agonist exposure 41, by various allosteric modulators, lipid-protein and protein-protein interactions, and secondary modifications of the receptor. Due to the low Ca2+ permeability and other specific properties, physiological role of the NR3-containing receptors probably differs from that of the receptor formed by the NR1 and NR2 subunits, see Chapter 3 for examples.  
NMDA receptors: ligand binding domain Agonist-induced control over the channel gating is similar in all types of iGluRs. Crystallorgaphic studies indicate that ligand binding to the cleft formed by S1/S2 domain is followed by cross-dimerization of both hydrophibic and 18 
nonhydrophobic regions of the S1 domains of the neighboring pairs of NMDAR subunits (Fig 3B). Mechanical movement of S1/S2 domain during the ligand binding leads to the rotation of M3 helices away from the central axis of the pore and opening of the channel gate.   The S1/S2 domain is forming clamshell-like structure with amino acid (agonist) binding pocket interacting with α-carboxyl and α-amino groups. In Glu-binding NR2 subunits ligand-interacting residues in S2 region are fully conserved within all four types (A-D). However, in S1 region the NR2 sequences are much more diverse. Glycine-binding NR1 and NR3 subunits together with non-functional delta receptors (GluD) have the lowest sequence similarities among all iGluRs (Fig 5). These differences suggest that Glu-binding ability was preserved during evolution of iGluR, while glycine/D-serine binding ability emerged later in time, and probably independently, for the NR1 and NR3 subunits. Pronounced differences in the LBD sequences of the NR1 and NR3 subunits S1/S2 domain are associated with a broad range of their ligand-binding properties. While the receptor formed by the NR1 subunits has fairly high affinity to glutamate (EC50 0.81  µM, see Table 1), heteromer containing NR1 and NR3 subunits has very low affinity to Glu with a Kd = 9.6 mM, which is well above the physiological range  (peak Glu concentration in the synaptic cleft in around 1 mM 42). Affinity of these heterotetramers to Gly is fairly high (Kd = 40 nM) and Kd for D-serine is within the micromolar range 43.  However, despite the similar affinity to the LBD of NR1 and NR3 subunits, D-Ser is activating only 25% of the current amplitude evoked by Gly in NR1/NR3 receptors 28.  
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Figure 1.5. Agonist-binding residues of human glutamate receptor subunits. Fully conserved residues are shown in yellow, conserved residues are shown in blue, and similar residues highlighted in green. # denotes residues capable of forming hydrogen bonds or electrostatic interactions with the agonist; + denotes residues capable of forming van der Waals contacts with the agonist. Red dots indicate residues replacement of which leads to dysfunctional binding site for Gly. Blue dot indicates residue replacement of which was not affecting Gly sensitivity. Modified from 1.  To evaluate role of NR3 subunits within the NMDA receptor point-mutagenesis studies were performed 22. Binding of both Gly and Glu is required to activate the “classical” NMDA receptor consisting of two NR1 and two NR2 subunits 19, Fig 3B. When Phe residue in position 484 of NR1 subunit (see Fig 5, red dot) was replaced by Ala, agonist binding to these subunits was completely abolished. The receptor formed by the mutated NR1(F484A) and NR2  was not producing detectible current in response to activation with 200 µM NMDA and 1 mM Gly. In contrast, NR1(F484A)/NR3 receptors were able to produce even higher Gly-activated currents than non-mutated NR1/NR3 receptors.  To explain these findings Furukawa et al have proposed the existence of a subconductance state in the NR3-containing receptors (Fig 3C). The subconductance state was described for AMPA (GluA) and kainite (GluK) receptors 44, however, was never observed for NR1/NR2 receptors. Amino acid sequence of S1 region of NR3 
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subunits resembles of GluA and GluK rather than NR2 subunits (see Fig 5). Smothers and Woodward showed that glycine-activated currents of NR1/NR3 receptors displayed characteristics similar to those shown by AMPA receptor 28. These currents with a fast onset showed rapid desensitization to the steady-state levels. But, unlike AMPA receptors, these currents were not activated by glutamate, and desensitization was unaffected by AMPA receptor allosteric modulator cyclothiazide 28. The NR1/NR3(Y605A) receptor with dysfunctional Gly-binding site in NR3 subunit was unable to conduct any currents. Thus, the NR3 subunit seems necessary for effective engagement of NR1 in NR1/NR3 receptor activation 22 and displays unusual properties of the receptor activation.    Enantiomers of Gly and Glu are capable to activate NMDA receptors with different efficiency. The most potent agonist binding to NR1 subunit is D-serine. D-Ser has about the same affinity to NR1-NR2(A-D) receptors as Gly (0.16-1.3 µM). D-serine is currently suggested to be the dominant NMDAR co-agonist in the brain 45. At the same time L-serine is 100 times less potent in induction the NMDA receptor activation than D-serine.  Furthermore, NR1 subunit is also capable to distinguish between D- and L- isoforms of other amino acids. For example, affinity of the receptor to L-alanine is 10- to 100-fold lower than that to D-alanine 1.    Similarly to NR1, NR2(A-D) subunits are also capable to distinguish between the  L and D isoforms of their main agonists Glu (IC50 for radiolabeled L-[3H]glutamate replacement is 0.31 µM for L-Glu and 23 µM for D-Glu) and NMDA (14.5 µM for L-isoform, NMLA, and 3.68 µM for D-isoform) 46. At the same time, for the other structurally similar amino acids, such as aspartate, NMDA receptors did not develop such strong selectivity for D over the L-isoforms. Thus, two main NMDA receptor agonists are D-amino acids. Similar to that highly conserved delta receptors are also capable of binding D-amino acid serine. Based on these observations a hypothesis has been proposed that D-amino acids were used earlier on in evolution for the signal transduction in attempt to distinguish them from metabolically active L-amino acids before glutamatergic synapse had appeared (see Chapter 2).  21  
 
NMDA receptors: physiological allosteric modulators Extracellular proton concentration is an important regulator of the NMDA receptor function within the living tissue. Amino acids in control of the receptor pH-sensitivity are highlighted as stars in Fig 3A. NMDA receptor channel opening probability for all known receptor types is  maximal with alkali pH above 9, and all types of NMDA receptors are inhibited when pH is below 4 47.  Human brain extracellular pH varies between 6.8 and 7.5 48. Within this interval different NMDA receptor subunits possess various pH sensitivity. About half of the receptors composed of NR1/NR2 (A or B or D) are inhibited at pH 7 49. NR1/NR2C receptors are resistant to “low” pH values and only 15% of them are inhibited at pH 7 47. In NR1 homotetramers pH sensitivity is highly dependent from the presence of exon 5 (Table 1) 50. NR1/NR3 receptors are very sensitive to proton-induced inhibition with either of NR1 splice variants 30.  Zn2+ is one more major regulator of NMDA receptor activity under physiological conditions is Zn2+ ion. Zn2+ accumulates in synaptic vesicles of specific neurons and can be released into the synaptic upon stimulation 51. In NR1/NR2A receptors low Zn2+ concentrations (nanomolar range, see Table 1) are reducing channel opening probability independently of the membrane potential 52. The apparent concentration of free Zn2+ ions in the brain is between 1 and 10 nM, that is sufficient for partial receptor inactivation 53. At higher Zn2+ concentrations (10-100 µM) and negative membrane potentials Zn2+ produced voltage-dependent fast channel block. Notably, Zn2+-dependent block was shown to form more than an order of magnitude faster than Mg2+ block. Furthermore, at depolarized potentials Zn2+ had higher affinity to the NMDA receptor channel than Mg2+ (Kd 0.9 mM vs 8.8 mM) 52. The amount of Zn2+ released into the synaptic cleft upon stimulation was estimated to be between 10 – 30 µM 53. Thus, we can conclude that both voltage-dependent and voltage-independent mechanisms of NR1/NR2 receptor inhibition may occur in the brain. Surprisingly, Gly-induced currents through the NR1/NR3 receptor were potentiated by 50 µM of Zn2+ at negative membrane potentials due to the relief of voltage-dependent Ca2+ block 5. Thus, while Glu-activated NR1/NR2 receptors 22  
are inhibited by Zn2+ during the Zn2+-sensitive synaptic transmission, Gly-activated NR1/NR3 receptors are potentiated.  
NMDA receptor: channel pore antagonists Many synthetic NMDA receptor antagonists were designed to study the receptor properties in vitro. Some of them are used in vivo for various purposes (anesthesia, treatment of neurological disorders, recreational drug abuse). In the present study three of NMDA receptor pore-targeting antagonists were investigated: the anesthetic drug ketamine, anti-Alzheimer drug memantine and MK-801 (the most popular channel pore targeting blocker of the NMDA receptor). Although it is believed that all of them are targeting the “PCP-binding site” within the channel pore, they are actually interacting with different amino acid residues. In rodent NMDA receptor MK-801 interacts with M1, M2 and M3 transmembrane domains, while memantine binds mostly to M2 domain and shows 100-fold lower affinity to the receptor than MK-801 23. The NR2 subunit composition does not influence the receptor affinity to MK-801, but does impact its affinity to ketamine and memantine (Table 1). Under physiological conditions Mg2+ ions act as an endogenous NMDAR channel blocker displacing the antagonists from their binding sites and reducing thereby their inhibitory power 54, 55).  NR1/NR2A and NR1/NR2B receptors have high affinity to Mg2+ (Table 1) and in such receptors memantine and ketamine inhibition is ineffective. In contrast NR1/NR2C and NR1/NR2D receptors with low Mg2+ affinity shows pronounced inhibition by memantine and ketamine 54. For that reason memantine and ketamine mostly affect NR1/NR2C and NR1/NR2D receptors in the rodent brain.   The presence of the NR3 subunits in heterotretrameric NR1-NR2-NR3 receptors does not affect the receptor sensitivity to ketamine (as well as its sensitivity to Mg2+ block) when compared to the corresponding NR1-NR2 receptor 33. NR1/NR3 receptors are highly resistant to the inhibition by MK-801, memantine and ketamine making these receptors difficult to study (Table 1).  
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Table 1.1. Pharmacological properties of NMDA receptors as a function of their subunit composition. Where possible, EC50 and IC50 values were taken from a single study for all variety of the heteromeric receptors.  Those values may be highly dependent from the experimental setup and the NR1 subunit splice variant. Note the highly specific properties of the NR1/NR3 receptors compared to those of the NR1 homomers and the receptors formed by the NR1 and NR2 subunits.   NR1 NR2A NR2B NR2C NR2D NR3A/B+NR1 
Glycine EC50 0.18 µM (homomer) 56 2.1 µM 57 0.3 µM 57 0.2 µM 57 0.1 µM 57 0.04 µM, 1-6 µM 18 20-50 µM 28 Glutamate EC50 0.81 µM (homomer) 56 1.7 µM 57 0.8 µM 57 0.7 µM 57 0.4 µM 57 Nd 43,  Kd = 9.6 mM 58 
τw (deactivation time) 
**NR1a 745 ms NR1b 194 ms NR1e 563 ms NR1g 167 ms 37 50 ms 
59 300 ms 59 280 ms 59 1.7 s 59 Seconds 60 
Mg2+ block High affinity 30 High affinity 
61, 34 µM (-80 mV),  0.7 mM (-40 mV)  62 
High affinity 61 Lower affinity 61 Lower affinity 
61, -80 mV: 91 µM, -40 mV: 1.6 mM 62 Resistant? 34, 25 
PCa2+/PCs+* ? 8 24 7 24 5 24 4 24 
0.8 or 0.6 for NR1/NR2/NR3 25 29, NR1/NR3 0.4 26 <0.25, voltage-depended Ca2+ block 5 
pH, IC50 
6.6 (+ exon 5) 7.4 (- exon 5) (homomer)  50   
7 47, 6.9 49, 7.2 57  
6.8 47, 7.5 49, 7.3 57  
6.4 47, 6.2 57 7.5 49, 7.3 57 Approx. 7.4 30 
Zn2+, IC50 + exon 5: <1 µM potentiation, >1 µM 10 nM 
49 1 µM 49 30 µM 64 10 µM 49 Potent activator 5 
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inhibition; 
- exon 5: inhibition only (homomer) 63 
MK-801, IC50 18 nM (homomer) 65 13 nM 66 13 nM 66 11 nM 66 38 nM 67 NR1/NR3 10 µM no effect 28 Ketamine, IC50 ? 16100 nM 67 1550 nM 67 1110 nM 67 1500 nM 67 NR1/NR3 5% inhibition by 100 µM 28 Memantine, IC50   ? 
4360 nM 67   
1200 nM 67   
601 n   M 6    820 nM 67 NR1/NR3 10 µM no effect 28 
Ifenprodil, IC50 0.28 µM (homomer) 68 146 µM 68 0.34 µM 68 Low 69   Low 
69   
NR1/NR3 10 µM no effect 28 * Na+ and Cs+ are considered to be equally permeable ** In combination with NR2B                  
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Chapter 2  NMDA receptors: origin and evolution 
Origin of iGluRs iGluRs were first discovered  and studied 70 in vertebrates, mainly in mammals. Since then iGluRs were mostly studied in the context of excitatory neurotransmission processes in the central nervous system of vertebrates. However, in 1998 the first four and by 2003 16 other homologue of mammalian iGluRs genes were discovered in organism lacking nervous system, in the plant 
Arabidopsis thaliana 71. This finding suggested that iGluRs-like receptors (GLR) were expressed in the ancestor organisms existing prior to divergence of plants and animals, sometime before 1.6 billion years ago 72.  iGluRs share physiological properties of ligand-gated ion channels with the acetylcholine and GABA receptors and transmembrane topology of a channel-forming domain in voltage-gated potassium channels 73. It was proposed that iGluRs appeared as a product of chimeric genes assembled by an exon shuffling between the genes coding for the K+ channel-like protein  and the amino acid binding protein 74, 75, (Fig 1).   
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Figure 2.1. Possible origin of iGluRs. Insertion of the channel-forming domain (KcsA) between the amino acid-binding protein (AABP) domains (S1 – M1 – P – 
M2 – S2) leads to the formation of a potassium-specific channel (GluR0) in bacteria. M4 transmembrane segment appears in eukaryotic receptors (iGluR) 75.   Such shuffling of mobile domains played a major role in the evolution at the time of metazoan radiation 76. That hypothesis was supported by discovery of GluR0 receptor in prokaryotic organisms 77. This receptor is highly homologous to eukaryotic iGluRs ligand-binding domain and at the same time the selective filter of the channel has sequence which is typical for K+ channels. Activation of GluR0 receptors induces potassium-mediated outward current hyperpolarizing the membrane thus stabilizing the negative resting potential (in E. coli resting membrane potential is between -220 and -140 mV depending on the growth stage 78). The iGluR channels of eukaryotic organisms lack cation selectivity and  the channel opening leads to membrane depolarization 75. Based on these findings it was suggested that such changes were developed during the rise of multicellularity for the purpose of the cell-to-cell signaling.  However, genealogical analysis showed that the animal iGluRs along with plant GLR are representing distinct ion channel class 77 (Fig 2). They claim that 
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similarity of the iGluR structure to other cation channels may be due to the convergent evolution.   
 
Figure 2.2. Absolute distances between plant GLRs and four classes of ion channels in transmembrane regions 73. The smaller the distance values, the more related the sequences.   It was proposed that iGluRs arose via series of point mutations from ancestral receptor most closely related to plant GLRs 79. At present 20 different GLR subunits were found to be encoded in the Arabidopsis genome (from that amount of subunits 8855 unique tetramers may be produced). Electrophysiological and pharmacological properties of one of them (GLR3.4) were studied in transfected animal cells. GLR3.4-based receptors showed several-fold higher preferences to Asn, Ser and Gly over the Glu and high selectivity for Ca2+ over Na+ (5*104) under physiological conditions 80. Sequences of GLR subunits are highly homologous to the animal NMDA receptor subunits. 19 of them are activated by Gly and only 28  
one subunit may efficiently bind Glu 81. In Arabidopsis seedlings (very young plants) GLR regulates hypocotyl (“stem”) elongation via Gly-activated Ca2+-dependent signaling. In young Arabidopsis plants GLR subunits were expressed in all tissues, but highest variety of subunits was found in roots 82. In plants GLN receptors play an essential role in maintenance of carbon to nitrogen balance 83, regulation of  abscisic acid (plant signaling molecule which regulates germination, transpiration, fruit ripening and other processes) biosynthesis, and in signaling and control of the root growth 84. During evolution of animal cells four types of iGlu receptors appeared: delta receptors, NMDA, AMPA and kainite receptors. Higher degree of conservation was found between the plant GLRs and animal delta iGluRs in all functional domains (ligand binding domains, transmembrane M1-M3 domains and intermediate protein sequences) 73. Thus, delta receptors are closest relatives of the ancestor animal iGluR and plant GLR. Similarly to plant GLRs delta receptors are non-responsive to Glu, but they bind glycine and D-serine 85.At some point of delta receptor evolution it lost its ligand-activating property. Therefore, delta receptor channel was studied only in chimeric proteins where ligand binding domain from delta receptors was replaced by the same domain from AMPA or kainite receptors 86. Remarkably, in contrast to AMPA and kainite iGluRs, chimeric delta receptors were permeable for Ca2+ with a ratio 0.86 to monovalent cations (Ca2+: X+). In mammalian brain delta receptors lack the channel activity, however they may participate in signal transduction via metabotropic signaling 87. Therefore, we may assume that the first ionotropic “glutamate” receptors of eukaryotic cells living more than a billion years ago were most likely Ca2+-permeable and activated by small molecules with Gly-like structure more resembling modern delta and NR1 receptors then glutamate binding AMPA and kainite receptors.    Apparently, rising complexity of the ionotropic glutamate receptors was associated with the raise of multicellularity. In genomes of unicellular organisms 
Paramecium and Tetrahymena no NMDA receptor homologous genes were detected 88, 89. However, in both organisms glycine-binding proteins similar to the NR1 amino acid binding domain were found.   29  
iGluRs in Hydra vulgaris Perhaps the most ancient iGluRs were reported to be present in hydras. Hydra belongs to the Cnidaria phylum, the most primitive eumetazoans. Cnidaria appeared around 580 million years ago and existed as non-mobile epibentic (sitting on the see bed) organisms (Fig 3A). They were closely associated with microbial mats where dissolved nutrients were abundant 90. For such animals chemoreception was driving their feeding behavior. Chemoreception in Hydra (Fig 3B) is mediated by iGluRs responding to the stimulation with reduced glutathione (GSH). GSH stimulates tentacle movements and mouth opening and oxidized glutathione (GSSG) inhibits that response. Glutamate itself, as well as other agonists of iGluRs (NMDA, D-Ser, quisqualate, kainate) affect feeding behavior and specific antagonists of NMDA receptor (D-APV, Glu site antagonist, DCKA and I2CA, Gly site antagonists, MK-801, channel pore blocker) prevent those effects 91, 92, 93, 94. [3H]glutamate competed with GSH and GSSG for the binding sites on isolated cellular membranes of Hydra 91. Moreover, GSH, as well as Glu and Gly, increased binding of [3H]MK-801 to Hydra membranes 94. Those observations indicated that GSH may binds to the ligand binding site of NMDA receptors and therefore increases channel opening probability and, as a result, facilitates MK-801 binding. Furthermore, agonists of other iGluRs, AMPA and kainate, were decreasing specific binding of [3H]glutamate and had functional effects on nematocyst discharge and tentacle pulses (Fig 3C and E) 91, 92, 95. Of note, physiological response in Hydra was observed only when both specific agonists NMDA and D-serine were present 94 (Fig 3D). Later only one type of NMDA receptor subunit was identified in Hydra genome. This subunit is highly homologous to Gly (or D-serine) specific NR1 subunit types 96 (Fig 4). Thus, it is possible that an ancient Hydra NMDA receptor subunit shares similarities with both NR1 and NR2 subunit types. In mammalian neurons function of the NMDA receptor is usually coupled with AMPA or kainate receptor. Activated by glutamate Na+/K+ permeable AMPA or kainate receptors initiate membrane depolarization releasing thereby voltage-dependent Mg2+-block from the NMDA receptor channel (see Chapter 1). Similar AMPA/kainate – NMDA receptor coupling was shown for Hydra. NMDA or 30  
kainate alone had on effect on Hydra’s feeding behavior, while together they produced same response as glutamate (Fig 3E,F).    
 
Figure 2.3. Ionotropic glutamate receptors in Cnidaria. A. Ediacara biota (635-541 million years ago). Members of the Ediacara biota belong to the first cnidarians and evolutionary precursors of annelids, arthropods and echinoderms 90. B. Hydra vulgaris, a modern cnidarian. C. Nematocyst discharge 
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in isolated tentacle of Hydra vulgaris. D. In a presence of glutathione (10 µM) 
Hydra opens its “mouth” for about 22 min. When both specific agonists of NMDA receptor NMDA and D-serine are present, about 40% reduction in the longitude of GSH-response was observed. Neither NMDA nor D-serine alone had any effect on the GSH-induced response. Specific Gly/D-Ser binding site targeting antagonist DCKA or Glu/NMDA binding site targeting antagonist D-APV both had no effect as well 94. E. Discharge of nematocysts can be activated by glutamate or by a combination of NMDA and kainate 92. F. Recordings from the electrode attached to the tentacle of Hydra from a single experiment. “Baseline” is a recording from the control period; “NMDA+AMPA” is a recording corresponding to the treatment period (0.1 μM of each drug) 91.  Functional studies of iGluRs were mainly conducted on Hydra. The genomic analysis was made on another cnidarian, sea anemone (Nematostella vectensis). Several types of AMPA-like and NMDA-like receptors’ subunits, and only one kainate-like receptor subunit sequences were described in Nematostella genome 97. The AMPA receptor orhtologues show higher similarity with their bilaterian counterparts than NMDA receptor. Among NMDA receptor orthologues one NR1-like and four NR2-like genes were identified, which were similar to higher animals where diverse properties of NMDA receptor complex are supported by different types of NR2 subunits. Nematostella belongs to the class Anthozoa, phylogenetically basal class of Cnidarians. Hydra represents class Hydrozoa, which is further from the ancestor of Cnidarians and bilateral animals (e.g. us). It is possible that Hydra’s ancestors lost some of the NMDA receptor genes and thus they were not detected in Hydra’s genome 96. In conclusion, NMDA receptor-based sensing was already used by the most primitive true multicellular organisms.  
NMDA receptor in animal evolution Based on the comparative genomic analysis of the modern animals belonging to different phyla, the conclusion was made that, along with gene duplication, gene loss has been a major factor in genome evolution since divergence from the common ancestor 98. Gene loss of NMDA receptor subunits probably occurred in roundworm Caenorhabditis elegance and fruit fly Drosophila melanogaster. These two species are standing much higher in evolutional hierarchy than Cnidarians, 
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however, both of them have only one type of NR2 subunit and their NR1 subunit gene produces only one type of NR1 protein 99. Moreover, in C. elegance NMDA receptors are expressed only in a few neuronal cells, and  their functional role is highly reduced in this animal 100.  Cnydarians are the closest relatives to the ancestor of modern multicellular organisms. The genome analysis of Nematostella and Acropora showed that ancestor organism had higher genetic complexity than modern worms and insects. However, most of the genes (coding cell signaling pathways, membrane receptors and channels, signaling peptides) were preserved in the chordate lineage 101. All of the three types NMDA receptor gene were identified in our primitive relatives Hemichordata – acorn worm (Saccoglossus kowalevslii, 96, Fig 4.). A simplified Chordata Ciona intestinalis lost many of its genes during the evolution 102, and only NR1 and one NR2A-like subunits were detected in their genome 103, 96.  
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Figure 2.4. The phylogenetic tree of NMDA receptor subunits in animal kingdom (GluR1 and GluR2 – AMPA receptor subunits) 96. There are three types of NMDA receptor subunits in Chordata (mouse, Mus musculus) and in Hemichordata acorn worm (Saccoglossus kowalevskii). A simplified Chordata (Ciona intestinalis) lost their NR3 subunit type. Animals from the non-chordata lineage (worms, insects and mollusks) have only one type of NR2 subunit and no NR3 subunits. In Hydra only NR1 subunit was identified, however, in more primitive Cnidarians from the class Anthozoa four types of NR2 subunits and one NR1 were detected 97.  Thus, it is uncertain to state which NMDA receptor subunits were present in our early Chordate ancestors. Modern primitive Chordates do not necessarily resemble ancient forms; moreover, they took the same long evolutionary pass as we did, adapting to the specific environmental conditions and loosing many of their genes along with anatomical and physiological characteristics. In our closest non-Chordate relatives Echinoderms NMDA receptors were not studied, however, accidentally NMDA receptor antagonist memantine was found to be toxic for the developing sea urchin embryo 104.  
 
Figure 2.5. A. Divergence of the vertebrate GRIN2 genes 105 B. Phylogenetic analysis of NMDA receptor subunits in mouse illustrating phylogenetic relations between NR3A and NR3B subunits and other NMDA receptor subunits 31. NR3 subunits were found in Hemichordatae, teleost fishes, amphibians, reptiles, birds and mammals.  
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In genome of bony fishes all types of NMDA receptor subunits similar to those in mammals are already present (Fig 5A). Moreover, in teleost fishes the whole-genome duplication event led to the doubling of all NMDA receptor subunits (for example, NR2D-1 and NR2D-2) 105. The genome duplication occurred in early Triassic period was beneficial for adaptation to diverse ecological niches 106. At present teleosts is the largest group of fishes populating salty and sweet waters. Curiously, none of NR2B paralogues appear to be expressed in zebrafish nervous system, but it is present in some other tissue types since expression  of NR2B subunit was shown in whole fish homogenate at certain developmental stages 107. These data suggest that in fishes NMDA receptor expression is not restricted to the neuronal system and its function is not limited to participation in the synaptic transmission.  In genome of lizard only NR2C subunit was duplicated, both genes share high similarity (>99%) and are located in tandem in chromosomal segment, which is a sign of single-gene duplication (Fig 5A). In birds NR2D genes are dysfunctional 105. Similarly, NR3B subunit is now degenerating in human lineage; about 10% of European population lacks the NR3B subunit 108. In non-human primates accelerated evolution of NR2A subunit increased the spatial orientation abilities 109. In humans variations in NR2A and NR2B genes were associated with episodic memory (contextual declarative memory) performance 110.  At present   no studies are available on the evolution ofNR3 subunits. However, it is known that mammalian NR3 shares higher homology with mammalian NR1 than with the NR1 subunits of nematode or fly NR1 111. Therefore, NR3 has most likely emerged somewhere in the lineage of chordate before the divergence of vertebrates (Fig5B). NMDA receptors of first multicellular organisms were activated by molecules coming from the environment. Later in evolution NMDA receptors were used for the cell-to-cell communication within the organisms. Thus, production and release of ligands for the NMDA receptors should be precisely controlled in the vicinity of the NMDA receptor complex.. The first NMDA receptor ligand probably was NMDA itself (Table 1). Neuronal tissues of Echinodermata and primitive Chordatae contain high amounts of NMDA, moreover, the highest NMDA concentration was found in the fish brain. Terrestrial animals produce 35  
much less NMDA in the brain but their Glu concentration is rather high compared to that in lancelet’s brain. Since metabolism of D-amino acids is slow, there is a possibility that NMDA is used for the tonic activation of neurons rather than for synaptic transmission.  Lancelets produce NMDA from D-aspartate in reaction catalyzed by D-aspartate methyl transferase, similar to rats, but in much higher amounts 112. The possible reason for “glutamate switch” in terrestrial animals is higher speed of glutamate turnover. Use of Glu allows to decrease the time of neuronal adaptation to new conditions and therefore may have a positive impact on learning abilities.   
Table 2.1. Concentration of NMDA and glutamate in neuronal tissues of animals placed in evolutionary order.  
Animal, tissue NMDA, nmol/g tissue Glu, nmol/g tissue Rat, brain 2.97 ± 0.34 113 6.0 ± 0.18 114 Sheep, brain 2.23 ± 0.49  113 ? Chicken, brain 2.22 ± 0.22  113 ? Frog, brain 2.24 ± 0.38  113 ? Fish, brain 30.55 ± 4.02  113 ? Lancelet, cephalic vesicle 10.52 ± 1.41 112 2.3 ± 0.4 112 Ciona, cerebral ganglion 25.5 ± 4.5 115 ? Starfish, radial nerve 17.8 ± 14.3 116 ?  Together with D-aspartate, D-serine is a second major D-amino acid synthesized in substantial quantities in mammals 117. Since D-serine has no known function in normal metabolism of animals, it was suggested to participate in the NMDA receptor activation. D-serine binds to glycine site of NR1 and together with NMDA or glutamate and activates the receptor. Unlike glycine, D-serine is a specific NMDA receptor ligand, it shows no cross reactivity with glycine receptors. Similarly to NMDA, D-serine transport systems possess low affinity to their substrate. Therefore, D-serine is retained in the extracellular spaces of the brain for a very long time and its concentration at the synapse is influenced mainly by synthesis and diffusion. However, in the evolutionary new regions 
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(forebrain) of mammalian brain concentration of D-serine is maintained much higher than in the spinal cord, brainstem, cerebellum and medulla 111 due to the low activity of D-amino acid oxidase in NMDA receptor-rich regions. Higher activity of D-amino acid oxidase discovered in some forms of schizophrenia causes NMDA receptor hypofunction. Moreover, D-serine supplementation was successfully used as a therapeutic approach for that disorder 111. The combination of two types of NMDA receptor specific agonists within the mammalian brain provides advanced regulation of neurotransmission. Slowly metabolizing D-serine and probably NMDA supports the basal receptor activity and Gly together with Glu are needed for the short-term activation episodes.   
Conclusion NMDA receptors appeared as early in animal kingdom as the first multicellular organisms. NMDA receptor in cnidarians exists beyond the highly specialized neuronal cells and is used for food sensing, hunting and feeding. That indicates a possibility that the NMDA receptors may have functions outside of neuronal system, in different cell types and organs. Studies using primitive laboratory animals such as C. elegance and Drosophila could be misleading for understanding of NMDA receptor evolution, since they most likely  lost some of the NMDA receptor genes during the evolution.   In much more complex organisms like vertebrates NMDA receptor subunit diversity and complexity was increasing along the evolution timeline. Already in bony fishes all types of NMDA receptor subunits are present. Moreover, in fish expression of NMDA receptor was detected outside of the brain. In recent years evidence was accumulating in support of the idea that NMDA receptor expression and function in mammals is not limited by neuronal system as well. NMDA receptors were found and characterized in kidney 118, bone 119 and white blood cells 120. Moreover, indirect evidences indicate that NMDA receptor has multiple organ-specific physiological functions.     
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Chapter 3 Implications for NMDA receptors in mammalian heart and red blood cells  Over the billions years of animal evolution NMDA receptors were selected and optimized as efficient ionotropic receptors. In mammalian genome seven types of NMDA receptor subunits coded by individual genes are present. Functions of human and rodent NMDA receptors were most extensively studied predominantly in neurons and in cellular model systems where NMDA receptors were artificially introduced. It was shown that NMDA receptors are involved in control of intracellular calcium levels and calcium-driven processes  such as  Ca2+-dependent control over kinases and phosphatases, free radical and NO production by NO synthases and NADPH oxidases, regulation of calcium-dependent proteases and gene expression machinery 121, 122, 123, 124. Unfortunately, too little information is currently available on the expression, composition and function of NMDA receptor in vast majority of tissues with one exception. We know a lot about the NMDA receptors in the brain. This chapter is an overview of the recent developments in our understanding on the role these receptors play in red blood cells and in the heart, on which my PhD project was formed. Before addressing this poorly explored area some selected information is given on the NMDA receptor in our “reference organ”, the brain.   
Brain In the brain NMDA receptors are used for modulation of synaptic transmission pathways involved in the formation of memory and in learning. These receptors are abundant in postsynaptic membrane, but also in adjacent astroglial cells contributing to the synapse formation (see Fig 1).  Postsynaptic receptors sense transient increase of glutamate levels in the synaptic cleft as it is released from the presynaptic terminal occurring along with the postsynaptic membrane depolarization. Astroglial cells contribute to the synaptic glutamate turnover and to the tonic activation of neurons by D-serine 125. In rat hippocampus astrocytes mediate glutamate reuptake, they sense the ambient glutamate levels by their 
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own NMDA receptors which may be formed by all the seven different NMDAR subunits they were found to express 126,127.   
 
Figure 3.1. NMDA receptors in the synaptic transmission. Activation of the presynaptic neuron results in glutamate release from the intracellular vesicles into the synaptic cleft (gray circles). Glutamate may activate NMDA and other glutamate receptors on both postsynaptic neuron and astrocyte. Astrocytes respond to the glutamate activation by releasing other NMDA receptor agonist D-serine (red circles). D-serine facilitates activation of the postsynaptic NMDA receptors 125).     Thus, two types of brain cells, neurons and astrocytes, are expressing functional NMDA receptors. In the interstitial fluid of   the brain glutamate concentration is controlled by glial cells within the 0.5 – 2 µM range 128. However, in the synaptic cleft local glutamate concentration may reach 1 mM during synaptic transmission. That glutamate concentration is sufficient for the NMDA receptor activation in neurons and astrocytes.  What may activate NMDA receptors in non-neuronal tissues? Glutamate is an abundant amino acid in mammalian tissues. In the blood plasma glutamate concentration in humans, rats and horses varies from 10 to at least 200 µM (Bogdanova, Makhro unpublished data). NMDA receptor co-agonist glycine also present in the blood plasma of those species in concentration above 300 µM, which should be saturating for the Gly binding site (see Table 1 in Chapter 1).  39  
Initial membrane depolarization is a second condition required for NMDA receptor activation as Mg2+ block renders the receptor non-functional under resting potential conditions. In the brain cells this initial depolarization is mediated by activation of the other class of ionotropic glutamate receptors located in the postsynaptic membrane, AMPA receptors. Other cell types, such as heart and muscle cells regularly undergo membrane depolarization-repolarization cycles. Membranes of some cells, like erythrocytes, are already depolarized to potential close to the -10 mV. One cannot exclude the presence of AMPA or kainite receptors assisting in depolarization similar to that in synaptic membranes (as it appears to be in Hydra, see Chapter 2). And finally, presence of the NR3 type subunits reduces receptor sensitivity to the potential-dependent Mg2+ block (Chapter 1, Table 1.1). Thus, NMDA receptors from non-neuronal tissues do not require membrane depolarization event for their activation if they have NR3 subunit.  NMDA receptors appeared long time before the formation of neuronal system. Therefore, it is highly improbable that in the modern organism their expression is restricted to the brain. In recent years functional NMDA receptors were described in various non-neuronal tissues, for example, in bone 125, kidney cells 118, smooth muscle 129, megakaryocytes 130 and leucocytes 120 as well as in the myocardium 131 and red blood cells (our group). The summary of glutamate receptors expression in the mammalian peripheral tissues is presented in the Table 3.1.            40  
 
Table 3.1. Expression of glutamate handeling proteins (receptors and transporters) in peripheral tissues. A – AMPA, K – kainate, N – NMDA receptors, mGluR – metabotropic glutamate receptors, GluT – glutamate transporter, VGLUT – vesicular glutamate transporter 132.  
  In the present study we have characterized the expression, composition and function of the NMDA receptors in the electrically active tissue with a resting potential of ~-60 mV, the myocardium, and in non-excitable type of cells with a transmembrane potential of -10 mV, red blood cells. 
 
Heart 
NMDA receptor expression in heart Several groups have been reporting the presence of the GRIN (Glutamate 
Receptor Ionotropic NMDA) gene transcripts of certain subunits and the corresponding proteins (NR1, NR2B) in the myocardium of a rat, mouse, Californian sea lion and humans. However, the reported findings have been 41  
somewhat controversial.  Using immunoblotting Leung et al 131 reported expression of the NR1 subunit protein in all heart regions including aorta and pulmonary artery. This subunit was detected in whole heart homogenates obtained from 4 days old, 12 days old and adult rats. At the same time, these authors could not detect any of the NR2 subunits in rat myocardium. Seeber and colleagues 133 showed transient expression of NR2B subunit (but not of NR1 or any other subunits) in developing heart from embryonic day 18 (average time of pregnancy in rats is 21-22 days) to postnatal day 21 using immunoblotting and immunihostochemistry. Interestingly, the NR2B-specific staining was localized in the cytosol within the perinuclear space. Later on the same group isolated NR2B protein by immunopecipitation and identified it by mass spectrometry 134. Surprisingly, NR2B protein co-immunoprecipitaded with ryanodine receptor 2 but not with the other NMDA receptor subunits.  Using antibodies against different parts of NR2B peptide, they found that C-terminal (cytoplasmic) domain of cardiac NR2B subunit underwent tissue-specific post-translational modifications. Transcripts of the Grin2B were reported in rat heart homogenates by Hu et al 135.  Several groups detected NMDA receptors in heart tissue of other mammalian species. NR1 subunit was cloned from heart tissue of sea lions 136. Based on immunohistochemical imaging Gill and co-workers claimed that NR1 protein expression was associated with heart conductive system. Same group detected NR1 in the heart conductive system in primates, human and monkey (Macaca 
fascicularis) 137, 138. The group of Tyagi monitored the NR1 subunit expression in mouse heart using immunoblotting and immunohistochemistry 139, 140. Similar to Seeber and colleagues, Tyagi and co-workers could not confirm membrane localization of the NR1 subunit in isolated cardiomyocytes. Lack of any positive (e.g. brain extracts and sections) or negative controls in both staining an Western blotting leaves some doubts in the antibody specificity. This group has been intensively investigating the role of cardiac NMDA receptors in homocysteine cardiotoxicity. Based on these studies we may conclude that (i) no systematic investigation of the expression of all known NMDA receptor subunits NR1, NR2A-D, NR3A-B in the myocardium at the transcript and protein levels has been performed; (ii) for some reasons immunostaining of the cardiac NMDA receptor 42  
subunits is technically demanding and caution has to be taken, and positive and negative controls used when detecting the NR proteins, which may undergo cardiac-specific secondary modifications;  (iii) no attempts to detect NR3 subunits were done; (iv) mostly NR1 subunit was studied, so NR3/NR2 receptor types could be missed.   
NMDA receptor activity in cardiac cells For the functional studies two cellular models were used, neonatal rat cardiomyocytes (NRC) obtained from 1-4 days old rats and growing in culture from 1 to 5 days and freshly isolated adult ventricular cardiomyocytes from rat (ARC). Whole cells recordings were performed by Seeber et al in NRCs derived from Wistar rats after 4 days of culturing revealed the inability of NMDA (up to 1 mM) or Glu (up to 3 mM) in the presence of 50 µM Gly to induce electric currents 133. Frequencies of calcium oscillations were monitored by Winter and Backer as a readout of responses of NRCs from Sprague-Dawley rats cultured for 1-3 days old to NMDA or Glu (100 µM each), as well as to kainate and AMPA. Each of the agonists mediated an increase in Ca2+ oscillation frequencies which were attributed to the presence of “novel glutamate receptor composed of both non-NMDA and NMDA subunits on cultured rat myocardial cells”. Increase in oscillations’ frequency caused by the agonists could be antagonized by MK-801, glutamate site-specific competitive antagonist AP7 and the AMPA/kainate receptor antagonist DNQX. Basal intracellular calcium levels remained unchanged 141. In contrast to that Gao et al reported an increase in the cytoplasmic calcium in the 1-3 days old NRC culture caused by the treatment with NMDA (100 µM). Raise in cytoplasmic calcium level caused by NMDA administration was followed by reactive oxygen species production and apoptosis. MK-801 and antioxidants protected NRC from NMDA-induced calcium overload and the following induction of ROS 142. Based on our own observations this controversy most probably is related to the gradual remodeling of NRCs in culture and the associated progressive modification of gene and protein expression. Exposure to the unphysiologically high oxygen levels (20% in the culture incubator vs 2% in newborn heart and 6-7% in adult heart 143, 144), 2-D culturing, lack of cell-cell interactions with other cell types forming the heart 43  
tissue, absence of tissue-specific cytokines and mechanical stress result in gross molecular and morphological changes in the course of transformation of the NRCs towards the embryonic phenotype initiated already after 1 day of incubation.  Therefore, the outcome of the study may differ remarkably if no standardized protocol is used and the cellular responses are not compared for the cultures of identical age.    These instabilities of experimental model may be avoided by using freshly isolated adult cardiomyocytes. This model has been used twice for testing of the effects of NMDA receptor antagonist MK 801 on the action potential duration and cation currents. In both studies the availability of the NMDA receptor agonists (Glu and Gly) was not controlled. Prolongation of the action potential duration during early and late phase of repolarization and maximal upstroke velocity observed in response to MK 801 treatment was attributed to the non-specific binding of MK 801 to sodium channels in inactivated state and to potassium channels in resting state 145. Treatment of adult guinea pig cardiomyocytes with the pore-targeting NMDA receptor antagonist ketamine resulted in a ~20% reduction in transsarcolemmal calcium entry observed by single cell voltage clamp 146.  
NMDA receptors in isolated heart models In the other set of studies rat and guinea pig heart preparations were exposed to the NMDA receptor antagonists. When added to the organ bath solutions, MK 801 in rat and ketamine in guinea pig spontaneously beating right atria dose-dependently reduced contraction rate. Preparations of artificially paced left atria and papillary muscles showed dose-dependent decrease in contraction force in response to MK 801 or ketamine 145, 147. Thus, in myocardial tissue NMDA receptor antagonists were producing negative inotropic and chronotropic effects.  Similar results were obtained when NMDA receptor antagonists were present in solutions used for coronary perfusion of isolated hearts.  In guinea pig heart ketamine dose-dependently reduced spontaneous heart rate starting from 100 µM concentrations and decreased left ventricular pressure at concentrations as low as 50 µM. These effects could not be attributed to the alterations in coronary 44  
flow which was insensitive to ketamine even at the concentration of 1 mM 148.  In rabbit heart model spontaneous heart rate was decreased by ketamine. Ketamine also dose-dependently (50 – 200 µM) reduced longitudinal and transverse conduction velocity measured at ventricular surface without the changes in anisotropy 149.  These observations suggest that cardiac NMDA receptor most likely participates in the spontaneous depolarization of the pacemaker cells and in conduction of the depolarization in the ventricular tissue. However, both MK-801 and ketamine have more than one target to interact with (see table in supplement data for the paper 1). Thus, more detailed studies of cardiac NMDA receptor properties and function are required.   
Systemic administration of NMDA receptor antagonists 
5. ECG Several cardiac-related effects of NMDA receptor antagonists were observed during clinical trials in human subjects 150. Both glutamate binding site antagonist (CGS19755) and channel blocker (aptinagel) induced ST segment abnormalities in healthy human volunteers.  ST segment of the ECG recording represents depolarized state of the ventricles and ST elevation is often associated with myocardial infarction, pericarditis, Brugada syndrome and other disorders; however, changes in the ST segment amplitude could be related to several conditions and are not per se an indicative of any myocardia disorder. NR2B specific (polyamine binding site) antagonist eliprodil at high doses induced prolongation of QTc interval in similar toxicity studies on human subjects. Prolongation of the QTc interval occurs when the action potential of a significant proportion of ventricular cardiomyocytes is prolonged due to the suppression of one or more repolarizing currents, or an augmentation of inward currents or both (151: Chapter 18). Ketamine was historically used for anesthesia in human patients and is currently acquired in special cases for treatment of depression and post-surgical and neurological pain in combination with other drugs, but has severe side effects and its repetitive use causes addiction. It is a common anesthetic in veterinary medicine and in animal experimentation. Ketamine overdose in healthy young 45  
individual results in transient ST elevation (Brugada-like ECG pattern) 152. Similar effects were observed in mouse model of ketamine abuse, where ST elevation appeared in 30% of mice 153. Used as anesthetic agent, ketamine induced P wave prolongation (prolonged atrial depolarization) in addition to the QT prolongation in mice 154. Thus, glutamate antagonists targeting amino acid-, polyamine- and channel pore binding sites NMDA receptor affect ECG intervals, mostly ST segment amplitude and QT interval longitude.  
6. Rhythmicity Autonomous heart rhythm is generated by the pacemaker cells located in the sinus node.  However, in vivo sinus node is innervated and the heart rhythm is regulated by sympathetic and parasympathetic fibers which also possess NMDA receptors. Therefore, application of NMDA receptor antagonists triggers complex effects driven by neuronal system and by the sinus node itself.  In conscious subjects different NMDA receptor antagonists applied systemically either increased or did not affected the heart rate (Table 3.2).  
Table 3.2. Treatment of the consciousness humans and rats with NMDA receptor antagonists.  Compound Species Effect on HR Link Ketamine 0,5 mg/kg Human ↑ 155 Memantine 0.16 mg/kg Human Not changed 155 MK-801 0.025-0.25mg/kg Rat ↑* 156 Ifenprodil 5 mg/kg Rat Not changed 157 _* Authors concluded that HR increase could be related to the increased mobility of animals. Drugged rats were showing stereotypical behavior (running in circles), head shaking and nodding.  Heart rate measured in anesthetized unconscious rats threated with NMDA receptor antagonists was decreasing similarly to that in isolated not-paced heart models 158, 159. Bradykardic effects of the antagonists were also observed in anesthetized rabbits 159. Thus, in the absence of vagal control NMDA receptor antagonists mediate bradycardia.  
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NMDA receptor antagonists applied to different pro-arrhythmogenic models reduced the frequency of arrhythmic events including tachycardia and ventricular fibrillations. Animals treated with these compounds recovered their mean blood pressure and normal heart rate faster than untreated controls and had higher survival rate (Table 3).  
Table 3.3. Antiarrhythmic action of NMDA receptor antagonists in experimental animal models. Compound Species Model Arrhythmia Other effects Link Ketamine  100 mg/kg Diazepam  10 mg/kg Rat 
Ischemia (6 min) – reperfusion ↓ High survival rate 160 
MK-801  0,5 mg/kg Dog Cocaine 2 mg/kg, electrical stimulation ↓  161 MK-801  0,3 mg/kg Ketamine  10 mg/kg Memantine 1,5 mg/kg 
Rat Ischemia (5 min) – reperfusion ↓ High survival rate 162 
 Most of the NMDA receptor antagonists have sedative or narcotic effects in  animals changing their behavior and, secondary to that, the heart rate. However, this is not always the case as, in contrast to sedative drug lorazepam, MK-801 (0,16 mg/kg) increased heart rate variability in Rhesus monkeys 163. At the same time heart rate and arterial pressure were not affected. Interestingly, similar dose of MK-801 (~0,2 mg/kg) which was well-tolerated by monkeys appeared to be lethal for humans 164.    47  
7. Pressure Like heart rate, arterial pressure-related effects of NMDA receptor antagonists were dependent on experimental conditions. In unconscious rats and rabbits systemic administration of NMDA receptor antagonists significantly reduced mean arterial pressure along with the heart rate 165, 159. Ifenprodil in low concentrations didn’t affect blood pressure in resting rats and prevented exercise-induced increase in systolic and diastolic pressure 157. In awake humans ketamine (0,5 mg/kg) increased systolic (~115 to ~130 mmHg) and diastolic (~60 to ~70 mmHg) pressure 155. Similarly, MK-801 dose-dependently increased mean arterial pressure in conscious rats 156.  
Central effects of NMDA receptors in heart regulation NMDA receptors participate in central regulation of heart contractility. Microinjections of NMDA or Glu into nucleus tractus solitarius reduced heart rate and arterial pressure in rats. MK-801 and AP-5 blocked these effects, but could produce the opposite effect on the heart function when applied at higher doses 166, 167. Moreover, NMDA receptor subunits (NR1, NR2A, NR2B) were found in vagal preganglionic neurons projecting to the heart (dorsal vagal 
nucleus and nucleus ambiguus) 168. Intracerebroventricular injections of MK-801 had no effect on the heart rate or arterial pressure, but modified chronotropic responses to other drugs 169. Thus, effects observed after systemic administration of NMDA receptor antagonists to conscious subjects (tachycardia, increase of the arterial pressure) may be at least in part attributed to the central regulation.   
Mechanosensitivity An important property of NMDA receptor is sensitivity to mechanical pressure 170. That feature was reported almost 20 years ago. However, since the mechanical deformation is highly atypical for glutamatergic neurons, possible physiological role of mechanosensing by the NMDA receptors was not investigated in detail. Patch-clump recordings showed that administration of pressure of 60 mbar (45 mmHg) resulted in facilitation of the stimulatory effect of 10 µM NMDA and 10 µM Gly on neuronal NMDA receptors by 2.5-fold, and 48  
application of 85 mbar (63.75 mmHg) amplified the receptor activity by 5.6-fold. In humans left ventricular pressure varies from 3-12 mmHg in diastole to 100-140 mmHg in systole. Mechano-stimulation within this pressure range is sufficient to alter the activity of NMDA receptors contributing to the mechano-electrical feedback mediated by the mechano-sensitive cation channels described in cardiomyocytes and fibroblasts in the heart 171. Over the past decades tight relationships was demonstrated between the mechano-sensitivity and cardiac disorders (arrhythmias, hypertrophy and ischemic heart disease) 172. It is therefore tempting to speculate that cardiac NMDA receptors could also be involved in pathophysiology related to pressure overload.  A variety of mechanosensitive channels appear to acquire this property early in evolution 173. Evolutionary mechano-sensitivity was used for osmotic regulation in single cells, gravitropism in plants, and probably in primitive sessile animals. At present mechano-electrical coupling is a key mechanism regulating cardiac output known as Frank-Starling law. Considering that, there is no wonder that NMDA receptors have retained mechanosensitive properties, which are not required within the brain. However, in non-neuronal tissues, such as the bone mechanosentitivity of these receptors turns to be very essential. In here NMDA receptors are involved in calcium reabsorption in osteoclasts and their activity and expression of the receptor subunits is reported to be tightly linked to the mechanical load in the limbs 174.   
Blood Several lineages of cells derived from hematopoietic stem cells were known to express functional NMDA receptors (Fig 3.2). The subunit composition of those receptors was not fully characterized so far, however, at least NR1 subunit protein or transcript was detected. Prior to our study, NMDA receptors were found in lymphocytes, macrophages, neutrophils and megakaryocytes (see below).   
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Figure 2. Hematopoietic lineages in humans (modified scheme from WikiMedia). NMDA receptors were detected in both lymphoid and myeloid lineages, mostly in the cells on the terminal stages of erythropoiesis: in lymphocytes 175, 176, neutrophils 177, macrophages 178 and megakaryocytes 179. Osteoclasts  are also derived from the multipotential hematopoietic stem cells 180. NMDA receptors 50  
were detected in osteoclasts’ precursors and influenced their development 181. In mature osteoclasts NMDA receptors regulate bone resorption processes 182.   
NMDA receptors in lymphoid lineage and in lymphocytes  Lymphocytes use NMDA receptor as a tool for the feed-back regulation of the inflammation. Lymphocyte activation induces expression of NMDA receptors. In turn, NMDA receptor-expressing lymphocytes decrease production of the interferon gamma. Thus, NMDA receptors participates in suppression of inflammatory response 175. NMDA receptors are also involved in autoimmune response by regulating the production of induced regulatory T-cells. In mice treatment with memantine (but not with antagonists of other glutamate receptors) promoted formation of regulatory T-lymphocytes and delayed the development of arthritis 183. NMDA antagonists (MK-801 and ketamine) could also suppress T-helper lymphocytes differentiation and cytokines production 184. For T-lymphocytes expression of NR1, NR2A, NR2B and NR2D but not NR2C and NR3 was shown 185, 186. NR1 and NR2B expression was also observed in immortalized Jurkat T cells (derived from human T cells). The receptors controlled cell growth and adhesion to fibronectin 187.    
NMDA receptors in myeloid  lineage  
8. Megakaryocytes and platelets Myeloid progenitor cells are the early precursors within the myeloid cell lineage. This lineage gives rise to thrombocytes, granulocytes, macrophages and RBCs. (Fig 2). Megakaryocytes are large nucleated cells responsible for the production of thrombocytes (platelets). The presence of NR1 and N2D subunit transcripts in rat bone marrow, human megakaryocytes, and MEG-01 clonal megakaryoblastic cells was shown using PCR analysis and northern blotting 179. Immunoblots revealed that molecular mass of the NR1 subunit in megakaryocytes is lower than that of brain-derived subunit (~100 kDa vs ~116 kDa respectively) which probably reflects the de-glycosylation. NMDA receptor activity was essential for differentiation of megakaryoblastic cells 179.  Furthermore, NMDA receptor 
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function was detected in platelets and its activation resulted in suppression of coagulation 188.  Enucleated platelets apparently inherited NMDA receptors from their precursors megakaryocytes. However, properties of platelet derived-NMDA receptors differ from neuronal NMDA receptors 189. Although Kd for [3H]glutamate and [3H]glycine binding was similar to neuronal NMDA receptors, presence of agonists was not required for [3H]MK-801 binding to platelet membranes. NMDA or glutamate alone were not affecting platelet aggregation. However, presence of agonists influenced Ca2+-mediated effects of arachidonic acid and cAMP-dependent pathway 189. That study raises the question: How glutamate may affect NMDA receptor-dependent Ca2+ influx if it doesn’t increase channel opening probability according to [3H]MK-801 binding studies? The possible answer is that functional experiments were conducted in the platelet rich blood plasma where some other NMDA receptor agonists may be present keeping the receptor in active state. Further studies of the same group in the platelet-enriched human blood plasma revealed that NMDA is a potent inhibitor of platelet aggregation and thromboxane B2 synthesis 188. The physiological function of NMDA receptor in platelets remains unclear. It is known that platelets express vesicular glutamate transporters and release glutamate  during the aggregation 190. That is quite confusing, because glutamate inhibits platelet aggregation. Another possibility is that glutamate release by platelets is affecting other cells participating in clot formation. For example injury requires both clot formation and activation of macrophages and neutrophils to confront invading microbes.   
(ii) NMDA receptors in granulocytes and macrophages Neuronal NMDA receptors are known to mediate ROS-depended signaling 191. Upon discovery of these receptors in macrophages 178 similar function of the NMDARs was suggested in these cells 192. Indeed, in rat macrophages Ca2+ influx triggered by NMDA receptor agonists was associated with induction of free radical generation and upregulated cyclooxygenase 2 (COX-2) expression.  These effects were abolished by pre-treatment with the NMDA receptor antagonist MK-801 and silencing of GRIN1 expression using mRNA interferences 192. In neuronal 52  
cells free radical and H2O2 generating systems responding to an increase in Ca2+ include NADPH oxidases (NOXes) 193, dual oxidases (DUOXes), uncoupled endothelial and neuronal NO synthases (eNOS and iNOS) and mitochondrial components 194. Leucocytes and neutrophils generate substantial amount of reactive oxygen and nitrogen species by controlled activation of  NOXes, iNOS, cytochrome 450 and 53 otentia oxidoreductase whereas mitochondrial production of free radicals is low 195. In each cell type calcium uptake by the NMDA receptors therefore  triggers superoxide anion production  (with the following increase in ONOO-, H2O2 and HO•-) 177 which is presumably mediated by NOXes. NOX activity is also required for megacariocyte differentiation 196. Calcium binding domain in the NOX protein appeared very early in evolution and already present in unicellular organisms like amoeba 197. Thus, NMDA receptor was probably used for the regulation of ROS production for feeding and protection of primitive unicellular organisms before neuronal system was developed 198.  The studies of NMDA receptors in the non-neuronal tissues including blood are in their initial phase and the reported findings are incomplete and raise more questions than answers. In the synapse NMDA receptors are sensing membrane depolarization and glutamate release. In the blood plasma two main NMDA receptor agonists glutamate and glycine are constantly present. Glutamate release machinery was recently shown to be present in bone marrow cells (Table 3.1). What are the mechanisms in control of NMDA receptor activity in blood cells?  These cells do not undergo depolarization-repolarization cycles and remain more or less permanently “depolarized” and thus most likely unable to preserve Mg2+ block. Permanent cycling between the basal activation and deactivation states may be expected. Blood cells experience significant changes in redox state which was shown to influence NMDA receptor activity in neurons 199, 200. Apart of possessing regulatory thiols these receptors in Hydra are sensing glutathione release into the extracellular space. What are the ligands for the NMDA receptors in blood cells? It could be Gly and Glu fluctuations, pro-inflammatory cytokines, GSH or some other unknown ligands.   53  
(iii) NMDA receptors in red blood cells: pharmacological and 
pathophysiological implications NMDA receptors studied in neurons and in artificial expression systems are known to function as sensors. They sense the presence of various agonists (amino acids, polyamines, Zn2+ ions), membrane potential, pH, redox state and mechanical stress. In response to various stimuli NMDA receptor provides Ca2+ entrance into the pre-membrane intracellular space resulting in activation of signaling cascades. In neurons, leucocytes and macrophages Ca2+ signaling is also involved in generation of reactive oxygen species. In erythrocytes intracellular free cytoplasmic calcium concentration is usually maintained between 20 – 60 nM being  50 000 times lower than that in blood plasma 201. This tremendous gradient is used to regulate the most important biochemical processes in human red blood cell including glycolysis and pentose phosphate pathway, protein cleavage, cell volume and pH. Many of red blood cell disorders, including the most widespread RBC disease like sickle cell anemia, are associated with abnormal cytoplasmic levels of Ca2+. The presence of NMDA receptors in RBCs has never been looked before and its role in Ca2+ homeostasis never studied.   
a) Calcium transport pathways in erythroid precursor cells and 
in circulating red blood cells Ca2+-dependent signaling plays an important role in erythroid precursor cells (EPC) maturation and differentiation 202, 203. In the absence of extracellular Ca2+ erythropoiesis is inhibited 204. In EPC Ca2+ influx is mediated by TRPC channels and regulated by Epo 205. However, in mature RBC more channels were identified suggesting that other transport pathways for Ca2+ are present in precursor cells as well (see below). At the latest stages of maturation these cells are getting rid of multiple receptors, most of the glycolytic machinery, ion transporters, and organelles including mitochondria. By the end of maturation cell size is dramatically reduced and energy is provided exclusively by anaerobic processes 206. Reduction in metabolic activity occurs along with a decrease in passive and active ion transport rates including those for Ca2+ ions. The remaining ion channels in membranes of circulating RBCs are dormant most of the time under normal physiological conditions 207. Due to the low abundance of 54  
ion channels permeable for Ca2+ very limited number of studies were focused on the molecular identification of these channels in mature RBCs. However, growing awareness of special importance of calcium overload in progression of various forms of hereditary anemia resulted in substantial progress in characterization of the Ca2+ uptake pathways in the recent past.  In human RBC those include:  1) P-type Ca2+ channel (Cav2.1) 208, 209 (slow, kinase-mediated process in response to platelet-generated lysophosphatidic acid). Similarly to NMDA receptors, this channel can be activated by mechanical stress (osmotic shock) 210. There is a possibility that mechano-sensitivity and some other properties of this channel actually belong to the NMDA receptor. 2) Transient receptor potential cation channel (TRPC) 6 expression at the mRNA level was observed in human erythroid precursor cells and TRPC6 protein was detected by antibodies in mature erythrocytes 211. Cation channels from this family are Ca2+-permeable and have polymodal activation properties, e.g. they can be activated by various ligands (endogenous lipids, purine nucleotides, inorganic ions) and by mechanical stress 212. However, for the TRPC6 no physiological extracellular ligands were discovered so far and their mechanosensitivity is also questionable 213. There is a possibility that TRPC6 proteins in circulating erythrocytes are remains from the early stages of erythropoiesis when they were participating in Epo-related signaling 214 and have no function in mature red blood cells.   3) The ligand-activated voltage-dependent non-selective cation channel 
(VDNSCC) in mature erythrocytes was well described electrophysiologically. However, the protein identity of this channel remains unknown. Some properties of VDNSCC including hysteresis 215 also can be attributed to Cav2.1 channels. Some of the VDNSCC properties listed below are similar to the NMDA receptors studied in neuronal cells or in artificial expression systems. Nevertheless, all known channel properties neither fit to the description of NMDA receptor nor to Cav2.1 channel. It is possible that the researchers recorded both channels simultaneously.  
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Table 3.4. Comparison between NMDA receptors and ligand-activated voltage-dependent non-selective cation channel from RBC. Similarities between NMDA receptor and VDNSCC  
Voltage-dependence 
Both channels are blocked at negative membrane potentials. NMDAR channel is blocked by divalent cations (Mg2+ or others depending on subunit composition), however, even in absence of Me2+ voltage-depended block is present 216. For VDNSCC mechanism is unknown, for divalent cations very short (about 10 ms) channel opening events at negative membrane potentials between −80 and −100 mV were observed 217.  
Hysteresis Open state probability depends on the history of changes of membrane potential for both channels 217, 216. 
Ion permeability Both channels are permeable for  Na
+, K+, Rb+, Cs+, NH4+, Ba2+; VDNSCC is permeable for  Ca2+ and Mg2+, NMDA receptor permeability for this cations depends from the subunit composition (see Chapter 1).  Ligand-depended activation VDNSCC can be further activated by nicotine and carbachol, however, channel properties are highly different from nAch receptors 218.  La3+   Inhibition 219 Differences between NMDA receptor and VDNSCC  Channel conductance 49 pS for NMDA receptors 220, 21 pS for VDNSCC 221 
Opening probability VDNSCC opening probability is shifted to the positive membrane potential 217 (above +20 mV), therefore, that channel is closed at the basal potentials of -10 mV reported in RBC under physiological conditions.  
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4) Piezo1 (mechano-sensitive channel) is involved in volume regulation in zebra fish erythrocytes 222. Mutations in Piezo1 are associated with pathology of dehydrated hereditary stomatocytosis 223, 224 although their function was never studied in human erythrocytes.  5) Voltage-dependent anion channels in the super-channel mode (S. Egée, ERCS meeting 2013, personal communication). 6) P sickle (sickling-induced permeability pathway in RBCs of sickle cell disease (SCD) patients) is a current present only in erythrocytes of patients suffering from sickle cell disorder. This current is further activated by deoxygenation and sickling process. Sickling process is increasing the Ca2+ permeability of the erythrocyte membrane six times over the normal physiological range (225: p 392). The molecular identity of P sickle channel (or channels) remains obscure and most likely is a superposition of several conductance pathways. Possible NMDA receptor contribution into the P sickle pathway is summarized below:  
Table 3.5. Similarities between NMDA receptor and P sickle. Ion permeability Both are permeable for: Li+, Na+, K+, Rb+, Cs+, Ca2+, tetraethylammonium 226, 227 Gd3+ Inhibits P sickle (IC50 2 µM) 228, partially inhibits NMDA-induced Zn2+ currents (10 µM) 229 
Zn2+ At 100 µM concentration Zn2+ inhibits P sickle current 228, same concentration induces fast channel block of NMDA receptor channel 52. Voltage-dependence P sickle (K+) is increased upon membrane depolarization 230 
pH sensitivity 
Activation of the deoxygenation-induced pathway was promoted by alkaline pH (7.5). Optimum for cation movements was observed around pH 6.9. However, the highest degree of sickling was achieved at alkaline pH independently from flux intensity 230. NMDA receptor pH dependence is related to the subunit composition (see Chapter 1), in general acidic pH (below 7,0) inhibit 
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the receptor, while at alkaline pH (more than 7.5) most of the receptors are active. pH changes upon the deoxygenation could be the direct mechanism of P sickle activation. Measured by nuclear magnetic resonance pH in intact healthy erythrocytes was changed from 7.15 in completely oxygenated cells (pO2 = 121 mmHg) to 7.29 in deoxygenated cells (pO2 = 1 mmHg) 231.  7) Carrier-mediated passive Ca2+ influx 232. 8) Ca2+-pump leak 232 (highly questionable under physiological conditions).  Besides sickle cell disease elevated Ca2+ (and ouabain-independent Na+) uptake was observed in erythrocytes of patients with thalassemia, PFK deficiency 233, congenital spherocytosis 234 and several other forms of hereditary anemia. In RBCs of patients with β-thalassemia increased Ca2+ uptake rates were suggested to be caused by the higher abundance Ca2+ transporters per cell 235.    There are three possible mechanisms underlying the high cation permeability of RBCs of patients with certain forms of hemoglobinopathy (SCD, thalassemia). (I) Abnormal forms of hemoglobin have altered proton dissociation constants and, since human hemoglobin is a main intracellular buffer in RBC 236, cellular pH is also altered. . This hypothesis is supported by studies of sickle cell hemoglobin solubility and pH, where was calculated that sickle cell erythrocytes in oxygenated state have intracellular pH 7.4, while healthy erythrocytes have pH 7.15 (increasing during deoxygenation) 237. This involuntary intracellular “alkalinisation” inevitably affects  structure and function of multiple proteins, including metabolic enzymes, signaling proteins, ion transporters, cytoskeletal elements and others resulting in uncoupling of multiple processes and reduction in cellular stability and life span. (II) Structural abnormalities in erythrocyte cytoskeleton due to the facilitated binding of mutated hemoglobin molecules to cytoskeletal proteins. Extensive adherence of HbS to the band 3 protein and the cytoskeleton demonstrated earlier 238, 239 reduces deformability of erythrocytes facilitating their premature clearance and hemolysis. (III) Third explanation is 58  
related to potential disruption of the maturation processes of erythroid precursor cells by mutated hemoglobin and abnormal clearance of ion transporters and other transmembrane proteins including receptors.   
b) Physiological and pathophysiological role of Ca2+ in red blood 
cells In erythrocytes Ca2+ regulates several groups of enzymes which are important for cell function and survival including metabolic pathways, regulation of cell volume and deformability (Figure 3.3). Glycolysis assessed as lactate production was reported to be dose-dependently stimulated by Ca2+ in cells in which intracellular Ca2+ was clamped using Ca2+-ionophore A23187 240. In particular, Ca2+ stimulated oligomerization and activation of the rate-limiting glycolytic enzyme phosphofructokinase (PFK) 241.  Ca2+- dependent activation of tyrosine-kinases lead to the increase Band 3 protein phosphorylation.  Phosphorylated Band 3 release membrane-bound (inactive) PFK into the cytoplasm. Thus, Ca2+-dependent phosphorylation increases cytoplasmic pool of oligomerized PFK molecules and intensifies glycolysis 242, 243. Glycolysis provides fuel for Ca2+- and Na+/K+-pumps, therefore, in pathologies such hereditary phosphofructokinase deficiency Ca2+ is accumulating inside erythrocytes presumably due to the ATP depletion, although facilitated Ca2+ leak in PFK erythrocytes was also observed 233). Increase in the activity of Ca2+-sensitive K+-channels (Gardos channels) results in excessive K+ loss and RBC dehydration 233. In healthy erythrocytes Gardos channels are believed to be inactive most of the time, since Ca2+ concentration needed for their activation is far above physiological levels 207, 244. However, stretch-activated Ca2+ influx, induced by the mechano-sensitive Ca2+ channels may provide transient increase of  Ca2+ concentration in pre-membrane space,  and  trigger Gardos channel activation in healthy red blood cells 245.   While glycolysis is stimulated by Ca2+ uptake, glucose transport can be dose-dependently inhibited by ionophore-mediated Ca2+ 246. Ca2+/calmodulin-depended activation of deaminase leads to decrease of cellular AMP content 247, 248. AMP is a positive modulator of GLUT1 transporter in erythrocytes 249. Therefore, Ca2+ accumulation decreases basal level of GLUT1 59  
activity. However, the apparent half maximal concentration of Ca2+-depended inhibition of glucose transport is 250 µM, which is way out of physiologically relevant Ca2+ concentration range (20-60 nM of free Ca2+ and up to 10 µM of protein-bound Ca2+ in unstimulated intact RBC). Though local Ca2+ concentrations in pre-membrane space close to the Ca2+ influx pathways and GLUT1 could be much higher, physiological relevance of Ca2+-depended glucose uptake inhibition needs to be confirmed.   Besides affecting cellular volume and metabolism, stimulation of Ca2+ uptake provokes echinocitic transformation in human RBCs 250. Those shape changes are independent of the presence of monovalent cations, transemembrane osmotic gradient and ghost volume. Ca2+-inducible formation of spiculi was prevented only by the removal of water-soluble membrane-bound proteins by repetitive washing procedures. Band 4.1R protein was reported to be the main Ca2+/calmodulin target within the cytoskeleton. Calcium-calmodulin complexes bind to the band 4.1R protein causing the changes in its conformation and decrease in affinity to the interacting partners within the cytoskeletal network such as p55, glycophorin C, spectrin and actin 251. These changes require Ca2+ levels as high as 0.1 µM (within calmodulin affinity to Ca2+). Therefore Ca2+-induced acute cytoskeletal modifications are physiologically relevant and may occur in pre-membrane space of circulating erythrocytes in which Ca2+ uptake is stimulated.   
Activation of PKCα by Ca2+ induces translocation of the kinase to the erythrocyte membrane 252. Phosphorylation of the protein kinase C (PKC) targets (band 4.1 and band 4.9 proteins) translates into an increase in erythrocyte deformability 253, 254. However, half-maximal activation of PKCα occurs in the presence of ~35 µM of free Ca2+ 255. Thus, that type of Ca2+-mediated response is unlikely to be directly implemented in healthy human RBCs. One possible scenario for induction of Ca2+-depended PKC activation in erythrocytes may involve phospholipase C (PLC). EC50 for 1.2-diacylglycerol production was reported to occur in the presence of 0.1 µM of Ca2+ in hemoglobin-free ghosts 256. Maximal activity of the enzyme is reached in the presence of 1 µM of free Ca2+ions. Activation of PLC translates into the stimulation of PKC and the changes 
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in RBC rheology within the physiological range of intracellular Ca2+ concentrations through the following scheme: Ca2+ entrance → active PLC → DAG → active PKC → 4.1-P and 4.9-P → RBC 
deformability↑ Artificially activated by phorbol 12-myristate 13-acetate, PKC in erythrocytes phosphorylates and stimulates Ca2+-pump  and decreases intracellular Ca2+ content 257. Similarly, activation of PKC down-regulates activity of Ca2+-depended K+-channels (Gardos channels) 258. Both these processes (mediated by PLC) may function as a feedback mechanism triggered in response to Ca2+ uptake.  Activity of the erythrocytic Ca2+-pump can be also modulated by direct interactions with Ca2+/calmodulin. Maximal activity (10-fold increase) of the Ca2+ pump (Vmax) may be reached in the presence of 10 µM of free Ca2+, while 1 µM Ca2+ triggered about 4-fold increase 259. Alternatively, up-regulation of the Ca2+-pump activity by excessive Ca2+ concentrations can be achieved by the regulatory cleavage of the cytosolic domain of the pump by calpain I. In cleaved enzyme (124 kDa instead of intact 136 kDa protein) both the initial rates of calcium ion uptake and ATP hydrolysis were increased to near maximal levels 260. Calpain activation is calcium-induced and occurs as free Ca2+ levels reach ~ 0. 5 µM 261. Thus, transient increase in Ca2+ uptake in RBCs is associated with adaptive stimulation of Ca2+ pump due to the 61otential61i cleavage of the Ca2+-pump by calpain 262. However, prolonged calpain activation by Ca2+ result in degradation of Ca pump protein (along with Band 3 protein cleavage) 262.  In RBCs loaded with Ca2+ the limiting factor of the Ca2+-pump transport rate is ATP availability. The pump is fuelled preferentially by a pre-membrane ATP pool 248, 251, 263. Under conditions of permanent Ca2+-leak, activation of the Ca2+-pump results in rapid ATP depletion. Since ATP is used to produce glucose-6-phosphate, a substrate for pentose phosphate shunt, ATP depletion results in decreased NADPH production. Therefore, Ca2+ overload suppresses glutathione regeneration in erythrocytes due to the reduction of intracellular ATP concentration 264. Glutathione is an important intracellular antioxidant that protects the cell against free radical damage. Erythrocytes depleted in reduced glutathione are subjected to oxidative damage. However, similarly to regulation of intracellular Ca2+ content, at some point, transient Ca2+ influx may help to 61  
prevent oxidative damage due to the activation of eNOS 265 (only then NOS substrates NADPH and arginine are also present). This enzyme is present in erythrocytes 266 and produces NO, which is a scavenger of superoxide anions. Endothelial NO synthase is activated by Ca2+-calmodulin and hence may sense even subtle changes in the intracellular Ca2+ levels 267. Oxidative state of erythrocytes is an important hallmark for senescence. Band 3 protein clusters forming as a result of oxidative damage serve as binding sites for naturally occurring anti-band 3 antibodies. So marked RBCs are recognized by the macrophages and targeted for clearance from the blood flow 268, 269.   
Figure 3.3. Several Ca2+-mediated mechanisms in human RBC featured above. Green rectangles designate Ca2+-ATPase activation induced by Ca2+ entrance directly and through the calpain, PKC and PFK-dependent pathways. Red rectangle shows Ca2+-ATPase deactivation as a result of excessive calpain activation caused by prolonged Ca2+ stimulation. Ca2+ entrance directly activates Gardos channels resulting in cellular dehydration. Simultaneously Ca2+ deactivate Gargos channel via PKC-dependent pathway and facilitates ion gradient recovery via stimulation of glycolysis (ATP as a fuel for Ca2+- and 62  
Na+/K+-ATPases is produced) as a feedback mechanism. In healthy erythrocytes Ca2+ entrance activates reversible volume changes, NO production, increases cell deformability and activates Ca2+-ATPase (transiently or permanently). Excessive Ca2+ leak/accumulation in pathological conditions (Table 3.6) result in Ca-pump degradation, decrease of deformability (as a result of dehydration and echinocytosis), oxidative stress, facilitated aging and RBC clearance from the circulation.   
Table 3.6. Pathological conditions associated with chronic elevation of intraerythrocytic Ca2+. [Ca2+] i Target Known related pathologies Possible related pathologies 
> 150 nM 244 Gardos channel (activation) 
Sickle cell anaemia;  Familial phosphofructokinase deficiency 233; Hb O(ARAB) mutation 270 
Drug-induced acute hemolytic anemia 271; Murine spherocytosis (4.1R-/-), compensatory 272; Murine spherocytosis, mild, 4.2(-/-) 273; Dehydrated hereditary stomatocytosis 274 
> 500 nM 275 Calmodulin 
Sickle cell anaemia, adenosine monophosphate deaminase hyperactivation leading to PS exposure and faster cellular clearance 276; Familial phosphofructokinase deficiency, similar mechanism 248; Sickle cell anaemia, lack of binding to PMCA 277 
Spectrin filaments formation abnormalities 278; Hereditary elliptocytosis (4.1R inefficiency) 279; 4.1 deficiency-related Na+/H+ exchanger hyperactivation  280 
> 200 nM 277 PKCα Sickle cell anaemia, ROS generation via NADPH Cell volume abnormalities (KCl contrasporter inhibitory 63  
activation 281; phosphorylation of adductin, cytoskeletal abnormalities in SCD 282 
phosphorylation) 283; Deformability abnormalities 253; Altered volume and cytoskeletal abnormalities due to elevated Band 3 phosphorylation 284; Band 3 related alterations in activities of metabolic enzymes 285 
> 200 nM 286 µ-Calpain 
β-thalassaemia, α-spectrin digestion 287; Acute hemolytic crisis in favism, spectrin, band 3 and band 4,1 digestion 288 
Sperocytosis related to cleaved spectrin, band 3 and band 4.1 proteins. 
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 5. Experimental part Standing hypothesis and rationale  The idea of the present work came from the epidemiological data indicating possible relationships between plasma concentration of homocysteine and the probability of cardiovascular disorders 289. Homocysteine and its metabolite homocysteic acid are known to be NMDA receptor agonists 290. Thus, cardiovascular effects of homocysteine at least in part could be attributed to cardiac NMDA receptor activation. Retrospective analysis of studies focusing on the cardiac effects of anesthetics showed that some of the effects caused by NMDA receptor antagonists originate directly from myocardium (see Chapter 3). Moreover, cardiomyocytes similarly to neurons were shown to undergo regular depolarization-repolarization cycles suggesting that voltage-dependent activation of NMDA receptors may occur in these cells. Based on this information we proposed that NMDA receptors could be present and function in mammalian myocardium.  Pilot studies were performed on the isolated blood-perfused rat heart model. We applied several types of NMDA receptor agonists and antagonists adding them to the blood used for coronary perfusion. Blood perfusion through the myocardium was provided by peristaltic pump. As in human heart-lung machine settings, contact of RBCs with the elements of our perfusion system (synthetic materials, peristaltic pump) resulted in RBC damage and visible hemolysis detected in the blood plasma after the experiment. We noticed that in our experimental settings NMDA receptor agonists triggered hemolysis and NMDA receptor antagonists had an opposite effect protecting erythrocytes (see Fig 1). These observations suggested that active NMDA receptors could be present in erythrocytes.  Application of NMDA receptor agonists produced tachy-arrhythmic response whereas antagonists produced bradycardia and regular heart rhythm. In sinus arrhythmia NMDA receptor antagonists normalized heart rhythmicity.    
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Figure 1. Separated blood plasma on top of sedimented erythrocytes colored by released hemoglobin. NMDA receptor agonists (here homocysteic acid, HCA) intensified hemolysis caused by mechanical damage in peristaltic pump. Pre-treatment with NMDA receptor antagonists (here MK 801) reduced hemolysis.   Based on this pilot study and the following facts discussed in detail in the previous chapters the standing hypothesis was formulated as a basis for the PhD thesis work:  
• NMDA receptors are not intrinsic feature of the brain  
This follows from the fact that NMDA-like receptors evolved before the 
appearance of nervous system and is supported by the current studies in 
which NMDA receptor presence was reported in multiple tissue types. Due to 
the impressive plasticity and numerous "building blocks" properties of these 
receptors and their physiological role may display marked tissue-specific 
variation depending on the tasks they fulfill.    
• These receptors are most likely present in the erythroid lineage and 
mature red cells  
Although no attempts were undertaken to search for the NMDA receptors in 
red blood cells and erythroid precursor cells, several hematopoietic stem 
cell lineages were shown to express functional NMDA receptors. 
Furthermore, homocysteine was showing distinct cytotoxicity when applied 
to red blood cells.   
• NMDA receptors are most likely expressed in the myocardium and 
are involved in control of heart function 
66  
Multiple evidences including those of our pilot study reveal cardiotoxicity of 
the NMDA receptor agonists. NMDA receptor antagonists used as 
anesthetics in the clinic were reported to have cardiac-specific side effects.   Based on these assumptions the following goals of the study were formulated:  Goals Our first goal was to prove the existence of NMDA receptor in myocardial tissue and erythrocytes. We intended to characterize subunit composition of NMDA receptors in cardiac and erythroid precursor cells and to characterize their pharmacological properties. The second goal was to investigate the physiological role of erythroid and cardiac NMDA receptors. We planned to explore the effects of NMDA receptor agonists and antagonists on autonomic heart rhythm regulation, depolarization and repolarization of the myocardial tissue.  The impact of NMDA receptors into the maintenance of intracellular Ca2+ concentration had to be investigated in normal (blood donors: healthy humans and rats) and pathophysiological (blood donors: sickle cell disease patients) conditions. Our goal was to reveal the role of NMDA receptor-mediated Ca2+ influx for red blood cell function in health and disease.    Experimental models 1. Isolated autonomously beating rat heart perfused with autologous blood or saline. 2. Rat erythrocytes and bone marrow cells. 3. Human erythrocytes and erythroid precursor cells obtained from the blood of healthy donors. 4. Human erythrocytes and erythroid precursor cells obtained from the blood of sickle cell disease patients.        
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Section 1: per-reviewed original articles                      
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Paper 1  
Functional NMDA receptors in rat erythrocytes  Asya Makhro, Jue Wang, Johannes Vogel, Alexander A. Boldyrev, Max Gassmann, Lars Kaestner and Anna Bogdanova. 
 
 
Am J Physiol Cell Physiol 298:1315-1325, 2010. First published Mar 24, 2010  Contribution: Makhro A. participated in study design and discussion. In the result section quantification of the number of [3H]MK-801 binding sites per cell and results showed on Figures 1, 2, 6, 7 were performed by Makhro A.           
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N-methyl-D-aspartate (NMDA) receptors are ligand-gated nonselec-
tive cation channels mediating fast neuronal transmission and long-
term potentiation in the central nervous system. These channels have
a 10-fold higher permeability for Ca2 compared with Na or K and
binding of the agonists (glutamate, homocysteine, homocysteic acid,
NMDA) triggers Ca2 uptake. The present study demonstrates the
presence of NMDA receptors in rat erythrocytes. The receptors are
most abundant in both erythroid precursor cells and immature red
blood cells, reticulocytes. Treatment of erythrocytes with NMDA
receptor agonists leads to a rapid increase in intracellular Ca2
resulting in a transient shrinkage via Gardos channel activation.
Additionally, the exposure of erythrocytes to NMDA receptor ago-
nists causes activation of the nitric oxide (NO) synthase facilitating
either NO production in L-arginine-containing medium or superoxide
anion (O2·) generation in the absence of L-arginine. Conversely,
treatment with an NMDA receptor antagonist MK-80, or the removal
of Ca2 from the incubation medium causes suppression of Ca2
accumulation and prevents attendant changes in cell volume and
NO/O2· production. These results suggest that the NMDA receptor
activity in circulating erythrocytes is regulated by the plasma concen-
trations of homocysteine and homocysteic acid. Moreover, receptor
hyperactivation may contribute to an increased incidence of throm-
bosis during hyperhomocysteinemia.
red blood cells; homocysteic acid; calcium
NMDA RECEPTORS (NRs) are ligand-gated nonselective cation
channels that mediate fast neuronal transmission and long-term
potentiation in the central nervous system (CNS) (4). Gluta-
mate is a primary regulator of activity of the NRs in the brain.
This specific class of glutamate receptors plays an essential
role in regard to memory, cognition, sensation, and motor
control. Itako contributes to the glutamate excitotoxicity that is
involved with numerous neurological disorders including
stroke, schizophrenia, Alzheimer’s disease, and Parkinson’s
disease (39). Recently, NR expression has been reported to
exist also outside the CNS in a number of peripheral tissues
such as the lungs, heart, kidney, liver, spleen, bone, vascular
endothelium, and lymphoid cells (7, 11, 18, 19, 29, 32). The
physiological role of NRs in nonneuronal tissues remains
largely unclear.
The nature of NR agonist(s) in control of receptor function
in nonneuronal tissues is a matter of debate. Glutamate con-
centration in the synaptic cleft of the brain reaches millimole
levels, whereas the circulating plasma concentrations of gluta-
mate in healthy human subjects ranges from 14 to 70 M (13,
47). These concentrations are below the 100 M threshold
recognized as the IC50 for the receptor activation in neurons
(26). Glutamate, thus, is most likely not a major contributor to
the regulation of the NRs in blood cells in healthy humans. In
addition to glutamate, homocysteine (HC), and homocysteic
acid (HCA) have also been shown to function as NR agonists
in mammals. Total plasma HC concentration in healthy sub-
jects is 7–10 M, which can increase to 22.3  12.6 M in
response to normal aging (42). Pathological increases of HC
have also been observed as a result of either a hereditary
predisposition affecting methionine metabolism or conditions
of folate or vitamin B12 deficiency (16). For instance, in
hyperhomocysteinemic patients HC has been observed to reach
as high as 476 M (43). Both HC and HCA possess a high
affinity to bind to NRs such that even a modest increase in
plasma concentrations may result in activation of the receptors
(6).
As previously mentioned, NRs are nonselective ligand-gated
cation channels; however, the selectivity of the NR channels
for Ca2 exceeds that for Na 10-fold and thus ligand-medi-
ated activation of the receptors typically results in an induction
of transient inward Ca2 current. Consequently, both activa-
tion and inactivation of NRs, irrespective of host tissue, are
linked to the local changes in intracellular Ca2 levels. Such
changes in intracellular Ca2 have been reported to assist in
facilitating the proliferation of the vascular smooth muscle
cells and aortic endothelia cells in response to HC- or HCA-
mediated NR activation (11, 46). Megakaryoblasts initiate
differentiation and reduction in pro-platelet formation in re-
sponse to NMDA exposure, whereas proliferation rate and
survival remain unaltered (25).
Lymphocytes and thrombocytes are among the blood cells
expressing NRs (7, 17). To the best of our knowledge no studies
have been performed to assess the presence of functional NRs in
erythrocytes, although interaction of noncompetitive and compet-
itive NR antagonists [3H]MK-801 and [3H]CGS-19755, respec-
tively, with red blood cells (RBCs) has previously been reported
(36). Furthermore, dehydration of erythrocytes was reported in
patents with hyperhomocysteinemia (34). In this study, with the
use of rat erythrocytes, we have demonstrated the presence of
functional NRs in RBCs and investigated their distribution pattern
in addition to their role in regulation of cell volume, osmotic
resistance, endothelial nitric oxide synthase (eNOS, NOS3) activ-
ity, and cellular redox state.
MATERIALS AND METHODS
Cell isolation and handling. For all experiments we used RBCs
from adult male Wistar rats (200–300 g). The animals were purchased
Address for reprint requests and other correspondence: A. Bogdanova,
Institute of Veterinary Physiology, Univ. of Zurich, Winterthurerstrasse 260,
CH-8057 Zurich, Switzerland (e-mail: annab@access.uzh.ch).
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from Elevage Janvier (Le-Genest-Saint-Ile, France) and kept on com-
mercial rodent chow in the sterile laboratory animal facilities at the
Institute of Veterinary Physiology. Animal handling and experimen-
tation were reviewed, approved, and carried out in accordance with
the Swiss animal protection laws and institutional guidelines. Blood
samples were withdrawn from the caudal vena cava into heparinized
syringes, and erythrocytes were isolated via centrifugation at 1,000 g
for 5 min. The buffy coat and plasma were discarded while the
remaining RBCs were washed three times with an incubation medium
of the following composition (in mM): 145 NaCl, 5 KCl, 1 CaCl2,
0.15 MgCl2, 15 glucose, and 10 Tris·HCl, pH 7.4. Packed cells were
then resuspended in the incubation medium supplemented with 0.1%
BSA to a hematocrit of 40%.
UT-7/Epo cells were cultured in -MEM supplemented with 20%
fetal calf serum and 3 U/ml human recombinant erythropoietin
(EPREX, Janssen-Cilag, Neuss, Germany). Bone marrow cells were
harvested from the femur bone. Cells were suspended, filtered through
a 200-nm mesh, concentrated by centrifugation at 2,000 g for 5 min,
and used for either [3H]MK-801 binding experiments or immunoblot-
ting.
Cerebellar tissue was isolated from rat pups at postnatal day 10
(n  5) and used for immunoblotting. Cerebellar granule cells were
isolated from rat pups at postnatal day 10 as described elsewhere (40)
and used for [3H]MK-801 binding experiments.
Erythrocyte cytoskeleton-free membrane preparation. Packed
RBCs (about 500 l) were hemolyzed in 2 ml of ice-cold lysis buffer
containing (in mM) 10 Tris·HCl (pH 7.4), 1 EDTA, 0.1 PMSF, 10
Na4P2O7, 10 NaF, plus 10 g/ml pepstatin A, 10 g/ml leupeptin, and
5 g/ml aprotinin. Membranes were pelleted at 47 000 g for 20 min
at 4°C. To enrich the membrane fraction for the NR protein, the
obtained ghosts were deprived of most of the cytoskeletal proteins as
described elsewhere (23). Protein concentration in the obtained
smooth membrane samples was determined by using BCA Protein
Assay (Pierce; Rockford, Ill) with BSA as standard.
Radiolabeling with MK-801. A radioactive labeling assay was used
to detect the number of putative NRs in erythrocytes, UT-7/Epo cells,
and cerebellar granule cells. The respective cells were washed in PBS
and incubated with 5 nM [3H]MK-801 (20 Ci/mmol American Ra-
diolabeled Chemicals) per 106 cells. The unspecific binding was
assessed by treatment of cells with the radiolabeled antagonist in the
presence of 100 M of unlabeled dl-5-methyl-10,11-dihydro-5H-
dibenzo[a,b]-cyclohepten-5,10-imine (MK-801) for 1 h. The amount
of bound [3H]MK-801 was assessed with a Packard 1600 TR liquid
scintillation counter, and the number of receptors were calculated
thereafter using the following equation:
NNR
Acells
Asp(MK 801) · NA · Ncells
, (1)
where NNR is a number of NRs, Acells is activity of the MK-801 bound
to the cells in [Bq], Asp is a specific activity of the [3H]MK-801 in
[Bq/mmol], NA is the Avogadro number (6.022  1023 mol1), and
Ncells are the number of cells in the sample.
Western blot analysis. For Western blot analysis cells were washed
two times in PBS (2,000 g, 5 min) and lysed in Laemmli buffer.
Membrane proteins were first separated on the 7.5% SDS-PAGE (500
g protein/lane) and then transferred to Protan BA83 nitrocellulose
membranes. Even protein transfer was controlled by Ponceau red
staining. Membranes were then blocked for 1 h at room temperature
followed by an overnight incubation at 4°C with primary antibodies
against the NR1 subunit of NRs (dilution 1:1,000; 1–564 fragment,
Novus Biologicals) dissolved in TBS containing 5% milk. The mem-
branes were then washed three times in TBST and incubated for 1 h
at room temperature with suitable horseradish peroxidase-conjugated
secondary antibodies (1:1,000 dilution; antimouse, Jackson Immu-
noResearch Laboratories, West Grove, PA). The enhanced chemilu-
minescent detection Western blotting system (Fujifilm LAS-3000
System, FUJIFILM Life Science) was used for detection and quanti-
fication of protein. Actin served as a loading control.
Immunohistochemistry and flow cytometry. To assess the NR levels
in the membranes of reticulocytes and mature erythrocytes, staining
for both the NR1 and NR2 subunits of the NR and for the transferrin
receptor (TrR) as a marker of reticulocytes was performed. For
fluorescent imaging the cells were suspended in the incubation me-
dium at hematocrit of 0.4% and incubated for 60 min on ice with a
cocktail of the following primary antibodies: mouse monoclonal
anti-NMDA NR1 Pan antibody (1:100 dilution, Novus Biologicals),
rabbit polyclonal anti-NMDA NR2 antibody (1:100 dilution; Affinity
BioReagents), and rat monoclonal anti-transferrin receptor antibodies
(1:100 dilution; Abcam). Thereafter, the cells were washed from the
primary antibodies (centrifugation for 5 min at 500 g at 10°C) and
incubated for an additional 60 min on ice with the corresponding
secondary antibodies: anti-rabbit Cy3-conjugated, and anti-mouse
Cy5-conjugated, and anti-rat Cy2-conjugated, all in dilution 1:50.
After one wash of the secondary antibodies was completed, the
specific staining was assessed microscopically (Zeiss Axiovert
200M). Flow cytometry was used to assess the distribution of the NR
in RBC population. Erythrocytes in suspension were treated with the
mouse monoclonal anti-NR1 antibody (dilution 1:50; Novus Biologi-
cals) for 60 min on ice and thereafter with the secondary anti-mouse
Cy-5 conjugated antibody (1:50 dilution) and fluo-4 (final concentra-
tion 10 M) for further 30 min at room temperature. Cells treated with
only secondary antibodies were used as a negative control.
Unidirectional K(86Rb) influx measurements. Unidirectional in-
flux rates for K were assessed by using 86Rb as a tracer. Unidirec-
tional residual (ouabain-resistant Cl-independent) K influx was
detected in erythrocytes incubated at hematocrit of 5–8% in the
chloride-free medium containing (mM) 145 NaCH3SO4, 5 KCH3SO4,
0.15 MgSO4, 1 Ca-gluconate (when not Ca2 free), 10 glucose, 10
sucrose, and 10 HEPES-Tris, pH 7.4 at room temperature. Incubation
medium was always supplemented with 1 mM ouabain to block active
K influx and with 100 M L-arginine. Various amounts of NMDA,
HCA or glutamate, 1 M clotrimazole, or 50 mol MK-801 were
added to some of the samples. Cells were preincubated for 15 min to
achieve full inhibition of the Na-K-ATPase and allow agonists and
inhibitor of the NRs and the blocker of Gardos channels, clotrimazole,
to bind to their targets. Influx was then initiated and measured by
addition of 86Rb. Aliquots of the RBC suspension (400 l) were
collected 10, 20, 30, 45, and 60 min after the onset of incubation with
the tracer and washed from the extracellular 86Rb with ice-cold
washing medium containing 100 mM Mg(NO3)2 and 10 mM imidazol
buffered with HNO3 to the pH 7.4 when on ice. After washing was
completed, the cell pellet was lysed in 5% trichloracetic acid (TCA),
and the amount of 86Rb accumulated in erythrocytes was assessed in
deproteinized supernatant and normalized to the amount of the radio-
active tracer in the incubation medium. Unidirectional K influx was
then calculated from the slope of the linear part of the radioactive
tracer uptake plot.
Intracellular calcium content monitoring. Live cell imaging was
performed to monitor intracellular Ca2 kinetics in individual cells
treated with NMDA. Cells were loaded with fluo-4 AM (Molecular
Probes) at a concentration of 5 M for 1 h at 37°C. Then cells were
washed in Tyrode solution containing (mM) 135 NaCl, 5.4 KCl, 10
glucose, 1 MgCl2, 1.5 CaCl2, and 10 HEPES. The pH was adjusted to
7.35 by using NaOH. Cells were plated on poly-L-lysin (Sigma)-
coated coverslips in Tyrode solution, and then the cell sedimentation
and dye de-esterification were allowed to occur. Fluorescence was
finally measured on an inverted microscope (TE2000, Nikon)
equipped with a 100 Plan Apo 1.4 objective. Attached to the
microscope was a video imaging setup (TILL Photonics) consisting of
a monochromator (Polychrome IV), a camera (Imago), and the control
hard- and software (TILL-vision). Cells were observed at an excita-
tion of 480 nm and images were collected every 5 s. A 505-nm
long-pass dichroic mirror separated the emission light from the
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excitation light, and a 535/40 bandpass filter was used to further
improve the image quality. A local perfusion system was utilized to
quickly exchange solutions in the field of view and to apply the
agonist NMDA at a concentration of 100 M. Images were processed
in ImageJ (Wayne Rasband, National Institute of Mental Health) and
traces handled by Igor Pro software (WaveMetrics).
Osmotic resistance and hemolysis. The effect of agonists and
antagonists of the NR on osmotic resistance was assessed acutely by
preincubated cells with 1 mM of NMDA or HCA for 1 min at room
temperature in the incubation medium. Thereafter, 3 l of packed
cells were added to the cuvette equipped with a magnetic stirrer
containing 2 ml of 0.9% NaCl solution (final cell number107 cells/2
ml). A bolus of distilled water was added to reduce the osmolarity
from 300 to 130 mosM. Optical density was monitored at 630 nm
every 0.25 s after the initiation of hypoosmotic stress to assess
hemolysis. A detailed description of this method may be found
elsewhere (48).
Cellular fragility was determined by monitoring shear stress-in-
duced hemolysis. The cells were suspended in either Ca2-containing
or nominally Ca2-free medium at hematocrit of 40% and incubated
for 1 h at 37°C in an Eppendorff Thermomixer (900 rpm shaking
speed) in the presence and absence of 100 M NMDA and/or 100 M
MK-801. Hemolysis was assessed at the end of the incubation as the
amount of hemoglobin released into the medium. After centrifugation
(5,000 g for 10 min at 4°C), supernatant was collected and hemoglo-
bin concentration was determined spectrophotometrically using Drab-
kin reagent.
Morphological changes of RBCs exposed to the NR agonist. Eryth-
rocytes were suspended in the incubation medium at a ratio 1:200,
allowed to settle on the imaging chamber bottom, and pretreated with
10 M clotrimazole or 5 mM Na3VO4 for 15 min at room tempera-
ture. Thereafter, HCA at a final concentration of 1 mM was added just
before the measurement, and time course of the morphological alter-
ations was followed.
Reduced and oxidized glutathione measurement. Cellular reduced
(GSH) and oxidized (GSSG) glutathione content was determined by
using Ellmann’s reagent as described elsewhere (44). After incubation
in the presence or absence of 100 M NMDA, 100 M HCA and/or
50 M MK-801 in L-arginine-free or L-arginine-containing medium
for 60 min, 100-l aliquots of erythrocytes suspension (40% hemat-
ocrit) were mixed with 900 l of 5% TCA, and the obtained lysates
were centrifuged for 10 min at 16,000 g to pellet denatured proteins.
Formation of the colored complex of GSH with the Ellmanns reagent
was assessed spectrophotometrically at 412 nm.
Nitrite and nitrate assessment. Erythrocytes in suspension (40%
hematocrit) or whole blood were incubated with 100 M of NMDA,
or HCA, or 50 M MK-801 for 60 min at 25°C in presence or in
absence of 200 M L-arginine or NG-nitro-L-arginine methyl ester
(L-NAME). After the incubation nitrite levels were assessed in the
incubation medium or plasma by using a chemiluminescence detec-
tion technique. After incubation the erythrocytes were pelleted by
centrifugation (16,000 g) and the supernatant (medium or plasma) was
collected. Nitrate was reduced to nitrite using Cd coated with Cu and
(NO2 NO3) assessed by a chemiluminiscence detector CLD 88
(Eco Medics AG, Switzerland) as described elsewhere (33).
Statistical analysis. All data are mean values of at least 5 indepen-
dent experiments and are presented as means  SE when not stated
specially. The comparison between the experimental groups was
performed by using a normality test followed by the two-tailed
Student’s t-test for paired or unpaired samples (GraphPad In-
stat.V3.05). The level of statistical significance was set at P 	 0.05,
P 	 0.01, or p 	 0.001. Fitting of the data obtained for the dose
dependence of the HCA and glutamate effects on the residual K
influx was performed by using SigmaPlot 8.0 nonlinear regression
module (100 iteration steps). The equation chosen for fitting was y 
y0ax/(bx), assuming pseudo-single binding site kinetics for the
agonist-receptor interaction.
RESULTS
Presence of NMDA receptor in mature RBCs and bone
marrow. The presence of NRs in rat erythrocytes and in
erythroid precursor cells has been addressed by using several
independent techniques including: immunoblotting, immuno-
histochemistry, flow cytometry, and radiolabled antagonist
binding assay. Double staining of the bone marrow-derived
precursor cells with the antibodies against CD36, a marker of
erythroid lineage, and against the NR1 subunit of the NRs
revealed the presence of cells expressing both CD36 and the
NR (Fig. 1A). These observations were confirmed via immu-
noblotting (Fig. 1B). NRs were expressed in rat bone marrow
and UT-7/Epo human erythroleukemic cell line and could also
be detected in the erythrocyte membrane fraction. The size of
NR1 subunit (120 kDa) in erythroid cells was similar to that
in rat cerebellum (Fig. 1B). The number of receptor copies per
cell was assessed from the binding of the radiolabeled NR
antagonist [3H]MK-801 covalently interacting with the recep-
tor unit (a tetramer composed of two NR1 and two NR2
subunits) at a 1:1 stoichiometry. Binding studies revealed the
presence of 3.5  105 copies/cell in UT-7/Epo cells and 8  106
copies/cell in dispersed cerebellar granule cells, whereas 8  1.4
binding sites are retained in circulating erythrocytes when equal
binding of the antagonist to all cells in the population was
assumed. This assumption proved to be false when the distribution
of NR (NR1 and NR2 subunits) was assessed in the RBC
population with immunocytochemistry and flow cytometry. As
depicted in Fig. 1C, very few cells contained a high number of
NR1 and NR2 subunits. Most of these receptor-possessing cells
showed positive staining for the reticulocytes marker TrR. Some
cells retained high number of NRs, whereas TrRs was already
lost. Figure 2 depicts the scatter plots for RBCs stained with only
secondary Cy5-conjugated anti-mouse antibody used as a nega-
tive control (Fig. 2A), and the cells were loaded with fluo-4
(Y-axis) and exposed to the monoclonal mouse anti-NR1 antibod-
ies (X-axis) followed by the above-mentioned secondary antibod-
ies (Fig. 2B). As can be seen from the Fig. 2B a low number
(2.37  0.32%, N  5) of cells appearing in the G1 quadrant are
characterized by high numbers of the NR copies and high intra-
cellular Ca2 levels. The amount of these receptor-enriched cells
could be underestimated as they were found to be more suscep-
tible to hemolysis under conditions of shear stress and could have
been lost during centrifugation and the passage through the cy-
tometer (see below). It varied from 0.5 and 4% in different
animals. Many more cells in the population residing in G2
quadrant at the scatter plot contained significantly less copies of
the receptor and low intracellular Ca2 levels (Fig. 2B).
Function of the NRs. NRs are nonselective cation channels
that are more sensitive to transport Ca2 into neuronal cells
upon activation. High intracellular Ca2 levels in RBCs con-
taining the highest number of NR copies, as indicated in Fig.
2B, suggests that the NRs in erythrocyte membrane are func-
tional and mediate basal Ca2 influx into the cells even in the
absence of the agonists in the incubation medium. Treatment of
the cells with NMDA dramatically facilitated Ca2 accumula-
tion in some but not all cells. Kinetics of the NMDA-induced
Ca2 entry into single rat erythrocytes was assessed with live
imaging. In agreement with flow cytometry data (Fig. 2B), live
imaging revealed presence of two subpopulation of RBCs:
1) “responders,” in which the addition of 100 M NMDA
C1317NMDA RECEPTORS IN ERYTHROCYTES
AJP-Cell Physiol • VOL 298 • JUNE 2010 • www.ajpcell.org
 o
n
 June 7, 2010 
ajpcell.physiology.org
D
ow
nloaded from
 
C1318 NMDA RECEPTORS IN ERYTHROCYTES
AJP-Cell Physiol • VOL 298 • JUNE 2010 • www.ajpcell.org
 o
n
 June 7, 2010 
ajpcell.physiology.org
D
ow
nloaded from
 
triggered a rapid Ca2 accumulation; and 2) NMDA-insensi-
tive “nonresponders” (Fig. 3). The subpopulation of “respond-
ers” consituted 92 of 627 erythrocytes (14.7%). However, of
the 92 responding cells only 60 could be used for the final
analysis (Fig. 3B) since the other 32 lysed during the 15 min of
observation. In the control group (524 cells recorded), the Ca2
levels remained stable and low (Fig. 3B). Minor but statisti-
cally significant increase in the intracellular Ca2 content was
thus observed in the whole erythrocyte population treated with
NMDA, although the separation of cells into “responders” and
“nonresponders” subpopulations revealed that changes in Ca2
were much more pronounced and restricted to the limited
number of cells.
Treatment of the cells with HCA, glutamate, or NMDA
caused a dose-dependent increase in a unidirectional, residual
(ouabain-resistant, chloride-independent) K influx, which was
measured by using 86Rb as a tracer for K transport (Fig. 4). Doses
of the agonists required to cause the half-activation of the K
influx (IC50) was estimated by fitting the respective curves and
were found to be 21.1 0.78 M for HCA and 88.2 0.1 M
glutamate (Fig. 4A). Although the exact estimation of the IC50
value for NMDA could not have possibly been determined,
maximal specific activation was already observed at 50 and 10
M without an effect (Fig. 4B). This suggests an IC50 value of
about 30 M. Higher supraphysiological concentrations (500–
1,000 M) of the synthetic NR agonist further resulted in a
nonspecific increase in the residual K influx. The NMDA
sensitivity of the K influx was lost in the presence of MK-
801, an antagonist of NRs (Fig. 5A). NMDA-mediated upregu-
lation in K influx was clearly secondary to the Ca2 uptake as
it was suppressed in Ca2-free medium (Fig. 5B). This finding
along with sensitivity of NMDA-induced fluxes to clotrim-
azole, a Gardos channel blocker, suggests that entry of Ca2
into the cells through the NR facilitates the opening of the
Gardos channel.
Cell volume control, osmotic resistance, and morphological
alterations. Activation of Gardos channels is known to have a
profound effect on cell volume. The Ca2 uptake kinetics (Fig.
3) suggests that NMDA-induced cellular shrinkage occurs
within the first several minutes of treatment. The correspond-
ing alterations in cellular morphology were observed in re-
sponse to HCA treatment in some cells within the first 80 s of
exposure to the NR agonist; however, this effect was not
ubiquitous among all cells (Fig. 6A). The respective alterations
in morphology were completely reversed within 180 s of
cellular exposure to HCA alone but not during the simulta-
neous treatment of HCA and the Ca2 pump inhibitor Na3VO4.
Vanadate treatment did, however, increase the number of
responding cells suggesting that the low Ca2 levels in eryth-
rocytes with few NRs (Fig. 2B) was maintained due to the
efficiency of the Ca2 pump. Activation of the Gardos chan-
nels was involved in the temporary morphological changes as
treatment of the cells with clotrimazole almost entirely sup-
pressed the HCA-induced cupping and echniocytosis (Fig. 6A).
Fig. 1. Presence of the N-methyl-D-aspartate (NMDA) receptors (NR) in the membranes of erythroid precuror cells and circulating erythrocytes. A: confocal
image of the bone marrow tissue stained using the antibodies against CD36 (red channel) and NR1 (cyan channel). The magnified area is framed and the single
channels and the overlay of the magnified area are shown. The staining was repeated four times. B: presence of the NR1 subunit at the protein level in rat
erythrocyte cytoskeleton-free smooth membranes, UT-7/Epo cell line, rat bone marrow cells, and rat cerebellum. The experiment was repeated four times.
C: abundance of NR in erythrocytes. Staining with the antibodies against transferrin receptor (TrR) (blue channel, i), NR1 (green channel, ii), and NR2 (red
channel, iii), was performed in nonfixed cells. Shown are the single channel recording and an overlay of all three fluorescent channels with the bright field image.
Cells in a and b subset of images contain both subunits of the NR and a TrR, whereas the cell in c subset contains NR1 and NR2 subunits but lacks TrR. Staining
was repeated four times and at least 10 fields were analyzed in a single experiment.
Fig. 2. Correlation between the abundance of the NRs and the intracellular Ca2 levels. A: negative control scatter dot plot showing red blood cell (RBC)
population chosen according the size (forward scatter) and granularity (side scatter) after incubation with secondary Cy5-conjugated anti-mouse antibodies only.
Gating conditions were chosen so that all the cells were located in the lower left quadrant when emission in green fluorescent channel (
em 488 nm) is shown
in Y-axes and far red fluorescence intensity (
em 650 nm) plotted at X-axes. B: scatter dot plot of the RBCs loaded with fluo-4 and incubated with the anti-NR1
mouse monoclonal primary antibody followed by Cy5-conjugated anti-mouse secondary antibody. Two subpopulations seen in the dot plot represent
subpopulation with the high intracellular Ca2 and high number of NR1 copies shifting to the G1 quadrant and the subpopulation with low intracellular Ca2
and low numbers of the NR1 copies in the G2 quadrant. Each plot represents readouts from 10,000 cells. Similar results were obtained in five independent
experiments with RBCs obtained from different animals of various age and gender.
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An acute osmotic resistance test also indicated that both HCA
and NMDA result in RBC shrinkage thus making the cells
more resistant to osmotic hemolysis (Fig. 6B). Hemolysis rate
was assessed via the observation of hemoglobin liberation into
the medium during the first 60 s of cells exposure to hypoos-
motic shock.
Cellular shrinkage is known to trigger a regulatory volume
increase response (RVI) mediated by the volume-sensitive
Na/H exchanger or Na-K-2Cl cotransporter in rat erythrocytes
(37). We have also observed the late RVI response in rat
erythrocytes treated with NMDA or HCA. Swelling of cells
treated with NR agonists for 1 h was monitored and water
content was seen to increase from 65.8  1.0% in control to
66.7  0.6% in cells exposed to 100 M HCA and 67.2 
1.7% after treatment with 100 M NMDA at 37°C. The fact
that long-term treatment with the NR agonists made the cells
more susceptible to the shear stress-induced hemolysis (Fig.
6C) could also be explained as a result of secondary swelling.
This agonist-induced hemolysis could be completely abolished
by treating erythrocytes with MK-801 and significantly re-
duced through the use of a nominally Ca2-free medium.
NO synthase activation and glutathione oxidation. Function
of the eNOS present in the red cell membrane of rodents and
humans (27, 33) is Ca2 dependent (45). Treatment of the
whole blood with MK-801 resulted in a dose-dependent inhi-
bition of NO2  NO3 accumulation in plasma, whereas
exposure to NMDA facilitated de novo NO production (Fig 7A).
These observations were confirmed using erythrocytes suspension
Fig. 4. Effect of NR agonists on the residual (ouabain-insensitive, chloride-
independent) K influx in rat erythrocytes. A: dose dependence of the effect of the
physiological agonists, glutamate, and homocysteic acid (HCA) on the residual
K influx. Data are means of five independent experiments SE. The curve was
obtained by fitting using the equation y  y0ax/(bx). The constants obtained
for the HCA plot were y0 0.229, a 0.0972, b 0.0211 and the corresponding
coefficient for the glutamate curve were y0  0.229, a  0.0854, b  0.0882. B:
dose-response curve for the effect of the synthetic agonist NMDA on the residual
K influx. Data are means of 6–10 experiments  SE. *P 	 0.05, **P 	 0.01,
and ***P	 0.001 in paired Student’s t-test compared with the nontreated control.
Fig. 3. Kinetics of Ca2 uptake by the NMDA-treated erythrocytes. A: original
recordings of the changes in the intracellular Ca2 levels in single cells
visualized by monitoring fluorescence from the fluo-4 Ca2 sensor in response
to 100 M NMDA treatment. Time of incubation with NMDA is shown with
a grey bar. Images of single cells are shown and those that were chosen for
analysis are marked as regions of interest with colored circles. The changes in
the fluorescent intensity (F) normalized to the initial one (Fo) over time is
plotted below in the corresponding colors. The color coding scale for the
relative changes in the intracellular Ca2 levels is shown above. B: statistical
analysis of cell populations exposed to 100 M NMDA (grey and black plots)
and control cells (dotted plot). The grey plot represents mean values  SE of
627 randomly chosen cells from three independent preparations of different
animals exposed to NMDA for 15 min, whereas the black plot shows means
SE for the responding subpopulation of 60 cells (for details see text). The
variety of the onset time of individual cells leads to a slower increase compared
with single erythrocytes as shown in A.
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(Fig. 7B). Conversely, exposure of erythrocytes to the NR ago-
nists NMDA or HCA for 1 h resulted in an increased (NO2 
NO3) generation in erythrocytes suspension (Fig. 7B). Agonist-
induced activation of NO production was initiated through the
activation of the NR, which can be antagonized by MK-801.
HCA-induced generation of NO required the presence of extra-
cellular L-arginine and was blocked by L-NAME, which suggests
that it was mediated by the eNOS (Fig. 7B).
Oxidative burst in cells suspended in L-arginine-free me-
dium was concomitant to the activation of the RBC-eNOS by
either NMDA or HCA as observed by the increase in the
intracellular GSSG levels (Fig. 7C). In the L-arginine-supple-
mented medium, treatment of the cells with HCA (Fig. 7C) or
NMDA (data not shown) had negligible effects on the intra-
cellular GSSG levels. HCA-induced oxidation was also inhib-
ited by the NR antagonist MK-801 or by L-NAME (Fig. 7C). In
the absence of NR agonists L-NAME or L-arginine supplemen-
tation to the incubation medium did not cause any changes in
the intracellular GSSG content (data not shown).
DISCUSSION
In this study we present data that demonstrates the presence
of functional NMDA receptors in mammalian RBCs. The
combination of both subunits (NR1 and NR2) are required to
form a functional channel in neurons (28), and we provide
evidence of both subunits in membrane of the erythrocyte (Fig.
1, B and C). Pharmacological characteristics of these receptors
resemble those reported for NRs in neurons. Agonists and
antagonist both interact with these receptors at concentrations
reported for neurons (14, 26, 30). We have established evi-
dence suggesting that the number and the activation state of
NRs in circulating erythrocytes (the latter dependent on HC
and/or HCA levels in plasma) are critical in control of the
intracellular Ca2 levels (Figs. 2 and 3).
The physiological role of the NR receptor may only be fully
understood once we know the abundance of the receptor
present in erythrocytes as well as the mechanisms regulating
the function of the receptor as well as the nature of agonists and
antagonists. Whereas some speculations may be made on the
nature of agonists, mechanisms in control over the NRs abun-
dance in red cell membrane remains unknown. Plasma gluta-
mate concentration in healthy subjects (14 to 47 M; 3, 13, 47)
are significantly lower than that measured in the synaptic cleft
where it reaches several millimoles (14). Our data indicate that
glutamate binding to the NRs in rat brain and erythrocytes
share similar IC50 of 96  2 M (26) and 88.2  0.01 M
(Fig. 4A), respectively. Plasma HC and HCA concentrations
reported in healthy subjects range between 8 and 15 M (24).
These values may rise substantially (up to 400 M) as a result
of folate or vitamin B12 deficiency, pregnancy, aging, or as a
result of a hereditary methionine metabolism-related disorder
(41). Values reported for the NR’s IC50 in the brain for HC
and HCA are 14  4 M (51) and 14 M (51), respectively,
whereas it is 21.1 0.78 M for erythrocytes (Fig. 4A). These
data suggest that in healthy subjects these two agonists pre-
dominantly control NR activity in circulating RBCs, whereas
glutamate will only be of importance in pathological cases such
as stroke when plasma glutamate concentration may rise up to
200 M (10). Magnesium is one of the physiologically rele-
vant inhibitors of NRs in the brain. In the present study we only
tested responses of NRs present in erythrocytes to pharmaco-
logical inhibitors that are more selective and well-character-
ized. In erythrocytes MK-801 irreversibly inhibits the receptor-
mediated ion transport and downstream processes at micromo-
lar concentrations used in electrophysiological studies on brain
slices (e.g., 49).
The NRs were not homogeneously distributed in the eryth-
rocyte population and were most prevelant in reticulocytes
(Fig. 1C). Although the number of receptor copies per reticu-
locytes were high compared with mature and senescent red
cells, they were 3500-fold lower than that in UT-7(Epo) cell
line suggesting that receptor levels are dramatically reduced
during the late stages of differentiation of the erythroid pre-
cursors. Moreover, reduction in numbers has also been shown
for other receptor types, some of which (e.g., TrR) are used as
a marker of reticulocyte count. Although not all cells lacking
TrR were also deprived of NR (Fig. 1C) suggesting that the NR
is not present solely in reticulocytes and thus cannot be used as
marker for them. Existence of erythrocytes with particularly
either high or low levels of NRs may also be observed by using
flow cytomery (Fig. 2). We have recently reported a similar
distribution pattern for the erythropoietin receptors in mouse
erythrocytes. These receptors are most abundant in reticulo-
cytes and present at much lower levels in young and mature red
cells while virtually absent in senescent cells (33).
Relatively high density of NRs in young cells may contrib-
ute to the process that selectively removes young erythrocytes
Fig. 5. Pharmacological inhibition of the NMDA-induced activation of the
residual K influx. A: inhibition of the NMDA-sensitive component of the K
influx by antagonist of the NR MK-801 (50 M). Data are means of six
independent experiments  SE. B: lack of the NMDA-induced stimulation of
the residual K influx in cell pretreated with the Gardos channel blocker
clotrimazole (1 M) as well as in Ca2-free incubation medium. Data are
means of five independent experiments  SE. *P 	 0.05 in paired Student’s
t-test compared with the nontreated control.
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Fig. 6. Secondary changes in erythrocyte morphology, osmotic resistance, and resistance to shear stress caused by NR agonists. A: acute morphological alterations
triggered by a high dose (1 mM) of NR agonist homocysteic acid (HCA) in the absence or in the presence of 10 M clotrimazole or 5 mM Na3VO4. Images
are taken from the cells before and 100 or 180 s after the addition of the HCA. Cells highlighted with arrows show characteristic reversible shape changes when
exposed to HCA alone and or in the presence of clotrimazole. Inhibition of the Ca2 pump with Na3VO4 facilitated the rate of echinocytic transformation and
the number of responding cells compared with that in the presence of HCA alone as well as made these changes irreversible. B: osmotic resistance of rat
erythrocytes treated with 1 mM HCA or NMDA. Osmotic resistance was assessed as a rate of hemolysis in response to acute hypoosmotic stress. Exposure of
cells to agonists of the NR for 1 min caused a significant decrease in hemolytic rates calculated from the linear slopes of the plots of hemoglobin release. Shown
are the representative hemoglobin liberation kinetics plots. Inset: statistical analysis of the rate of osmotic hemolysis for nine independent experiments; **P 	
0.01 compared with the nontreated control. C: shear stress-induced hemolysis in cells after a long-term exposure to NMDA. Accumulation of hemoglobin in the
incubation medium during 1 h at 37°C in an Eppendorff Thermomixer (900 rpm shaking speed) was assessed in control cells and in the cells exposed to 100
M NMDA  100 M MK-801 in the presence or absence of 1 mM Ca2 in the incubation medium. Data are means of seven independent experiments  SE;
**P 	 0.01.
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when Epo receptors are dormant, which is known as neocy-
tolysis (2, 12). In contrast to the common opinion that Ca2
levels increase with red cell maturation and senescence (15),
our data indicates that reticulocytes contain more Ca2 than the
either adult or senescent cells (Fig. 2). Thus Ca2-induced
processes may control the rapid decrease in blood cell mass,
whereas clearance of senescent cells is regulated by other
factors (31). Assessing the effects that Epo has on the
activation state of NR and intracellular Ca2 levels may
shed light on the mechanism(s) involved in selective clear-
ance of reticulocytes and young erythrocytes during condi-
tions of Epo deficiency and the potential effects of Epo on
the “non-selective cation channels” described my Myssina
et al. (35).
Accumulation of Ca2 in the cells following treatment with
NR agonists is a common mechanism demonstrating NMDA/
HCA cytotoxicity in erythrocytes and neurons (28) (Figs. 2 and
3). Exposure of erythrocytes to NMDA or HCA gives rise to
numerous Ca2-dependent responses. Downstream targets of
the Ca2-sensitive signaling cascade have different Ca2 sen-
sitivity thresholds. Gardos channel activation requires 1–3 M
Ca2 to reach half-activation (20). These channels remain
closed under most physiological conditions and are only acti-
vated by maneuvers that result in intracellular Ca2 accumu-
lation (5). Activation of the Ca2-dependent, clotrimazole-
sensitive K influx can be observed in the presence of 50–100
M NMDA, whereas treatment of the cells with MK-801 or
clotrimazole shows no effect (Fig. 5). Changes in the intracel-
lular Ca2 trigger characteristic alterations in erythrocyte mor-
phology (21, 22) resembling those we have observed in
NMDA-treated cells (Fig. 6B). These reversible alterations in
cell shape, which can be blocked by clotrimazole, reveal the
result of Gardos channel activation.
De novo NO production by RBC-eNOS is Ca2 dependent.
Half-activation of eNOS requires 50–300 nM Ca2 depending
on the phosphorylation state of the enzyme (45). Thus thresh-
old levels of intracellular Ca2 for eNOS activation are lower
than those for Gardos channel activation (1–3 M). Inhibition
of Ca2 uptake via NRs by MK-801 compromises eNOS
function as Ca2 levels drop below 50–100 nM due to its
removal from the cytosol by the Ca2 pump (Fig. 7A). On the
other hand, treatment of the cells with NMDA further stimu-
lates NO production in the presence of L-arginine, which
suggests that steady-state Ca2 levels are insufficient to sup-
port function of the eNOS at maximal rates. Changes in the NO
production by erythrocytes in turn are reported to affect de-
formability, redox state, and oxygen-carrying capacity of
RBCs(33, 38).
In rat erythrocytes, alterations in activity of RBC-eNOS had
an immediate effect on the intracellular redox balance. As
shown before in mouse erythrocytes (33), activation of eNOS
in rat RBCs by NR agonists was pro-oxidative under condi-
tions of L-arginine deprivation as eNOS was forced into the
O2·-generating mode (Fig. 6C). Similar effects were observed
in mouse erythrocytes upon treatment with Epo (33). Oxidative
stress triggered by NR activation may possibly contribute to
an increased susceptibility of erythrocytes to shear stress-
induced hemolysis after a long-term exposure to NMDA or
HCA (Fig. 5C).
Taken together our findings indicate that an increase in the
number or activity of NRs may cause oxidative stress, abnor-
Fig. 7. Effect of the NR agonists and antagonist on the NO production and the
intracellular redox state. A: total oxidized NO (RNO: NO2  NO3) levels in whole
blood as a function of treatment with various concentrations of MK-801 or NMDA for
1 h. Data are means of five5 experiments SE; *P	 0.05 and **P	 0.01 compared
with the basal levels of RNO in plasma. B: RNO levels in the incubation medium in
which the RBC were exposed to the 100 M of the NR agonists NMDA or HCA
(right side-facing hatched bars) or 50 M antagonist MK-801 (dark grey bar) in the
presence or in the absence of either 100 M L-arginine (grey bar) or nitro-L-arginine
methyl ester (L-NAME) (left side-facing hatched bar) for 1 h. Combined treatment is
represented as a combination of the corresponding bar filling. *P	 0.05 and **P	
0.01 compared with the untreated control (open bars). C: intracellular GSSG content in
percentage of total GSH levels in erythrocytes treated similar as in B. Right side
facing-hatched bars represent agonist-treated cells, left side-facing hatching stands for
the L-NAME-treated ones, dark and light grey filling represents MK-801 and L-
arginine exposure, respectively. The corresponding controls for the GSSG content in
the cells treated with L-arginine, MK-801, or L-NAME alone are not shown and did not
differ from the control shown as an open bar. Data are means of five independent
experiments SE. *P	 0.05 compared with control (open bars) and ###P	 0.001
compared with the values in cells treated with HCA alone (right side-facing hatched
bars).
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mal volume regulation, and hemolysis. These events may
contribute to the increased incidence of thrombosis and anemia
that has been reported in patients with high concentration of
HC, which can reach 200–300 M (1, 8). Macrocytosis and
abnormal RBC morphology are reported in patients with hy-
perhomocysteinemia (1) in which similar mechanisms as those
described here may actually occur in vivo. So far the effect of
HC on platelets has been suggested to be the only cause of
thrombotic complications (34). If our observations on rat
erythrocytes reflect the conditions in human red cells, these
cells would also contribute to HC-induced thrombus formation
and hemolytic anemia in patients with vitamin B12 and folate
deficiency (50). The final impact of HC/HCA on the survival
prognosis or mortality risk in hemodialysis patients was shown
to increase by 3% per each additional 1 M of HC in the
plasma (9). The next step therefore would be to assess the
levels of NRs in erythrocytes of healthy subjects and patients
with various forms of anemia. This work is currently in
progress.
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The presence of N-methyl-D-aspartate receptor (NMDAR) was previ-
ously shown in rat red blood cells (RBCs) and in a UT-7/Epo human
myeloid cell line differentiating into erythroid lineage. Here we have
characterized the subunit composition of the NMDAR and monitored
its function during human erythropoiesis and in circulating RBCs.
Expression of the NMDARs subunits was assessed in erythroid
progenitors during ex vivo erythropoiesis and in circulating human
RBCs using quantitative PCR and flow cytometry. Receptor activity
was monitored using a radiolabeled antagonist binding assay, live
imaging of Ca2 uptake, patch clamp, and monitoring of cell volume
changes. The receptor tetramers in erythroid precursor cells are
composed of the NR1, NR2A, 2C, 2D, NR3A, and 3B subunits of
which the glycine-binding NR3A and 3B and glutamate-binding
NR2C and 2D subunits prevailed. Functional receptor is required for
survival of erythroid precursors. Circulating RBCs retain a low
number of the receptor copies that is higher in young cells compared
with mature and senescent RBC populations. In circulating RBCs the
receptor activity is controlled by plasma glutamate and glycine.
Modulation of the NMDAR activity in RBCs by agonists or antago-
nists is associated with the alterations in whole cell ion currents.
Activation of the receptor results in the transient Ca2 accumulation,
cell shrinkage, and alteration in the intracellular pH, which is associ-
ated with the change in hemoglobin oxygen affinity. Thus functional
NMDARs are present in erythroid precursor cells and in circulating
RBCs. These receptors contribute to intracellular Ca2 homeostasis
and modulate oxygen delivery to peripheral tissues.
NMDA receptors; calcium; red blood cells; erythroid precursors
INTRACELLULAR CALCIUM IS A regulator of multiple processes in
mammalian red blood cells (RBCs; Ref. 6). Functions of key
glycolytic enzymes are calcium sensitive (e.g., Refs. 2, 36, 75).
Increase in the intracellular calcium to 1 M and more causes
activation of Ca2-dependent K channels (Gardos channels),
loss of KCl from the cells, cell shrinkage, and dehydration
(37). Along with the changes in cell volume and cation content,
accumulation of Ca2 was shown to facilitate intercellular
adhesion (60). Upregulation of the intraerythrocytic Ca2 re-
sults in activation of calpain and promotes cleavage of cyto-
skeletal proteins (actin, spectrin, ankyrin, and band 4.1 protein)
as well band 3 protein and the plasma membrane Ca2 pump
(PMCA; Ref. 6). Thus the cell membrane becomes destabilized
in RBCs upon Ca2 overload. The changes in rheology asso-
ciated with cell dehydration and proteolysis of cytoskeletal
proteins are followed by the alteration of hemodynamics.
Uncontrolled Ca2 accumulation upon treatment of RBCs with
Ca2 ionophore A23187 was reported to cause phosphatidyl-
serine (PS) exposure to the outer membrane leaflet (16). This
process may contribute to enhanced RBC clearance by macro-
phages in patients with a number of diseases. Apart of PS
exposure, high intracellular Ca2 may promote oxidative stress
due to the activation of NADPH oxidase and nitric oxide
synthase in its uncoupled mode (20, 51). Whereas extracellular
Ca2 concentration in the plasma reaches 1.8 mM, the intra-
cellular free Ca2 level is precisely controlled and does not
exceed 50–100 nM in healthy human RBCs (64). This impres-
sive transmembrane gradient is maintained by an active Ca2
extrusion via the PMCA and low passive permeability of the
RBC plasma membrane for Ca2 which is mainly mediated by
ion channels (28). PMCA in RBCs has been well characterized,
whereas our knowledge on the ion transport systems mediating
Ca2 uptake in human RBCs is rather limited. Among the
transport systems contributing to Ca2 uptake into human
RBCs are several classes of cation channels (28). An increase in
Ca2 “leak” and the concomitant elevation of intracellular Ca2
concentrations are typical for RBCs of patients with phosphofruc-
tokinase deficiency (75), thalassemia (7), and sickle cell disease
(7, 70). The importance of electrogenic Ca2 uptake pathway
(Psickle) in promoting sickle cell transformation upon deoxygen-
ation has been acknowledged (8, 70, 72). The molecular
identity of the nonselective cation channels, including those
mediating Psickle, remains unknown.
Recently, we have reported the presence of N-methyl-D-
aspartate receptors (NMDARs) in the plasma membrane of rat
RBCs and in the human erythroid precursor cell (EPC) line
UT-7/Epo (38). These receptors are ligand-gated, nonselective
cation channels showing a 10-fold preference for Ca2 over
Na or K (12).
These receptors are comprised of four subunits of which
eight different isoforms coded by independent genes have been
described (68). Subunits NR1 and NR3A and B are binding
glycine or D-serine whereas NR2A, B, C, and D interact with
glutamate and its homologues homocysteine, homocysteic acid
* A. Makhro and P. Hanggi contributed equally to this work.
Address for reprint requests and other correspondence: A. Bogdanova,
Institute of Veterinary Physiology, Vetsuisse Faculty, and Zurich Center for
Integrative Human Physiology (ZIHP), Univ. of Zurich, Winterthurerstrasse
260,, CH-8057 Zurich, Switzerland (e-mail: annab@access.uzh.ch).
Am J Physiol Cell Physiol 305: C1123–C1138, 2013.
First published September 18, 2013; doi:10.1152/ajpcell.00031.2013.
0363-6143/13 Copyright © 2013 the American Physiological Societyhttp://www.ajpcell.org C1123
(HCA), or NMDA. Subunit composition defines gating prop-
erties and ion preferences of the channel, as well as its affinity
to the agonists and antagonists. Whereas channels composed of
NR1-NR2A/B generate large currents and deactivate quickly,
the channels built up by the NR1-NR2D generate smaller
currents and are slow-deactivating (10). Physiological role of
the “inhibitory” NR3 subunits making the receptors in the brain
glutamate insensitive are not well defined (52). Local expres-
sion pattern vary within the brain (21, 40). Apart of that in the
brain NMDARs have been shown to be expressed in a number
of nonneuronal tissues including the bone and the kidney (42,
57). Subunit composition, physiological function, and regula-
tion of activity of these “atypical glutamate receptors” in
megakaryocytes (19, 24) and in rat RBCs (38) have been
reported. In rat RBCs activation of the NMDARs by adminis-
tration of agonists triggered Ca2 accumulation whereas ex-
posure of the cells to antagonists on the contrary reduced the
intracellular Ca2 levels (38). Furthermore, activation of the
receptor by glutamate, NMDA, or HCA triggered opening of
the Gardos channel followed by cell shrinkage as well as
activation of the endothelial nitric oxide synthase (38).
Herein we report the presence of NMDARs in membranes of
EPCs and circulating RBCs of healthy human subjects. We
characterize subunit composition of the receptor and explore its
function and contribution to the maintenance of intracellular
Ca2 homeostasis and in regulation of hemoglobin oxygen
affinity.
DESIGN AND METHODS
Human subjects. Our subject pool consisted of 36 adult subjects
(Caucasians, both genders, median age 32.5; range 25–49) with no
history of hematological disorders. Five to ten milliliters of venous
heparinized blood were obtained after informed, written consent, in
accordance with the Declaration of Helsinki, at the Divisions of Hema-
tology of the University Hospital and the Children’s Hospital Zurich as
well as at the Medical Faculty, Saarland University, Homburg/Saar,
Germany and processed immediately. The Institutional Ethics Board of
the University Hospital in Zurich and that of the Canton of Zurich as well
as the Ethics committee of the medical association of the Saarland
approved the study protocol.
RBC purification for flow cytometry and quantitative real-time
PCR. Blood was washed three times with 10 ml of PBS containing 2
mM EDTA and separated in a Ficoll-Hypaque gradient (GE Health-
care, Glattbrug, Switzerland) to remove mononuclear cells and plate-
lets. Reticulocytes were then filtered through a leuco-depletion filter
(Purecell Neo; Pall, Basel, Switzerland). The leuco-depleted reticulo-
cytes were washed and resuspended in PBS/EDTA. The purity grade
of reticulocytes was assessed by an automated blood cell analyzer
(Sysmex Digitana, Horgen, Switzerland), as well as by flow cytometry
for surface expression of CD45 with fluorescence-labeled antibodies
(Becton Dickinson, Rotkreuz, Switzerland). In addition, depletion of
leukocytes and platelets and enrichment of late EPCs and reticulo-
cytes were analyzed by quantitative real-time PCR (qPCR). The
pan-leukocyte marker CD45 was used as a white blood cell (WBC)
marker, and mRNAs encoding hemoglobin subunits were chosen to
detect late EPCs and reticulocytes.
Ex vivo hematopoiesis. EPCs were cultured using a two-phase
liquid system as described elsewhere (41, 42). At phase I mononuclear
cells were isolated from peripheral blood according to the protocol
provided by the GE Healthcare producing Ficoll-Paque PLUS and seeded in
StemSpan SFEM Medium supplemented with a cytokine mix supplements
CC100 StemSpan (StemCell Technologies, Grenoble, France) and peni-
cillin/streptomycin. Cells were maintained in phase I medium at a
density of 0.1–1  106 cells/ml for 5 days. Thereafter, nonadherent
cells were reseeded in StemSpan SFEM Medium with 2% penicillin/
streptomycin, 20 ng/ml SCF, 1 U/ml Epo, 5 ng/ml IL-3, 2 M
dexamethasone, and 1 M -estradiol and maintained in it for 6, 12,
or 18 days.
mRNA isolation and qPCR. Total RNA was purified from cells by
the TRIzol/glycogen/osopropanol. GRIN1, GRIN2A, GRIN2C,
GRIN2D, GRIN3A, GRIN3B, and CD45 mRNAs, as well as control
GAPDH mRNA, were quantified using the TaqMan Gene Expression
Kits acquired from Applied Biosystems (Rotkreuz, Switzerland). The
following primers were used: Hs02758991_g1 Gapdh: GTC-
CCCATCCCAACTCAGCCCCCAA; Hs00609557_m1 Grin1: TCA-
TCTCCAGCCAGGTCTACGCCAT; Hs00168219_m1 Grin2a: GGAA-
TGGGAAAAGGTGGGCAAGTGG; Hs00168230_m1 Grin2b: TGG-
GAAAGGGTGGGGAAGTGGAAAG; Hs01016626_m1 Grin2c:
TGGCTTTCAGCAGGGGCATCTACAG; Hs00367969_m1 Grin2d:
CAGCTCAAGGCAGGGAAGCTGGACG; Hs00370290_m1 Grin3a:
ACATGACCCCAAGTTACATCATCCT; and Hs00367969_m1 Grin3b:
GCTTCTTGGCACGGTTCCTGGCCAA.
Flow cytometry for detection of NMDAR abundance and distribu-
tion in EPCs. Staining of EPCs for the NMDAR subunit-specific
antibodies was performed as follows. Cells were washed once with
working solution (PBS supplemented with 0.1% BSA) and centri-
fuged for 30 s at 3,000 rpm. The supernatant was discarded and the
cells resuspended in working solution and fixed with 0.05% glutarald-
hyde solution prepared in PBS for 9 min. Cells were washed twice,
supernatant was discarded, and cells were resuspended in Tween
solution (working solution supplemented with 0.1% of NaN3 and
0.1% of Tween20) to permeabilize them. Before the primary antibody
was added, the EPCs were washed once and resuspended in working
solution.
After incubation with primary antibodies for 15 min in the darkness
at room temperature, the cells were washed once and exposed to the
allophycocyanin-conjugated secondary antibodies for 15 min in the
darkness. The following antibodies were used: IgG1 mouse anti
human Anti-CD45 PerCP, clone 2D1 (BD, San Jose, CA) as a marker
of WBCs; IgG2a mouse anti-human CD71, clone M-A712 FITC-
conjugated (BD) as a marker of reticulocytes; anti-NMDAε3 (NR2C),
goat polyclonal IgG, no. sc-1470; anti-NMDAε4 (NR2D), mouse
monoclonal IgG, no. sc-178221; anti-NR3A (NR3A), goat polyclonal
IgG no. sc-51160; and anti-NR3B, goat polyclonal IgG, no. sc-55731.
All primary antibodies against the NMDAR subunits used were
provided by Santa Cruz Biotechnology (Dallas, TX) and used at a
final concentration of 0.2 g/ml. Allophycocyanin-cojugated Affini-
Pure F(ab’)2 Fragment Donkey Anti-Goat IgG, Code 705–136-147,
and allophycocyanin-cojugated AffiniPure F(ab=)2 Fragment Goat
Anti-Mouse IgG, Code 155–136-146 were used as secondary anti-
bodies at 1:625 and 1:2500 dilutions, respectively.
Stained cells were washed once with the working solution supple-
mented with 1% formaldehyde and resuspended in an appropriated
volume of the working solution, and fluorescence intensity was
measured using the BD Biosciences FACSCalibur flow cytometer
(BD Biosciences). Cells stained with the secondary antibodies alone
were used as a negative control. Data were analyzed by using FCS
express software (De Novo Software, Los Angeles, CA). All chemi-
cals were provided by Sigma-Aldrich (St. Louis, MO).
Fractionation of RBCs on Percoll density gradient. Fractionation
of RBCs into light (L), medium (M), and dense (D) fractions was
performed in 90% isotonic Percoll solution prepared by mixing a
90-ml aliquot of sterile Percoll (GE Healthcare; density 1.130 g/ml)
with 10 ml  10 PBS (Sigma-Aldrich) and 11 ml  1 PBS (Sigma-
Aldrich). Blood or RBC suspension was prefiltered on cellulose filter
to remove WBCs, platelets were as described elsewhere (5), and
1.0–1.5 ml was overlaid then over 12.5 ml isotonic Percoll and
centrifuged using Sorvall RC 5C plus centrifuge equipped with a
SM-24 rotor at 4°C for 30 min at 45,000 g. The obtained L, M, and
D fractions of RBCs were collected and washed three times with the
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incubation medium containing the following (mM): 145 NaCl, 4 KCl,
10 glucose, 10 Tris·HCl, 0.1 EDTA, and 0.1% BSA (pH 7.4 at room
temperature). Therefore, the obtained RBCs were used for detection
of the number of [3H]MK-801 binding sites or for fluorescence live
imaging. The amount of reticulocytes in L, M, and D fractions was
18.1  8.2, 1.5  4, and 0.89  0.08% respectively, with mean
reticulocyte counts of 1.9  0.6%. Mean cell volume (MCV) of cells
in fractions was 103.6  1.9, 90.9  0.7, and 82.6  1.5 fl for the L,
M, and D fraction, respectively, mean MCV being 86.5  1.4 fl
(means  SD; Sysmex Digitana, Horgen, Switzerland).
Percoll solutions of lower density (82–86% Percoll) were used to
monitor rapid changes in volume occurring within the M fraction
containing the majority of mature RBCs in response to the NMDAR
stimulation. Final ion composition in Percoll solution was adjusted to
145 mM NaCl, 5 mM KCl, 20 mM HEPES (pH 7.4 at room
temperature), 10 mM glucose, and 2 mM CaCl2. Control samples
were agonists free. Stimulation of the NMDARs was performed by
supplementation of Percoll solution with 200 M of 1:1 NMDA-
glycine mixture. Washed RBCs (0.5 ml packed cells per 12 mM of
Percoll solution) were added to the Percoll solution, mixed with it and
centrifuged for 2 min at 48,000 g at room temperature. Due to the
interindividual variability in basal cell density and in the amplitude of
responses, Percoll density was slightly adjusted for each of five
healthy subjects tested to achieve better separation of the M fraction.
In four out of five donors, the agonists-induced changes in RBC
density developed within 2 min and were reversed already after 5 min
of stimulation. In one subject the volume changes prevailed even 15
min after the onset of exposure to the agonists.
NMDAR activity measurements in circulating RBCs. Changes in
the intracellular Ca2 levels in RBCs caused by exposure to the
NMDAR agonists or antagonists were monitored in L, M, and D
fractions by means of microfluorescent live imaging using fluo-4 AM
(Molecular Probes, Eugene, OR) as a marker (31). Loading of RBCs
with the fluorescent dye (1–5 M) was performed for 30 min at room
temperature in the darkness. During loading, the cells were resus-
pended in the incubation medium supplemented with 0.1% BSA and
2 mM CaCl2 to a density of 4  106 cells/ml. Thereafter, the cells
were placed in an imaging chamber and allowed to settle for 10 min.
In experiments in which kinetics of responses of individual cells to the
NMDA agonists and antagonists was monitored over time, the cov-
erslip serving as a bottom of the imaging chamber was coated with
polylysine to immobilize the cells. A series of images (bright field and
fluorescent images excited at center wavelength of 480 nm with a
half-width of 25 nm and a 510-nm longpass emission filter to reach
maximal detection efficiency) were taken with a100 objective using
Axiovert 200M microscope (Carl Zeiss, Jena, Germany). At least five
images were taken before the addition of agonists or antagonists and
used to calculate baseline levels of fluorescence. Solvent (incubation
medium) addition was performed in control samples.
Calibration was performed using cells resuspended in calcium
buffer containing 20–200 nM free Ca2 (a set of CaCl2-EGTA
mixtures) in the presence of Ca2 ionophore A23187 (10 M) and the
Ca2 pump blocker sodium orthovanadate (4 mM). These cells were
addressed to as calcium-clamped cells.
Analysis of the obtained images was performed using CellFinder
program developed by Dr. M. Makhinya (Computer Vision Lab; ETH
Zurich). This software was designed to detect the cell projection area
as an indicator of cell volume, the average fluorescent intensity within
this area corrected for the background fluorescence, and anisotropy (a
longest to shortest diameter ratio).
Radiolabeled antagonist binding assay was used as an alternative
approach to assess the number of active receptors per cell. [3H]MK-
801 is a specific NMDAR antagonist interacting with the channel pore
of active receptors exclusively (18). The number of [3H]MK-801
binding sites per cell in the absence or in the presence of a 200-fold
excess of nonlabeled MK-801 was assessed for evaluation of specific
and nonspecific binding.
Washed RBCs were incubated with [3H]MK-801 (20 Ci/mmol;
American Radiolabeled Chemicals) at a concentration of 5  107
mmol/ml (1 h, room temperature) in the presence of 300 M NMDA
and 100 M Gly. Thereafter the cells were fractioned according to
their density on 90% Percoll gradient (45,000 g, 30 min). L, M, and
D fractions were collected, washed three times in buffer 1 containing
the following (in mM): 145 NaCl, 5 KCl, 10 glucose, 0.1 EDTA, 10
Tris·HCl (pH 7.4 room temperature) supplemented with 0.1% BSA,
and lysed. One part of packed RBCs was mixed with 30 parts of lysis
buffer containing 25 mM NaH2PO4 and 1 mM EDTA (pH 7.0 at 0°C)
and incubated on ice for 30 min. Thereafter, RBC membranes were
precipitated (45,000 g for 30 min at 4°C) and the amount of [3H]MK-
801 bound to the membranes was assessed using Packard 1600 TR
liquid scintillation analyzer. The number of [3H]MK-801 binding sites
per cell was then calculated using the following equation:
NNR
Acells
AspMK 801  NA  Ncells
NNR is a number of NMDARs per cell, Acells denoted activity of bound
[3H]MK-801 after nonspecific binding is subtracted [Bq] and Asp
stands for specific activity of the [3H]MK-801 in [Bq/mmol], NA is the
Avogadro constant (6.022  1023 mol1), and Ncells are the amount
of cells in the sample.
Whole cell currents were measured using a NPC-16 Patchliner
(Nanion, Munich, Germany). The “pipette” solution contained the
following (in mM): 50 KCl, 10 NaCl, 60 KF, 20 EGTA, and 10
HEPES (pH adjusted to 7.2 by KOH), while the bath solution
contained the following (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2,
5 glucose, and 10 HEPES (pH adjusted to 7.4 by NaOH). NMDA,
glycine, and MK-801 were added as indicated in the experiments. The
pipette resistance was in the range of 3–5 M, and the seal resistance
was between 800 M and 5 G at a holding potential of 40 mV.
Measurements were performed with fresh RBC samples from three
healthy donors within 2–3 h after blood withdrawal.
pH measurements in RBCs and in RBC lysates. Shifts in the
intracellular pH were monitored over 10 min using microfluorescence
live imaging. RBC were washed three times in isotonic buffer con-
taining the following (in mM): 15 NaCl, 5 KCl, 10 glucose, 20
HEPES-imidazol buffer, 0.1 EDTA, and 0.1% BSA. The cells were
centrifuged and resuspended in the same buffer supplemented with 2
mM CaCl2 and 2 M of pH-sensitive fluorescent dye BCECF-AM
and incubated for 45 min at 37°C in the darkness to achieve optimal
dye loading. Some samples were supplemented with 50 M of MIA
during loading with the dye. The kinetics of the changes in BCECF
fluorescence in response to the treatment with 300 M of 1:1 NMDA-
glycine mixture were recorded at 488-nm excitation and 535-nm
emission wavelengths using Axiovert 200M fluorescent microscope
(Zeiss). The images were taken in time laps mode at 100 magnifi-
cation at a constant rate of 1 frame per min. The obtained data were
analyzed using CellFinder software. Fluorescent intensities were nor-
malized to those at time zero (first frame) and expressed as changes
compared with the readouts obtained for nontreated cells to correct for
the BCECF photobleaching.
Calcium-induced changes in pH were monitored in fresh hemo-
globin solution obtained by lysing 10 l of packed RBCs in 5 ml
of distilled water. Final hemoglobin concentration obtained that
way was 0.25 M. Sodium chloride concentration was then
adjusted to 150 mM, and 2,3-diphosphglycerate pentasodium salt
(2-mM final concentration; Sigma) was added to it. These solutions
were supplemented with various CaCl2 doses (0 –200 M), and pH
was measured at 37 0C using glass pH electrode of the ABL 700
blood analyzer (Radiometer). Thereafter, oxygen dissociation
curves were recorded from these cell lysates as described below.
Hemoglobin oxygen dissociation curves. Oxygen affinity of hemo-
globin was assessed using Hemox analyzer (TCS Scientific, New
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Hope, PA). Measurements were performed in Ca2-clamped cells, in
intact RBCs resuspended in buffer containing 2 mM CaCl2, and in
RBC lysates. Ten microliters of packed RBCs were added to 5 ml of
buffer in the presence or absence of NMDAR agonists NMDA (300
M) and glycine (100 M). Oxygen dissociation curves were re-
corded at 30 or 37°C and P50 calculated from them using Hemox
Analytical Software (HAS). Similar recordings were performed in
cell lysates [10 M of cells lysed in 5 ml H2O supplemented with
150 mM NaCl, 2 mM 2,3-diphosphoglycerate (2,3-DPG), and
various concentrations of CaCl2] obtained as stated above after pH
detection.
Statistical analysis. The obtained data were analyzed using
GraphPad Instat v.3.0 (GraphPad Software,) and presented as
means  SE. Statistical significant differences were assessed using
normality test followed by either one-way ANOVA test (when
distribution was normal) or Kruskal-Wallis test (when normality of
distribution cannot be confirmed) with the Bonferroni or Dunn’s
posttest correspondingly (accepted at P 	 0.05).
RESULTS
Expression of the NMDAR subunits in erythroid progenitors
during erythropoiesis. The number of functional NMDAR
heterotetramers in the immortalized human erythroid cell line
UT-7/Epo was estimated to be350,000 copies per cell (38).
We have then performed characterization of the expression
pattern of NMDAR subunits during ex vivo erythropoiesis
derived from peripheral stem cells and in circulating human
RBCs. Subunit speciation of the NMDARs in human EPCs
during their differentiation was monitored in the course of
transformation from pluripotent precursor (day 0) cells through
the proerythroblast (day 6) and basophilic and polychromatic
erythroblast (day 12) stages to normoblasts and enucleated
reticulocytes (day 18). Differentiation stages were verified
morphologically (Fig. 1, A–C) as well as by expression of
CD71 (Fig. 2). We have detected transcripts of the genes
Fig. 1. Peripheral blood-derived erythroid cultures express N-methyl-D-aspartate receptor (NMDAR) subunits. Representative cytospins of erythroid cells on day
6 (d6, A), 12 (d12, B), and 18 (d18, C). Cytospins were stained with May Grünwald Giemsa, and images were acquired with a Zeiss Axioskop2 microscope
equipped with a Zeiss Plan-Apochromat 63/1.4 oil immersion objective lens and a Zeiss AxioCam MRc digital camera. Images were recorded using Zeiss
AxioVision AC release 4.5.0 software. D: relative amounts of the GRIN gene transcripts in erythroid precursor cells (EPCs) harvested at day 6, 12, and 18
measured by TaqMan quantitative PCR. Values are represented as box plots of 9 erythroid cultures, each started with cells from a different donor. An overall
comparison indicated significant increase in expression of GRIN1 and GRIN2C between the days 6 and 18 in culture. *P 
 0.0391; **P 
 0.0078.
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Fig. 2. Changes of protein levels of NMDAR subunits
during erythropoiesis. Peripheral blood-derived erythroid
cultures were analyzed by flow cytometry on day 6 (d6),
12 (d12), and 18 (d18) after seeding. NMDAR subunit
expression at various EPC differentiation states was as-
sessed. Surface expression of CD71 (CD71 FITC) was
used as a marker of EPCs in the presented dot blots. The
number of cells expressing NMDAR subunits are shown as
histograms. Grey plots show the signal obtained from
staining with secondary APC-conjugated antibodies alone,
and black plots show specific anti-NR-APC signal. The
geometric mean fluorescence intensity (MFI) and the frac-
tion of cells showing specific anit-NR-APC signal were
analyzed from 60’000 cells each measurement and repre-
sented as box plots for the subunits NR2C (A), NR2D (B),
NR3A (C), and NR3B (D). Values are represented as box
plots of 9 erythroid cultures, each started with cells from a
different donor (n 
 9).
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GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A, and GRIN3B
encoding NMDAR subunits NR1, NR2A, 2C, and 2D and
NR3A and 3B in EPC at various stages of erythropoiesis (Fig.
1; Table 1). Relative expression of GRIN1 and GRIN2C
mRNA increased substantially from day 6 to day 18 in culture
(P 	 0.05; Fig. 1E). A tendency to increased expression of
GRIN2A, GRIN3A, and GRIN3B mRNA over 18 days in
culture was detected but was not statistically significant (Fig.
1E). Maximal expression of GRIN2D mRNA was found in
cells after 12 days in culture, whereas in 18-day-old cells the
expression levels dropped to the values similar to those de-
tected at day 6 (Fig. 1G). No transcripts of GRIN2B were
detected at any differentiation stage. In peripheral RBCs we
were not able to detect any GRIN transcripts, indicating that
those were eliminated during erythrocyte maturation (data not
shown).
Protein levels of subunits NR2C, 2D, 3A, and 3B were
measured using flow cytometry (Fig. 2). The number of ery-
throid cells in culture expressing NMDAR subunits varied
between 10 and 30%. The number of erythroid cells expressing
NR2C and NR2D increased during the basophilic and poly-
chromatic cell stages and decreased again once cells matured
towards normoblasts and reticulocytes (Fig. 2, A and B).
However, the number of copies for these subunits was rather
stable throughout the culture period as follows from the mean
fluorescence intensity levels (Fig. 2, A and B). The subunit
NR3A appeared to be expressed by an increasing proportion of
cells throughout erythropoiesis; however, its expression de-
creased slightly (Fig. 2C). The number of cells expressing
NR3B remained stable during the erythropoietic culture,
whereas its expression increased slightly (Fig. 2D). Specifi-
cally during ex vivo differentiation, the GRIN2D levels of the
median subunit per cell remained relatively unchanged from
day 6 (proerythroblast) with 186,000 (41,000–320,000) to day
12 (basophilic erythroblast) with 140,000 (18,300–540,000)
subunits per cell. Towards days 18–24 in culture (polychro-
matic- and normoblast, and also reticulocytes), expression of
the NR2D subunit dropped to 120,000 (4,100–240,000) sub-
units per cell. Thus the stable expression of GRIN2D mRNA
during differentiation from myeloid progenitor towards the
basophilic/polychromatic erythroblast was mirrored by a stable
expression in GRIN2D protein levels. During differentiation
towards erythrocytes the transcripts appear to become de-
graded, as they are not detected anymore, whereas NR2D
protein is retained although at much lower levels (data not
shown).
The importance of functional NMDARs in EPCs in the
course of differentiation was explored. The kinetics of changes
in the intracellular Ca2 levels in EPCs in response to stimu-
lation of the NMDARs with a mixture of NMDA and glycine
(300 M each) in the absence or presence of 50 M MK-801
were monitored using fluorescence microscopy. Administra-
tion of NMDA/glycine to the cells at day 12 resulted in acute
increase in the intracellular Ca2 levels as shown in Fig. 3A.
Table 1. Expression of NMDAR subunits in WBCs
Gene ID* Protein Ct
Ct (fold mRNA
expression compared with
EPCs)
GRIN1 2902 NR1 19.8 1.6 7.0
GRIN2A 2903 NR2A 15.8 1.9 11.2
GRIN2B 2904 NR2B 18.8 1.4 (Not expressed in EPCs)
GRIN2C 2905 NR2C 15.6 1.8 0.7
GRIN2D 2906 NR2D 12.0 0.9 11.0
GRIN3A 116443 NR3A 18.3 2.3 1.0
GRIN3B 116444 NR3B 17.3 1.6 10.8
Values are SE for 3 cultures, each started with cells from a different donor
(n 
 3). EPC, erythroid precursor cell. Relative amounts of transcripts of
N-methyl-D-aspartate receptor (NMDAR) subunits were detected by TaqMan
quantitative PCR. White blood cells (WBCs; predominantly monocytes) were
obtained from mononuclear cells in culture and separated from the hemato-
poietic stem cells (HSC) at day 3 of culturing as “adherent cell fraction.”
Individual values were normalized to GAPDH (Ct), and the individual fold
change compared with the median Ct values of erythropoiesis at day 6 was
calculated (expCt, fold change in mRNA expression). Comparison with the
values for mRNA expression in HSCs at day 3 was not possible as too few
cells were available at that time. GRIN2B expression in HSCs was fixed to 40
cycles. *NCBI gene ID.
Fig. 3. NMDAR function in EPCs. A: cells on day 12 were loaded with 3 M fluo-4 AM for 45 min at 37°C in cell culture medium and thereafter fluorescence
recordings were initiated using Axiovert 200M microscope in time-lapse mode at a frequency of one frame in 7 s. Cells were stimulated with 300 M of
NMDA/glycine 1 min after the onset of recordings and the changes in fluorescence followed for 10 min. Some cells were pretreated with 50 M of MK-801
for 45 min before the imaging procedure. The antagonist was present in the cell culture medium during the imaging. The number of cells analyzed was 542 for
control nontreated group (closed squares), 511 for the NMDA/Glycine-stimulated group (grey triangles), and 494 for the cells pretreated with MK-801 before
the stimulation with antagonists (open circles). B: cells at day 12 (closed circles) or at day 18 (open circles) were exposed to various concentrations of MK-801
for 24 h and cellular viability was assessed thereafter using flow cytometry (FacsCalibur; BD). Nuclear staining of propidium iodide was used as a marker of
cell death.
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Whenever MK-801 was present in the incubation medium
before the receptor activation, the response was biphasic. A
transient and incomplete Ca2 accumulation during the first 30
s upon NMDA/glycine addition was followed by a decrease in
the intracellular Ca2 significantly below the levels observed
in control nontreated cells. On day 18, EPCs lost their sensi-
tivity to NMDA/glycine and stimulation of the receptors did
not result in any acute significant changes in the intracellular
calcium along with higher intercellular variability in the intra-
cellular Ca2 levels and responsiveness to the stimulation (data
not shown). The effects of long-term exposure on the EPCs to
different concentrations of the pore blocking NMDAR antag-
onist MK-801 were explored. In line with the data on NMDA/
Gly-sensitivity of the intracellular Ca2 levels, exposure of
EPCs at day 12 to 50 M MK-801 for 24 h resulted in
significant increase of mortality whereas the cells at day 18
were antagonist resistant (Fig. 3B).
NMDAR expression pattern in WBCs. To evaluate the im-
pact of potential contaminations of myeloid progenitors in our
culture systems and that of WBCs in our RBCs preparations,
we used CD45 as a marker of myeloid and WBCs (45). We
were unable to detect myeloid cells in our culture system after
day 6. No WBCs were detected in purified RBCs, as shown
previously (3). We have assessed the expression GRIN tran-
scripts in adhesive WBCs separated at day 2 from our erythroid
culture. These cell preparations contained predominantly
monocytes. Expression of GRIN1 in this myeloid cell popula-
tion exceeded that in erythroid cells at day 6 of the erythro-
poietic culture by 4.4-fold, that of GRIN2A by 6.5-fold, and
that of GRIN2D by 9.8-fold whereas GRIN2C was 50% lower
in WBCs than in erythroid progenitors (Table 1). Compared
with erythropoietic cultures at day 18, WBCs expressed 0.6-
fold less GRIN1, 3.8-fold more GRIN2A, 0.06-fold less
GRIN2C, and 10.8-fold more GRIN2D compared with the
levels in basophilic and polychromatic erythroblasts (Table 1).
These findings provided further evidence for the absence of
myeloid cells or WBCs in erythroid cell culture. Expression
profiles for NMDAR subunits GRIN1, GRIN2C, and GRIN3A
in differentiated erythroid cells differed substantially from
those in WBCs. Furthermore, WBCs appeared to express
GRIN2B subunit whereas in erythroid cells the GRIN2B tran-
scripts remained below detection level at any time in culture
(Table 1).
NMDAR activity and intracellular Ca2concenrtation. In
the following set of experiments, the activity of NMDAR was
assessed in circulating RBCs. Changes in the intracellular
calcium levels in RBCs upon treatment with agonists NMDA,
glutamate, and HCA are shown in Fig. 4A. Increase in the
intracellular Ca2 levels, which was induced within minutes of
exposure to the agonists, could be blocked by the pore-block-
ing antagonist interacting with the open receptor channel MK-
801 (Fig. 4, A and B). Responses of individual cells to the
NMDAR stimulation varied substantially (Fig. 4C). However,
despite pronounced intercellular variability, the majority of
cells responded to the treatment with the NMDAR agonists
with acute Ca2 uptake.
NMDAR-induced whole cell currents in RBCs. Calcium
uptake following activation of the NMDAR was associated
with an increase in whole cell currents across the RBC plasma
membranes (Fig. 5). Changes in membrane conductance were
assessed using automated patch clamp platform Patchliner
(Nanion). Similar to the observations obtained using micro-
fluorescence live imaging (Fig. 4C), sensitivity of the cells to
agonists and antagonists varied markedly between individual
cells. An increase in currents associated with exposure to the
NMDA-glycine mixture was observed in 29.4% of cells. Cur-
rents induced by the treatment of cells with agonists could be
blocked by the treatment of cells with MK-801. Examples of the
NMDA-sensitive currents are shown in Fig. 5, A and C, and
statistical analysis of the findings in responding cells is given in
Fig. 5E. The appearance of the current-voltage (I-V) curves
changes when the NMDAR is activated (green line in Fig. 5D) or
when it is blocked (blue line in Fig. 5D). To relate the current
traces to the other data in the paper the slope of the I-V curves was
analyzed in the physiological relevant range between 30 and 0
mV (Fig. 5D). At stimulated NMDAR, the whole cell conduc-
tance is significantly increased compared with naïve RBCs (green
column vs. red column in Fig. 5E). When the RBCs with activated
NMDARs are treated with MK-801 to block NMDAR activity,
the whole cell conductance is significantly decreased (green col-
umn vs. blue column in Fig. 5E).
NMDAR abundance in RBC fractions of high medium and
low density. In the next sets of experiments RBCs were
separated into fractions according to their density using Percoll
density gradient centrifugation. D, M, and L fractions were
isolated as shown in Fig. 6A. The basal activity of the receptor
and total number of the functional NMDAR units was mea-
sured in each fraction using two independent approaches:
radioactive antagonist binding assay and agonists/antagonists-
induced changes in the intracellular calcium levels. Basal
receptor activity was evaluated as the cells were allowed to
interact with [3H]MK-801 in plasma and then fractioned on
Percoll gradient. The number of binding sites for radiolabeled
antagonist per cell obtained that way reflected the number of
NMDARs active in plasma-borne RBCs. The values for the
[3H]MK-801 binding to “activated” cells were obtained in the
presence of saturating concentrations of NMDA in plasma and
hence represented the total number of receptors. As shown in
the Fig. 6B, the number of active receptors interacting with
[3H]MK-801 was maximal in the L fraction enriched with
reticulocytes and young cells (see DESIGN AND METHODS). In this
fraction, no further activation of the receptor could be caused
by glutamate/NMDA supplementation of plasma. In contrast to
that, the receptors in M and D fractions, although significantly
lower in number, could be further activated by addition of
agonist to plasma (Fig. 6B).
These experimental settings could give rise to artefacts due
to the WBCs contamination (average of 5.6, 4.9, and 1.4 per
1,000 cells in the L, M, and D fractions; Ref. 45). To avoid the
overestimation of the receptor activity in RBCs, we have used
an alternative approach monitoring the agonist-induced Ca2
uptake in individual RBCs of L, M, and D fractions isolated
from blood of three healthy individuals by microfluorescence
live imaging. Receptor activity in RBCs of these donors was
assessed by [3H]MK-801 binding and presented in the right
panel of Fig. 6 (in red for donor 1, in green for donor 2, and in
blue for donor 3). The observations obtained by means of
microfluorescence imaging were in agreement with the ones
generated using radiolabeled antagonist binding assay. Maxi-
mal amount of “responding” RBCs of each individual donor
was present in the L fraction (Fig. 7A). Maximal amplitude of
NMDA-induced Ca2 uptake was recorded in the least dense
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Fig. 4. Changes in the intracellular Ca2 lev-
els in red blood cells (RBCs) exposed to
agonists and antagonist of NMDARs. A: an
increase in the intracellular Ca2 in response
to administration of 100 M NMDA, 100 M
NMDA  100 M glycine, 100 M gluta-
mate, or 50 M homocysteic acid (HCA) was
observed. Data are means of 34–80 single cell
recordings  SE. The orange bar on top of
each panel schematically indicates the dura-
tion of exposure to the agonists. B: sensitivity
of the HCA-induced Ca2 uptake by RBCs to
the NMDAR antagonist MK-801 (50 M).
Pretreatment with antagonist for 10 min abol-
ished the effects of subsequent exposure to
HCA. The green trace represents the average
Ca2-sensitive fluorescent signal recordings
for 444 unstimulated control HBA RBCs in
Tyrode’s solution. The red trace shows the
F/Fo ratio for RBCs stimulated with NMDAR
agonist HCA (100 M) 1 min after the start of
the recordings averaged from 776 single cell
recordings. Preincubation of the cells with
NMDAR antagonist MK-801 (100 M) ad-
ministered 10 min before the onset of the
recordings did not affect the basal intracellular
Ca2 levels during 20 min of exposure (blue
trace, average of 775 individual cell record-
ings), but effectively inhibited the HCA-sen-
sitive Ca2 influx, as depicted by the brown
trace (average of 742 individual cell record-
ings). Each curve shows data from 9 indepen-
dent measurements of 3 healthy donors  SE.
(C) A selection of traces from individual cells.
The images above the diagram exemplify the
original fluorescent images of cells at the time
points indicated by the dotted lines. The false
color coding scale is shown next to the origi-
nal tracks of the changes in fluorescence in-
tensity over time. The colors of traces corre-
spond to those of the circles marking the
individual cells in the leftmost image. The
tremendous cell-to-cell variation is obvious in
both the images and the traces.
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fraction of RBCs of donor 2. Transient Ca2 accumulation in
RBCs was associated with a transient shrinkage of cells that
could be caused by the activation of Gardos channel. Medium
density fraction of the donor 2 was also rich in responding
RBCs and showing a transient reduction in cell volume in
response to the NMDAR stimulation (Fig. 7B, middle).
We used Percoll density gradient to assess the amount of
cells changing their volume in response to the NMDAR stim-
ulation in the M fraction to which majority of RBCs belong
(Fig. 6A). The density of Percoll solution used in these exper-
iments was adjusted to resolve the changes in the M fraction.
As shown in Fig. 7D, most of the cells forming M fraction
migrated downwards in Percoll gradient 2 min after the onset
of stimulation with 300 M of 1:1 NMDA/glycine mixture.
This increase in RBC density was transient and could not be
detected 5 min after the onset of exposure to the NMDAR
agonists in four out of five donors. Cells of the fifth donor
remained dehydrated even after 15 min of exposure to the
agonists. No volume changes were observed in RBCs of all
donors suspended in nominally Ca2-free Percoll solution
containing 0.1 mM EDTA supplemented with NMDA and
glycine (data not shown).
In fraction D (Fig. 7C), the cells remained largely insensitive to
the agonist treatment and showing modest transient increase in the
intracellular Ca2. The obtained data revealed vast interindividual
and intercellular variation in the number of functional receptor
units and the amplitude of responses to the NMDAR agonists.
Among typical morphological characteristics of responding cells
are big volume (cell surface projection) and low density as L
fraction is enriched with responding cells. Medium fraction also
contains some of the responders, whereas D fraction is largely
deprived of them.
The impact of NMDAR activation state on Gardos channel
function. The following experiments were performed to assess
the possible influence of NMDA-sensitive Ca2 uptake on K
transport across the RBC membrane. Ouabain-resistant chlo-
ride-independent K (86Rb) influx was assessed at room tem-
perature, as was the case for Ca2 imaging presented in Fig. 7.
Fig. 5. Whole cell currents of RBC under
activation and blocking of the NMDARs.
Measurements as shown in A were per-
formed on 56 gigasealed RBCs. However,
for an observation period of 15–20 min only
34 cells were stable enough to allow analy-
sis. 29% of the analyzed RBCs were classi-
fied as “responders.” Similar in size fraction
of responding cells was obtained in Ca2
imaging experiments and when the number
of NR2D subunits was assessed using flow
cytometry. Responding cells were the RBCs
showing an increase in conductance with the
application of NMDA (100 M) and glycine
(300 M) and a decrease when MK-801 was
added. A: original current traces of an RBC
under the conditions presented above the traces
as a response to the voltage protocol given in
B. The current-time (I-t) diagram in C depicts
the temporal distribution of the currents at80
and 80 mV over the experimental course
starting with naïve RBC, application of
NMDA and glycine for NMDAR activation
and finally MK801 for NMDAR block as
indicated. The current traces in A correspond
to the time points at 2, 10, and 18 min,
respectively in C. D: current-voltage (I-V)
curves of the responding RBCs under the
conditions indicated (data are mean of 10
measurements). The slope of the curves in
the range between 30 and 0 mV was ana-
lyzed by linear regression and the results are
presented in E, revealing significant differ-
ences in the whole cell conductance at the
physiologically relevant membrane potential
for the different experimental conditions.
Significance was tested by comparing the
slopes using a 2-way ANOVA test and is
expressed as *P 	 0.05, **P 	 0.01, and
n.s., P  0.05.
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No density fractioning was performed before flux measure-
ments. As shown in Table 2, treatment of RBCs suspended in
Ca2-containing but not in nominally Ca2-free incubation
medium with 50 M memantine caused reduction in unidirec-
tional K influx. Administration of 100 M NMDA triggered
the activation of clotrimazol-sensitive Ca2-dependent K
influx. In nonactivated cells, Gardos channels remained quies-
cent.
Effect of the NMDAR activation on hemoglobin oxygen
affinity. The effect of the intracellular Ca2 on oxygen binding
to hemoglobin was tested. Intracellular free Ca2 concentra-
tion was clamped as cells were treated with Ca2 ionophore
A23187, and extracellular concentration of free calcium ions
was adjusted to 10–200 nM by using an EGTA-CaCl2 buffer
system. Oxygen dissociation curves were then measured and
PO2 required to achieve hemoglobin oxygen saturation of 50%,
P50, was assessed for the calcium-clamped RBCs. Calcium
levels in clamped RBCs were assessed using microfluores-
cence imaging. As shown in Fig. 8, the fluorescent signal
intensity of fluo-4 follows linearly the changes in the intracel-
lular Ca2 within the 10- to 200-nM interval (Fig. 8A). Intra-
erythrocytic Ca2 levels in intact and NMDA-stimulated cells
lies within this concentration range (triangle symbols). Oxygen
affinity of Ca2-clamped cells drops (P50 increases from
2.28  0.01 to 4.1  0.27 kPa) as intracellular Ca2 increased
from 20 to 200 nM (Fig. 8C). Exposure of RBCs in suspension
to 300 M NMDA-100 M glycine mixture was also associ-
ated with an increase in P50 (Fig. 8, B and D).
Acute transient RBC shrinkage triggered by exposure to the
NMDAR agonists results in transient increase in the intracel-
lular levels of 2,3-DPG and ATP due to the cytosolic water
loss. Additional experiments were performed to explore if this
factor contributed to a decrease in hemoglobin oxygen affinity.
Oxygen dissociation curves were monitored in RBCs sus-
pended in the medium containing 100 mM KCl/50 mM NaCl
medium or in the presence of clotrimazol. The effect of
NMDA/glycine on P50 was less pronounced but still preserved
in both conditions, (3.04 0.65 kPa in control vs. 3.16 0.04
kPa in depolarizing high KCl medium, P 
 0.011).
The effect of NMDAR agonists on the intracellular pH was
assessed microscopically using proton-sensitive fluorescent
dye BCECF-DA. Treatment of RBCs with NMDA/glycine
resulted in a modest transient decrease in pH-dependent
BCECF fluorescence indicating transient intracellular acidifi-
cation (Fig. 8F). The signal we reported was underestimated as
shrinkage following the NMDAR activation caused concentra-
tion of the fluorescent dye. This acidification reaction moni-
tored in bicarbonate-free medium was insensitive to the inhib-
itor of Na/H exchanger methyl isobutyl amiloride applied at
the concentration of 50 M. The ability of Ca2 to cause the
proton release from hemoglobin was explored as RBC lysates
(Hb concentration of 0.25 M, equilibrated with ambient air)
were exposed to various concentrations of Ca2. Cell lysates
prepared in 150 mM NaCl solution showed no changes in pH
in response to Ca2 administration. However, dose-dependent
acidification was observed if cell lysates were exposed to Ca2
Fig. 6. Activity and abundance of the NMDAR units in light (L), medium (M), and dense (D) RBC fractions. Cells were incubated with radiolabeled [3H]MK-801
in the absence or presence of saturating concentrations of NMDA (300 M) and glycine (100 M) added to plasma (activated cells, orange dots). Thereafter,
the cells were separated according to their density into L, M, and D fractions on Percoll gradient as shown in A. B: presents binding of radio-labeled MK-801
to the activated NMDARs was then determined in RBCs in L, M, and D fractions. Non-specific binding was assessed in the presence of 200-fold excess of
non-labeled MK-801 and subtracted from the obtained values. Thus the number of active NMDARs was obtained. Values obtained in plasma were shown as
“basal receptor activity” in nonstimulated RBCs. Upon stimulation with agonists all receptors in cells were activated and therefore binding of [3H]MK-801. Thus
the number of [3H]MK-801 binding sites within activated cells reflected total number of receptors in cells forming L, M, and D fractions. The measurements
were performed in blood samples per cell collected from 31 healthy human subjects. Data are presented as box and whisker plots in which each dot represent
a value obtained for an individual subject. Specifically marked in red (1), green (2), and blue (3) are the number of active receptors in blood samples of donors
blood of which was used to generate data shown in Fig. 7. In L, M, and D fractions distribution of values for individual donors did not show normal Gaussian
distribution and statistical analysis of the data was performed using nonparametric Kruskal-Wallis test with Dunn’s posttest (**P 	 0.01, and ***P 	 0.0001
compared with the basal activity of the NMDAR in corresponding fraction).
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Fig. 7. Kinetics of Ca2 uptake and volume changes in response to NMDAR activation in L, M, and D fractions. Intracellular calcium levels were assessed in
RBCs forming L (A), M (B), and D (C) fractions after their separation on Percoll density gradient using fluorescent live cell imaging. The experiments were
performed using blood of subjects 1 (red), 2 (green), and 3 (blue). The values of [3H]MK-801 binding obtained for RBCs of these subjects are highlighted in
corresponding colors in Fig. 6. Presented in the left panels are quantification of Fluo-4 fluorescence intensity F upon stimulation with glutamate (300 M) and
glycine (100 M) normalized to that at time zero in agonist-free medium (Fo). Middle: changes in cell projection area in the bright field images over the period
of stimulation with the NMDAR agonists. The numbers of cells used for analysis varied from 13 to 35. Data are presented as mean  SE. Right: representative
fluorescent images at 3 points in time (before, 1, and 6 min after the stimulation) for the cells in L, M, and D fractions obtained from blood of subject 2 (green
plots). Kruskal-Wallis test was performed to follow the changes in Ca2 levels and cell surface (a marker of volume) after the receptor activation. *P 	 0.05,
** and **P 	 0.01 and ***P 	 0.001 compared with time zero. D: shift of RBCs within the M fraction down the Percoll density gradient in response to 2 min
of stimulation with 300 M of 1:1 NMDA/glycine mixture in donors 1, 2, and 3.
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in the presence of 2 mM 2,3-DPG (Fig. 9). Exposure of
2,3-DPG alone to Ca2 did not result in the changes in pH (Fig.
9). Oxygen binding to hemoglobin within RBC lysates was
tested in the presence of 2,3-DPG and various concentrations
of Ca2. As shown in Fig. 9 Ca2-induced proton release was
associated with a dose-dependent rightward shift in oxygen
binding curve, the effect observed in Ca2-loaded or NMDA-
glycine stimulated RBCs (Fig. 8). Similar to that of pH, oxygen
binding to hemoglobin in lysates remained calcium-insensitive
in the absence of 2,3-DPG (data not shown).
DISCUSSION
Following up on our earlier observations on the presence of
NMDARs in rat RBCs and in human myeloid cell line differ-
entiating into erythroid progeny, UT-7/EPO (38), we have
demonstrated that NMDAR subunits are expressed in human
EPCs. Circulating human RBCs retain a limited number of
functional receptor units compared with the EPCs. Mammalian
RBCs may therefore be added to the list of cells possessing
NMDARs along with neurons and a number of nonneuronal
cells and tissues (22, 57). Expression of the GRIN transcripts
coding for the NMDAR subunits was changing dynamically
during erythropoiesis, as did the protein abundance. NMDARs
appear to be essential for survival, particularly at the early
stages of differentiation of precursor cells during erythropoie-
sis. Subunit composition of the erythroid receptors differed
substantially between the erythroid progeny and WBCs.
Calcium uptake was reported to be of key importance for
promoting differentiation and proliferation of EPCs at the
stages of burst-forming units erythroid (BFU-E) colony-form-
ing units erythroid (CFU-E; Refs. 43, 56). Increase in the
intracellular Ca2 is an integral part of signaling pathway
activated by binding of erythropoietin to its receptor (44). Our
data suggest that glutamate released from megakaryocytes (63)
Table 2. Effects of NMDA and memantine on the
unidirectional ouabain-insensitive Cl -independent K
(86Rb) influx in Ca2-containing and Ca2-free medium
Treatment
1.8 mM Ca2,
mmol·lcells1·h1
Ca2-free,
mmol·lcells1·h1
Control 0.0134 0.0017 0.0176 0.0029
Memantine 0.0056 0.0012* 0.0162 0.0015
Clotrimazol 0.0158 0.0016 NA
NMDA 0.0201 0.0017* 0.0160 0.0008
NMDA-memantine 0.0102 0.0059 0.0168 0.0028
NMDA-clotrimazol 0.0126 0.0023 NA
Values are means  SE. *P 	 0.05, in one-way ANOVA analysis with
Dunnett multiple comparison posttest; NA, not assessed.
Fig. 8. Ca2 sensitivity of hemoglobin oxygen affinity. Intracellular Ca2 concentration in RBCs was clamped using A23187 and EGTA-CaCl2 buffer to 5–200
nM. A: efficacy of clamping of intracellular Ca2, which was monitored as the change in fluorescence intensity of fluo-4 (open circles). Fluorescence intensity
measured in cells clamped at 50 nM Ca2 was chosen as Fo. Closed triangles show the fluorescence intensity of fluo-4 in native cells in the absence of presence
of 300 M NMDA/100 M glycine, which were resuspended in buffer containing 1.8 mM CaCl2. B: data on P50 detection obtained for the blood of one single
donor on four occasions. Before the P50 detection RBCs were loaded with various concentrations of calcium (clamping at 20 or 200 nM free Ca2). Oxygen
dissociation curves for calcium-clamped cells were recorded at 30°C. C: changes in P50 caused by exposing RBCs of 7 healthy donors to a mixture of NMDA
(300 M) and glycine (100 M). Intact RBCs were resuspended in the medium containing 2 mM Ca2 at 37°C and agonists added at the onset of oxygen
dissociation curve recording. Each point represents P50 of one donor (mean of triple recordings). Also presented are median values with variance shown as
whiskers. D: rightward shift in oxygen dissociation curve observed 1 min after the onset of stimulation with 300 M of 1:1 mixture of NMDA/glycine at 37°C.
E: opposite leftward shift in the same blood sample monitored between the 3d and 4th min of NMDAR stimulation. These reciprocal changes in P50 were
associated with the opposite shifts in the intracellular pH over shown in F. RBCs of 4 different donors were used for measurements of the intracellular pH by
means of microfluorescence live imaging. Due to the technical difficulties imaging was performed at room temperature. Shown are the differences in mean
fluorescence intensity between the unstipulated control and cells exposed to the 300 M of 1:1 mixture of NMDA/glycine. The number of cells analyzed at each
time point ranged between 343 and 412. P 	 0.05 resulting from Mann-Whitney test (normal distribution was not confirmed). ***P 
 0.0002, *P 	 0.05.
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may contribute to the regulation of Ca2 levels in EPCs at day
12 corresponding to the stage of basophilic and polychromatic
erythroblasts (Fig. 3A). The number of EPCs possessing NR2C,
2D, and 3A subunits is maximal at this stage (Fig. 2). Accord-
ingly, the cells display high sensitivity to treatment with NMDAR
agonists in our ex vivo erythropoietin system (Fig. 3A).
Ca2 uptake is inhibited and differentiation and survival of
EPCs is compromised in calcium-free medium (43, 56). Sim-
ilar to that, inhibition of Ca2 uptake by MK-801 in our ex
vivo erythropoiesis system resulted in 45.5  12.8% mortality
of cells at the stage of basophilic and polychromatic erythro-
blasts (Fig. 3B). Cells at later differentiation stages (normo-
blasts at day 18 and enucleated RBCs) are less or not at all
damaged by MK-801.
Transient receptor potential channels TRPC2, 3, and 6 were
suggested to mediate Ca2 currents in EPCs (23, 67). How-
ever, observations on the activation of the TRPC channels by
the downstream targets of erythropoietin [e.g., phospholipase
C (PLC), and protein kinase C (PKC)] were exclusively re-
ported in nonerythroid channel expressing systems (CHO and
HEK cells). Similar to TRPCs, NMDARs were shown to be
sensitive to the activation of PLC-inositol-3-phosphate kinase
signaling cascade and targets of regulatory PKC-induced phos-
phorylation (39, 73). Thus both types of ligand-gated channels
may coexist in membranes of EPCs (63).
Subunit composition of the erythroid NMDARs. From the
data shown in this study, we conclude that human erythroid
NMDARs are hetero-tetramers composed of NR1, NR2A, 2C,
and 2D and NR3A and 3B subunits. Subunit composition of
the erythroid NMDARs differs strikingly from that of the
neuronal receptors. As follows from our observations, NR2D
and NR2C are most abundant NMDAR subunits in EPCs and,
most likely, in circulating RBCs. In the mammalian brain, this
subunit shows particularly restricted temporal and spatial ex-
pression pattern. Very high levels of expression of NR2D in
some areas of embryonic rat brain (precocious midline dien-
cephalic structures and medial geniculate, anteroventral nu-
cleus, and periaqueductal grey zones) drop down dramatically
during postnatal period (49). In adult rodent brain, NR2D is
only detected in cerebellum and Golgi structures (9, 47) and is
highly expressed in motoneurons of the spinal cord (66). In
bone marrow and in megakaryoblasts derived from CD34
precursor cells, the NR2D subunit was found along with NR1
and NR2A (19, 24). Among the characteristic features reported
for the NR2D/NR1 heterodimers are reduced Mg2 block,
lower ion conductance and slow inactivation (15, 54). How-
ever, based on the available data obtained in transfected cells
by other groups, one can suggest that the erythroid-specific
receptor channels share at least some of these features, such as
slow inactivation, since glutamate-binding NR2D subunit is
highly abundant in these cells. Calcium accumulations ob-
served upon activation of the receptor activity with glutamate,
NMDA, and homocysteic acid that could be blocked by MK-
801 (Fig. 4) are in line with this hypothesis (33, 46, 48).
However, in erythroid precursors the glycine-binding NR3A
and B subunits were highly expressed, whereas the expression
of a common NR1 subunit was modest compared with that in
the brain (Figs. 1 and 2). These subunits are known as “inhib-
itory subunits” in the brain as they are glutamate-insensitive
but excited by glycine only (35). Currents induced by glycine
in NR1/NR3 diheteromers are insensitive to MK-801 or me-
mantine (58). This is not the case for the erythroid NMDARs,
as the receptors respond to the pore-targeting antagonists in
both EPCs and circulating RBCs. Thus the receptors are either
NR1/NR2 heterodimers or are built up of all three subunit
subtypes (NR1/NR2C, D/NR3 heterotetramers), although the
existence of the latter has been questioned (69). Any specula-
tions on the electrophysiological characteristics of erythroid
NMDARs require verification upon detailed investigation.
Receptor function in circulating RBCs of healthy human
subjects. NMDARs retained in circulating RBCs remain func-
tional and keep responding to stimulation with glutamate,
HCA, or NMDA as well as to the inhibition by MK-801 (Figs.
3–6). Calcium transport through the receptor is electrogenic,
putting NMDARs in line with other calcium-transporting ion
channels (Fig. 4). The number of such ion channels in RBC is
rather limited and their molecular identity often remains un-
known (28). Among the TRP channels, only TRPC6 is de-
scribed in RBC (17). Furthermore, there is biochemical and
functional evidence for a CaV2.1 channel (1, 71). There are
numerous electrophysiological reports of Ca2-permeable
channels that can be grouped in two categories: nonselective
voltage activated cation channels (NSVAC; e.g., Refs. 4, 29)
and receptor-mediated channels (e.g., Refs. 13, 25). Although
the I-V curve for NSVAC in whole cell conductance mode (55)
differs from that shown in Fig. 4D, NMDARs and NSVACs
have one common property. Both channels share the hysteresis
of whole cell current-voltage curves as their opening probabil-
ity depends on the direction in which membrane potential
changes occur (50).
The receptor-activated channels previously described in
RBCs share some conductance properties with the channel
described in Fig. 5 (13, 25). However, it is premature to make
any conclusions on the molecular identity of these channels.
Our findings strongly suggest that the currents presented in Fig.
5 are NMDAR mediated. Stimulation of RBCs with NMDA
induced an increase in conductance whereas administration of
the pore-blocking antagonist suppressed it. Asymmetrical al-
terations in conductance in response to NMDA treatment
Fig. 9. Dose-dependent Ca2-induced changes in pH and in P50 measured in
RBC lysates. Changes of pH and hemoglobin oxygen affinity in RBC lysates
in the presence of 2,3-diphosphoglycerate (2,3-DPG). RBCs were lysed in the
distilled water, and then NaCl was added to a final concentration of 150 mM
with the final hemoglobin concentration 0.25 M. 2,3-DPG (2 mM) and
various concentrations of CaCl2 were added and pH (closed circles) was
measured at 37 0C for each sample in prior to the P50 measurements (grey
diamonds). The impact of 2,3-DPG-Ca2 interactions into the observed shifts
in pH was assessed (open circles). Data shown are means of triplicate
measurements form one representative donor. The experiment was repeated
with blood of 3 different healthy individuals.
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suggest that is it may be channel mediated. The current mea-
sured is a superposition of NMDAR-channel current, currents
mediated by other ion channels (e.g., those reported elsewhere;
Refs. 11, 62), and a leak current. Channel-mediated compo-
nents show a slight outward rectification and a positive reversal
potential (Fig. 5D, blue I-V curve). Considering the composi-
tion of the bath and pipette solutions this could well be chloride
channel activity (61). The contribution of the NMDAR channel
can be estimated as the difference between putative fully
activated channels (Fig. 5D, green trace) and the corresponding
inhibited channels (Fig. 5D, blue trace). In the physiological
relevant range between30 and 0 mV, this difference amounts
to a conductance of 930 pS (Fig. 5E). The decreased current
at negative membrane potentials in the presence of Mg2 in the
bath solution is another indication for the NMDAR identity of
the channel (15).
So far channel-mediated Ca2 uptake by RBC was always
associated with pathophysiological conditions, such as clot
formation (30, 74) or Ca2-induced clearance (34). To our
knowledge, our study is the first one revealing possible phys-
iological role of controlled transient Ca2 uptake following the
activation of NMDARs, namely the regulation of oxygen
affinity of hemoglobin (Figs. 8 and 9).
Among endogenous regulators of the erythroid NMDAR
activity are plasma-borne glutamate, glycine, D-serine, homo-
cysteine, and HCA. The rodent NMDAR EC50 for glutamate is
96  20 M (26), being 10 M for HCA (53), and 40 M
for glycine (38, 58). These data were obtained for the receptors
in neurons and in artificial expression systems. These values
are close to the EC50 for glutamate (88.2 M) and homocysteic
acid (21 M) reported for the NMDARs in rat RBCs (38).
Glutamate concentrations in plasma of healthy human subjects
vary substantially depending on physical condition, exercises,
gender, diet, and age, making up from 7 1 M (14) to 255
26 M (32). Local glutamate and glycine availability in vicin-
ity of RBC membranes may exceed the bulk plasma levels due
to high abundance of these amino acids in the cytosol (32).
Homocysteine and HCA also contribute to the activation of
erythroid NMDARs. Plasma total homocysteine levels ranges
from 4.2 to 17.2 M in healthy human subjects to up to 470
M in patients with hyper-homocysteinemia (59).
Transient activation of the NMDARs by glutamate released
from the exercising muscle (14) or obtained with meal (27)
might also contribute to a transient increase in the intracellular
Ca2 promoting thereby oxygen release from hemoglobin (Fig.
8). The exact mechanism of a cross talk between calcium levels
in RBCs and hemoglobin oxygen affinity remains to be studied
in details.
Shrinkage (Fig. 8; Table 2) results in a rapid transient
increase in 2,3-DPG levels in the cytosol, which in turn could
stabilize hemoglobin in T state and promote oxygen release
(Fig. 7, B and D). However, a shift in oxygen affinity of
hemoglobin caused by the stimulation of the NMDARs was
preserved in the presence of clotrimazol or in high KCl
medium, conditions preventing Ca2-induced KCl and water
loss from RBCs. The obtained data reveal that changes in the
intracellular pH result from the shifts in protonation of hemo-
globin (Fig. 8). The latter result in the 2,3-DPG-dependent
alterations in P50 (Figs. 8 and 9). These observations are
consistent with earlier reports on an increase in free Ca2
concentration in the cytosol of RBCs undergoing deoxygen-
ation in which hemoglobin gets protonated (65). Conforma-
tional changes responsible for these Ca2-induced changes in
oxygen affinity of hemoglobin await further characterization.
Taken together, the obtained findings reveal the presence of
functional NMDARs in EPCs and, at much lower levels, in
circulating RBCs. The abundance and activity of these recep-
tors in plasma membrane of RBCs and their progenitors are
proportional to the intracellular Ca2 levels. Among the down-
stream targets of Ca2 accumulation are cell volume and
hemoglobin oxygen affinity.
ACKNOWLEDGMENTS
We thank Maxim Makhinya for the excellent program CellFinder for
intracellular calcium content estimation and morphometric analysis of RBCs
he has written for us.
GRANTS
This study was supported by the Swiss National Science Foundation (No.
112 449 and 310030 124970/1 to A. Bogdanova), by Zurich Center for
Integrative Human Physiology (cooperative grant to J. Goede, O. Speer, and A.
Bogdanova), as well as by Hartmann Müller-Stiftung (to O. Speer and J.
Goede). Financial support was provided by the Saarland Graduate School (to
J. Wang).
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: A.M., P.H., J.W., A. Brüggemann, L.K., O.S., and A.
Bogdanova performed experiments; A.M., P.H., J.W., A. Brüggemann, L.K.,
O.S., and A. Bogdanova analyzed data; A.M., P.H., J.S.G., J.W., A. Brügge-
mann, M.G., M.S., L.K., O.S., and A. Bogdanova interpreted results of
experiments; A.M., P.H., J.W., L.K., O.S., and A. Bogdanova prepared figures;
A.M., L.K., O.S., and A. Bogdanova drafted manuscript; A.M., J.S.G., A.
Brüggemann, M.G., M.S., L.K., O.S., and A. Bogdanova edited and revised
manuscript; A.M., P.H., J.S.G., J.W., A. Brüggemann, M.G., M.S., L.K., O.S.,
and A. Bogdanova approved final version of manuscript; J.S.G., M.S., L.K.,
O.S., and A. Bogdanova conception and design of research.
REFERENCES
1. Andrews DA, Yang L, Low PS. Phorbol ester stimulates a protein kinase
C-mediated agatoxin-TK-sensitive calcium permeability pathway in hu-
man red blood cells. Blood 100: 3392–3399, 2002.
2. Assouline-Cohen M, Beitner R. Effects of Ca2 on erythrocyte mem-
brane skeleton-bound phosphofructokinase, ATP levels, and hemolysis.
Mol Genet Metab 66: 56–61, 1999.
3. Azzouzi I, Moest H, Winkler J, Fauchere JC, Gerber AP, Wollscheid
B, Stoffel M, Schmugge M, Speer O. MicroRNA-96 directly inhibits
gamma-globin expression in human erythropoiesis. PLoS One 6: e22838,
2011.
4. Bennekou P, Kristensen BI, Christophersen P. The human red cell
voltage-regulated cation channel. The interplay with the chloride conduc-
tance, the Ca(2)-activated K() channel and the Ca(2) pump. J
Membr Biol 195: 1–8, 2003.
5. Beutler E, West C, Blume KG. The removal of leukocytes and platelets
from whole blood. J Lab Clin Med 88: 328–333, 1976.
6. Bogdanova A, Makhro A, Wang J, Lipp P, Kaestner L. Calcium in red
blood cells-a perilous balance. Int J Mol Sci 14: 9848–9872, 2013.
7. Bookchin RM, Ortiz OE, Shalev O, Tsurel S, Rachmilewitz EA,
Hockaday A, Lew VL. Calcium transport and ultrastructure of red cells
in beta-thalassemia intermedia. Blood 72: 1602–1607, 1988.
8. Browning JA, Staines HM, Robinson HC, Powell T, Ellory JC, Gibson
JS. The effect of deoxygenation on whole-cell conductance of red blood
cells from healthy individuals and patients with sickle cell disease. Blood
109: 2622–2629, 2007.
9. Cull-Candy SG, Brickley SG, Misra C, Feldmeyer D, Momiyama A,
Farrant M. NMDA receptor diversity in the cerebellum: identification of
subunits contributing to functional receptors. Neuropharmacology 37:
1369–1380, 1998.
C1136 NMDA RECEPTORS IN HUMAN RED BLOOD CELLS
AJP-Cell Physiol • doi:10.1152/ajpcell.00031.2013 • www.ajpcell.org
10. Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor
subtypes at central synapses. Sci STKE 2004: re16, 2004.
11. Desai SA, Bezrukov SM, Zimmerberg J. A voltage-dependent channel
involved in nutrient uptake by red blood cells infected with the malaria
parasite. Nature 406: 1001–1005, 2000.
12. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor
ion channels. Pharmacol Rev 51: 7–61, 1999.
13. Duranton C, Huber SM, Lang F. Oxidation induces a Cl()-dependent
cation conductance in human red blood cells. J Physiol 539: 847–855,
2002.
14. Durham WJ, Miller SL, Yeckel CW, Chinkes DL, Tipton KD, Ras-
mussen BB, Wolfe RR. Leg glucose and protein metabolism during an
acute bout of resistance exercise in humans. J Appl Physiol 97: 1379–
1386, 2004.
15. Erreger K, Chen PE, Wyllie DJ, Traynelis SF. Glutamate receptor
gating. Crit Rev Neurobiol 16: 187–224, 2004.
16. Foller M, Huber SM, Lang F. Erythrocyte programmed cell death.
IUBMB Life 60: 661–668, 2008.
17. Foller M, Kasinathan RS, Koka S, Lang C, Shumilina E, Birnbaumer
L, Lang F, Huber SM. TRPC6 contributes to the Ca(2) leak of human
erythrocytes. Cell Physiol Biochem 21: 183–192, 2008.
18. Foster AC, Wong EH. The novel anticonvulsant MK-801 binds to the
activated state of the N-methyl-D-aspartate receptor in rat brain. Br J
Pharmacol 91: 403–409, 1987.
19. Genever PG, Wilkinson DJ, Patton AJ, Peet NM, Hong Y, Mathur A,
Erusalimsky JD, Skerry TM. Expression of a functional N-methyl-D-
aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood
93: 2876–2883, 1999.
20. George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P,
Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH
oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines
contributes to oxidative stress in sickle cell disease. Blood 121: 2099–
2107, 2013.
21. Goebel DJ, Poosch MS. NMDA receptor subunit gene expression in the
rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com,
NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 69:
164–170, 1999.
22. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y. Gluta-
mate signaling in peripheral tissues. Eur J Biochem 271: 1–13, 2004.
23. Hirschler-Laszkiewicz I, Tong Q, Conrad K, Zhang W, Flint WW,
Barber AJ, Barber DL, Cheung JY, Miller BA. TRPC3 activation by
erythropoietin is modulated by TRPC6. J Biol Chem 284: 4567–4581,
2009.
24. Hitchcock IS, Skerry TM, Howard MR, Genever PG. NMDA receptor-
mediated regulation of human megakaryocytopoiesis. Blood 102: 1254–
1259, 2003.
25. Huber SM, Gamper N, Lang F. Chloride conductance and volume-
regulatory nonselective cation conductance in human red blood cell
ghosts. Pflügers Arch 441: 551–558, 2001.
26. Jasek MC, Griffith WH. Pharmacological characterization of ionotropic
excitatory amino acid receptors in young and aged rat basal forebrain.
Neuroscience 82: 1179–1194, 1998.
27. Jinap S, Hajeb Glutamate P. Its applications in food and contribution to
health. Appetite 55: 1–10, 2010.
28. Kaestner L. Cation channels in erythrocytes–historical and future per-
spective. Open Biol J 4: 27–34, 2011.
29. Kaestner L, Christophersen P, Bernhardt I, Bennekou P. The non-
selective voltage-activated cation channel in the human red blood cell
membrane: reconciliation between two conflicting reports and further
characterisation. Bioelectrochemistry (Amsterdam, Netherlands) 52: 117–
125, 2000.
30. Kaestner L, Tabellion W, Lipp P, Bernhardt I. Prostaglandin E2
activates channel-mediated calcium entry in human erythrocytes: an indi-
cation for a blood clot formation supporting process. Thromb Haemost 92:
1269–1272, 2004.
31. Kaestner L, Tabellion W, Weiss E, Bernhardt I, Lipp P. Calcium
imaging of individual erythrocytes: problems and approaches. Cell Cal-
cium 39: 13–19, 2006.
32. Kiessling K, Roberts N, Gibson JS, Ellory JC. A comparison in normal
individuals and sickle cell patients of reduced glutathione precursors and
their transport between plasma and red cells. Hematol J 1: 243–249, 2000.
33. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E,
Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina
M. Molecular diversity of the NMDA receptor channel. Nature 358:
36–41, 1992.
34. Lang F, Lang KS, Wieder T, Myssina S, Birka C, Lang PA, Kaiser S,
Kempe D, Duranton C, Huber SM. Cation channels, cell volume and the
death of an erythrocyte. Pflügers Arch 447: 121–125, 2003.
35. Low CM, Wee KS. New insights into the not-so-new NR3 subunits of
N-methyl-D-aspartate receptor: localization, structure, and function. Mol
Pharmacol 78: 1–11, 2010.
36. Magnani M, Serafini G, Stocchi V. Effects of Ca2 and lipoxygenase
inhibitors on hexokinase degradation in rabbit reticulocytes. Mol Cell
Biochem 85: 3–7, 1989.
37. Maher AD, Kuchel PW. The Gardos channel: a review of the Ca2-
activated K channel in human erythrocytes. Int J Biochem Cell Biol 35:
1182–1197, 2003.
38. Makhro A, Wang J, Vogel J, Boldyrev AA, Gassmann M, Kaestner L,
Bogdanova A. Functional NMDA receptors in rat erythrocytes. Am J
Physiol Cell Physiol 298: C1315–C1325, 2010.
39. Mandal M, Yan Z. Phosphatidylinositol (4,5)-bisphosphate regulation of
N-methyl-D-aspartate receptor channels in cortical neurons. Mol Pharma-
col 76: 1349–1359, 2009.
40. Masu M, Nakajima Y, Moriyoshi K, Ishii T, Akazawa C, Nakanashi
S. Molecular characterization of NMDA and metabotropic glutamate
receptors. Ann NY Acad Sci 707: 153–164, 1993.
41. Migliaccio G, Migliaccio AR, Druzin ML, Giardina PJ, Zsebo KM,
Adamson JW. Long-term generation of colony-forming cells in liquid
culture of CD34 cord blood cells in the presence of recombinant human
stem cell factor. Blood 79: 2620–2627, 1992.
42. Migliaccio G, Sanchez M, Masiello F, Tirelli V, Varricchio L, Whitsett
C, Migliaccio AR. Humanized culture medium for clinical expansion of
human erythroblasts. Cell Transplant 19: 453–469, 2010.
43. Miller BA, Cheung JY. Mechanisms of erythropoietin signal transduc-
tion: involvement of calcium channels. Proc Soc Exp Biol Med 206:
263–267, 1994.
44. Miller BA, Cheung JY, Tillotson DL, Hope SM, Scaduto RC Jr.
Erythropoietin stimulates a rise in intracellular-free calcium concentration
in single BFU-E derived erythroblasts at specific stages of differentiation.
Blood 73: 1188–1194, 1989.
45. Minetti G, Egee S, Morsdorf D, Steffen P, Makhro A, Achilli C, Ciana
A, Wang J, Bouyer G, Bernhardt I, Wagner C, Thomas S, Bogdanova
A, Kaestner L. Red cell investigations: art and artefacts. Blood Rev 27:
91–101, 2013.
46. Mishina M, Mori H, Araki K, Kushiya E, Meguro H, Kutsuwada T,
Kashiwabuchi N, Ikeda K, Nagasawa M, Yamazaki M, Masaki H,
Yamakura T, Morita T, Sakimura K. Molecular and functional diver-
sity of the NMDA receptor channel. Ann NY Acad Sci 707: 136–152,
1993.
47. Misra C, Brickley SG, Farrant M, Cull-Candy SG. Identification of
subunits contributing to synaptic and extrasynaptic NMDA receptors in
Golgi cells of the rat cerebellum. J Physiol 524: 147–162, 2000.
48. Misra C, Brickley SG, Wyllie DJ, Cull-Candy SG. Slow deactivation
kinetics of NMDA receptors containing NR1 and NR2D subunits in rat
cerebellar Purkinje cells. J Physiol 525: 299–305, 2000.
49. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH.
Developmental and regional expression in the rat brain and functional
properties of four NMDA receptors. Neuron 12: 529–540, 1994.
50. Nowak LM, Wright JM. Slow voltage-dependent changes in channel
open-state probability underlie hysteresis of NMDA responses in Mg(2)-
free solutions. Neuron 8: 181–187, 1992.
51. Ozuyaman B, Grau M, Kelm M, Merx MW, Kleinbongard P. RBC
NOS: regulatory mechanisms and therapeutic aspects. Trends Mol Med
14: 314–322, 2008.
52. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacol-
ogy. Curr Opin Pharmacol 7: 39–47, 2007.
53. Patneau DK, Mayer ML. Structure-activity relationships for amino acid
transmitter candidates acting at N-methyl-D-aspartate and quisqualate
receptors. J Neurosci 10: 2385–2399, 1990.
54. Qian A, Johnson JW. Permeant ion effects on external Mg2 block of
NR1/2D NMDA receptors. J Neurosci 26: 10899–10910, 2006.
55. Rodighiero S, De Simoni A, Formenti A. The voltage-dependent non-
selective cation current in human red blood cells studied by means of
whole-cell and nystatin-perforated patch-clamp techniques. Biochim Bio-
phys Acta 1660: 164–170, 2004.
56. Schaefer A, Magocsi M, Marquardt H. Signalling mechanisms in eryth-
ropoiesis: the enigmatic role of calcium. Cell Signal 9: 483–495, 1997.
C1137NMDA RECEPTORS IN HUMAN RED BLOOD CELLS
AJP-Cell Physiol • doi:10.1152/ajpcell.00031.2013 • www.ajpcell.org
57. Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues.
Trends Pharmacol Sci 22: 174–181, 2001.
58. Smothers CT, Woodward JJ. Pharmacological characterization of gly-
cine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate
NR1 and NR3 subunits. J Pharmacol Exp Ther 322: 739–748, 2007.
59. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Linden-
baum J. Elevation of total homocysteine in the serum of patients with
cobalamin or folate deficiency detected by capillary gas chromatography-
mass spectrometry. J Clin Invest 81: 466–474, 1988.
60. Steffen P, Jung A, Nguyen DB, Muller T, Bernhardt I, Kaestner L,
Wagner C. Stimulation of human red blood cells leads to Ca2-mediated
intercellular adhesion. Cell Calcium 50: 54–61, 2011.
61. Thomas SL, Bouyer G, Cueff A, Egee S, Glogowska E, Ollivaux C. Ion
channels in human red blood cell membrane: actors or relics? Blood Cells
Mol Dis 46: 261–265, 2011.
62. Thomas SL, Egee S, Lapaix F, Kaestner L, Staines HM, Ellory JC.
Malaria parasite Plasmodium gallinaceum up-regulates host red blood cell
channels. FEBS Lett 500: 45–51, 2001.
63. Thompson CJ, Schilling T, Howard MR, Genever PG. SNARE-depen-
dent glutamate release in megakaryocytes. Exp Hematol 38: 504–515,
2010.
64. Tiffert T, Bookchin RM, Lew WL. Calcium homeostasis in normal and
abnormal human red cells. In: Red Cell Membrane transport in Health and
Disease, edited by Bernhardt I, Ellory JC. Berlin, Germany: Springer,
2003, p. 373–405.
65. Tiffert T, Etzion Z, Bookchin RM, Lew VL. Effects of deoxygenation
on active and passive Ca2 transport and cytoplasmic Ca2 buffering in
normal human red cells. J Physiol 464: 529–544, 1993.
66. Tolle TR, Berthele A, Zieglgansberger W, Seeburg PH, Wisden W.
The differential expression of 16 NMDA and non-NMDA receptor sub-
units in the rat spinal cord and in periaqueductal gray. J Neurosci 13:
5009–5028, 1993.
67. Tong Q, Chu X, Cheung JY, Conrad K, Stahl R, Barber DL, Mignery
G, Miller BA. Erythropoietin-modulated calcium influx through TRPC2
is mediated by phospholipase C and IP3R. Am J Physiol Cell Physiol
287: C1667–C1678, 2004.
68. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. Glutamate
receptor ion channels: structure, regulation, and function. Pharmacol Rev
62: 405–496, 2010.
69. Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor
subunits. Proc Natl Acad Sci USA 105: 14163–14168, 2008.
70. Vandorpe DH, Xu C, Shmukler BE, Otterbein LE, Trudel M, Sachs F,
Gottlieb PA, Brugnara C, Alper SL. Hypoxia activates a Ca2-perme-
able cation conductance sensitive to carbon monoxide and to GsMTx-4 in
human and mouse sickle erythrocytes. PLoS One 5: e8732, 2010.
71. Wagner-Britz L, Wang J, Kaestner L, Bernhardt I. Protein kinase
Calpha and P-type Ca channel CaV2.1 in red blood cell calcium signalling.
Cell Physiol Biochem 31: 883–891, 2013.
72. Weiss E, Rees DC, Gibson JS. Role of calcium in phosphatidylserine
externalisation in red blood cells from sickle cell patients. Anemia 2011:
379894, 2010.
73. Xiao Z, Jaiswal MK, Deng PY, Matsui T, Shin HS, Porter JE, Lei S.
Requirement of phospholipase C and protein kinase C in cholecystokinin-
mediated facilitation of NMDA channel function and anxiety-like behav-
ior. Hippocampus, 2011.
74. Yang L, Andrews DA, Low PS. Lysophosphatidic acid opens a Ca()
channel in human erythrocytes. Blood 95: 2420–2425, 2000.
75. Zancan P, Sola-Penna M. Calcium influx: a possible role for insulin
modulation of intracellular distribution and activity of 6-phosphofructo-
1-kinase in human erythrocytes. Mol Genet Metab 86: 392–400, 2005.
C1138 NMDA RECEPTORS IN HUMAN RED BLOOD CELLS
AJP-Cell Physiol • doi:10.1152/ajpcell.00031.2013 • www.ajpcell.org
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72  
Paper 3 
Red blood cells of sickle cell disease patients 
exhibit abnormally high abundance of N-methyl 
D-aspartate receptors mediating excessive 
calcium uptake  Pascal Haenggi*, Asya Makhro*, Max Gassmann, Markus Schmugge, Jeroen S. Goede, Oliver Speer and Anna Bogdanova.  *Denotes equal contribution of the authors.  Br J Haematol. 2014 Jul 18. Doi: 10.1111/bjh.13028. [Epub ahead of print]  Received 6 February 2014; accepted for publication 29 May 2014   Contribution: Makhro A. proposed the hypothesis for the study. Results showed on Figures 1, 2, 3, 4, S2-S8 and Table 2 were produced by Makhro A.             
73  
Red blood cells of sickle cell disease patients exhibit
abnormally high abundance of N-methyl D-aspartate receptors
mediating excessive calcium uptake
Pascal H€anggi,1,2* Asya Makhro,2,3*
Max Gassmann,2,3 Markus Schmugge,4
Jeroen S. Goede,1,2* Oliver Speer2,4 and
Anna Bogdanova2,3*
1Division of Haematology, University Hospital
Zurich, 2Zurich Centre for Integrative Human
Physiology (ZIHP), University of Zurich,
3Institute of Veterinary Physiology, University
Children’s Hospital, and 4Division of Haematol-
ogy, University Children’s Hospital, Z€urich, Swit-
zerland
Received 6 February 2014; accepted for
publication 29 May 2014
Correspondence: PD Dr Anna Bogdanova,
Institute of Veterinary Physiology, and Zurich
Centre for Integrative Human Physiology
(ZIHP), University of Zurich,
Winterthurerstrasse 260, CH-8057 Zurich,
Switzerland.
E-mail: annab@access.uzh.ch
*Denotes equal contribution of the authors.
Summary
Recently we showed that N-methyl D-aspartate receptors (NMDARs) are
expressed in erythroid precursors (EPCs) and present in the circulating red
blood cells (RBCs) of healthy humans, regulating intracellular Ca2+ in these
cells. This study focuses on investigating the possible role of NMDARs in
abnormally high Ca2+ permeability in the RBCs of patients with sickle cell
disease (SCD). Protein levels of the NMDAR subunits in the EPCs of SCD
patients did not differ from those in EPCs of healthy humans. However,
the number and activity of the NMDARs in circulating SCD-RBCs was
substantially up-regulated, being particularly high during haemolytic crises.
The number of active NMDARs correlated negatively with haematocrit and
haemoglobin levels in the blood of SCD patients. Calcium uptake via these
non-selective cation channels was induced by RBC treatment with glycine,
glutamate and homocysteine and was facilitated by de-oxygenation of
SCD-RBCs. Oxidative stress and RBC dehydration followed receptor stimu-
lation and Ca2+ uptake. Inhibition of the NMDARs with an antagonist me-
mantine caused re-hydration and largely prevented hypoxia-induced
sickling. The EPCs of SCD patients showed higher tolerance to memantine
than those of healthy subjects. Consequently, NMDARs in the RBCs of
SCD patients appear to be an attractive target for pharmacological inter-
vention.
Keywords: red blood cells, calcium, sickle cell disease, N-methyl
D-aspartate receptors, memantine.
Sickle cell disease (SCD) is a well-known one-gene disease. A
point mutation in position 6 of the beta-globin chain gives
rise to polymerization of deoxyhaemoglobin S (HbS), loss of
deformability and increase in cell adhesion. Haemolysis,
vaso-occlusive and pain crises are hallmarks of this disease.
Gene therapy and bone marrow transplantation are the opti-
mal, but rarely available and very expensive treatment strate-
gies for this group of patients (Locatelli et al, 2013;
Chandrakasan & Malik, 2014). Treatment with hydroxycar-
bamide (HC), which aims to increase haemoglobin F levels
in RBCs, is part of the current standard care (Manwani &
Frenette, 2013). This therapy significantly decreases the inci-
dence and severity of pain crises and can be combined with
regular blood transfusions. Further management includes
symptomatic care, such as iron chelation, antibiotic treat-
ment and psycho-social support. However, not all patients
respond equally well to HC treatment. Thus, there is a stand-
ing need for novel treatment strategies.
Extensive experimental efforts have resulted in the sugges-
tion of a number of novel potential targets for pharmacologi-
cal intervention. Inhibition of the Gardos channel with the
selective blocker Senicapoc (ICA-17043; Neusentis, Cam-
bridge, UK) was used in a clinical trial aiming to reduce
dehydration, which promotes haemoglobin S (HbS) polymer-
ization. (Eaton & Hofrichter, 1990). This strategy alone sup-
pressed haemolysis but failed to decrease the incidence of
pain and vaso-occlusive crises (Ataga & Stocker, 2009). Inhi-
bition of the calcium-dependent cysteine protease l-calpain,
was recently suggested as an attractive clinical strategy to
reduce proteolysis and thereby suppress premature clearance
and lysis of RBCs carrying human haemoglobin S (De
Franceschi et al, 2013). Further suggestions include protec-
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tion of RBCs from oxidative stress by blocking NADPH ox-
idases (NOXes) which generate superoxide anions and are
particularly abundant in the RBCs of SCD patients (George
et al, 2013). Pathological hyperactivation of Gardos channels,
l-calpain and NOXes in diseased RBCs are not directly trig-
gered by mutated HbS expression. However, all three pro-
teins are known to respond to the up-regulation of the
intracellular Ca2+ levels which were reported in the RBCs of
SCD patients (Bogdanova et al, 2013). Furthermore, calcium
overload is known to increase the adherence of RBCs to
vascular endothelium in SCD patients (Hebbel et al, 1980;
Mohandas & Evans, 1985). The steady-state passive channel-
mediated permeability of red cell membranes for Ca2+ in
healthy humans is very low (c. 50 lmol/(lpacked cells•h)).
Thus, even a minor increase in Ca2+ uptake due to the acti-
vation of one or several types of ion channels is associated
with a substantial transient increase in intracellular Ca2+. In
SCD-RBCs abnormally high Ca2+ uptake is mediated by a
conductive transport pathway known as Psickle. This pathway
is activated by deoxygenation, shear stress and a number of
other stimuli (Bookchin & Lew, 1981) and, when activated,
results in a 6- to 10-fold increase in intracellular free Ca2+
levels (Tiffert et al, 2003). The molecular identity of ion
channel(s) mediating Psickle remains unknown. Identification
and characterization of these channel(s) is of key importance.
Inhibition of the Psickle pathway and the consecutive decrease
in intracellular Ca2+ levels will cause inhibition of Gardos
channels, l-calpain, and NOXes. We have recently shown
that N-methyl D-aspartate receptors (NMDARs) are involved
in Ca2+ uptake by the RBCs of healthy humans (Makhro
et al, 2013). These ionotropic glutamate receptors are non-
selective cation channels requiring glutamate and glycine for
their activation. They are known to mediate synaptic Ca2+
uptake in the brain (Paoletti et al, 2013). This study focuses
on the involvement of NMDARs in the control of intracellu-
lar Ca2+ levels in SCD-RBCs. We have been able to follow
the abundance and activity of NMDARs in erythroid
precursor cells and in the circulating RBCs of SCD patients.
Pathological hyperactivation of the NMDARs monitored in
SCD-RBCs resulted in an increase in membrane permeability
for Ca2+. Haemolytic crises were associated with further up-
regulation in receptor activity. Correlation of NMDAR activ-
ity with red cell number and C-reactive protein levels in
plasma suggests that NMDAR is an active player in regulat-
ing red cell properties and life span in SCD patients.
Subjects and methods
A detailed description of materials and methods is available
as a supplementary file.
Patients and healthy subjects
Our subject pool consisted of 16 adult patients (21–44 years
old) with symptomatic SCD and 31 age-matched healthy
adult subjects with no history of SCD. The group of 16 SCD
patients consisted of 9 subjects with HbS/HbS, 3 patients
with HbS/HbC, 3 with HbS/b-thalassaemia and one patient
with HbS/HbD genotype. All patients experience mild and
severe SCD crises, and show chronic haemolytic anaemia and
persisting reticulocytosis. Blood samples were collected after
obtaining informed consent from the subjects. The study was
approved by the Ethics Commission of the Canton of Zurich
and was performed in accordance with the declaration of
Helsinki. General information on the patients is presented in
Table I.
Protein abundance of the GluN1 subunit of the NMDAR
in SCD-RBC membranes
Immunoblotting was used to explore the alterations in pro-
tein abundance of the GluN1 subunit in membrane fractions
obtained from the SCD-RBCs and cells of healthy donors
after centrifugation on 90% isotonic Percoll gradient (Lutz
et al, 1992). Blood or pre-filtered RBC suspension was used
for fractionation, and membrane preparation from cells
forming the light (L), medium (M) and dense (D) fractions
of RBCs was obtained (see Fig 1A). Immunoblotting was
performed using mouse monoclonal antibodies against the
GluN1 subunit on the NMDAR (#MAB1586 Millipore,
Temecula, CA) as well as rabbit polyclonal antibodies against
total actin (#A2066, Sigma-Aldrich, St. Louis, MO, USA).
Rat cortex lysate was used as a positive control, and total
actin as a loading control.
NMDAR activity in SCD-RBCs
The number of active receptors per cell was detected using
radiolabelled antagonist binding assay as described earlier
(Makhro et al, 2013). Blood samples were incubated with
[3H]MK-801 (740 GBq/mmol, Perkin Elmer, Boston, MA)
with subsequent fractionation on Percoll gradient. The
potential impact of white blood cells (WBCs) on the [3H]
MK-801 binding assay in RBCs in fractions was assessed, as
binding of the radiolabelled antagonist was tested in blood
samples with and without filtration through a cellulose col-
umn. As filtration resulted in a substantial increase in the
number of [3H]MK-801 binding sites due to the shear stress
filtration step, it was avoided in cases when basal activity of
the erythrocytic NMDARs in plasma was determined. Micro-
fluorescence live imaging was used to confirm the data on
receptor activity and abundance obtained using [3H]MK-801
binding assay.
Ca2+ uptake through NMDARs as a function of
oxygenation of SCD-RBCs
Changes in the intracellular Ca2+ levels in RBCs upon treat-
ment with agonists (300 lmol/l of NMDA, glutamate or hom-
ocysteine mixed with 100 lmol/l glycine) and/or antagonist
P. H€anggi et al
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(memantine, 50 lmol/l) of the NMDARs were monitored
using the fluo-4 AM dye, as described elsewhere (Makhro et al,
2013). RBCs were loaded with 5 lmol/l of the dye for
30 min at room temperature. Incubation medium con-
tained 145 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l CaCl2,
015 mmol/l MgCl2,10 mmol/l Tris-HCl (pH 74), 10 mmol/l
glucose and 01% bovine serum albumin. The effect of hypoxia
on cell shape and Ca2+ content was tested in the RBCs of SCD
patients. The cells were loaded with fluo-4 AM and exposed to
15% O2 (normoxia) or 05% O2 (hypoxia), 5% CO2, balanced
with N2 for 10 min, with or without supplementation of the
NMDAR antagonist memantine (100 lmol/l) and/or
300 lmol/l NMDA/100 lmol/l glycine mixture. Calcium
uptake, cell surface projection and anisotropy as markers of
cell volume and sickle cell transformation were then measured
microscopically and analysed using CellFinder (Dr. M. Mak-
hinya, Computer Vision Laboratory, Z€urich, Switzerland) as
described (Makhro et al, 2013).
NMDARs in control of SCD-RBC density, K+ content
and intracellular reduced (GSH) and oxidized (GSSG)
glutathione levels
The changes in red cell density upon activation or inhibition
of the NMDARs were measured in blood from four selected
SCD patients using centrifugation in Percoll density gradient
in the presence or absence of NMDA or memantine.
Together with mean cell volume (MCV), haematocrit and
cell water content, distribution in Percoll gradient was used
as an indication of dehydration-rehydration. Changes in the
intracellular K+ content in oxygenated and deoxygenated
SCD-RBCs were monitored using flame photometry, and
unidirectional chloride-independent K+ influx was measured
using 86Rb as a tracer, as described elsewhere (Makhro et al,
2013). The effects of an NMDA/glycine mixture and meman-
tine on the intraerythrocytic GSH:GSSG balance was tested
using Ellman’s reagent (5,50-dithio-bis-[2-nitrobenzoic acid]).
Proteins were precipitated with 5% trichloroacetic acid and
removed; non-protein reduced thiols assessed with or with-
out pre-treatment with glutathione reductase and NADPH,
as described elsewhere (Tietze, 1969; Bogdanova et al, 2003).
Ex vivo erythropoiesis and expression of NMDARs in
erythroid precursor cells
Mononuclear cells were isolated from the peripheral blood of
healthy people and SCD patients and cultured ex vivo, using
a 2-phase StemSpan liquid system. After seeding in serum-
free expansion medium (SFEM) supplemented with a cyto-
kine mix and penicillin/streptomycin the cells were cultured
in it for 5 d. Thereafter non-adherent cells were reseeded
and maintained for up to 21 d in StemSpan SFEM with 2%
penicillin/streptomycin, 20 ng/ml stem cell factor, 1 u/ml
erythropoietin and 5 ng/ml interleukin 3. At day 5, 2 lmol/l
dexamethasone and 1 lmol/l b-estradiol were added. DuringTa
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that time the cells progressed from pluripotent cells to pro-
erythroblasts, to basophilic and polychromatic erythroblasts
and finally, to normoblasts and enucleated reticulocytes
(Makhro et al, 2013). High performance liquid chromatogra-
phy (HPLC) was used to verify globin synthesis in fully dif-
ferentiated cells. The preferential production of HbA/A2 or
HbS in reticulocytes was measured in cells derived from the
CD34+ cells using HPLC (Figure S1). Expression of GRIN
genes was monitored in the course of differentiation of EPCs
(at days 6, 12 and 18 in culture) using TaqMan Gene
Expression Kits containing specific primers. Protein levels of
NMDAR subunits were assessed in EPCs using flow cytome-
try. CD45 (Anti-CD45 peridinin chlorophyll [PerCP], clone
2D1, BD, San Jose, CA, USA) was used as a WBC marker
and CD71 (clone M-A712 fluorescein isothiocyanate [FITC]-
conjugated, BD, San Jose, USA) as reticulocyte marker.
Abundance of the NMDAR subunits GluN2C (anti-NMDAe3
(NR2C), goat polyclonal IgG, sc-1470); GluN2D (anti-
NMDAe4 (NR2D), mouse monoclonal IgG, sc-178221);
GluN3A (anti-NR3A (NR3A), goat polyclonal IgG sc-51160)
was measured in EPCs at various stages of differentiation.
Stained cells were fixed with 1% formaldehyde and fluores-
cence intensity was measured using the BD Biosciences FAC-
SCalibur flow cytometer (BD Biosciences, San Jose, USA).
Memantine toxicity was probed for the EPCs of healthy
donors and SCD patients after 6, 12 or 18 d in culture. Cells
were exposed to 001–1 mmol/l memantine for 24 h and cell
mortality monitored by flow cytometry, using propidium
iodide (PI) nuclear staining.
Statistical analysis
The data obtained were analysed using GraphPad Instat v.30
(GraphPad Software, Inc., La Jolla, CA) and presented as
means  standard error of the mean (SEM) if not stated
otherwise. Statistically significant differences were assessed
using a one-way analysis of variance (ANOVA) test with the
Bonferroni post-test, when a normal distribution test was
passed, or, if normal distribution was not confirmed, with a
Kruskal Wallis test with Dunn’s post-test and accepted at
P < 005. Pearson product-moment correlation coefficients
were used to assess covariance between the NMDAR activity
in RBC fractions and the appearance of blood markers of
haemolytic events.
Results
Presence and activity of NMDARs in circulating RBCs of
SCD patients during stable periods and in crises
Immunoblotting was used to assess the protein levels of the
obligatory GluN1 subunit in membrane fractions prepared
from light (L), medium (M) and dense (D) fractions of
RBCs of healthy people and SCD patients (Fig 1A). The L
fractions of both healthy and SCD-RBCs were enriched with
young cells and reticulocytes as follows from cytological
estimation using Sysmex (182  82& reticulocytes
(mean  standard deviation [SD]) in healthy human sam-
ples and 243& in the SCD sample shown in Fig 1B) and the
(A) (B)
(C)
Fig 1. The abundance and activity of NMDARs is altered in the RBCs of SCD patients compared to that in the cells of healthy humans. (A) Sep-
aration of RBCs from a healthy donor (HbA) and SCD patient (HbS) into the light (L), medium (M) and dense (D) fractions on Percoll gradient
and protein 41a/b ratio in cells forming the L, M and D fraction of the SCD patient. (B) Relative abundance of GluN1 subunit protein in the
membranes of RBCs forming the L, M and D fraction of a healthy subject (HbA) and a SCD patient (HbS) with or without pre-treatment with
memantine (100 lmol/l, 1 h) and in rat cerebellar protein extract. (C) The number of active NMDARs per cell in RBCs of L, M and D fractions
of SCD patients during asymptomatic periods and during crises. The means  SEM for 9 patients are shown. Circles denote individual values.
NMDAR, N-methyl D-aspartate receptor; SCD, sickle cell disease; RBCs, red blood cells.
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band 41a/b ratio (Fig 1A). For SCD-RBCs the L fraction
was highly enriched with GluN1 and showed higher receptor
activity per cell in RBCs (Fig 1B and Table II). The receptor
activity in all fractions of the RBCs of asymptomatic SCD
patients exceeded that in cells of healthy donors by 50% and
more (Table II). Notably, HC treatment had no effect on the
receptor function in SCD-RBCs (Table II). The number of
active receptors per cell was similar in RBCs of homozygous
HbSS patients and those presented with compound HbS-b
thalassaemia (data not shown). Activity of the NMDARs in
the L-fraction of SCD-RBCs increased substantially during
the crises compared to the asymptomatic values (Fig 1C).
Furthermore, the activity of NMDARs in SCD-RBCs
appears to be intimately related to the severity of patients’
condition. Up-regulation of the NMDAR activity of mature
SCD-RBCs forming the M fraction correlated negatively with
haemoglobin and haematocrit levels and positively with
plasma lactate dehydrogenase (LDH) and C-reactive protein
content (Fig 2). These observations suggest that hyper-activa-
tion of NMDARs was associated with onsets of haemolytic
events. Furthermore, receptor activity in cells forming frac-
tions L (younger cells) and D (terminally dehydrated cells)
correlated positively with neutrophil counts in blood (data
not shown). It is noteworthy that all patients studied showed
only mild neutrophilia and neutrophil counts did not exceed
12–14 9 109/l.
Effect of NMDAR agonists and antagonists on
intracellular Ca2+ levels, cell volume and ion content
The role of the NMDAR activation state in the maintenance
of intracellular Ca2+ levels, RBC volume and redox state was
explored ex vivo.
RBCs of SCD patients loaded with the calcium-sensitive
dye fluo-4 AM responded to treatment with the agonists
NMDA and glycine (300 and 100 lm respectively), with an
acute temporary increase in intracellular Ca2+. Exposure of
the SCD-RBCs to memantine (50 lmol/l) caused a modest
decrease in Ca2+-sensitive fluorescence (Fig 3A,C, Figures S2
and Supplementary Animated Figures S3-S8). Uptake of Ca2+
triggered the activation of Ca2+-sensitive Gardos channels,
K+ loss, and cell shrinkage. Passive K+ flux through the
membranes of SCD-RBCs substantially exceeding that in
the RBCs of healthy humans could be further facilitated by
the NMDAR agonists, and partially suppressed by the recep-
tor antagonist memantine (Fig 3B). Inhibition or stimulation
Table II. NMDAR activity in light, medium and dense fractions of RBCs of healthy people and SCD patients off or on hydroxycarbamide
treatment.
Fraction Healthy subjects (n = 31) SCD patients Off-HC (n = 11) SCD patients On-HC (n = 6)
Light (L) 349  75 69  11** 72  17**
Medium (M) 41  07 22  6*** 16  3***
Dense (D) 43  06 30  11*** 12  2***
NMDAR, N-methyl D-aspartate receptor; SCD, sickle cell disease; HC, hydroxycarbamide.
**Denotes P < 001 and ***stands for P < 0001 when compared with healthy control subjects.
(A) (B)
(C) (D)
Fig 2. Correlation between the NMDAR
activity in the M fraction of SCD-RBCs and
markers of haemolysis [haemoglobin (A),
haematocrit (B) and lactate dehydrogenase in
plasma (C) and inflammation [C-reactive
protein (D)]]. Covariance analysis of the
receptor activity and the markers of haemolysis
and inflammation was performed using
Pearson product-moment correlation coeffi-
cients for the 34 blood samples taken from 16
patients on different occasions during
asymptomatic periods and during haemolytic
crises. HB, haemoglobin, Hct, haematocrit;
LDH, lactate dehydrogenase; CRP, C-reactive
protein.
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of the NMDARs resulted in the re-distribution of RBCs in
Percoll gradient. Interestingly, the cells containing more
receptors underwent dehydration as soon as they were
exposed to shear stress while passing through the Percoll, as
follows from Fig 1B. These GluN1-enriched cells moved
down the Percoll gradient to the D fraction. In line with this
observation, filtration of RBCs through the cellulose column
was associated with an increase in the NMDAR activity
detected using 3H-MK-801 binding assay (data not shown).
Dehydration induced by passing through the Percoll gradient
could be abolished by the pre-treatment of blood samples
with memantine prior to the separation. Memantine-treated
cells showed a maximum of GluN1 levels associated with the
L fraction, whereas the D fraction was almost deprived of
GluN1 (Fig 1B).
Incubation of whole blood from asymptomatic SCD
patients with NMDA resulted in further dehydration of cells,
which were then shifted down the gradient (Fig 3D). Treat-
ment of blood with memantine, on the other hand, induced
re-hydration and a corresponding upward shift within the
Percoll gradients (Fig 3D). Monitoring of the kinetics of the
morphological responses to the stimulation of the NMDARs
in SCD-RBCs in the absence or presence of memantine was
performed microscopically. The cells were pre-incubated with
saturating concentrations of glutamate and glycine with or
without memantine in a Ca2+-free medium. During the
recording, Ca2+ (final concentration 1.8 mM) was adminis-
tered to the medium and the changes in cellular morphology
monitored over 12 min. The corresponding Supplementary
Animated Figures S3-S8, can be viewed online in the supple-
mentary section. These video files show substantial reduction
or complete abolishment of echinocytic transformation in
the cells pre-treated with memantine before exposure to cal-
cium.
The oxidative stress characteristic of SCD-RBCs was moni-
tored as a four-fold increase in the intracellular oxidized glu-
tathione (GSSG) levels over the GSSG content of RBCs in
healthy human subjects. Further accumulation of GSSG was
observed upon stimulation of NMDARs in SCD-RBCs with
NMDA. Inhibition of the NMDARs with memantine pre-
vented an oxidative burst triggered by NMDA (Fig 3E).
NMDARs and sickle cell transformation caused by
deoxygenation
Polymerization of deoxygenated HbS was induced ex vivo by
equilibration of SCD-RBCs with a humidified gas phase con-
taining 5% CO2 and 05% O2 in Eschweiler tonometers.
These oxygen levels have been recorded in some areas in the
brain (Erecinska & Silver, 2001). Cells exposed to a gas phase
supplemented with 15% O2 served as the normoxic control,
mimicking pO2 in human lungs under normoxic conditions
(133 kPa). At the onset of deoxygenation, the NMDARs in
SCD-RBCs were either stimulated with NMDA (300 lmol/l)
and glycine (100 lmol/l) or suppressed with memantine
(50 lmol/l). Following 2 min of equilibration with the gas
phase, the cells were incubated under normoxic or hypoxic
conditions for 15 min. Thereafter RBC morphology (Fig 4A–
D,F,G and Figure S2), intracellular Ca2+ (Fig 4E) and the
intracellular ion content (Fig 4H) were assessed.
Deoxygenation of SCD-RBCs resulted in characteristic
alterations in cell morphology, including the formation of
drepanocytes (indicated with arrows in Fig 4B,C), “holy leaf”,
and “granular” cells (Figure S2C) and echinocytes (Fig 4 and
Figure S2C). Quantitatively, these changes were assessed as an
increase in anisotropy (Fig 4G, Figure S2A). Intracellular Ca2+
accumulation was induced by deoxygenation, as exemplified
in Fig 4B–D and quantified in Fig 4E. Intake of Ca2+ trig-
gered loss of K+ (Fig 4H) and a decrease in cellular projection
areas, signifying dehydration and shrinkage (Fig 4F, Fig S2B).
The presence of extracellular Ca2+ was critical for initiating
Ca2+-driven dehydration which in turn facilitated polymeriza-
tion of deoxy-HbS (Figure S2A). Chelation of the intracellular
Ca2+ with 1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-
tetraacetic acid (BAPTA) in addition to omission of the extra-
cellular Ca2+ further reduced sickling and shrinking of hyp-
oxic SCD-RBCs (Figure S2A).
Polymerization rate of deoxy-HbS is inversely related to
the Hb concentration to an extremely high power (Hebbel,
2009). Stimulation of the NMDARs with NMDA and glycine
aggravated the morphological changes induced by deoxygen-
ation, including impressive induction of echinocytosis and
RBC fragmentation (Fig 4D). Potassium loss from the oxy-
genated agonists’-treated SCD-RBCs reached its maximum
and could not be further stimulated by hypoxia (Fig 4H).
Some of the cells were showing signs of irreversible HbS
polymerization (“holy leaf” appearance) even under normox-
ic conditions (Figure S2C). Memantine administration effec-
tively prevented hypoxia-induced sickling and echinocytosis
(Fig 4C,G). A decrease in Ca2+ uptake by deoxygenated cells
was observed upon memantine treatment followed by the
suppression of hypoxia-induced K+ loss and dehydration
(Fig 4H and F respectively).
Subunit composition of NMDARs and their expression in
erythroid precursor cells of patients (SCD-EPCs)
Previously we explored the expression profile of GRIN genes
in EPCs derived from healthy human blood (Makhro et al,
2013). A similar approach was used to monitor the presence
of transcripts of GRIN genes and changes in protein levels of
all subunits of the NMDARs in SCD-EPCs. Pluripotent
mononuclear cells were isolated from the peripheral blood of
healthy subjects and patients. These cells were cultured to
obtain pro-erythroblasts (day 6), basophilic and polychro-
matic erythroblasts (day 12) or normoblasts and enucleated
reticulocytes (day 18). Expression profiles obtained for the
transcripts of GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A
and GRIN3B in SCD-EPCs at each differentiation stage are
shown in Fig 5. The expression of GRIN1 and GRIN2C tran-
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(A)
(C)
(D) (E)
(B)
Fig 3. Intracellular Ca2+ and oxidized glutathione levels, cell density, and residual K+ flux in SCD-RBCs upon activation (300 lmol/l glutamate
and 100 lmol/l glycine) or inhibition (100 lmol/l memantine) of the NMDARs. (A) Kinetics of changes in the intracellular Ca2+ in SCD-RBCs
(fluorescence intensity at each time-point (F) normalized to the average signal intensity at time zero (Fo)). Number of cells analysed per time
point ranges from 24 to 42. * denotes P < 005 and ** stands for P < 001 when compared to the signal at time zero. (B) Chloride-independent
ouabain-insensitive unidirectional K+ influx into the RBCs of healthy humans and SCD patients. ** indicates P < 001 when fluxes were com-
pared between the HbA and HbS-RBCs under the same conditions. Data are means of six independent experiments  SD. ## denotes P < 001
for the K+ fluxes in SCD-RBCs treated with either memantine or NMDA/Gly. (C) Representative experiments showing the alterations in Ca2+-
sensitive fluo-4 fluorescent signal intensity in response to NMDA/Gly or memantine treatment quantified in panel A. (D) Distribution of SCD-
RBCs in Percoll gradient after pre-treatment of whole blood with either 300 lmol/l NMDA or 100 lmol/l memantine. Numbers below the
images indicate the corresponding haematocrit values. (E) Oxidized glutathione (GSSG) content of RBCs exposed to agonists in the presence or
absence of memantine for 30 min. # denotes P < 005 compared to the values in the RBCs of healthy humans (HbA-control). *stands for
P < 005 compared to control levels in SCD-RBCs (HbS-control). NMDA, N-methyl D-aspartate; SCD, sickle cell disease; RBCs, red blood cells;
Gly, glycine.
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scripts in healthy subjects increased progressively during ex
vivo differentiation. Peak levels of GRIN2D transcripts were
found at the stage of basophilic and polychromatic
erythroblasts (12 d). In SCD-EPCs these stage-dependent
variations in expression levels of all GRIN genes were
blunted. No significant changes in NMDAR transcript levels
were detected during differentiation. Compared to healthy
controls, relative expression of GRIN3B was significantly
higher in SCD throughout erythropoiesis. Similar to those in
EPCs of healthy humans (Makhro et al, 2013), transcripts of
GRIN2B in EPCs obtained from SCD patients were below
the detection threshold at any differentiation stage.
(A) (A)
(E)
(F)
(G)
(H)
(B)
(C) (C)
(D) (D)
(B)
Fig 4. Responses of SCD-RBCs to deoxygenation in the presence of the NMDAR agonists (300 lmol/l NMDA/100 lmol/l glycine) and antagonist
(50 lmol/l memantine). RBCs in suspension were exposed to either 15% or 05% O2 in gas phase in Eschweiler tonometers (15 min, 37°C).
Shown are (A-D) the representative images of erythrocytes in different conditions, cell morphology and intracellular Ca2+ levels; (E) quantifica-
tion of the changes in the intracellular Ca2+ levels; (F) alterations in RBC projection area; (G) changes in anisotropy as a marker of sickle cell
transformation in deoxygenated SCD-RBCs and (H) changes in the intracellular K+ concentration. NMDA, N-methyl D-aspartate; SCD, sickle cell
disease; RBCs, red blood cells; Gly, glycine.
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Protein levels per cell and the number of cells expressing
GluN2C, 2D, 3A and 3B were assessed in EPCs during differ-
entiation. On average, the percentage of cells expressing the
NMDA subunits varied from c. 10% for pro-erythroblasts to
20–40% at the later differentiation stages, independent of the
presence of the HBB E6V mutation (HbS gene) (Fig 6A,C,D,
and E). The number of copies of the dominant GluN2D and
3B subunits per cell, expressed as the mean fluorescence inten-
sity, were the highest at the normoblastic stage (Figs 6D and
3B). A tendency towards an increased number of cells express-
ing GluN3A and 3B subunit in the EPCs of SCD patients was
observed at the stage of basophilic and polychromatic erythro-
blasts (Fig 6E and G). However, this tendency did not reach
statistical significance and was not preserved at the normoblas-
tic stage. All in all, the protein levels for all subunits at each
differentiation stage tested did not differ between the EPCs of
healthy humans and those of SCD patients. This observation
suggests that the striking enrichment of the circulating SCD-
RBCs with NMDARs resulted from the disturbed clearance of
the receptors from reticulocytes.
Sensitivity of the EPCs to memantine exposure was tested
as a function of antagonist concentration. As shown in Fig 7,
memantine was well-tolerated by both the EPCs of control
subjects and those of SCD patents within a pharmacologi-
cally relevant concentration range (1–50 lmol/l). At higher
concentrations (01–1 mmol/l) the highest mortality rate was
observed in control EPCs at the pro-erythroblast stage (6 d
in culture, Fig 7A). The EPCs of SCD patients showed maxi-
mal sensitivity to high doses of memantine only at the stage
of polychromatic erythroblasts (12 d in culture, Fig 7B),
being generally more tolerant to memantine than the cells of
healthy humans. Cell death was accompanied by characteris-
tic changes in morphology, including a high degree of vacuo-
lization and vesiculation (Fig 7C).
Discussion
The present study indicates that an abnormally great abun-
dance of functional NMDARs is characteristic of the circulat-
ing RBCs of SCD patients (Fig 1, Table II). Hyperactivation
of the NMDARs in RBCs was associated with the severity of
haemolytic events, as the number of active receptors in the
majority of cells forming M fraction correlated negatively
with haemoglobin/haematocrit levels and positively with
plasma LDH (Fig 2). Induction of HbS polymerization in
vitro by exposing the RBCs of SCD patients to low oxygen
(A) (B)
(C) (D)
(E) (F)
Fig 5. Expression of NMDAR subunits during
erythropoiesis. (A-F) relative amounts of the
different NMDAR isotypes (as indicated). Cells
were harvested and analysed at days 6, 12 and
18, transcripts were measured by TaqMan real
time polymerase chain reaction. Values are rep-
resented as box plots of 9 erythroid cultures
from healthy subjects (open boxes, n = 9) and
10 erythroid cultures from SCD (grey boxes,
n = 10), each started with cells from a different
donor. An overall comparison indicated signifi-
cant differences between days of culture only
for the expression of GRIN2C (P < 005) and
GRIN1 (P < 005).
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levels revealed that hypoxia-induced Ca2+ uptake, dehydra-
tion and the polymerization rate itself could be substantially
slowed down in the presence of the NMDAR antagonist me-
mantine (Fig 4). Activation of the NMDARs with NMDA
and glycine, on the other hand, could induce a complex cell
response resembling that occurring during crises, including
some sickle cell transformation Ca2+ uptake, K+ and water
loss and oxidative stress (Fig 3).
Taken together, all these findings suggest that inhibition
of the NMDARs may be beneficial as it hits multiple cal-
cium-sensitive targets, preventing the dehydration, sickling
and oxidation associated with haemolytic crises in SCD
patients (Bogdanova et al, 2013). The design of the present
ex vivo study did not allow testing for the long-term effects
of memantine supplementation on SCD-RBCs, such as
changes in calpain activity, or changes in the adherence of
SCD-RBCs to the endothelial layer. The lack of active
NMDARs in the circulating C57B6 mouse red blood cells
was documented by using [3H]MK-801 binding assay (A.
Makhro and A. Bogdanova, unpublished observations). This
observation limits us to the use of human cells in the future,
making mouse models of SCD useless for such a long-term
study.
We have previously shown that the number of NMDARs
and the amplitude of response to the stimulation of
NMDARs in the RBCs of healthy humans is particularly high
in the light fraction enriched with reticulocytes and young
cells (Makhro et al, 2013). Similarly, the number of copies of
GluN1 and the number of active receptors assessed as the
[3H]MK-801 binding sites per cell is maximal in the upper
light fraction of SCD-RBCs (Table II, Fig 1B, C). As reported
by Bookchin et al (1991), the reticulocytes of SCD patients
(A) (B)
(D)
(E)
(c)
(F)
(G) (H)
Fig 6. Protein levels of GluN2C, 2D, 3A and
3B in EPCs at various differentiation stages.
Shown are the numbers of cells in which fluo-
rescent signal from the corresponding antibod-
ies was detected by means of flow cytometry
(A, C, E, G) and the mean intensity of this sig-
nal per cell (B, D, F, H). Numbers above boxes
represent medians of the corresponding signal
in EPC cultures obtained from healthy control
subjects. Cells were harvested and analysed at
day 6, 12 and 18. Data were obtained from
cultures grown from CD34+ cells of four differ-
ent SCD patients (open boxes) and six healthy
subjects (grey boxes). EPCs, erythroid precur-
sors; AU, arbitrary units.
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show maximal susceptibility to dehydration and sickling.
This paradoxic predisposition of young cells to premature
clearance may be caused at least in part by higher susceptibil-
ity to calcium overload resulting from hyperactivation of
NMDARs.
Substantial up-regulation of NMDAR abundance and
activity in SCD-RBCs was observed in all RBC fractions,
being particularly high in the L fraction (Table II). A fur-
ther increase in the number of active receptors in the L
fraction of SCD-RBCs was detected in patients showing
symptoms of haemolytic crises manifested as a decrease in
haematocrit, and the onset of a pain crisis (Fig 1C). These
observations suggest that the greater abundance and activity
of NMDARs may be associated with the onset of crises.
Dissection of the factors involved in hyperactivation of the
NMDARs in RBCs of patients with SCD during the crisis is
of key importance. Plasma glutamate and glycine levels are
determinants of NMDAR activity in RBCs. Increased levels
of glycine and a c. 35-fold increase in the intraerythrocytic
levels of both agonists have been reported for SCD patients
during asymptomatic periods (Kiessling et al, 2000). No
data for plasma amino acid composition during crises are
currently available. One can expect that haemolysis would
be associated with the release of these excitatory amino
acids, resulting in progressive activation of the receptors in
RBCs.
Mechanisms that control NMDAR abundance in the RBCs
of SCD patients await further in-depth characterization,
which is beyond the scope of this study. Although relatively
high, the number of receptors per cell in circulating SCD-
RBCs is within the 102 range and is thus not comparable
with that in EPCs, which range from 105 to 103 receptor
copies per cell (Makhro et al, 2010, 2013). Terminal stages of
EPC differentiation are clearly associated with massive clear-
ance of the receptors from the plasma membrane. Even a
slight disturbance in clearance efficiency would result in sig-
nificant up-regulation of the number of NMDARs remaining
in membranes of circulating RBCs. The mechanisms involved
in clearance of NMDARs in EPCs have not yet been studied.
Unusually high levels of membrane-bound haemoglobin
resulting from its higher affinity to the cytosolic domain of
band 3 protein may at least partly explain the inclmplete
clearance of the receptors (Rotter et al, 2010).
The conductive pathway involved in the increased perme-
ability of the membranes of SCD-RBCs to cations, including
calcium ions, is known as Psickle. Analysis of the properties
and pharmacological profile of Psickle suggests that the current
is mediated by more than one channel type. Among the
hallmarks of Psickle are activation upon deoxygenation
(Browning et al, 2007; Vandorpe et al, 2010) and filtration
(shear stress) (Brain et al, 2004), permeability for K+, Na+
and Ca2+ (Bookchin & Lew, 1981), sensitivity to Zn2+ and
(A)
(C)
(B)
Fig 7. Memantine and MK-801 toxicity studies
performed for healthy human-derived EPCs
and SCD-EPCs at days 6, 12 and 18 in culture.
The EPCs were exposed to memantine added
to the culturing medium at concentrations of
10 lmol/l-1 mmol/l for 24 h (A,B). Thereafter
the cells were harvested and mortality assessed
using propidium iodide staining. Data are the
means of four cultures obtained from four
independent healthy subjects or HbSS
patients  SD. (C) SCD-EPCs were treated
with 05 mmol/l MK-801 for 12 h at the vari-
ous differentiation stages. Vacuolization is
present at days 14 and 19 and indicates apop-
tosis. Cells at the early stage of erythropoiesis
(day 10) are less sensitive to MK-801 treatment
and mature RBCs (day 21) are completely
resistant. SCD, sickle cell disease; EPCs,
erythroid precursors.
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stilbene disulfonate (DIDS) (Joiner, 1990; Browning et al,
2007), voltage- and pH-dependence (Joiner et al, 1993).
These properties are shared by NMDARs. We have demon-
strated that NMDAR function in the RBCs of SCD patients
is oxygen-dependent (Fig 4). Sensitivity to 4,40- diisothiocy-
anostilbene-2,20-disulfonic acid (DIDS) (Tauskela et al, 2003)
and voltage-dependence were demonstrated in the NMDARs
in neurons. Sensitivity of NMDARs to Zn2+ appears to be
particularly interesting in view of reports that 1 year of zinc
sulphate supplementation was found to reduce the incidence
of pain crises and infections in SCD patients in several clini-
cal trials (Swe et al, 2013). Whether this beneficial action of
Zn2+ is, at least in part, mediated by suppression of the
NMDARs remains to be confirmed.
We have demonstrated the sensitivity of NMDARs in
SCD-RBCs to filtration as a manifestation of shear stress
(Fig 1B, and text). These receptors have been shown to be
mechano-sensitive (Paoletti & Ascher, 1994; Singh et al,
2012). Other features of Psickle, such as sensitivity to Gd
3+,
CO and to a toxin produced by the tarantula spider GsMTx-
4 (Vandorpe et al, 2010) have not been tested for NMDARs.
NMDAR function is known to be highly sensitive to changes
in pH, but the optimal pH range for the NMDARs in the
brain differs from that of Psickle. These are the indications
that Cav21 channels and voltage-dependent anion channels
(VDACs) may contribute to Psickle along with NMDARs, each
responding to a characteristic set of stimuli related to stress
and inflammation (Kaestner, 2011).
Our observations clearly show that the inhibition of
NMDARs hits multiple targets in RBCs. In addition, meman-
tine has recently been reported to effectively suppress neuro-
pathic pain after surgery (Morel et al, 2013). Failure to
reduce the number and severity of acute pain episodes was
the reason for the negative outcome of several trials in which
a Gardos channel blocker, the anti-adhesion drug poloxamer
188, and inhaled nitric oxide were used in treatment of
patients with SCD (Gee, 2013). A combination of the pre-
vention of haemolytic crises and reduction in vaso-occlusive
events with potential effective pain management makes
memantine an attractive candidate for therapy of SCD.
The number of patients with SCD is growing rapidly in Swit-
zerland and other European countries due to the increasing
flow of migrants from Africa and Asia to Europe (Schmugge
et al, 2008). Currently, most of the SCD patients in Switzerland
are children. Moreover, when proven efficient in treatment of
SCD, calcium-lowering therapy could be extended for treat-
ment of other types of rare hereditary forms of anaemia associ-
ated with abnormal intracellular Ca2+ levels, such as
thalassaemia, phosphofructokinase deficiency and others.
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Abstract  
Aims: This study focuses on the cardiac N-methyl D-aspartate receptors (NMDARs) as a target for 
endogenous and synthetic agonists and antagonists.  
Methods and Results: Using isolated perfused rat hearts, we have shown that intracoronary 
administration of  agonists and antagonists of the NMDAR have a pronounced effect on autonomous 
heart function. Perfusion of rat hearts with autologous blood supplemented with NMDAR agonists 
was associated with induction of tachycardia, sinus arrhythmia and ischemia. Intracoronary 
administration of the NMDAR antagonists exerted an anti-arrhythmic effect and resulted in 
bradycardia and improvement of capillary perfusion. Half-maximal increase in heart rate and heart 
rate variability occurred in the presence of 150 and 270 μM glutamate/glycine mixture respectively. 
Action of the NMDAR antagonists on autonomous heart function differed strikingly from that of the 
L-type Ca
2+
 channel blockers verapamil and diltiazem. [
3
H]-MK-801 displacement studies 
performed for eliprodil, Ro25-6981, memantine, ketamine, and MK-801 in rat heart tissue sections 
and in isolated sarcolemmal membranes proved selectivity of [
3
H]-MK-801 interaction with cardiac 
NMDARs. Subunit composition of cardiac NMDARs was explored. Transcripts of the GluN3A and 
GluN2D were found in all heart chambers, whereas expression of GluN1 and GluN2A,C were 
restricted to the atria. Expression of the GluN2B protein in ventricles increased markedly with age 
of the animals. Subunit composition and unusual pharmacological characteristics reveal the unique 
features of cardiac NMDARs. 
Conclusions: The obtained data reveal that NMDARs are expressed in rat heart contributing to the 
autonomic heart rate regulation and the function of the cardiac conduction system. 
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Introduction 
The role of N-methyl D-aspartate receptors (NMDARs) in brain development, cognitive function 
and progression of neurological disorders cannot be overestimated. These ligand-gated cation 
channels formed by glycine-binding (GluN1 and GluN3A/B) and glutamate-binding (GluN2A, B, C 
and D) subunits show high preference for Ca
2+ 1
. Gating properties, conductance, deactivation 
kinetics as well as responses to inhibitors and allosteric modulators vary greatly depending on the 
subunit composition of the receptor complex
2
. The pivotal importance of this class of ionotropic 
glutamate receptors in the brain gave rise to a rapid progress in pharmacology during the past 30 
years and resulted in development of numerous antagonists targeting specific subunits that form the 
receptor or specific binding sites
3
. These compounds are currently used for medication of patients 
with Alzheimer's disease, Huntington's disease, and various forms of dementia. Some of them are 
broadly used as anaesthetics and others were tested for treatment of epilepsy and stroke
4
. Each 
antagonist used to target the NMDARs in the central nervous system has been shown to produce 
multiple systemic effects. In particular, compounds targeting 1-(1-phenylcyclohexyl)piperidine 
(phencyclidine, PCP)-binding site within the receptor channel pore (e.g. memantine, ketamine, and 
MK-801) were reported to act as antiarrhythmic drugs in animal models
5-7
. The PCP-targeting 
antagonist aptiganel HCl decreased the incidence of arrhythmia, suppressed  premature ventricular 
complexes (PVCs) and reduced the S-T interval depression in human patients affected by stroke 
4
.  
Eliprodil, another NMDAR antagonist interacting selectively with the glutamate-binding GluN2B 
subunit, was shown to modulate oxygen consumption in the heart
8, 9
 and cause prolongation of the 
rate-corrected QT interval (QTc) in human subjects at high doses
4
. Initially, all the changes in the 
heart function triggered by the NMDAR agonists and antagonists were attributed to the action of 
these compounds on the central and peripheral nervous system. Indeed, microinjections of NMDA 
4 
 
or glutamate directly into nucleus tractus solitaries caused bradycardia and reduced arterial pressure 
in rats. These effects were inhibited by the receptor antagonists MK-801 and AP5
10, 11
. The GluN1, 
GluN2A, and GluN2B subunits were detected in vagal preganglionic neurons projecting to the rat 
heart
12
.   
However, the effects of agonists and antagonists of the NMDARs were retained in denervated 
hearts. MK-801 in rat and ketamine in guinea pig spontaneously beating right atria caused a dose-
dependent reduction in heart rate (HR) and contractile force
13,14
. Similar negative inotropic and 
chronotropic effects were observed in isolated hearts from rabbits and guinea pigs perfused with 
Krebs-Ringer or Tyrode buffer supplemented with ketamine
15, 16
. Recently, expression of the GluN1 
and GluN2B subunits of the NMDARs was confirmed in heart tissue of several mammalian 
species
17-19
. However, detailed characterisation of autonomous heart responses to the NMDAR 
agonists and antagonists was lacking. Subunit composition of cardiac NMDAR complexes, 
pharmacology of cardiac NMDARs, and kinetics of responses of the heart to the alterations in 
receptor activity remained unidentified. This study presents detailed characterization of autonomous 
responses of the isolated blood-perfused rat heart to agonists and antagonists of the NMDARs. 
Using autoradiography and qPCR the heart was mapped for the NMDAR activity and subunit 
composition and the specific interaction of antagonists with cardiac NMDARs was explored. The 
obtained results indicate that cardiac NMDARs actively participate in regulation of HR and heart 
rate variability (HRV). 
Materials and methods
# 
(
#
For more details on the methods and protocol see the supplementary Method section). 
Animals  
Wistar rats of both sexes, aged from 3 months to 2 years, were used for the study. Animals were 
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purchased from Janvier (Le Genest Saint Isle, France). All animal experiments were approved by 
the Veterinary Office of the canton Zurich and performed in accordance with Swiss animal 
protection laws and institutional guidelines that comply with guidelines of the American 
Physiological Society and the Institute of Laboratory Animal Resources. 
Ex vivo blood-perfused rat-heart model 
Animals were anesthetized using 3% isoflurane in O2/N2O mixture (800 mL/min), heparinized 
intravenously (5000 U/kg), and 8-10 mL blood were collected from the caudal vena cava. The hearts 
were collected immediately thereafter and chilled in ice-cold perfusion buffer. The hearts were then 
perfused retrograde via the aorta with autologous rat blood or washed human erythrocytes 
suspensions to maintain optimal oxygen delivery to the tissue and to achieve intracoronary delivery 
of the compounds used. Human blood was collected from healthy donors at the University Hospital 
Zurich following written consent. Blood collection was approved by the cantonal ethic committee 
and conformed to the principles outlined in the Declaration of Helsinki. Haemoglobin oxygen 
saturation was maintained at 87-90%. Stock solutions of the NMDAR agonists (N-methyl D-
aspartate (NMDA), glutamate, glycine, homocysteic acid, D-serine), and NMDAR antagonists 
(phencyclidine-targeting blockers (PCPBs): memantine, MK-801, ketamine; polyamine binding site-
targeting antagonists (PAAs): eliprodil, Ro25-6981; and ZnCl2) were used for intracoronary 
perfusion. L-type calcium channel blockers (CCBs) diltiazem and verapamil were always used at 
concentrations 10 µM and 5 µM respectively. Concentrations of the NMDAR agonists and 
antagonists were chosen based on the affinities and IC50 values reported for the neuronal 
NMDARs
20, 21
. Each of the antagonists chosen for the study was not absolutely specific, but 
NMDARs were the only receptors shared by all the compounds tested, whereas the other targets 
were not always overlapping (Table 1 and supplementary Table 1). All compounds were 
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administered 20 min after the onset of blood perfusion and applied for 40 min if not stated 
otherwise.  
Evans Blue was added intracoronary and efficacy of capillary perfusion in ventricular tissue was 
monitored as stated elsewhere
22
  in the presence or absence of 300 μM HCA or 50 μM of memantine 
in blood. 
Classical Langendorff model 
Changes in heart rate and heart rate variability were monitored as a function of glutamate and 
glycine concentration in Krebs-Henseleit solution. These experiments were performed to assess the 
action of physiological doses of agonists on autonomous heart function and EC50 detection. 
ECG recordings, heart rate, and heart rate variability 
ECG electrodes were fixed vertically on either side of the hearts so that the resulting recordings 
corresponded to the aVL projection. Heart rate (HR) was calculated from the RR intervals extracted 
from the ECG using MLS360/7 ECG Analysis Module of the LabChart7 Pro Software, 
ADInstruments Ltd, and manually corrected for artefacts. Heart rate variability (HRV) was assessed 
using time-domain analysis of consecutive artefact-free RR intervals. The values averaged over the 
last 5 minutes of the 20 min restitution period were used as controls and compared with the readouts 
averaged over the period between the 10
th
 and 15
th
 minute after the onset of treatment. This 
approach, i.e. comparing HR and HRV before and after treatment, allowed minimising the 
contribution of heart-to-heart variability into the observed effects of tested compounds on HR and 
HRV. HR as well as ECG recorded from the isolated rat hearts perfused with autologous rat blood 
(Fig S2H) or washed human red cell suspension was stable over the first two hours of perfusion 
despite certain variability in absolute values between the individual hearts. 
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mRNA isolation and qPCR analysis 
RNA was isolated from the rat brain, left and right ventricles, septum, left and right atria and a 
region containing mitral, tricuspid, aortic and pulmonary valves as described elsewhere 
23
. cDNA 
was synthesized from RNA samples by “High Capacity RNA-to-cDNA Master Mix”, Applied 
Biosystems. “TaqMan® Gene Expression Master Mix”. Sixty cycles at 95°C for 15 s and 60°C for 1 
min were performed using 7500 Fast Real-Time PCR System, Applied Biosystems. Rat GAPDH 
was used as a reference. Triplicate readings were taken and the average was calculated. The results 
were normalised to a randomly selected value obtained for the control sample, which was accepted 
as equal to 1. 
Protein detection by Western Blotting  
Rat hearts were homogenized and proteins were separated on 7.5% acrylamide gel and transferred to 
nitrocellulose membrane. Staining performed with mouse monoclonal anti-GluN1 antibody, and 
rabbit polyclonal anti-GluN2C antibodies  (NB300-118 and NB300-107, Novus Biologicals), rabbit 
polyclonal anti-GluN2A and mouse monoclonal anti-GluN2B antibodies (ab14596 and ab28373, 
Abcam) and the corresponding secondary antibodies.  
Isolation of sarcolemmal membranes (SM) and detection of Ki for MK-801, ketamine, memantine, 
eliprodil and Zn
2+
 using [
3
H]-MK-801 displacement approach 
SM fraction was isolated from rat atrial and ventricular tissue according to the protocol described 
elsewhere
24
. Membranes were pre-incubated with 3 nM [
3
H]-MK-801 and thereafter exposed to 
MK-801, memantine, eliprodil or Zn
2+
 at various concentrations for 60 min. Thereafter membranes 
were sedimented on a nitrocellulose filter and washed twice with 5 ml of assay buffer. Filters with 
sedimented membranes were then dissolved in the scintillation fluid and the amount of [
3
H]-MK-
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801 bound to the membranes was assessed using TRI-CARB liquid scintillation analyser (Packard, 
Canada). 
Autoradiography 
Autoradiography was performed as described elsewhere
25
 to detect the active NMDAR complexes 
in intact hearts and in cryosections. Radiolabeled [
3
H]-MK-801 was administered intracoronary and 
allowed to circulate for 100 min. Extraction of the [
3
H]-MK-801 from plasma by the myocardium 
was monitored using liquid scintillation analyzer (Fig S1B). Localisation of the bound [
3
H]-MK-801 
within the heart was assessed in 10 µm cross-sections through the whole organ using X-ray Kodak 
film. The film was developed after 2 months of exposure and the obtained images digitalized and 
analyzed using MCID Image analysis software (InterFocus Imaging Ltd, Cambridge, UK).  
A similar approach was used to detect [
3
H]-MK-801 binding and assess displacement efficiency of 
MK-801 and other antagonists in the 20 µm-thick cryosections of rat hearts and rat brain. Sections 
were rinsed in sucrose buffer, air-dried and incubated with 30 nM [
3
H]-MK-801 (20.5 Ci/mmol) in 
the presence of 300 μM NMDA and 300 μM glycine. After 20 min of incubation, the sections were 
washed free from non-bound antagonist and exposed to the film for 1 month. Displacement efficacy 
was tested. Non-specific binding tests were performed in which [
3
H]-MK-801 binding to the 
cryosections was assessed in the presence of non-labelled MK-801, memantine, eliprodil or Ro-25-
6981 (200 µM each), or ketamine (4 mM).  
Statistical analysis 
Data are presented as means±SEM if not stated otherwise. Data analysis and statistics were 
performed using GraphPad Instat Software. Normality test was performed followed by one-way 
Analysis of Variance (ANOVA) test followed by the Bonferroni or Dunnett Multiple Comparisons 
post-tests. The level of significance was accepted at p<0.05.   
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Results 
Heart rate (HR) 
Intracoronary administration of the NMDAR agonists (NMDA, glutamate, homocysteic acid) 
resulted in tachycardia developing within the first few minutes and reaching a plateau after 10 min 
of treatment (Fig 1A,F, S2A). Intracoronary supplementation of NMDAR antagonists belonging to 
PCPBs (MK-801, memantine, ketamine; Fig1B,F,S2C) and PAAs  (eliprodil, Ro25-6981; Fig 1C,F, 
S2D) produced acute bradycardic response within 2-3 min which reached 30-40% of initial HR at 
the end of 40 min exposure. The degree of bradycardia was proportional to the antagonists 
concentration (Fig S5). Partial additively in effects was observed when 50 µM of MK-801 was 
administered subsequently after Ro25-6981 (Fig S2D) or eliprodil (data not shown) 
supplementation. Treatment with ZnCl2 resulted in tachycardia, produced PVCs and was pro-
arrhythmogenic (Table 2, Fig 1D,S3). Due to the similarities in responses to the individual agonists 
(Fig 1A) PCPBs (Fig 1B), PAAs (Fig 1C) and CCBs (Fig 1E), results were pooled together for 
further analysis (Fig 1F-I, Table 2).  
Hearts perfused with Krebs-Henseleit saline developed dose-dependent tachycardia when treated 
intracoronary with equal concentrations of glutamate and glycine. Half-maximal response was 
observed at a concentration of 149 µM (Fig 2 A,B). Furthermore, stimulation of the NMDARs with 
glutamate and glycine produced a dose-dependent increase in heart rate variability (EC50 271 μM, 
Fig S3, B). No further changes in HR were observed above 1 mM of glutamate and glycine. Less 
potent, but more NMDAR-specific agonists NMDA (glutamate analogue) and D-serine (glycine 
analogue) were causing tachycardia although at doses significantly exceeding those of glutamate 
and glycine (EC50 of 1.55 and 2.1 mM for NMDA and D-serine respectively, Fig 2C).  
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The agonist-induced tachycardic response was not reversed after the 15 min of perfusion with the 
agonists-free buffer (Fig 2B). Flattening or inversion of ST segment on ECG recordings was 
consistent with the myocardium becoming ischemic upon stimulation of the receptors with agonists 
(Fig  2B,D). This observation was in line with results obtained on blood-perfused heart in which 
tachycardia and arrhythmia was associated with a decrease of ST segment amplitude (Fig 1A). 
Using Evans Blue capillary perfusion was visualised in ventricular tissue upon hyperactivation or 
inhibition of the cardiac NMDARs by HCA and memantine respectively. The number of perfused 
capillaries recognised by Evans Blue fluorescent signal was drastically reduced in ventricular tissue 
exposed to HCA and significantly improved upon administration of memantine (Fig 2C). These 
changes were associated with the onset or suppression of tachycardia and arrhythmia (Fig 2B,C, Fig 
S3B).  
 
Heart rate variability (HRV) 
Persisting stimulation of the cardiac NMDARs with agonists was associated with an increase in 
HRV (Table 2, Fig 2 A, D, Fig S2-S4). Increase in HRV was directly proportional to the dose of 
agonists present in the circulation with a half-maximal effect observed at 271 μM (Fig 2A,C). 
Spontaneous sinus arrhythmia observed in ~ 35% of harvested hearts exposed to a brief episode of 
global ischemia-reperfusion could be suppressed by treatment with PCPBs and PAAs. The anti-
arrhythmic action of antagonists was reflected by a decrease in SD1, SD2, SDNN, and RMSDD (for 
abbreviations see Supplementary Methods section) back to the values observed in rhythmic hearts 
(Table 2). Representative Poincaré plots confirmed induction of sinus arrhythmia in autonomously 
beating hearts by the NMDAR agonists (Fig S4A-C). The action of Zn
2+
 ions generally mimicked 
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that of the NMDAR agonists (Fig 1D, Table 1). Tachyarrhythmia caused by exposure to Zn
2+
 could 
not to be reversed by the subsequent MK-801 administration (Fig S2F).  
In contrast to the NMDAR antagonists, CCBs had a pronounced pro-arrhythmic effect in 
autonomously beating rat hearts (Table 2, FigS3D, S4H-E). 
ECG 
In blood-perfused as well as in RBC-perfused and KH-perfused hearts hyperactivation of the 
NMDARs with any agonist was associated with lowering or reversion of the ST segment (Figs 
1A,2D). PCPBs MK-801 and memantine, or ketamine significantly increased QTc interval, while 
PR and QRS intervals were not changed (Fig 1B,G,H,I). Similar to that in RBC-perfused setup 
supplemented with NMDA and D-serine MK-801 produced biphasic dose-dependent bradycardic 
response (apparent IC50=40 µM) which was associated with the prolongation of PR, QRS and QTc 
intervals in the presence of agonists NMDA and D-serine (Fig. S5). Prolongation of QTc was not 
observed if Zn
2+
 (50 µM) was present in blood along with MK-801 (Fig 1D). Zinc alone did not 
alter ECG intervals despite is pro-arrhythmogenic action. GluN2B-specific PAAs did not alter QTc 
intervals significantly, but have prolonged QRS duration (Fig 1C,H,I).  
Intracoronary administration of the CCBs resulted in disappearance of P-waves on the ECG (sinus 
arrest or sinus exit block) and induction of marked sinus arrhythmia (Fig S3E). Bradycardia (Fig 1F, 
S2F) and increase in RR intervals in the hearts exposed to the CCBs (Fig 1A) was associated with a 
pronounced decrease in QTc interval (Fig 1E,I). 
Cardiac NMDAR pharmacology and localisation  
Two approaches were used to assess the receptor activity and its pharmacological profile. Isolated 
SM fraction was pre-incubated with [
3
H]-MK-801 and thereafter displacement of the bound 
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antagonist with various concentrations of non-radiolabeled MK-801 revealing that at least 90% of 
specific [
3
H]-MK-801 binding to the SM. Similar dose-dependent [
3
H]-MK-801 displacement 
experiments were performed for ketamine, memantine and Zn
2+
. The IC50 values and the 
representative curves where [
3
H]-MK-801 displacement efficiency was plotted against the 
concentration of non-labelled antagonists in semi-logarithmic coordinates and fitted using single or 
dual sigmoid functions are shown in Fig 3. In atrial SM, two types of binding sites with high (IC501 
15±4 nM) and low (IC502>1 µM) affinities were detected for MK-801, whereas memantine 
displaced [
3
H]-MK-801 at a single binding site (IC50 37±9 nM). The IC501 for the NMDAR 
antagonists in ventricular SM made up (in nM): 1.8±0.3 for MK-801, 1.3±0.4 for memantine, and 
1206±417 for ketamine (Fig 3B). Binding of MK-801 was altered in NMDARs pre-treated with 50 
µM of eliprodil (Fig 3C). Treatment of the SM with Zn
2+
 increased [
3
H]-MK-801 binding rate to the 
membranes at low nanomolar (e.g. 2 nM) concentration and antagonised [
3
H]-MK-801 binding at 
higher doses (e.g. 50 µM, inset of Fig 3D).          
Localisation of active cardiac NMDAR units within the rat heart chambers was explored using 
autoradiography. When administered intracoronary, [
3
H]-MK-801 was gradually extracted from 
blood (Fig S1) as it interacted with the myocardium. In young hearts, maximal signal from the 
bound [
3
H]-MK-801was obtained from the atria, when in old hearts [
3
H]-MK-801 mostly bound 
within the ventricles and septum (Fig 4A). Antagonist displacement studies similar to those in SLM 
were performed using heart cryosections. Incubation of heart tissue with [
3
H]-MK-801 revealed 
substantial specific binding of the radiolabeled antagonist to the cardiac as well as to the neuronal 
NMDARs. The bound [
3
H]-MK-801 could be successfully displaced by non-labelled PCPBs like 
MK-801, memantine, ketamine as well as by PAAs as eliprodil and Ro25-6981 (Fig 4B,C). The 
PAAs antagonized [
3
H]-MK-801 binding to the heart, but not to the brain cryosections (Fig 4B,C).  
Targets of the NMDAR agonists and antagonists in the heart 
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Expression pattern of GluN (GRIN) genes encoding NMDAR subunits were assessed in the rat brain 
and in  rat heart chambers, septum, and in the valvular region using RT-PCR. As shown in the Table 
3, GluN1 and GluN2A were expressed in atria only, whereas transcripts of GluN2B and 2D, and that 
of GluN3A genes were detected in all regions of the heart. GluN2C was only detected in septum and 
in the left atrium. In adult rat brain, prominent expression of the GluN1, 2A and 2B was found. In 
rat heart most abundant were the transcripts coding for the glutamate-binding GluN2D and glycine-
binding GluN3A subunits of the receptor. In cardiomyocytes isolated from ventricular tissue and 
septum, GluN2B, GluN2D, and GluN3A transcripts were detected. In fibroblasts obtained from the 
same areas in the heart, transcripts of GRIN genes remained below detection limit. (Table 3).  
The presence of the NMDAR subunits at the protein level in whole heart homogenate was explored 
using immunoblotting. Total rat brain protein extracts were used as a positive control. Cardiac 
GluN1, GluN2A, 2B and 2C subunits recognised by the corresponding antibodies appeared to be 
similar to those in the brain (Fig 4D). The signal for GluN2D subunit was identical for in rat brain 
and heart-derived protein, but its weight (170 kDa) was somewhat higher than 135 kDa reported for 
this subunit (data not shown). In agreement with [
3
H]-MK-801 binding studies (Fig 4A), the 
abundance of GluN2B subunit protein in ventricular tissue increased with age (Fig 4E).  
Discussion 
The importance of cardiac NMDARs activation state in autonomous control of HR and HRV, 
function of conductive system (QRS intervals), and ventricular repolarisation (QT) is a major 
finding of the present study.  
Our data indicates that a substantial number of the cardiac NMDARs are active in blood-perfused rat 
heart. Their activity is maintained by endogenous agonists of which glutamate (35-200 µM) and 
glycine (180-310 μM)26-29 are most abundant in plasma and the most potent activators of the cardiac 
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NMDARs (Fig 2A). Glutamate EC50 concentration reported for the neuronal NMDARs is 100 μM30 
whereas for the HR response the EC50 was 149 µM (Fig 2A). Recordings of ionic currents mediated 
by the NMDARs are required to assess EC50 of the cardiac NMDARs more precisely. Paracrine 
release of glutamate from the cardiac muscle where it is highly abundant (30 µmol/mgprotein), 
hemolysis, and other processes causing alterations of plasma glutamate levels may thus contribute to 
the development of tachycardia and arrhythmia. Glutamate is currently extensively used as an 
essential component of cardioplegic solution, where its concentrations may exceed 20 mM. 
Exogenous glutamate is effectively extracted by cardiomyocytes, and taken into the mitochondria 
where it is fed into the tricarboxylic acid cycle via malate-aspartate shuttle supporting respiration, 
particularly in ischemic heart
31
. In rats, these supra-physiological glutamate concentrations were 
shown to acutely reduce infarct size during the first minutes of reperfusion, but did not improve 
hemodynamic recovery
24, 32
. Our observations suggest that exogenous glutamate has more than one 
target, acting on the pacemaker function (HR, Table 2), conductive system (QRS interval, Fig 1H) 
and ventricular repolarisation (QT interval, Fig 1I) along with facilitation of mitochondrial 
respiration. 
Pharmacological profile for cardiac NMDARs was assessed using [
3
H]-MK-801 displacement 
approach. Biphasic dose-response curves obtained for PCPBs interaction with sarcolemmal 
membranes (Fig 3A,B) were similar to those reported for the neuronal NMDARs earlier on (see 
references to the supplementary Table 1). GluN2B-specific PAAs eliprodil and Ro25-6981 were 
equally efficient in displacement of [
3
H]-MK-801 (Fig 4B,C, Fig3C) and producing bradycardia as 
were PCPBs (Fig1F, Fig S2, S3A). The absolute IC50 values obtained for neuronal and cardiac 
NMDARs using [
3
H]-MK-801 displacement in membranes are not always within the same range 
(Table 1). Affinity of the cardiac NMDARs to memantine is three orders of magnitude higher than 
that of neuronal receptors (Table 1). This suggests that cardiac NMDARs, not the neuronal receptors 
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are the primary target of memantine in rats. Whether this hold true for patients with Alzheimer's 
disease remains to be explored. Furthermore, rat cardiac NMDARs respond to ketamine which is 
commonly used in veterinary practice. 
Differences in receptor-antagonists interactions reflect variance in subunit composition of the 
cardiac and neuronal NMDARs. Whereas adult rat neuronal NMDARs are composed of GluN1, 2A 
and 2C, cardiac NMDARs are built of GluN3A, GluN2D, GluN2B is less abundant, and GluN1, 2A, 
and 2C are present at low levels in certain areas of the heart only (Table 3). These molecular settings 
explain the dual (pro-agonistic at low doses and antagonistic at high concentrations) action of Zn
2+
 
on the cardiac NMDARs (Fig 3D). Earlier the stimulatory effect of Zn
2+
 on the receptors composed 
of GluN3A-GluN1 and its inhibition by interaction with the GluN2B subunits was reported 
15, 32
.   
Anti-arrhythmic properties of the PCPBs were associated with a prolongation of QTc intervals (Fig 
1D,F). This is not the case for the PAAs targeting the GluN2B subunit (Fig 1C,D,G). Expression of 
this subunit appeared to be amplified with aging, suggesting that antiarrhythmic effects of PAAs 
will be more pronounced in senescent rat hearts (Fig 4E). Reduction in abundance of this subunit in 
adult and senescent brain (Fig 4E, and
33, 34
) makes eliprodil action in adult rats largely restricted to 
the cardiac NMDARs. In contrast to the CCBs, NMDAR antagonists are anti-arrhythmic whereas 
verapamil and ditiazem were pro-arrhythmic, producing a HRV pattern resembling 2
nd
 degree AV 
block or sinus exit block (Figs S3E and S4H,I).  
One more striking observation is a potent cardioprotective effect of NMDAR antagonists related to 
the improvement of capillary perfusion (Fig 2E). Hyperactivation of the NMDARs due to the 
hypoxia-induced glutamate release contribute to brain oedema, which is in part caused by the 
suppression of Na,K-ATPase 
35, 36
. Administration of antagonists (both PCPBs and PAAs) has been 
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shown to reduce brain oedema associated with deoxygenation
37, 38
. Detailed mechanisms involved in 
NMDAR-driven control of cardiomyocyte volume regulation await further investigation.  
  Taken together, these findings indicate that the NMDAR agonists and antagonists are potent 
modulators of autonomous rat heart function. The observed responses are clearly distinct from those 
produced by the CCBs and are mediated by a set of cardiac NMDARs. The obtained results turn 
cardiac NMDARs into potentially interesting targets for prevention and treatment of malignant 
arrhythmias and heart failure.  
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Figure legends 
Figure 1.The effects of agonists and antagonists on HR and ECG in autonomously beating rat heart. 
A: Waterfall diagrams of the changes in ECG in agonist-treated heart (300 µM of each). B: 
Responses to the PCPBs (MK-801 (50 µM), memantine (50 µM), ketamine (1 mM)). C: Responses 
to the PAAss (eliprodil, Ro25-6981,(60 µM)). D: Responses to ZnCl2 (50 µM). E: Responses to the 
CCBs (Diltiazem (10 µM), Verapamil (5 µM)). Statistics on the HR (F), PR (G), QRS (H), and QTc 
(I) intervals for all the compounds used. Presented are box plots (medians, of  6-25 experiments and 
variance) of the values of the respective intervals overlaid with dots representing the values recorded 
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for individual hearts. Paired t-test was used for statistical analysis. "ns" stands for not significantly 
different, and *, ** and *** denote p<0.05, 0.01 and p<0.001, respectively.  
Figure 2. Dose dependence and reversibility of action of the NMDAR agonists and antagonists on 
the autonomous heart function. A: HR and HRV (assessed as and RMSSD, for details see 
Supplementary materials) in KH-perfused rat heart as a function of (Glu+Gly) concentration.   . 
EC50 values ± SD are shown  (N=4). B: original recording of the acute HR changes caused by 
Glu+Gly and MK-801 in KH-perfused rat heart. C: Acute changes in RR interval caused by 
intracoronary administration of specific NMDAR antagonists NMDA and D-serine in RBC-perfused 
rat heart. D: Partially reversible pro-arrhythmogenic action of 500 µM of (Glu+Gly) in KH-perfused 
heart. Shown as insets are the changes in ECG shape averaged for the highlighted time intervals  E: 
Evans blue staining for the perfused capillaries in frozen sections of ventricular tissue of rat heart 
perfused with autologous blood without (control) or with either 300 µM of HCA or 50 µM MK-801. 
Shown are representative images obtained in 4 animals per group. 
Figure 3 Dose dependent displacement of [
3
H]-MK-801 by other NMDAR antagonists in atrial and 
ventricular SMs. Dose-dependent displacement of [
3
H]-MK-801 by PCPBs in artial (A) or 
ventricular (B) SMs. C: Displacement of [
3
H]-MK-801  by MK-801 in the presence or absence of 
eliprodil in ventricular SM D: Dual effect of Zn
2+
 on the NMDAR activity in ventricular SMs. Inset 
shows [
3
H]-MK-801 binding rate to the SMs in the presence of 2 nM or 50 µM ZnCl2 
Figure 4. Local heterogeneity and subunit composition of cardiac NMDAR. A: Receptor activity in 
blood-perfused young (1.5 months old) and old (1.5 years old) rat heart chambers visualized using 
[3H]-MK-801 localization (autoradiography). B: Quantification of autoradiographic images 
obtained in [3H]-MK-801 displacement studies. Data are means ±SD from 4-6 sections. 0 stands for 
control, NG for NMDA-glycine-treated sections, MK, Mem, Ket Ro25/Eli standing for MK-801, 
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memantine, ketamine, Ro25-6981 and eliprodil. One-way two-tailed ANOVA with Dunnett post-
test were used for statistical analysis. C: Representative autoradiographic images from rat heart and 
brain sections obtained in antagonist displacement study. False scale is showing the colour coding of 
the signal strength. D: Results of immunoblotting for the GluN1, GluN2A, 2B and 2C in brain and 
heart homogenates are shown in panel. E. Changes in abundance of the NR2B subunit in rat heart 
with ageing from 0.5 months to 18 month 
 
 
1 
Table 1 
NMDAR antagonists, IC50 for selected targets 
Ketamine MK-801 Memantine Eliprodil 
ACh  receptors 6-15 μM 21 μM 1 - 7 - 11 μM - 
Opiate receptors 27 μM - - 27 μM 
5-HT receptors 3-30 μM - ~1 μM - 
Ca2+ channels 33 μM - - - 
K+/Na+ channels 1-20μM ? - - 
 Neuronal NMDA 
receptors 
10 - 40 ->100 μM 10-40 nM 1 μM 1-10 μM 
[3H]MK-801 displacement 
in neurons 
1-2.5 μM 2-14 nM 0.4-0.7 μM 
[3H]MK-801 displacement 
rat in atria 
na 15.0±4.0 nM, 
N=15 
36.8±9.2 nM, 
N=15 
na 
[3H]MK-801 displacement 
rat in ventricles 
1.2 ± 0.4 μM, 
N=6 
1.8 ± 0.3 nM, 
N=7 
1.3 ± 0.4 nM, 
N=5 
6.2 ± 1.7*ƚ nM, 
N=7 
ƚ – displacement by MK-801 in a presence of 50 μM eliprodyl. * - p<0.05 vs MK-801.
Details and references are presented in supplementary table 1. 
Table(s)
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Table 2. Time domain analysis of the heart rate variability for autonomously 
beating rat hearts exposed to the agonists and antagonists of the NMDARs or to the 
L-type Ca2+ channel blockers 
Agonists (300 µM NMDA, homocysteic acid, glutamate) and antagonists (MK-801 or memantine 
(50 μM); ketamine (1 mM); Ro25-6981 r eliprodil (60 µM); 50 μM ZnCl2, and L-type Ca2+ channel 
blockers (diltiazem (10 µM) or verapamil (5 µM)). Shown in the table are the maximal NN interval 
within 5 min period (NNmax),  minimal NN intervals (NNmin), means of NN intervals (NNmean), 
standard deviation of NN intervals (SDNN),  square root of the mean squared difference of adjacent 
NN (RMSSD; quantitative characteristics of the Poincaré plots (SD1 and SD2). All values are 
presented as means ±SE. *p<0.05, **p<0.01, ***p<0.005. 
 
 
 
 
 
 
 NNmax NNmin NNmean SDNN RMSSD SD1 SD2 N 
Baseline: normal 297.4±16.1 209.7±17.8 266.8±13.0 5.5±0.9 4.58±0.79 2.37±0.44 2.94±0.39 25 
Baseline: arrhythmia 696.1±95.1*** 188.3±22.6 311.0±18.3* 33.2±4.2*** 40.0±6.7*** 22.9±5.0*** 27.5±5.1*** 15 
Normal before 
agonists 
300.9±29.7 179.8±32.7 265.6±20.7 5.4±1.4 4.98±1.2 2.1±0.5 3.0±0.6 7 
Normal after agonists 386.4±53.2 189.8±37.2 272.8±21.2 20.8±6.8 20.21±7.95 25.7±12.6* 24.6±10.9*** 7 
Arrhythmia before 
agonists 
633.0±122.0 150.3±20.3 347.3±20.6 35.1±6.1 41.8±12.4 7.53±0.9  13.6±1.4 5 
Arrhythmia after 
agonists 
802.0±297.5 234.78±40.42 336.89±15.43 40.44±9.28 51.27±13.66 17.3±1.83 29.27±2.53 5 
Normal before 
antagonists 
305.68±22.88 236.79±21.8 277.7±17.6 5.3±1.3 3.9±1.0 2.8±1.1 3.3±0.9 13 
Normal after 
antagonists 
370.1±29.86** 329.6±22.2*** 346.6±25.1*** 4.2±1.2 3.02±0.94 4.24±1.86 5.68±1.84 13   
Arrhythmia before 
antagonists 
773.54±138.6 219.09±32.39 296.1±26.6 33.2±6.3 40.77±9.26 33.05±6.49* 31.29±6.42* 9 
Arrhythmia after 
antagonists 
423.26±31.86* 246.76±29.74 349.4±32.13* 9.48±1.77** 10.42±2.38* 8.31±3.1** 10.2±2.2** 9 
Normal before Zn2+ 398.68±37.06 347.15±42 379.57±36.41 6.51±0.91 4.68±1.69 2.81±1.06 5.41±1.02 10 
Zn2+ 557.4±136.9 241.0±65.3* 343.4±35.9* 28.0±8.0 30.6±18.2 27.6±17.1 22.6±9.9 10 
Zn2+ and MK 801 478.4±78.8 268.7±34.8 345.8±33.0 19.0±7.4 13.8±5.9 5.8±1.6 1.9±0.6 10 
 Normal before L-type 
blockers 
349.7±52.6 210.2±9.6 259.3±23.7 4.9±0.9 5.9±1.5 2.2±0.8 3.1±0.4 6 
 Normal after L-type 
blockers 
543.5±40.2 334.7±90.8 465.4±55.4* 38.4±16.9 51.7±27.0 35.9±16.7 41.8±15.7 6 
Arrhythmia, before L-
type blockers 
1339.0±450.3 206.2±67.2 319.7±20.4 42.8±13.6 61.3±17.8 38.0±19.6 34.0±21.6 4 
Arrhythmia,  L-type 
blockers 
835.3±338.1 261.1±65.9 410.9±43.1 58.3±36.8 72.01±42.1 36.8±34.5 53.8±50.0 4 
3 
Table 3. Local pattern of NMDAR subunits' expression in rat heart (Δct, GAPDH 
expression used for normalisation) 
Tissue/ cells  GluN1 GluN2A GluN2B GluN2C GRIN2D GluN3A GluN3B 
Brain 6.18 6.42 6.55 8.42 10.77 8.69 18.62 
Septum - - 20.9±0.6 21.1±1.0 15.6±1.9 19.1±0.6 - 
LV - - 20.2±1.9 - 15.2±2.6 17.7±2.6 - 
RV - - 19.8±2.1 - 15.4±2.9 17.6±3.4 - 
LA 20.2±1.4 20.6±0.6 21.1±1.2 20.3±1.8 14.9±1.1 18.2±1.0 - 
RA 18.3±1.0 19.1±1.1 19.0±1.0 - 15.3±1.9 18.3±4.1 - 
Valves - - 20.4±1.8 - 13.6±2.6 11.9±4.2 - 
ARCs - - 21.5±0.6 - 18.5±0.5 22.0±0.03 - 
Presented are values obtained for whole brain homogenate (Brain), various areas of the heart: 
septum, left and right ventricles (LV and RV), left and right  atria (LA and RA), and valvular region 
(Valves), as well as in fresh-isolated adult ventricular rat cardiomyocytes (ARCs). Presented are 
means ± SD for 42 hearts and 3 brains.  Cells were isolated from 3 different hearts. Hyphen 
indicates the levels below detection limits (60 cycles).    
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Supplementary information 
Detailed materials and methods 
Animals 
Wistar rats of both sex, aged from 0.5 months to 2 years were used for the 
study. Animals were purchased from Janvier (Le Genest St Isle, France). All 
animal experiments were approved by the Veterinary Office of the canton 
Zurich and performed in accordance with Swiss animal protection laws and 
institutional guidelines that comply with guidelines of the American 
Physiological Society and the Institute of Laboratory Animal Resources. 
Ex vivo blood-perfused rat-heart model 
The model was described elsewhere in detail 1. Animals were anesthetized 
using 3% isolfurane applied in O2/N2O mixture (800 ml/min), heparinized 
intravenously (Heparin-sodium, B.Braun, 5000 U/kg), and 8-10 ml blood 
were collected from the caudal vena cava. The hearts were collected 
immediately thereafter and chilled in the ice-cold perfusion buffer containing 
(mM): 120 NaCl, 25 NaHCO3, 5 KCl, 10 glucose, 10 TRIS-HCl, 1 CaCl2, 0.15 
MgCl2, pH 7.4. The blood perfusion circuit including a hollow fibre 
oxygenator was primed with perfusion buffer and then filled with blood 
which, upon mixing with the buffer, was diluted to a final hematocrit of 30-
35%. The hearts were mounted on a cannula and perfused retrogradely via 
aorta through the coronaries with autologous diluted blood pre-warmed to 
37⁰C. Hemoglobin oxygen saturation was maintained at 87-90% 1, 2. 
Supplementary Material - Other
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To reduce amount of plasma-borne NMDAR agonists, washed human red 
blood cells (RBCs) were used in a separate set of experiments in which dose-
response of the changes in heart rate (HR), heart rate variability (HRV), and 
ECG. Human blood was collected from the vein healthy donors in 
heparinized syringes. Blood collection was performed at the University 
Hospital Zurich  on written consent and was approved by the cantonal ethic 
committee and conforms with the principles outlined in the Declaration of 
Helsinki. RBCs were washed 6 times by centrifugation (4000xg 5 min) and 
resuspension in the buffer containing (in mM): 120 NaCl, 5 KCl, 25 NaHCO3, 
2 CaCl2, 0.15 MgCl2, 10 TRIS-HCl, 10 glucose, 2 pyruvate, 0.1 arginine, 0.1 
taurine, pH 7.4. Finally RBC were resuspended to 25% hematocirt in the 
same buffer, reoxygenation was assessed by humidified 95% O2 and 5% CO2 
at 37 0C.  Human RBC were chosen due to their  relative stability and higher 
resistance to trauma mediated by passing through the peristaltic pump. 
Thus we could minimise gradual accumulation of glutamate and glycine 
leaking from RBCs in the course of lysis. Heart responses to the increasing 
concentrations of agonists (D-serine, and NMDA) and antagonist  MK-801 
were measured as a function of increasing agonists' and antagonists' 
concentrations. Dose dependence of heart responses to the NMDA, D-Ser 
and MK-801 was explored as boluses of the stock solutions of these 
compounds were added to the RBC suspension used for coronary perfusion 
every 5 min until maximal response was reached. We also performed wash-
out experiments exploring reversibility of the observed effects. 
Stock solutions of the agonists (N-methyl D-aspartate (NMDA), glutamate, 
glycine, homocysteic acid, D-serine), and antagonists (PCPBs): memantine, 
3 
MK-801, ketamine; polyamine binding site-targeting antagonists (PAAs): 
eliprodil, Ro25-6981; and ZnCl2) of the NMDARs were used for intracoronary 
perfusion. L-type calcium channel blockers (CCBs) diltiazem, and verapamil 
were always used at concentrations, 10 µM and 5 µM respectively. The 
concentrations of agonists and antagonists were chosen based on their 
affinities to the neuronal NMDARs reported elsewhere 3, 4. Each of the 
antagonists used in the study was not absolutely specific, but NMDARs were 
the only receptors shared by all the compounds tested, whereas the other 
targets were not always overlapping (Table 1 and supplementary Table 1).  
All compounds were administered 20 min after the onset of blood perfusion 
and applied for 40 min if not stated otherwise. 
Classical Langendorff isolated perfused blood model 
This model was used to assess the affinity of the cardiac NMDARs by 
monitoring HR and HRV as a function of the circulating agonists' 
concentration within physiolgocical concentration range. Wistar rat hearts 
(N=10) were perfused with Krebs-Henseleit buffer (KH) containing (in mM) 
118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.25 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 0.1 L-
arginine, 2 pyruvate, 0.1 taurine and 11 glucose equilibrated with gas phase 
containing 95% O2 and 5% CO2 and warmed to 37⁰C and supplemented with 
glutamate/glycine mixture (0-500 µM each) with or without 50 µM MK-801. 
Heart rate, heart rate variability and ECG were monitored and analyzed as 
described below. 
ECG recordings, HR, HRV 
4 
ECG electrodes were fixed vertically on either side of the hearts so that the 
resulting recordings corresponded to the aVL projection. Due to high inter-
individual variability, all observed effects were compared with baseline 
values from the same heart. 
Heart rate was calculated from the RR intervals extracted from the ECG or 
as a peak-to-peak interval. Analysis was performed using the MLS360/7 
ECG Analysis Module of the LabChart 7 Pro Software (ADInstruments Ltd). 
The values averaged over the last 5 minutes of the 20 min restitution period 
were used as controls and compared with the readouts averaged for the 
same heart over the period between the 10th and 15th minute after the onset 
of treatment. This approach allowed to minimise the contribution of  heart-
to-heart variability into the observed effects of tested compounds on HR and 
HRV. HR as well as ECG recorded from the isolated rat hearts perfused with 
autologous rat blood (Fig S2H) or washed human red cell suspension (Fig 
2E) were maintained stable over the first two hours of perfusion despite 
certain variability in absolute values between the individual hearts. 
Characterisation of the HRV included identification of intervals between 
normal heart beats (N), calculation of maximum, minimum and mean NN 
intervals (NN_max, NN_min, NN_mean) and the standard deviation of NN 
intervals (SDNN). The latter reflected overall variation. The square root of the 
mean of the sum of squares of successive NN differences (RMSSD) reflected  
short-term variability. Based on these indices hearts were allocated to one of 
two groups: those with stable rhythm (mean basal SDNN ±2xSD: 5.5 ± 1.8 
msec, see Table 2)  and the hearts with spontaneous sinus arrhythmia 
5 
(SDNN>7.3 msec). Graphic representation of the HRV was generated in the 
form of Poincaré plots (Fig 4s). The standard deviation of the NN intervals 
variability  perpendicular (SD1) or along (SD2)  the line of identity (SD1) was 
calculated to characterise the short-term and the long-term variability 
respectively  5. The ECG time intervals measured included  RR interval, PR 
interval, QRS duration, and QT interval. The QT interval was corrected for 
differences in heart rate using Bazett formula (QTc =QT/√RR). 
Evans Blue as a marker of capillary perfusion 
Stock solution of Evans Blue (6% in PBS)  was prepared and added to blood 
used for coronary perfusion to a final concentration of  0.006% 60 min after 
5the onset of coronary perfusion in the presence or absence of either  50 µM 
memantine or 300 µM homocysteic acid. Blood with Evans blue was allowed 
to circulate for 5 min and then perfused was stopped and the hearts were 
snap-frozen in isopentane and stored at -80°C. Cryosections (7 μm) of the 
ventricular tissue were prepared and rapidly dehydrated as described 
elsewhere 6. Efficacy of capillary perfusion was then assessed as the number 
of Evans Blue-positive capillaries using fluorescent microscopy (Axiovert 200 
M, Carl Zeiss, excitation and emission wavelength of 546 and 590 nm 
respectively). 
Adult rat cardiomyocytes and fibroblasts isolation 
Adult rat hearts (N=4) were dissected and perfused via aorta with a solution 
containing (mM) NaCl 137, KCl 5, HEPES 20, MgCl2 1.2, glucose 15, and 
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NaH2PO4 1, with pH 7.4 at 37°C (solution A). After 2 minutes of perfusion, 
the perfusion solution was switched to a solution containing (mM): NaCl 130, 
KCl 4.8, NaHCO3 25, MgCl2 1.2, glucose 12.5, and NaH2PO4 1.2 (solution B) 
with the type 4 Collagenase (Worthington, ~100 U/ml) and 1 mg/ml BSA for 
30 minutes. Solution B without collagenase, but with 100 μM CaCl2 and 1 
mg/ml BSA was then used to wash the hearts free from collagenase for 
several minutes. The hearts were then minced and gently agitated to 
separate the cells. Debris was removed by filtration through a 200 µm mesh 
filter. Fibroblasts were separated by allowing the cells to attached to the non-
coated plastic petri dishes for 2 h. Non-adgerent cells were removed by 
washing with solution B and restitution of fibroblasts  in DMEM with 10% 
foetal calve serum and penicillin-streptomycin. Cardiomyocytes were 
permitted to settle for 10 min and then washed in solution A and then in 
PBS,  and RNA extracted from the cells using Trizol reagent. 
mRNA isolation and qPCR analysis 
Male Wistar rats aged 12-14 weeks were euthanized by exposure to pure CO2 
followed decapitation. Brains and hearts were quickly collected, chilled on 
ice and hearts  dissected to six functionally different regions: left and right 
ventricles, septum, left and right atria and a region containing mitral, 
tricuspid, aortic and pulmonary valves. Brain tissue was obtained from the 
same animals. Tissue pieces were than rinsed in ice cold PBS and stored in 
liquid nitrogen. RNA isolation procedure was used as described elsewhere 7 
with some modifications. Frozen tissue was grinded in liquid nitrogen, 
obtained powder was mixed with TRIzol and minced further. The obtained 
7 
lysates (approx. 1 ml) were incubated at RT for 5 min and then transferred 
into tube contained 0.2 ml of chloroform, mixed and incubated 5 further min 
at RT. After centrifugation (16000xg, 5min, 4 oC), the supernatant was 
transferred into a mixture of 0.2 mL isopropanol and 2.5 µl glycogen, mixed 
and incubated 10 min at RT. The pellet was separated after the 15 min 
centrifugation (16 000g, 4 oC) and washed twice with 1 mL of 80% EtOH 
(16000xg, 5min, 4 oC). Then pellet was air dried, dissolved in nuclease free 
water and stored at -20 oC. cDNA was synthetized from RNA samples by 
“High Capacity RNA-to-cDNA Master Mix” (Applied Biosystems). “TaqMan® 
Gene Expression Master Mix” and commercially available primers for rat 
GluN1, GluN2A-D and GluN3A-B. were purchased from Applied Biosystems 
(see supplementary Table 1 for details). Sixty cycles at 95°C for 15 s and 
60°C for 1 min were performed using 7500 Fast Real-Time PCR System, 
Applied Biosystems driven by the Fast System SDS software Rat  GAPDH 
was used as a reference. Triplicate readings were taken and the average was 
calculated. The results were normalised to a randomly selected value 
obtained for the control sample, which was accepted as equal to 1. 
Protein detection by Western Blotting 
Rats were anesthetized and euthanized as described above. Hearts were 
rinsed in ice-cold PBS, cut into pieces and rinsed again. Tissue was 
immediately homogenized on ice in sucrose buffer containing 0.6 M sucrose, 
10 mM imidazole, 1/100 inhibitors cocktail III, pH 7.0 in a ratio of 1 g of 
tissue in 3.5 ml of buffer. Homogenate was centrifuged (10000xg, 5 min, 4
oC) and supernatant then was mixed with Laemli sample buffer. Proteins 
8 
were separated on a 7.5% acrylamide gel and transferred to nitrocellulose 
membrane. TBST (0.1% Tween) with 5% dry milk was used for membrane 
blocking. Staining was performed with the following primary antibodies: 
mouse monolconal  anti-GluN1 antibody, and rabbit polyclonal anti-GluN2C 
antibodies  (NB300-118 and NB300-107, Novus Biologicals), and rabbit 
polyclonal anti-GluN2A and mouse monoclonal anti-GluN2B antibodies 
(ab14596 and ab28373, Abcam). After triple washing of the membranes in 
TBST the membranes were incubated for 1 h at room temperature with 
suitable horseradish peroxidase-conjugated secondary antibodies (1:1000 
dilution; anti-mouse, Jackson ImmunoResearch Laboratories, West Grove, 
PA). The enhanced chemiluminescent detection Western blotting system 
(Fujifilm LAS-3000 System, FUJIFILM Life Science) was used for detection of 
protein. 
Isolation of the sarcolemmal membranes from atria and ventricles and their 
utilization for 3H-MK-801 displacement experiments 
Hearts were harvested from the male and female Wistar rats (250-350 g) and 
ventricles and atria used for the isolation of the sarcolemmal membranes as 
described elsewhere 8. Briefly, frozen atrial and ventricular tissue was 
homogenized in liquid N2 and than mixed with a buffer containing (mM): 600 
sucrose, 10 imidazol-HCl buffer  adjusted to the pH 7.0 in a ratio 3.5 ml/g 
tissue using standard glass homogenizers. The obtained homogenates were 
centrifuged at 12 000xg for 30 min at +4 ⁰C. The resulting pellets was 
discovered and supernatants were diluted with a KCl-MOPS buffer (140 mM 
KCl and 10 mM MOPS-KOH buffered to the pH of 7.4) to the ratio of 5 ml per 
9 
1 g of tissue. The suspension was centrifuged at 95 000xg for 60 min using 
Sorvall Discovery 90 ultracentrifuge and the obtained pellet enriched with 
sarcolemmal membranes  re-suspended in KCl-MOPS buffer and layered 
over the 30% sucrose solution containing  0.3 M KCl , 50 mM Na4P2O7 and 
0.1M Tris-HCl (pH 8.3). The membranes were collected, diluted with 3 
volumes of KCl-MOPS buffer and sedimented by centrifugation at 95 000xg 
for 30 min and suspended in KCl-MOPS buffer. All procedures were 
performed on ice and centrifugation performed at 4⁰C. So obtained 
sarcolemmal membranes were re-suspended in assay buffer containing (in 
mM): 118 NaCl, 4.7 KCl, 1.2 MgSO4, 5 NaHCO3, 20 HEPES, 1.2 KH2PO4, 2.5 
CaCl2, 11 glucose, pH 7.4 and used immediately after the isolation.  
Membranes were pre-incubated with 3 nM [3H]-MK-801 for 20 min and 
thereafter exposed to PCPBs (MK-801, ketamine, memantine), eliprodil, or 
Zn2+ at various concentrations for 60 min. Thereafter, membranes were 
sedimented on a nitrocellulose filter and washed 2 times with 5 mL of assay 
buffer and the filters with sedimented membranes were dissolved in 10 ml of 
Hionic-Fluor (Packard) scintillation fluid. The amount of [3H]-MK-801 bound 
to the membranes was assessed using TRI-CARB liquid scintillation analyser 
(Packard, Canada). 
[3H]-MK-801 binding rate was determined with SM pre-incubated with 2nM 
or 50 µM of ZnCl2 for 60 min. [3H]-MK-801 was added in concentration range 
from 0.3 to 3 nM and incubated for 1 min before the sedimentation and 
washing as described above. The linearity of [3H]-MK-801 binding kinetics 
over the time period from 10 sec to 20 min was proven in preliminary 
experiments. 
10 
Autoradiography 
NMDA receptor autoradiography was performed as described elsewhere 9. 
Hearts and brains were harvested, briefly washed in ice-cold PBS, frozen in 
liquid nitrogen and stored on -80oC before use. After preparation, 20 µm 
cryosections of heart and brain were mounted on glass coverslips and dried 
at RT. The sections were then rinsed in sucrose buffer (190 mM sucrose, 50 
mM Tris-HCl, pH 7.4) and allowed to air-dry. Thereafter sucrose buffer 
solution containing 300 μM NMDA and 300 μM glycine, 30 nM [3H]-MK-801 
(20.5 Ci/mmol) was applied on sections.  Non-specific binding and [3H]-MK-
801 displacement was explored as the buffer was supplemented with 200 µM 
of either unlabeled MK-801, or memantine, or Ro-25-6981, or 4 mM 
ketamine, or 200 µM eliprodil, or 200 µM Ro25-6189. Following 20 min of 
incubation at RT (25 oC) the sections were washed twice with 250 ml sucrose 
buffer at RT, dried and placed on X-ray Kodak film for 4 weeks. Developed 
films were scanned and converted into digital images which were then 
analyzed using MCID Image analysis software (InterFocus Imaging Ltd, 
Cambridge, UK). 
Radiolabeled antagonist binding assay was also used ex vivo as 30 nM [3H]-
MK-801 was administered intracoronary and allowed to circulate for 100 
min. Accumulation of the [3H]MK-801 in the heart and its extraction from 
blood was monitored. The hearts were washed free from blood using ice-cold 
isotonic sucrose buffer and immediately frozen in liquid nitrogen thereafter. 
Series of 10 µm cross-sections through the whole organ were prepared from 
aorta to apex and dried out at RT on glass slides. X-ray Kodak film was 
11 
exposed to those slides during 2 months, and then film was developed and 
digitized by the same way as described above. Kinetics of extraction of the 
radiolabeled antagonist from blood is exemplified in Fig S1. 
Statistical analysis 
Data are presented as means ±SEM if not stated otherwise. Data analysis 
and statistics were performed using GraphPad Instat Software. Normality 
test was performed followed by either one-way two-tailed ANOVA tests 
followed by the Bonferroni post-test, or either Mann-Whitney or Wilcoxon 
tests depending on the distribution type. The level of significance was 
accepted at p<0.05.  Correlation analysis performed for analysis of left 
ventricular pressure and heart rate variability was performed using linear 
(Pearson) correlation test. 
12 
Supplementary figures 
Figure S1 Kinetics by the 3H-MK-801 uptake from blood during the artificial 
perfusion into the myocardial tissue 
13 
Figure S2. Isolated heart rate recording examples after the treatment with drugs of 
interest. A: positive chronotropic response to the treatment with NMDA receptor 
agonist NMDA (300 µM). B: Severe arrhythmia induced by the intracoronary 
supplementation of NMDA (300 µM). C: Intracoronary supplementation of the 
NMDAR channel blocker MK-801 (50 µM) induced bradycardia within 2-3 min after 
treatment. D: Polyamine site-specific NMDAR antagonist Ro25-6981 (60 µM) 
causing bradycardia which may be further accentuated by successive treatment 
with MK-801 (50 µM). E: Anti-arrhythmic action of MK-801 (50 µM) in the heart 
presented with spontaneous sinus arrhythmia (note the expanded BPM axis). F: 
Intracoronary administration of Zn2+ (50 µM) induces tachyarrhythmia and 
abolishes chronotropic effect of MK-801. G: Development of arrhythmia and 
bradycardia triggered by supplementation of the L-type channel blocker verapamil 
(5 µM). H: Untreated heart preparation with PQRST complex showed over the time. 
14 
 
Figure S3. A: Original slips exemplifying the changes in ECG recorded in 
spontaneously beating blood-perfused heart in caused by the NMDAR agonist 
(NMDA, 300  µM, panel) application, antagonists eliprodil (60 µM) and memantine 
(50 µM), PVC induced by administration of 50 µM ZnCl2 and L-type Ca2+ channel 
blocker verapamil (5 µM). Left sides of the panel represent ECG before the treatment 
and right sides show the ECG obtained from the same heart 15 min after the onset 
of treatment. Note the signs of sinus arrhythmia and wandering pacemaker in the 
heart treated with NMDA, intrinsic sinus arrhythmias in the hearts receiving 
eliprodil and the sinus arrest and escape rhythm pattern upon verapamil 
supplementation. B: Arrhythmia induced in buffer-perfused heat preparation 
subsequently treated with increased concentrations of Glu and Gly in 5 min 
interwals. MK-801 was applied after 5 min perfusion with 1 mM of Glu and Gly. 
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Figure S4. Representative Poincaré plots for the hearts treated with the NMDAR 
agonists, antagonists or L-type Ca2+ blockers. X-axis represents NN interval (RR 
interval between normal sinus beats at fixed time point), Y-axis shown the Next 
following NN interval. A, B, C: NMDAR agonists increased variety of distances 
between consecutive NN intervals and therefore increased variety of dot distribution 
over the Poincaré plot. C: Treatment with 300 µM of Glu on top of the plasma-born 
Glu induced arrhythmia and subsequent treatment with MK-801 reduced 
arrhythmia though led to increase of NN interval (bradycardia). D, E, F: Examples of 
how NMDAR channel blockers reduced pre-existing arrhythmia. G: Treatment with 
NMDAR 2B antagonist eliprodil showed the same decrease in arrhythmia. H, I: 
Diltiazem and verapamil provoked severe arrhythmia. Regular irregularity patterns 
can be seen for both drugs.  
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Figure S5. Analysis of ECG intervals in hearts exposed to various concentrations of 
MK-801 in the presence of saturating concentrations  of NMDAR-specific agonists 
NMDA (3 mM) and D-Ser (6 mM). Changes in the A: RR intervals, B: PR, C: QRS 
and D: QT duration are shown as a function of MK-801 dose in RBC suspension. 
Panel E shows stability of these readouts in agonists and antagonist-free control 
over 120 min of perfusion. Presented are means of 4 independent experiments. * 
denotes p<0.05 and ** stands for p<0.01 compared to antagonist-free control. 
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Supplementary table 1 Specificity of NMDAR antagonists 
Drug Target, IC50 
Ketamine 
C13H16ClNO, Mr = 237.7 g/M 
Plasma concentration: ~1µM 
(274 ng/ml) 
Ki (vs 3H-MK-801) 1-2.5 μM 
10
ACh receptors 
nicotinic acetylcholine receptor  15 µM 
m1 muscarininc acetylcholine  receptor 6.5 µM11 
NMDA receptors 
neuronal NMDA receptors, phencyclidine binding 
site  10-15 µM  
classical 40 µM12 
NR1-NR3: 100 μM - 7-9% of current blocked13 
GABA receptor – stimulation14 
Opioid receptors 
µ-opioid receptor15 IC50 27 μM15 
Serotonin receptors 
5-HT3 receptor 3-30 µM16 
Ion channels 
Ca2+-sensitive  (BK) K+ channels: 0.77 -1.66 µM17 
20±5 µM (cell line) 18 
voltage-activated K+ channels16 
hyperpolarization-activated cyclic nucleotide-gated 
cation channel HCN1 channels, 4-8 µM19 
L-type Ca2+ channels  33 µM16 
Pentameric ligand-gated ion channels (pLGICs) in 
bacteria, 58 µM20 
Memantine 
C12H21N · HCl  Mr= 215.76 
g/M  
ACh receptors 
α4β2 neuronal nicotinic receptors IC50 6.6-11.3 
μM22, 23 
18 
 
Daily dose: 10-20 mg,  
Plasma concentrations in rat 
1 µM 21 and in humans 1 µM 
22.   
Ki (vs 3H-MK-801)  0.4-0.7 μM 
10 
α7 nicotinic receptors 0.33-1.68 μM22, 24 
 
Dopamine D2 receptor 
Kd (vs 3H-domperidone) ~ 1 μM25 
 
NMDA receptors 
Currents: 11.6±0.53µM26;  
Memantine in NMDARs expressed in oocytes: 
NR1/NR2A: 0.9 µM, NR1/NR2B 0.4µM; NR1/NR2C: 
0.3  µM, NR1/NR2D: 0.3 µM (-70 mV, Mg-free) ; 
and 10.3, 10.9, 2.0, 1.9 µM (at -30 mV in the 
presence of 1 mM Mg2+)27  
Average IC50 ~ 1 µM at -60 mV28 
Does not inhibit NR1/NR3 receptors!29 
IC50 in striatum and hippocampus 1-3 µM 
 
Serotonin receptors 
5-HT3 receptors IC50 similar to those for NMDARs 
(around 1 μM)30 
 
GABA receptors 
No effects27 
 
Eliprodil (SL-82.0715)  
 
C20H23ClFNO, Mr= 347.85 
g/M 
 
Daily dose 2.5-10-20 mg 31 
 
Plasma concentration in 
Opiate Sigma-Receptor  
IC50 29 nM31, 34 
 
NMDA receptors  
IC50 for Ca2+ uptake by rat cerebellar granule 2 
µM35 
Two binding sites in spinal cord:  
IC50(high) 3.6 µM and IC50(low) 102 µM 
19 
humans   2.9 μM 32 
Ki (vs 3H-MK-801) high and 
low affinity sites  ∼7 and 100 
μM 33 
single type in cortex and mid-brain 7-12 µM36. 
Eliprodil/3H-ifenprodil replacement studies: IC50 
0.13 μM37  
Ion channels 
R- and L-type Ca2+ channels are insensitive to 
eliprodil38 
MK-801 (dizocilpine) 
C16H15N, Mr=221.297 g/M 
Daily dose -  
47 nM - protective 
concentration in rat plasma39 
Ki (vs 3H-MK-801) 2-14 nM 
Kd 5-26 nM10 
ACh receptors  
IC50 for Ca2+ fluxes in neurons 21 ± 2 µM 
IC50 for [3H]-MK-801 binding 1.9 µM 40 
Serotonin receptors  
No information available 
GABA receptors 
No effect on the GABA-R mediated currents41 
NMDA receptors  
IC50 13-38 nM 
NR1/NR3 heterotetramer : 10 µM - no effect 
Currents: 0.13 + 0.02 µM26 
Bi-phasic inhibition of Ca2+ uptake into cerebellar 
granule cells:  IC50(1) 5 nM and IC50(2) 3 µM35 
Ion channels 
(+)-MK801 may be a strong I(Na) and I(to) also 
showing some blocking activity for I(Ca). The 
outward current through K(1) channels was 
unaffected and only slightly reduced the amplitude 
of L-type calcium channels 42 
20 
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Abstract: Ca2+ is a universal signalling molecule involved in regulating cell cycle and fate, 
metabolism and structural integrity, motility and volume. Like other cells, red blood cells 
(RBCs) rely on Ca2+ dependent signalling during differentiation from precursor cells. 
Intracellular Ca2+ levels in the circulating human RBCs take part not only in controlling 
biophysical properties such as membrane composition, volume and rheological properties, 
but also physiological parameters such as metabolic activity, redox state and cell clearance. 
Extremely low basal permeability of the human RBC membrane to Ca2+ and a powerful 
Ca2+ pump maintains intracellular free Ca2+ levels between 30 and 60 nM, whereas blood 
plasma Ca2+ is approximately 1.8 mM. Thus, activation of Ca2+ uptake has an impressive 
impact on multiple processes in the cells rendering Ca2+ a master regulator in RBCs. 
Malfunction of Ca2+ transporters in human RBCs leads to excessive accumulation of Ca2+ 
within the cells. This is associated with a number of pathological states including sickle 
cell disease, thalassemia, phosphofructokinase deficiency and other forms of hereditary 
anaemia. Continuous progress in unravelling the molecular nature of Ca2+ transport 
pathways allows harnessing Ca2+ uptake, avoiding premature RBC clearance and 
thrombotic complications. This review summarizes our current knowledge of Ca2+ 
signalling in RBCs emphasizing the importance of this inorganic cation in RBC function 
and survival. 
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1. Introduction 
Ca2+ is a universal and ubiquitous signalling molecule [1,2], regulating cell cycle and fate, 
metabolism and structural integrity, motility and volume. Most of the Ca2+ in the cytosol is bound and 
buffered by numerous Ca2+ binding proteins, phospholipids and inorganic phosphate. When bound and 
buffered Ca2+ are included, total intracellular Ca2+ in red blood cells (RBCs) reaches 5.7 µM [3]. Basal 
free Ca2+ concentration in RBCs of healthy human beings under physiological conditions is estimated 
to be in the range of 30 to 60 nM [4]. A tremendous gradient of at least 40,000-fold between the 
cytosol and blood plasma where free Ca2+ concentration reaches up to 1.8 mM is maintained due to 
particularly low permeability of membranes to Ca2+ (~50 µmol/(lcells h)) and efficient extrusion of Ca2+ 
from the cells by the plasma membrane Ca2+ pump (PMCA) [4]. This gradient may be used for 
signalling purposes as opening of a few hundreds of channels transporting 106 ions per second over 
several milliseconds may result in >10-fold changes in free Ca2+ levels in the sub-membrane space, 
causing acute changes in the activity of multiple Ca2+ sensitive proteins involved in structural, 
signalling, metabolic and transport functions. Such a huge Ca2+ influx seems to exceed the RBC’s 
Ca2+-buffering abilities. Long-term increases in the Ca2+ permeability result in serious dysregulation of 
multiple cellular functions. The subsequent onset of proteolysis, oxidation, irreversible shrinkage and 
phosphatydylserine (PS) exposure to the extracellular membrane leaflet facilitate clearance of Ca2+ 
overloaded cells in case the latter have not been haemolysed when passing through capillaries. 
This review summarizes the current knowledge on the regulation of RBC Ca2+ levels, Ca2+ 
dependent processes and the potential role that Ca2+ might play in the development of RBC 
pathologies. For obvious reasons this review makes no claim to be complete, but wants to draw 
attention to open questions and mechanisms to be resolved in the field of Ca2+ signalling in RBCs. 
2. Ca2+ Transport across the RBC Membrane 
2.1. Ca2+ Extrusion Pathway: Plasma Membrane Ca2+ Pump  
It was realised very early on that the inhibition of the energy supply in RBCs leads to a Ca2+ 
increase [5]. Although the nature of the Ca2+ influx remained unknown for several decades, the 
extrusion mechanism was realized to be mediated by a plasma membrane Ca2+ pump (PMCA). For 
human RBC membrane the presence of the B-splice isoform of the PMCA1 was shown [6]. This  
P-type ATPase is ubiquitously expressed. It is composed of 1220 amino acids forming  
ten transmembrane domains, two intracellular loops containing ATP binding and phosphorylation sites 
and inward-facing N- and C-terminals. The latter contains a Ca2+ calmodulin binding domain, 
phosphorylation sites and a PDZ-binding domain serving as a docking terminal for a number of 
proteins [7]. The maximal Ca2+ extrusion rate in RBCs can vary within RBC populations of a single 
donor between >60 mmol/(lcells h) and <4 mmol/(lcells h) [8]. The maximal turnover rate of the PCMA 
is significantly higher in RBCs from light fractions compared to that in RBCs within dehydrated RBC 
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fractions following density centrifugation [9]. This reduction in Vmax in cells from the dense fraction 
was referred to as a hallmark of RBC senescence [10]. The maximal Ca2+ turnover rate of PMCA in 
the RBC membrane of healthy humans not loaded with Ca2+ is most likely never reached. The apparent 
Vmax for PMCA measured in such cells is ~50 μmol/(lcells h), the value equal to the passive Ca2+ uptake. 
The enzyme half-activation constant for Ca2+ was reported to be 4 μM, far above the actual free 
cytosolic Ca2+ levels in human RBCs [11]. 
Increases in the intracellular free Ca2+ are sensed by the PMCA and occur in response to the 
interaction of the Ca2+ calmodulin complex with the C-terminus of the enzyme. In Ca2+-loaded RBCs 
the limiting factor of the PMCA transport capacity is ATP availability. The pump is fuelled 
preferentially by a pre-membrane ATP pool [8,12,13] and has a Kd (ATP) of 145 μM [5,14]. Under 
conditions of permanent Ca2+ leak, activation of PMCA results in rapid ATP depletion. 
RBC-derived plasma membrane vesicles contain factors activating PMCA, such as arachidonic 
acid, ceramide and acidic phospholipids, whereas sphingosine suppresses its function [15–17]. The 
function of the PMCA is extremely temperature-sensitive with ~30-fold reduction in turnover rate for 
every 10 °C drop [18]. 
2.2. Ca2+ Influx Pathways 
Ca2+ influx through the plasma membrane of healthy human RBCs is extremely slow but increasing 
up-to 5-fold in cells of patients with sickle cell disease (SCD) and several other forms of hereditary 
haemolytic anaemia [4]. Several cation channels mediate inward movement of Ca2+. Significant 
progress in identification of ion channels in control of Ca2+ uptake has recently been reviewed [19]. 
Voltage-activated non-selective cation channels [20–22] were shown to be Ca2+ permeable [23]. 
These initial observations have all been performed on excised patches, but the presence of the channel 
was also shown in the whole cell configuration [24] and further flux-based characterisations have been 
performed [25–27]. However, a proof of the molecular identity remains to be provided. 
Furthermore, a P-type Ca2+ channel was pharmacologically identified [28] and shown to be a 
CaV2.1 channel by Western blot analysis [29]. This channel can be inhibited by ω-agatoxin TK [29]. 
However, in contrast to the initial investigations, in which activation by protein kinase C (PKC) was 
proposed, recent findings depicted a rather indirect interaction with PKC [30]. 
A recent report provided evidence for the presence of a transient receptor potential (TRP) channel 
of subtype C6 in the RBC membrane [31]. However, most of the work done so far was performed on 
murine RBCs and detailed characterization of this channel in human RBCs is missing. 
In addition, the expression of an NMDA receptor channel was initially reported for rat [32] and 
later in human RBCs using molecular biological and electrophysiological approaches [33]. NMDA 
receptor agonists include glutamate, N-methyl D-aspartate (NMDA), homocysteine, homocysteic acid, 
glycine and D-serine [34]. 
Recently, the protein PIEZO1 was reported as being mutated in RBCs in hereditary xerocytosis [35] 
without knowing its physiological function. However, PIEZO1 is characterized as a mechano-sensitive 
cation channel in heterologous expression systems [36,37]. 
Furthermore there is evidence for an AMPA receptor related channel activity in RBCs [38]. 
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All the channels mentioned above were reported to be present in human RBCs from healthy donors. 
However, some currents were only shown to be present in cells of patients. An example is an increase 
in non-selective cation conductance on RBC of SCD patients mediating or contributing to  
Psickle [39,40], an increased membrane permeability in SCD RBC. It is still not completely clear if this 
reflects an increased activity of one or more of the above mentioned channels or yet another 
conductance [40,41]. However, recent investigations provide evidence for the involvement of the 
NMDA receptor [42]. 
3. Ca2+-Sensitive Proteins in RBCs 
3.1. Onset of Ca2+-Inducible Events and Ca2+ Sensors in RBCs 
When in the cell, Ca2+ activates numerous Ca2+ dependent proteins. Each of them has its own 
activation threshold. Thus, gradual increase in Ca2+ levels is associated with gradual activation of 
various groups of Ca2+-sensitive proteins involved in physiological and pathophysiological processes 
in RBCs. In Figure 1 we compiled current knowledge about the activation ranges of some selected 
proteins. This list of Ca2+ sensitive proteins is by far not comprehensive and can hardly be covered 
within one review. Despite a large number of such proteins and diversity of their functions, only few of 
them are “true” Ca2+ sensors interacting directly with calcium ions [43]. One of such ubiquitous 
sensors highly abundant in RBCs is calmodulin. Calmodulins 1–4 (CaM) are 17 kDa proteins 
comprising two globular EF hand Ca2+ binding domains enriched with carboxyl and carbonyl groups 
(Asp, Glu and Thr) interconnected with a flexible linker (for details see, e.g., [44,45]). Upon 
interaction with Ca2+, CaM wraps around amphipathic regions of the protein compacting into a 
globular shape and pulling the interacting domains of the target out of lipophilic pockets or out of the 
membrane lipid bilayer moiety. In RBCs the proteins regulated by interaction with the Ca2+ calmodulin 
2 complex (Ca-CaM) include, e.g., elements of the cytoskeletal network, the Na+/H+ exchanger NHE1, 
PMCA and the endothelial NO synthase (eNOS). Cytoplasmic CaM becomes active when recruited to 
the plasma membrane where its action is often coupled to that of phosphatidylinositol 4,5-bisphosphate 
(PIP2) localised at the inner leaflet of the membrane. An example of such coupling is a competitive 
binding of both co-regulators to the intracellular domain of NHE1 (see Figure 2A). 
Another class of “true” Ca2+ sensors (~650 proteins included) contain Ca2+ binding C2 domains 
interacting with 2–3 Ca2+ [43,46]. In RBCs proteins with C2 domains include phospholipases, PKCα, 
phosphoinositide 3-kinase (PI3K) and many others. Binding of Ca2+ to the C2 domains, triggers 
translocation of these proteins to the specific areas within plasma membrane containing their  
substrates [46]. 
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Figure 1. Overview of concentration dependence of Ca2+ activated events in RBCs. The 
yellow column indicates the estimated range of RBCs’ resting free Ca2+ [4]. The gray/black 
bars indicate the activation of the proteins with the intensity of darkness related to the 
activation level (details see below). The red lines depict the half activation concentration. 
For orientation, the green line provides the in vivo kD for Fluo-4 [47], probably the most 
appropriate Ca2+ fluorophore to be used in RBCs [48]. The universal intermediate 
messenger calmodulin has a dissociation constant for Ca2+ of 920 nM [49], which can be 
shifted down to 100 nM (see main text), indicated by the red arrow. The Gardos channel 
has an open probability of EC50 of 4.7 µM with a Hill slope factor of approximately 1 [50]. 
Values were measured in excised patches at a membrane potential of 0 mV. The curve of 
the opening frequency is almost superimposable (EC50 of 4.3 µM) [50] keeping the values 
given in the figure valid also for whole cell and hence population based investigations. The 
values for half maximal activation of the scramblase were determined by different studies 
with varying methodologies and a slightly different result. Values varied between 
approximately 30 µM determined in liposomes [51] and 70 µM measured in RBC  
ghosts [52]. The flippase depicts almost full inhibition already at a Ca2+ concentration of 
400 nM [53]. µ-Calpain, a protein that cleaves cytoskeleton and membrane proteins depicts 
half activation at 40 µM Ca2+ [54] but can be activated and then shifting half-maximal 
activation down to 200 nM [55]. Transglutaminase mediating polymerisation of RBC 
membrane proteins in its native form has a dissociation constant for Ca2+ of 190 µM [56]. 
Adenosine monophosphate (AMP) deaminase is an enzyme that converts AMP into inosin 
monophosphate and is directly stimulated by Ca2+ at a half maximal concentration of  
50 µM free Ca2+ [57]. The binding of Ca2+ to the C2-domain of PKCα was determined in 
vitro to be 35 µM with a Hill coefficient of 0.9 [58]. Although the Ca2+ dependence of the 
membrane binding was measured to be an order of magnitude lower [58], the initial Ca2+ 
binding is the crucial step for PKCα activation and therefore the relevant number in  
this compilation. 
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Figure 2. Ca2+ and RBC cytoskeleton. (A) Ca2+ sensitive elements of the cytoskeleton: 
band 4.1 and adducin interact with the Ca2+-calmodulin (Ca-CaM) complex. Adducin binds 
to actin blocking elongation of the fast-growing (barbing) ends of actin filaments within 
junctional complexes (J). When interacting with the band 3 dimers anchoring the spectrin 
network to the membrane, J become a part of bigger multi-protein complexes known as 
4.1R-comples (4.1RC). Interaction with Ca-CaM down-regulates capping activity of 
adducin regulating thereby actin filament assembly [59]. Furthermore, adducin tetramers 
participate in docking of carbonic anhydrase II (CAII) to band 3 tetrames. NHE1 is 
activated as it joins CAII and thereby becomes associated with the ankyrin complex  
(AC) [60,61]. Band 4.1R is an interacting partner of a number of proteins. Those include 
spectrin and actin which bind to the 10 kDa domain of the band 4.1R protein; band 3 
protein, p55, and GPC docking to the FERM domain of it and NHE1 interacting with its  
C-terminal 24 kDa domain. Interaction of band 4.1R with Ca-CaM triggers the reduction of 
the affinity of this protein to all interacting partners. As a result, spectrin network 
interaction with the integral proteins becomes loose. Decrease in affinity of band 4.1R to 
the cytosolic domain of NHE1 favours its dissociation from 4.1R and interaction with 
phoshatidylinositol 4,5-phosphate (PIP2), thus causing NHE activation [62]. PIP2 also 
modulates interaction of band 4.1R with glycophorin C and band 3 protein [63];  
(B) Schematic representation of the FERM (4.1/ezrin/radixin/moesin) domain of band 4.1 
protein, indicating docking ports for interacting partners and Ca-CaM binding sites (for 
details see [64]). 
 
3.2. Ca2+-Dependent Phosphorylation 
Changes in phosphorylation are among the most important modulations of protein activity in RBCs. 
Among the kinases there is a group of Ca2+ activated protein kinases, the conventional protein kinase C 
(cPKC) [65]. Among cPKCs, only protein kinase Cα (PKCα) can be found in RBCs [66]. Upon Ca2+ 
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binding, PKCα translocates to the plasma membrane, where it phosphorylates its target proteins.  
The kinase domain of PKCs lacks specificity [67,68] and therefore numerous proteins can be 
phosphorylated. Reports include the PMCA [69], cytoskeletal proteins ([70,71] and see below), 
NADPH oxidase [72] and possibly further proteins [29,30,73] are affected. 
3.3. Ca2+ and RBC Cytoskeleton 
Opening of cation channels in response to mechanical stress and the presence of activators, such as 
amino acids, proinflammatory cytokines and others, result in local transient increase in Ca2+ levels in 
the vicinity of the plasma membrane. The latter, most likely serves as a signal to mediate rapid 
reversible changes in cytoskeletal flexibility. 
The calcium-calmodulin complex (Ca-CaM) plays a key role in regulation of cytoskeletal stability. 
Selected elements of the cytoskeletal architecture interacting with Ca-CaM are schematically shown in 
Figure 2 together with their interacting partners. Those include major components of the cytoskeletal 
network, protein 4.1R, and adducin. These proteins function as docking stations for spectrin and actin, 
band 3 protein, glycophorins protein 4.2 and p55 and form a complex known as ankyrin-based 
complex and junctional complex (Figure 2A) [74,75]. The junctional complex is formed by the three 
principal components of the skeletal network junctions (spectin, actin, and 4.1R, together with 
tropomyosin, tropomodulin, adducin, dematin, p55). When associated with transmembrane proteins, 
GPC, XK, Kell, Duffy, band 3, and Rh junction complex forms a multiprotein 4.1R-based  
complex [76]. 
It is shown in Figure 2A, that the band 4.1R protein is a key constituent of all three complexes. 
Upon interaction with Ca-CaM, affinity of the 4.1R protein to all the interacting partners decreases and 
the cytoskeletal structure including spectrin-actin-tropomyosin junctions and the spectrin-actomyosin 
web interaction with the transmembrane protein clusters becomes loose and unstable. Such, Ca-CaM 
induced dissociation of NHE1 from the ankyrin complexes and band 4.1R protein. This facilitates the 
interaction of NHE1 with PIP2 resulting in activation of this ion transporter and dysregulation of cell 
volume and cytosolic alkalosis [62,77]. 
The Ca2+ concentration required for half-activation of calmodulin is 100 nM [78]–920 nM [49], 
Figure 1, thus no significant dissociation of the membrane cytoskeleton is expected to occur under 
physiological concentration of intracellular free Ca2+ [79]. Phosphorylation of calmodulin at Ser-80 
and -84 affects its affinity to 4.1R reducing their binding [80]. 
Ca2+ dependent phosphorylation is a second mode of action of Ca2+ on cytoskeletal proteins. 
Phosphorylation of the 4.1R protein at serine 312 and serine 331 by PKC was reported [81]. These two 
phosphorylation sites are localised within a domain flanked by the spectrin- and actin binding domain 
and a domain containing the interaction sites for transmembrane proteins (Figure 2B). When 
phosphorylated the 4.1R-β-spectrin interaction appears to be weakened by ~30% [81]. As Ca2+ uptake 
is known to be triggered by mechanical deformations [82], controlled reversible loosening of 
cytoskeletal network in cells passing through capillaries is an advantage. Uncontrolled irreversible loss 
of cytoskeletal stability in RBCs of patients with haemolytic anaemia, in which Ca2+ is permanently 
upregulated, on the contrary compromises mechanical stability of the RBC membrane [83]. In RBCs 
of healthy humans the 4.1R protein is not phosphorylated [81]. One more target of PKC is α-adducin 
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which, upon phosphorylation at Ser-726 decreases its affinity to F-actin, as it was observed in SCD 
RBCs. After the loss of F-actin capping dissociation of spectrin from actin occurs [84], which results 
in RBC inability to change shape. 
In RBCs transaminase 2 responds to Ca2+ entry with a rapid release of its inhibitory GTP and 
activation resulting in formation of Nε (γ-glutaminyl)lysine cross-linking (Figure 1). As a result, in 
Ca2+ overloaded RBCs formation of numerous polymeric protein complexes such as  
Glut1-adducin-dematin adducts as well as cross-linked complexes of Band 3-ankyrin-spectrin and 
glycophorin C-band 4.1-p55 occurs [85]. This Ca2+ induced remodelling of the cytoskeletal structure 
and concomitant changes in cell shape and membrane plasticity are suggested to contribute to 
premature RBC clearance. 
3.4. Ca2+ and RBC Volume Regulation 
RBC volume regulation is a complex process with contributions of numerous molecular players 
including, e.g., band 3 protein [86]. A marked volume decrease is mediated by the so-called Gardos 
effect, which was among the first Ca2+ dependent processes recognized in RBCs [87]. The 
corresponding Gardos channel was the first channel measured by patch-clamp in RBCs [88,89]. This 
channel is a Ca2+ activated K+ channel and the Gardos effect represents the Ca2+ induced K+ loss of 
RBCs. The channel is characterized by a single channel conductance of approximately 20 pS [88], a 
selectivity of K+ to Na+ of about 15:1 [90] and an EC50 (Ca2+) of 4.7 µM, Figure 1 with a Hill-slope of 
approximately 1 [50]. Later, the molecular identity of the Gardos channel was shown to be the hSK4 
channel [91]. Functionally, the opening of the Gardos channel leads to a hyperpolarisation and a loss 
of K+, Cl− and water resulting in cell shrinkage. Although the physiological function of the Gardos 
channel is not completely elucidated, there are two complementary concepts: (i) Openings of RBC 
Ca2+ channels by platelet released substances [92,93] initialy trigger the consecutive activation of the 
Gardos channel. This Gardos channel mediated dehydration of the RBC fosters their contribution in 
clot formation as outlined below. (ii) Local membrane deformation of RBCs was shown to trigger a 
transient increase in Ca2+ permeability with secondary activation of the Gardos channels [82]. This was 
proposed to induce significant dehydration even during a brief deformation event in the 
microcirculation [82]. 
3.5. Ca2+ and Lipid Bilayer 
Scramblase is a protein responsible for bidirectional transmembrane movement of phospholipids [94] 
leading to the break-down of the originally asymmetrical distribution of phospholipids between the 
inner and outer membrane leaflet [95]. It is a passive transport, but Ca2+ activated [51,52]. Its Ca2+ 
sensitivity is mediated by an EF hand motif [96]. The scramblase activity is complemented by the 
flippase (aminophospholipid translocase) inhibition [97]. This protein actively builds up phospholipid 
asymmetry and such can be regarded as the opponent of the scramblase. As shown in Figure 1, flippase 
activity is almost completely suppressed by 400 nM Ca2+ [53]. 
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3.6. Ca2+ and Metabolism 
Numerous reports emphasize the possible role of the Ca-CaM system in regulation of activity of 
glycolytic enzymes including pyruvate kinase [98,99]. However, even more important is its pivotal 
role in assembling the glycolytic enzymes at the RBC membrane. Band 3 protein and its cytosolic 
domain was shown to serve as a docking station for multiple glycolytic enzymes [100]. Ca2+ in turn 
was suggested to promote band 3 tyrosine phosphorylation [101]. Phosphorylation of the cytosolic 
domain of band 3 protein (cdb3) at Tyr9 and Tyr21 results in displacement of LDH, PK, GAPDH, 
PFK and aldolase from RBC membrane in intact cells [102]. A similar effect is induced by interaction 
of deoxyHb with band 3 protein [103]. 
3.7. Ca2+ and Redox State Preservation 
In RBCs there is a direct link between the intracellular free Ca2+ concentration and the haemoglobin 
oxygen saturation. In cells of healthy individuals, passive Ca2+ uptake was unaffected by 
deoxygenation, but the Vmax of the PMCA was reduced by 18%–32% [104]. This is not the case in 
RBCs of patients with SCD [4]. An increase in free Ca2+ levels was mainly attributed to changes in 
haemoglobin protonation, increases in protonation of deoxyhaemoglobin and a shift in the intracellular 
pH towards more alkaline values [104,105]. Along with augmentation of 2,3-diphosphoglycerate and 
ATP binding to haemoglobin, interaction of deoxyhaemoglobin with protons is associated with a 
decrease in Ca2+ buffering capacity of haemoglobin. In the cytosol of deoxygenated RBCs release of 
Ca2+ ions from protein binding sites and lowering of extrusion capacity of the PMCA contribute to 
both an increase in the ionised Ca2+ fraction by 34%–74% even in the absence of Ca2+ influx from the 
extracellular medium [104]. 
Increases in the free Ca2+ were recently linked to a lower oxygen affinity of haemoglobin promoting 
the release of oxygen [33]. Deoxygenation induced transient release of Ca2+ from intracellular buffers 
may promote further deoxygenation enhancing O2 dissociation from haemoglobin. Molecular 
mechanisms of this phenomenon remain to be investigated. 
Aside to the control of haemoglobin oxygenation, Ca2+ is also involved in the regulation of the 
RBC’s redox state. Ca-CaM complexes are co-activators of endothelial NO synthase (eNOS)  
activity [106,107]. Recently eNOS was shown to be present in circulating RBCs [108,109] and is 
activated by Ca2+ uptake during shear stress [82,110]. Nitric oxide is a scavenger of superoxide anions, 
which interacts with them two orders of magnitude faster than superoxide dismutase (SOD) [111]. 
However, following shortage of tetrahydrobiopterin or L-arginine eNOS itself gets uncoupled and is 
capable of generating superoxide anions, which is turned into H2O2 in a reaction catalysed by  
SOD [106]. Pro-oxidative action of uncoupled eNOS was demonstrated in RBCs [112]. 
3.8. Calpain and Its Targets in RBCs 
While the Ca2+ dependent cysteine protease µ-calpain (calpain-1) was mainly detected in human 
RBCs, m-calpain (calpain-2) was found to be virtually absent [113]. µ-Calpain is highly sensitive to 
Ca2+ with a half-activation concentration in the range of 3–50 µM [114,115]. The enzyme isolated 
from human RBCs displayed a value of 40 µM [54]. This is well above the free Ca2+ concentration 
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found in both human RBCs from healthy individuals (30–60 nM) and values of 100–300 nM reported 
in RBCs from patients with hereditary forms of anaemia [4]. However, a 40 kDa activator protein 
which makes µ-calpain more Ca2+ sensitive, shifts Ca2+ concentrations required for half-maximal 
activation from 40–50 µM down to 0.2 µM [55]. In human RBCs a fraction of membrane-associated 
active µ-calpain was detected [116,117]. Activation mediated recruitment of calpain to the  
membrane [118] was used to estimate the protease activity revealing that ~7% of the calpain pool is 
constitutively active in RBCs from healthy individuals [117]. Consequently, the µ-calpain activity in 
RBCs from patients with hereditary anaemia forms was also increased because their resting Ca2+ levels 
were raised when compared to those from healthy donors. [4]. 
Targets of activated calpain are mainly transmembrane or membrane-associated proteins including 
PMCA, and bands 1, 2, 2.1, 3, 4.1, 4.2 proteins, but also calpain itself [119]. Autolysis occurs at Ca2+ 
levels beyond physiological concentrations, namely in the range 50–150 µM [114]. Limited digestion 
of haemoglobin α and β chains by calpain was also reported [120]. 
Recently, RBCs of a μ-calpain knock-out (KO) mouse displayed an improved deformability [121]. 
Furthermore it was demonstrated that ankyrin, band 3, band 4.1R, adducin and dematin were degraded 
in the Ca2+ loaded normal RBCs but not in the KO RBCs [121]. 
Cleavage of the PMCA by µ-calpain was associated with an activation of the pump, rapid ATP 
depletion, inactivation of the pump and gradual loss of the transmembrane Ca2+ gradients [122]. 
Calpastatin, an endogenous inhibitor of μ-calpain, is a natural regulator of the enzyme activity in 
RBCs. Both major and minor components of calpastatin, calpastatin H and L were detected in human 
RBCs [54]. Interaction of calpastatin with calpain is also Ca2+ sensitive. Half-maximal activation of 
calpastatin occurs at 40 µM Ca2+ [114], in bovine skeletal muscle derived enzyme. Activity of calpain 
and a decrease in calpastatin levels in RBCs was shown to occur in elderly humans [123,124]. 
3.9. Ca2+ and Inter-Cellular Interactions 
Due to the protein activity and lipid remodelling described above one would expect changes in 
rheological properties of RBC suspensions and indeed in numerous studies provoking increased 
cytosolic Ca2+ levels, an altered rheology was observed [125–127]. These changes were majorly 
explained by altered RBC deformability [128,129]. However, a second possibility to explain changes 
in rheological properties of RBC suspensions is RBC aggregation. 
A participation of RBC Ca2+ channels in blood clot formation was proposed previously [92,93] 
following earlier work already suggesting an active participation of RBCs in blood clot  
formation [130–132]. Further support was given by investigations showing Ca2+ mediated aggregation 
of RBCs [133–136] and RBC adhesion to the endothelium [137–139]. Further investigations are 
necessary to specify the required and sufficient conditions for such processes, e.g., the threshold of the 
intracellular Ca2+ concentration at which aggregation occurs. Additionally the modulations of the 
aggregation properties under in vivo conditions need to be elucidated. 
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4. The Physiological Role of Intracellular Ca2+: From RBC Birth to Clearance 
4.1. Ca2+ in RBC Haematopoiesis 
Ca2+ uptake is of key importance for promoting differentiation and proliferation of erythroid 
precursors at the stages of burst-forming units erythroid (BFU-E) colony-forming units erythroid 
(CFU-E) [140,141]. Increase in the intracellular Ca2+ is an integral part of the signalling pathway 
activated by binding of erythropoietin to its receptor [142,143]. In Ca2+-free medium, Ca2+ uptake is 
absent and differentiation and survival of erythroid precursors is compromised [140,141]. Inhibition of 
Ca2+ uptake by erythroid precursor cells cultured from mononuclear cells by the NMDA  
receptor antagonist MK-801 resulted in 45.5% ± 12.8% mortality of cells at the stage of basophilic  
and polychromatic erythroblasts suggesting that these receptors are actively contributing to 
erythropoiesis [33]. Additional evidence indicating that Ca2+ levels in reticulocytes are higher than in 
mature RBCs comes from secondary Ca2+-dependent processes such as phosphorylation [144]. Protein 
4.1R phosphorylation by PKC appeared to be markedly elevated in reticulocytes resulting in weakened 
interaction between β-spectrin and actin [145]. 
4.2. Ca2+ in Relation to the Physiological Function of RBCs 
For a long time, the physiological function of Ca2+ in mature RBCs was obscure and was believed 
to be limited to the involvement in RBCs aging and clearance [10,146,147]. However, a prominent part 
of this report reviews the physiological functions of Ca2+ in RBC regulating a broad range of processes 
including O2 transport [33], rheology [148], clotting [135,136] and half-life of cells (see Section 4.3). 
Each of these functions is vital for the organism. Thus, aberrant Ca2+ homeostasis in RBCs results in 
development of severe life-threatening systemic pathologies. 
Very recently, additional evidence in favour of a physiologically important Ca2+ associated 
mechanism was reported. Here, rises in the intracellular Ca2+ appear to promote the ability of RBCs to 
deliver oxygen [33]. 
4.3. Ca2+ in RBC Clearance 
At present it is suggested that in senescent RBCs the intracellular Ca2+ levels exceed those in 
reticulocytes and young RBCs [149]. However, such conclusions on the relationship between cell age 
and steady-state Ca2+ levels largely depend on the age markers employed. Typical age markers include 
glycosylated haemoglobin HbA1c, band 4.1a/b ratio, cell density, de-sialation and changes in CD47 
abundance at the membrane surface, PS exposure, and several others [149–151]. 
Activity of the PMCA in RBCs was shown to decrease with progressing HbA1c  
accumulation [152]. However, based on the pump-leak theory, this process will result in Ca2+ 
accumulation only when coupled to the unchanged or increasing activity in Ca2+-transporting ion 
channels. However, according to recent findings, this is not necessarily the case. Young rat and human 
RBCs contain higher number of NMDA receptors, that upon stimulation with plasma glycine and 
glutamate can cause significant Ca2+ influx [32,33]. Young cells are preferentially removed in subjects 
with induced or chronic polycytemia, phenomenon known as neocytolysis [112,153–155]. Finally, 
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phosphatydylserine (PS) exposure does not always correlate with high Ca2+ levels [156]. Thus, both 
young and senescent RBCs appear to be prone to Ca2+ overload, which may well trigger RBC 
clearance, but the relation of this mechanism to other Ca2+ independent clearance mechanisms and to 
in vivo relevance is still obscure. 
5. Ca2+ Dysbalance and Haemolytic Anaemia 
Independent of its origin, hereditary haemolytic anaemia is often associated with an increase in the 
intracellular Ca2+ levels [4]. “Leakiness” of RBC plasma membrane for Ca2+ that could not be 
compensated for by the activation of PMCA was reported for patients with SCD [157–159],  
beta-thalassemia (although most of the Ca2+ seem to be sequestered in vesicles or bound to cytosolic 
proteins) [160–162], phosphofructokinase deficiency [163]. Most of the information on Ca2+ transport 
in diseased RBCs was so far obtained for SCD patients. In these cells relatively high rates of Ca2+ 
uptake in RBCs are partially compensated for by sequestration of Ca2+ into intracellular inside-out 
vesicles, in which Ca2+ is pumped actively by PMCA [164]. Apparently, this process also exists in 
RBCs of patients with β-thalalssemia intermedia [162,165]. Furthermore, part of Ca2+ taken into the cells 
is immobilised by the intracellular proteins. Sickle cell transformation associated with polymerisation 
of deoxygenated mutated S-haemoglobin is amplified by 20–40-fold by dehydration [166]. Deoxygenation 
promotes Ca2+ uptake and release of ionised Ca2+ from the intracellular proteins (reduction in buffering 
capacity) [104,105,167]. In deoxygenated SCD RBC, an acute increase in the intracellular free Ca2+ 
RBCs causes opening of the Ca2+ sensitive Gardos channel and anion channels [168–170]. 
Downstream events triggered by augmentation of free intracellular Ca2+ comprise activation of  
µ-calpain [171] and activation of tyrosine phosphorylation [172]. In RBCs from SCD patients, protein 
4.1R and p55 appear to be phosphorylated thus contributing to the weakened interaction with  
beta-spectrin [84]. 
Cross-linked polymers have been observed in RBCs of patients with SCD suggesting 
hyperactivation of transglutaminase [85]. 
Oxidation of membrane proteins and impaired NO production by eNOS [173,174], increase in 
intercellular and RBC-endothelial adhesion [175] are hallmarks of SCD. Cross-linking of the nature of 
carrier of sickle cell conductance (Psickle) mediating Ca2+ uptake by RBCs remains unknown (compare 
Section 2.2). 
6. RBC Ca2+ Content and Medicinal Side Effects 
6.1. Transfusion Medicine 
Ca2+ overload is involved in dramatic reduction of the life span of stored RBCs used for  
transfusion [176]. Storage of leuco-depleted RBC concentrates is currently performed in Ca2+ free 
glucose-containing preservation citrate buffers at low temperatures. These storage conditions favour 
Ca2+ depletion of the cytosol, oxidative stress and ATP deprivation [177,178]. These processes induce 
deactivation of PMCA, facilitate passive Ca2+ transport and evoke acute Ca2+ overload when  
re-exposed to the plasma of patients receiving transfusions. The resulting processes include 
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dehydration, rigidity, fragmentation of cytoskeletal proteins and oxidative stress and increased 
adherence of RBCs to the endothelium and to each other [179,180]. 
6.2. Therapeutic Side Effects 
Additionally, unwanted modulations of the Ca2+ entry into RBC may cause side effects of drugs 
involved in therapies unrelated to RBCs. An example is photodynamic therapy, where the oxidative 
stress produced by the photosensitizer leads to the activation of cation channels in the RBC membrane 
and the consecutive Ca2+ entry triggers the mechanism described above, which is the major cause of an 
increased formation of blood aggregates as well as haemolysis [181]. Thus, RBC remain to be model cells 
to develop pharmacological strategies [182] and can even be used in automated safety screens [183]. 
7. Conclusion and Perspective 
The role of Ca2+ in RBCs physiology and pathophysiology cannot be overestimated. Many links 
between Ca2+ and RBC related diseases still need to be explored [184]. Methodologically single cell 
based methods will increase in their importance and contribution and complement cell population 
measurements [185]. This is due to the recent hindsight that intercellular heterogeneity and, in some 
cases, inhomogeneous distribution of Ca2+ within the cytosol are essential to predict the onset of 
changes related to the abnormally high Ca2+ levels, which are particularly important in patients with 
haematological disorders [42,186]. However, the properties of Ca2+ binding entities within the cells 
will need further attention and research. Following the broad variety of Ca2+ mediated processes 
mentioned here, monitoring the following parameters may be used to indirectly predict abnormally 
increased intracellular free Ca2+ levels in RBCs: (i) changes in cell volume and morphology 
(microcytosis, high MCHC, increase in cell density, echinocytosis or stomatocytosis); (ii) congenital 
haemolytic anaemia associated with stomatocytosis, reticulocytosis, and shortened RBC survival; 
(iii) decrease in the intracellular K+ levels, pseudohyperkalemia; (iv) loss of RBC deformability, 
changes in osmotic resistance, an increase when dehydration has occurred but cytoskeletal stability is 
still maintained, or a decrease when cytoskeleton is partially disassembled; (v) appearance of  
calpain-induced band 3 cleavage fragments; (vi) oxidative stress or unusually high NO production 
(nitrosated Hb, met-Hb); (vii) ATP depletion due to hyperactivation of PMCA; (viii) increase in  
inter-RBC aggregability; and (ix) increase in PS exposure. 
For many years the RBC was the cell of choice for membrane transport investigations. In the age of 
genomics, interest in RBC research decreased, but numerous signalling cascades—also in respect to 
the second messenger Ca2+ that occur in other cells and may involve several organelles—have been 
rediscovered in a modified and/or simplified form in RBCs. 
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Red blood cell research is important for both, the clinical haematology, such as transfusionmedicine or anaemia
investigations, and the basic research ﬁelds like exploring general membrane physiology or rheology.
Investigations of red blood cells include a wide spectrum of methodologies ranging from population measure-
ments with a billion cells evaluated simultaneously to single-cell approaches. All methods have a potential for
pitfalls, and the comparison of data achieved by different technical approaches requires a consistent set of
standards.
Here, we give an overview of common mistakes using the most popular methodologies in red blood cell re-
search and how to avoid them. Additionally, we propose a number of standards that we believe will allow for
data comparison between the different techniques and different labs. We consider biochemical analysis, ﬂux
measurements, ﬂow cytometry, patch-clamp measurements and dynamic ﬂuorescence imaging as well as
emerging single-cell techniques, such as the use of optical tweezers and atomic force microscopy.
© 2013 Elsevier Ltd.
1. Introduction
Contrary to a common belief, the red blood cell (RBC) is a cell type
that is neither simple, nor easily obtainable in a pure form. Yet, it is
probably the most studied cell type in the history of the life sciences
starting with the microscopic observations of Jan Swammerdam in
approximately 1660.1 Nevertheless, as in most other ﬁelds of science,
contradictory data are common. Sometimes it is possible to unify initial-
ly opposing results, e.g., reconciling reports on the electrogenic perme-
abilities inmalaria-infected RBCs2,3 or on the isolation of lipid rafts from
RBCs.4–6 In other cases, speciﬁc issues have not been completely re-
solved, for example, the number of Gardos channels per RBC7,8 or con-
tradictory data regarding prostaglandin E2-induced cation ﬂuxes.9–11
However, discrepancies often originate from different experimental
protocols, inducing different or even opposing degrees of artefacts.
Sometimes, artefacts may lead to completely wrong conclusions. This
is a serious problem, as revealed in a recent publication12 in Nature.
Here, a standard method intended for the isolation of mononuclear
cells (MNCs), based on the density-gradient centrifugation of blood,
was mistakenly used to isolate RBCs in an allegedly pure form. This ar-
tefact affects the entire paper, but it obviously passed the review pro-
cess in one of the most prestigious journals.
To avoid this and other common artefacts, as well as to establish a
basis for good laboratory practices in RBC research, a subgroup of the
European Red Cell Society (ERCS) was formed to initiate standards for
a better inter-methodological as well as inter-laboratory comparison
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of RBC-derived data. As an initial attempt, here, we present the ﬁrst
“guidelines” for avoiding artefacts in RBC research: In the ﬁrst part,
we discuss the general challenges, such as obtaining pure RBC prepa-
rations, experimental conditions in general and the comparison of
studies between different species. In the second part, we review a se-
lection of methods in RBC research, discussing possible pitfalls, how
to avoid them and the conditions for comparing/combining different
methodologies. Obviously, this cannot be a comprehensive selection,
but covers a bunch of the most popular methods and emerging
technologies.
Our hope is that this report will be useful to all scientists ap-
proaching the study of RBCs or considering RBC research, to avoid
stumbling into major artefactual conditions and obtaining or conclud-
ing the best from the experiments.
2. Ethics
The data presented in this paper has been acquired after approval
by the local ethical committees related to the authors institutions.
3. General considerations
3.1. Obtaining pure cell preparations
The vast majority of biochemical studies, but also all other types of
cell population measurements, have been carried out, and still are,
using bulk suspensions of supposedly pure RBCs. The RBCs are obtained
by sedimenting the cells by centrifugation froma sample ofwhole blood
that has been “washed”with variants of a physiologic solution, followed
by removal of the supernatant and the thin superﬁcial layer of cells. The
latter, the so-called “buffy-coat”, is indeed enriched in white blood cells
(WBCs), or leukocytes, but these cells belong chieﬂy to the MNC type,
i.e., lymphocytes and monocytes. The most abundant WBCs, however,
the polymorphonuclear neutrophil granulocytes (PMNs), tend to re-
main mixed with the RBCs owing to the similar density of the two cell
types, contaminating the RBC sample.6 The only way of removing
most of the WBCs is by ﬁltering the blood with leukodepletion ﬁlters.
Roughly speaking, if the total content of PMNs per million RBCs is
1000 in whole blood, it will decrease, at best, to 100 in washed blood
and to b10 in ﬁltered blood.6
3.1.1. Puriﬁcation of RBCs
A simple and reliable procedure for RBC puriﬁcation that is suit-
able for samples of small volumes and easy to implement in every
lab is ﬁltration through cellulose, as was originally proposed by
Beutler et al.13 and described in detail in the supplementary material
of Achilli et al.14
We propose this simple concept as a standardmethod and good lab-
oratory practice in RBC research. It should be emphasised, however, that
ﬁltration might not be applicable in all instances, e.g., for pathological
RBCs, because its functioning principle appears to be based largely on
the difference in deformability between RBCs and WBCs.15 The latter
are much less deformable than normal RBCs and are therefore retained
in the ﬁlter for a longer time than RBCs. However, in certain RBC pathol-
ogies, RBC deformability is abnormally reduced, and this may result in
reducedﬁlterability (hereditary spherocytosis, hereditary elliptocytosis,
ovalocytosis, sickle cell anaemia).
3.1.2. Quantifying RBC purity
The task of quantifying lowWBC levels is by nomeans a simple one,
and special techniques have been devised for this purpose. As a general
remark, microscope counting using conventional haemocytometer
chambers is impractical and not sensitive enough. The ﬂow cytometry
(FCM) approach is meaningful only if the number of total events
counted in each analysis is sufﬁciently high to reveal 1 WBC per 106
RBCs, which implies long analysis times.16 An extremely sensitive and
inexpensive method for the quantiﬁcation of PMNs in blood samples
that can be easily implemented in all labs is the technique of gelatin
zymography, as recently adapted.14
3.1.3. Consequences of contaminated RBC suspensions
The consequences of having a PMN-contaminated RBC suspension
can be deleterious. Two main types of artefacts can result from such a
situation: (i) attribution to the RBCs of a component/function that in
fact belongs to the PMNs; (ii) damage to RBCs resulting from hydro-
lases and oxidases released by activated or broken PMNs.
The ﬁrst issue has already been exempliﬁed in the Introduction. The
wrong method used in a recent Nature article12 for the puriﬁcation of
RBCs results, instead, in the isolation of a fraction of RBCs together
with all the PMNs that were originally present in the blood sample,
without even reducing the number of PMNs, as would occur if a con-
ventional centrifugation-based wash of the blood and removal of the
“buffy-coat” were performed. Fig. 1A indicates the amount of PMNs
left by different separation methods.
The artefactual results that originate from PMN hydrolases damag-
ing RBC components are exempliﬁed by the controversy on the isolation
and characterisation of lipid rafts from RBCs.6 The most powerful and
constitutively active hydrolases in the PMNs are the serine proteases
elastase and cathepsin G. These hydrolases are normally conﬁned at
high concentrations in cytoplasmic vesicles (granules) and only re-
leased upon cell activation. Detergents can easily free the proteases
from the granules. It was shown that even the presence of one PMN
permillion RBCs is able to release enough proteolytic power to damage,
if not fully inhibited, highly sensitive RBC proteins such as ankyrin and
protein 4.1.6
Another common situation that could give rise to artefactual results
is the preparation of “ghosts” from RBCs by hypotonic haemolysis.17 If
the RBCs are contaminated by PMNs and the buffers used are not effec-
tively supplemented with anti-proteases, the RBC membrane proteins
will almost certainly be damaged (Fig. 1B, C). The workaround to this
problem is the ﬁltration of the blood and the use of freshly prepared lys-
ing buffers containing a working concentration of anti-proteases.
3.2. Experimental conditions
Other factors that must be standardised to be able to compare the
obtained data between different laboratories are the temperature,
shear stress, medium content, especially traces of serum, and the con-
dition of cells used in the experiments. Furthermore, recent studies
emphasise the importance of co-factors and substrates of several re-
ceptors, which may contribute to the experimental outcome.
3.2.1. Possible artefacts and their causes
3.2.1.1. The inﬂuence of temperature. Temperature-related artefacts in-
clude ion misbalance and the ensuing changes in cell volume and
Ca2+-dependent processes. Temperature sensitivity depends on the
particular approach, but it can be severe, differing, e.g., between differ-
ent types of ion transporters. The decrease in the activity of ion trans-
porters with a decrease in temperature by 10° (Q10) is approximately
30-fold for the Ca2+ pump,18 approximately 3-fold for the Na+/K+
pump19 and approximately 1.5–3-fold for most of the ion transporter
systems.20,21 Thus, temperature changes may have a pronounced effect
on the intracellular Ca2+ levels and the Na+/K+ distribution. The tem-
perature may not necessarily be ﬁxed at 37 °C in particular experimen-
tal settings (e.g., controlling the temperature can be complicate for
patch-clamp investigations). However, temperature as a factor has to
be taken into account, and the potential side effects must be controlled.
3.2.1.2. Impact of medium supplements. Serum and the multiple biolog-
ically active factors it contains, including albumin and factors bound
to it, such as interleukins, prostaglandins, insulin and amino acids,
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can introduce artefacts. Depending on the experimental settings, in-
vestigations are conducted in serum-containing or serum-free
media. Proteins introduced with serum have been shown to play an
active role in regulating the activity of ion transporters in RBCs
obtained from healthy and diseased subjects. Little is known about
the serum components mediating the effects. It has been shown
that lysophosphatidic acid (LPA) activates Ca2+ uptake by RBCs.22
Insulin interacts with its receptors, inducing activation of endothe-
lial nitric oxide synthase (eNOS) in RBCs.23 From studies on
malaria-infected cells, it is now well recognised that traces of serum
change the membrane conductance upon infection.2,24 Nevertheless,
such a phenomenon may also be observed when performing ex-
periments on uninfected cells.25 This leads to the conclusion that
serum-proteins play a role in modulating the activity of transport pro-
teins.26 This is a potential source of discrepancy between single cell
and bulk measurements. In most of the latter, at least serum albumin
is present (usually 5%) as a supplement in the suspending medium.
The presence of several amino acids in the incubation medium makes
a substantial difference in the response of cells to oxygen, insulin and
erythropoietin stimulation. Among these amino acids are L-arginine,
which is a substrate for eNOS,27 and the N-methyl D-aspartate receptor
agonists glutamate and glycine, as well as homocysteine, which stimu-
lates Ca2+uptake byhuman and rat RBCs.28 Treatment of RBCswith rel-
atively high concentrations of orthovanadate, the most popular Ca2+
pump inhibitor, in the presence of 1–2 mM extracellular Ca2+ results
in irreversible pathological alterations of cell morphology, followed by
blebbing and ﬁnally the loss of membrane integrity, particularly at
room temperature when the Ca2+ pump function is reduced (Fig. 2A).
This often remains unnoticed when working with RBC suspensions.
3.2.1.3. Pre-treatment of RBCs. Intercellular differences originating from
storage (fresh cells vs. stored cells and storage conditions), inter-
individual and inter-cellular variability are sources of artefacts. Often,
stored/conserved RBCs are used for measurements. RBC preservation
media are Ca2+-free, low in Na+ and enriched with K+ and glucose.
RBC preservation results in gradual adenosine triphosphate (ATP) and
2,3-bisphosphoglycerate deprivation and oxidation of glutathione,
which begin after one day of storage. Replacement of the storage medi-
um with Ca2+-containing plasma-like medium (1.8 mM CaCl2,
150 mM NaCl, 4 mM KCl, 5 mM glucose) results in acute morphologi-
cal alterations illustrated in Fig. 2B. The cells will shrink due to acute
Ca2+ overload, and further ATP deprivation occurs due to acute acti-
vation of the Na+/K+ pump and Ca2+ pump caused by acute Na+
and Ca2+ overload. The results obtained using such cells may hardly
be compared with those obtained from fresh RBCs. Restitution of
stored cells may be useful for avoiding storage-induced artefacts.
Preconditioning of stored blood (rejuvenation) has been proposed,29
and the corresponding “Rejuvenation Solution” (Rejuvesol; enCyte Sys-
tems, Inc., Braintree, Mass) containing phosphate, inosine, pyruvate,
and adenine, or 15 mM D-ribose was shown to be beneﬁcial when ap-
plied before the transfusion.30 Because the components of rejuvenation
solutions actively interferewith intracellularmetabolism and the redox
state, we propose to use a “minimally invasive” preconditioning proto-
col. The stored cells are re-suspended in the incubation medium of
interest in the presence 0.5 mM Ca2+, 10 mM glucose and 0.1% BSA at
room temperature one hour prior to the experiment. This time is
required to restore the activity of the Ca2+ pump at a sub-physiological
temperature and to provide substrates for glycolytic enzymes.
3.2.1.4. Consequences of different conditions. Most artefacts arise from
the lack of attention to these factors. The composition of incubation
media varies markedly between experiments. The impact of oxida-
tion, methaemoglobinemia, phosphatidyl serine (PS) exposure and
other membrane-related events, as well as that of the addition of
ion transport inhibitors (e.g., vanadate often present during Ca2+ up-
take measurements, see Fig. 2A), on the cell morphology, ion content,
Fig. 1. (A) Gelatin zymography of the pelleted cell fraction obtained by the “Accuspin™ System-Histopaque®-1077” method (Sigma-Aldrich, Inc., St. Louis, MO, USA) used in a re-
cent work for isolating RBCs in supposedly pure form.12 As per the manufacturer's instructions, a blood sample was freshly drawn in 0.1 volumes of 3.8% (w/v) tri-sodium citrate as
the anticoagulant and immediately layered in the Accuspin™ tube. After centrifugation, the RBC pellet was collected (after removal of the septum from the Accuspin™ tube),
washed two times in ten volumes of PBS and processed for gelatin zymography, as previously described.14 The arrows indicate the bands corresponding to the typical pattern of
in-gel digestion of gelatin by the granulocytic pro-metalloproteinase 9 and its higher molecular weight aggregate with lipocalin and are indicative of the presence of PMNs in
the RBC fractions. The lane marked “T” corresponds to unseparated blood cells. The lane marked “F” contains a sample of RBCs that was passed through a cellulose ﬁlter to remove
leukocytes and platelets and is indeed free of PMNs. The pellet of supposedly pure RBCs resulting from theAccuspin™ separation contains almost all of the PMNs thatwerepresent in the
unseparated blood (“AH“). The lanemarked “H” is a sample of RBCs obtained by density centrifugation in the Histopaque®-1077 solution but in a standard tube (not Accuspin™). In each
lane, the equivalent of 107 cells was loaded. In the lane “PMNs”, 2×102 pure PMNswere loaded. (B) Contaminating PMNs are carried all along during the preparation of ghostmembranes,
and they ended up in the ﬁnal sample of supposedly pure ghosts. PMNswere detected using gelatin zymography14 in ghosts prepared fromwashed (“W”) or ﬁltered (“F”) RBCs with the
method of Dodge17 as previously detailed,5 but with the omission of phenyl-methyl-sulphonyl-ﬂuoride to show the consequences of proteolysis. Where proteolysis was inhibited,
diisopropylﬂuorophosphate (DFP) was used at a ﬁnal concentration of 1 mM in PBS, to pre-treat RBCs for 5 min at 25 °C before hypotonic haemolysis to prepare the ghosts. During
ghost preparation, at the end of the third sedimentation, the “button” of dark, thick material that forms at the bottom of the ghosts and that is especially visible in samples where con-
tamination by PMNs is high was either removed or left in place (“button”− or +). After preparation, the ghost suspension was brought to the volume of the original packed RBCs and
processed for gelatin zymography as described.14 In each lane, the equivalent of 107 RBCs was loaded. Pure PMNs were loaded as a standard in the adjacent lanes, in the numbers given.
(C) The ghosts prepared in the various modes described above were processed for SDS-PAGE andWestern blotting. Analysis of ankyrin and protein 4.1 revealed that both proteins were
quantitatively decreased when the ghosts were prepared from ﬁltered or washed RBCs in the absence of DFP. When the “button” of debris was not removed, both proteins were heavily
damaged.
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redox state and metabolic status may be dramatic, but it has rarely
been taken into account.
The redox status of the cells is an important parameter to control.
Oxidation has a profound effect on metabolism, regulation of cell vol-
ume, and cytoskeletal structure. Reducing cell deformability induces
Ca2+ entry, leading to PS exposure, membrane blebbing and eventu-
ally premature cell death.31 Nevertheless, it was also shown that ox-
idation may activate anion channels, mimicking pathways that are
activated upon malaria infection.32,33 Even if the threshold seems to
be rather high, the oxidation level might be high enough in some
cells to trigger artiﬁcial responses in some protocols. Most important-
ly, throughout their lifetime, RBCs are continuously exposed to high
oxidative stress. Oxidative defence capacities may decrease with
RBC aging,34 and senescent RBCs show alterations (e.g., increased de-
naturation of haemoglobin, membrane binding of hemichromes and
free iron, aggregation of band 3 protein, deposition of antibodies
and complement fragments, PS exposure) similar to those of oxidised
cells.35,36
Facilitated ageing occurring under conditions of shear stress
(e.g., in patients with polycythaemia) is also associated with oxida-
tive stress.37 Furthermore, storage of RBCs results in progressive
oxidative stress and loss of reduced glutathione along with ATP
deprivation. For that reason experimental observations obtained using
RBCs from a blood bank may differ signiﬁcantly from those generated
using freshly withdrawn blood. Further support comes from whole-cell
patch-clamp experiments reporting oxidation induced anion selective
currents.32,38,39
Sufﬁcient levels of glucose, a lack of Ca2+ overload and shear stress
are essential formaintenance of the glutathione pool. Recent studies re-
vealed that someplasma components are required for eNOS to function.
L-arginine (100–300 μM) and nitrite (~150 nM in human plasma) are
essential for maintenance of NO production by RBCs under normoxic
and hypoxic conditions, respectively,23,40 and their absence in the incu-
bationmedium, aswell asmanipulation of the intracellular Ca2+ levels,
will result in uncoupling of NO production and progressive oxidative
stress, especially when the treatment includes manipulation of oxygen
levels or activation of eNOS.27,28,41
Another example of the importance of the ionic composition of the
incubation media arises from patch-clamp measurements of malaria-
infected RBCs: Whereas at physiological saline concentrations, at least
two different types of anion channel activity can be described, when
supraphysiological concentrations of Cl− are used,42,43 one of the chan-
nels has (i) a saturated single conductance and (ii) an open probability
close to zero above the threshold chloride concentration.3 This last phe-
nomenon explains the majority of the discrepancies reported in the
ﬁeld, and it is tempting to think that the same limitation may apply to
uninfected RBCs.
3.3. Interspecies studies
The challenge of how to compare studies performed in different spe-
cies is widespread in biomedical science. The power of genetic manipu-
lation in combination with the short generation cycle makes mice an
increasingly popular animal model. Obvious advantages often over-
whelm concerns about the reliability of results derived from animal
models of human diseases. This problem also applies to RBC research
and originates from the fact that the basic characterisation of mouse
RBCs is rather limited. Before the advent of transgenic animals, mice
were not a particularly widespread model for studying RBCs.
3.3.1. Potentials of comparative studies
Comparative RBC research continues to build on species-speciﬁc
studies involving, e.g., domestic animals. In this ﬁeld, a substantial num-
ber of publications and even textbooks are available.44,45 Sometimes,
Fig. 2. (A) Changes in morphology and in the intracellular Ca2+ levels in RBCs from a
sickle cell patient caused by inhibition of the Ca2+ pump. RBCs from a sickle cell disease
patient suspended in isotonic medium containing 1.8 mM CaCl2, 10 mM glucose and
0.1% bovine serum albumin. The cells were loaded with 10 μM Fluo-4AM for 40 min in
the presence or absence of 5 mM Na-orthovanadate (OV). The upper panels show bright
ﬁeld images of control and orthovanadate-treated cells, and the lower panels represent
the corresponding readouts of Fluo-4 ﬂuorescence. Extensive vesiculation, cell disintegra-
tion and echinocytosis followed uncontrolled Ca2+ loading. (B) RBCs from two healthy
subjects (P1 and P2) were collected, ﬁltered and stored for 1–21 days in Ca2+-free citrate-
containing glutathione (GSH) conservation solution, and they were then re-suspended in
the incubationmedium containing 145 mMNaCl, 4 mMKCl, 1.8 mM Ca2+, 10 mM glucose
and 0.1% bovine serum albumin. The cells of both donors retained normal discocyte mor-
phology over at least one week in the citrate phosphate dextrose solution, and P1 was con-
sidered “a better quality donor” during conventional quality control tests. Of importance are
the inter-individual differences in the responses and acute changes in morphology in the
presence of extracellular Ca2+ and the progressive deterioration of cellular quality associated
with ATP and GSH depletion and changes in the ion and water content.
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the switch to animal RBCs may provide invaluable advantages over
human RBCs. These advantages might be such simple properties as the
cell size. For instance the amphiuma RBCs have an elliptical size
of ~62 μm in length and ~36 μm in width and are used to perform the
initial potential measurements in RBCs.46 The RBCs of ﬁsh (6.5–44.6 μm
diameter), amphibians (16–70 μm) and birds (9.7–15.4 μm) contain or-
ganelles such as a nucleus,mitochondria and ribosomes. These qualitative
differences compared to human RBCs might be advantageous or
disadvantageous and can be used as experimental tools.
The great variations in RBCs between species on the one hand and a
broad conservation on the other hand allows the use of animal RBCs
as particular models for certain protein manipulations, even in the
organelle-free mammalian RBCs, that would otherwise require the
breeding of transgenic animals. Examples include the RBCs of carnivora
that lack theNa+/K+ pump47 (instead, they have aNa+/Ca2+ exchang-
er, which is absent in the RBCs of other species) or sheep RBCs that do
not seem to contain scramblase.48 There is list of differences49 that can-
not be covered in this paper— furthermore, the protein and lipid distri-
butions of RBCs between species can differ considerably.50,51
Thus, vast amounts of information on the alternative models that
may be used to study the pathological alterations in human RBCs are
not used. Making the results of comparative studies on RBCs more
“visible” will help to acknowledge the advantages that these cells
provide.
3.3.2. Guideline for “switching” species within a study
Knowing all these differences, it should be a habit of good laboratory
praxis (as well as reviewing praxis) to either perform studies (publica-
tions) just within a deﬁned species or, whenmixing species (except for
comparative studies), to show — whenever possible — explicitly the
transferability of the “previous step”, at least in the supplementalmate-
rial. This rule of course needs to be adapted if the animal model is used
as a “modiﬁed source” of RBCs.
4. Methodological considerations
4.1. Proteomics
Proteomics is likely the method that is most affected by contamina-
tion of cell preparations. This holds true because proteomic studies are
still carried out on cell suspensions, although single-cell approaches
have been introduced.52 The importance of the pure cell preparations
is efﬁciently and impressively illustrated by some of the most recent
proteomic studies, where carewas taken to reduceWBC contamination
of theRBCs, resulting in a list of less than 300 recognised RBCmembrane
proteins,53,54 compared to the much larger number of supposedly
erythrocytic proteins presented in earlier catalogues.
Presently, the proteomic studies of RBCs are still somewhat separat-
ed from functional studies, resulting in protein catalogues that do not
(yet) ﬁt with functional identiﬁed proteins from, e.g., patch-clamp re-
cordings. Bridging this gap will be one of the challenges of future RBC
research.
4.2. Ion ﬂuxes
Measurements of ion ﬂuxes through the RBC membrane are per-
formed using various approaches. Radioactive tracers have been used
for unidirectional ﬂux measurements for many decades.55,56 This tech-
nique allows quantiﬁcation of unidirectional movements of ions by
electroneutral and electrogenic ion transporters as well as residual ion
ﬂuxes. Othermethods to assess ionmovements through themembrane
are based on monitoring of net ion uptake/loss by means of ion-
selective electrodes, ﬂame photometry, atomic absorption spectropho-
tometry, etc.
Accumulation or loss of radioactive tracers may be estimated with
high sensitivity (up to single disintegration events) using beta- and
gamma-counters. For most ions, the corresponding radionuclides,
which may play a role as isotopic carriers, have relatively long half-
lives (weeks to months). Rubidium-86 (T1/2=18.6 d) is often used
as a tracer because the most suitable 42K+ radionuclide has a rather
short half-life (T1/2=12.5 h) and requires a supply for fresh radioiso-
topes, e.g., the proximity of a cyclotron to the lab where the ion ﬂuxes
are assessed. With some rare exceptions,57 discrimination between
K+ and Rb+ by ion transport systems in RBCs does not exceed 20%.58
4.2.1. Pitfalls and limitations
Formonitoring the kinetics of the radioactive tracer distribution, one
may assess the unidirectional inward and outward ﬂuxes as well as a
steady-state distribution of selected ion species between the cell and
the medium, considering that the cell lacks compartmentalisation. If
this is not the case, as for intracellular Ca2+ in RBCs of patients with
sickle cell disease,59 cytosolic free Ca2+ cannot be estimated from
the 45Ca2+ distribution between the cells and the medium. Most of the
Ca2+ in that case is accumulated in the intracellular inside-out vesicles
that are most likely enriched with Ca2+ pumps,60 and an increase in the
intracellular45Ca2+ levels is not always followed by the activation of
Ca2+-sensitive K+ (Gardos) channels.
Measurements of ion ﬂuxes bear a common limitation: ﬂux mea-
surements are performed in suspension, and the considerations dis-
cussed above in “Obtaining pure cell preparations” (Section 3.1)
apply. So far, studies to assess the role of WBC and platelet contamina-
tion in possible artefact generationwhenmeasuring ion ﬂuxes using ra-
dioactive tracers are lacking.
Another point that is seldom taken into account is the effect of the
electro-neutrality of compartments on ion movements. Cation move-
ments, such as those mediated by Gardos channel activity, that lead to
cell dehydration are known to be rate limited by anion movements. In
many cell suspension experiments, thiocyanate (SCN−) is used to by-
pass this limitation of anion movements. Ten millimolar is usually
sufﬁcient to saturate this effect,61 avoiding important changes in the
isoelectric point of impermeant anions and RBC hydration that are
observed at higher SCN− concentrations.62 Apart from ion ﬂux exper-
iments, this could also apply to patch-clamp experiments aiming to
investigate cation channel activity. Even if this consideration does
not apply in the whole-cell conﬁguration because the anion supply
is provided by the pipette content, it can impair the movement of
cations in the cell-attached conﬁguration. In this case, run-down of
channel activity might be observed and conclusions can be drawn
erroneously.
4.3. Patch-clamp
During the past three decades, electrophysiological studies have re-
vealed that the human RBC membrane is endowed with a large variety
of ion channels.63–67 However, their physiological role remains widely
unclear; they barely participate in the RBC homeostasis, which is
based on an almost total absence of cationic permeability and minute
anionic conductance.68 Nevertheless, due to the pioneering work of
Hamill on human and frog RBCs,61,69 the patch-clamp technique
applied to RBCs has proven to be a powerful method to decipher the
involvement of ionic conductances mainly in pathophysiological
scenarios.32,42,62,65,70–72
4.3.1. Challenges to patch-clamp RBCs
The main problem when attempting to perform patch-clamp on
RBCs lies in the small size of the cells, which especially holds true
for mammalian RBCs (2.1–9.4 μm) (cp. Section (3.3) “Interspecies
studies”). This small size imposes major challenges.
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4.3.1.1. Optomechanical requirements. The opto-mechanical properties
of the hardware require high-quality microscopes and at least 20×
objectives. A 40× objective with phase or Nomarski contrast is usual-
ly necessary for recordings on malaria-infected cells to recognise the
infected RBCs. When approaching the pipette to form a seal, very pre-
cise micromanipulators are required.
4.3.1.2. Patch pipettes and seal formation. RBCs are “designed” for pass-
ing through small capillaries. When passing through the spleen, RBCs
have to go through tiny slits whose mean size has been recently mea-
sured at 1.89 μm in length and 0.65 μm in width.43 Therefore,
patch-pipette tips must be rather thin, with an opening smaller
than 1 μm (corresponds to roughly 10–15 MΩ in physiological saline
solutions) to avoid the entry of the cell into the pipette. Besides the
pipette size, its shape has to be adapted such that a piece of mem-
brane enters the pipette for seal formation without totally entering
into the pipette when depression (typically 20 mbar) is applied. The
pipette tip must be thin enough, but at the same time tapered
enough, to preserve a low electrical access resistance. Another issue
arises from RBC's high deformability. The portion of the RBC mem-
brane that enters into the pipettes during seal formation varies. Fur-
thermore, it has been recognised that membrane deformation
induces transient Ca2+ entry in RBCs.73 Such transient activity may
generate secondary transient anionic channel activity.74 This phe-
nomenon leads to a change in the intracellular K+ concentration
that has to be taken into account for data interpretation. Therefore,
the time of seal formation and calibrated depression must be men-
tioned in publications.
4.3.1.3. Transition between conﬁgurations. The small RBC size results in
a small membrane capacitance of approximately 1–1.3 pF.75,76 This
becomes relevant during the transition from the cell-attached to
whole-cell conﬁguration. The rupture of the membrane fragment in-
side the pipette tip is typically achieved by a brief electrical pulse
(200 ms, 500 mV). A successful whole-cell conﬁguration can be
checked via the sudden appearance of membrane capacitance tran-
sient currents, which can be easily compensated on the ampliﬁer.
Nevertheless, the situation is different in plate-based “pipettes” as
they are used by automated patch-robots (Fig. 3). There, the basal ca-
pacitance of the plate is much higher and an increase of 1 pF is almost
invisible. Therefore, the major indication for reaching the whole-cell
state is the increase in current, which is a challenge because differen-
tiation between the loss of seal resistance and the whole cell current
needs to be probed in the experimental protocol. However, if the seal
resistance is approximately 10 GΩ, the current leakage at +100 mV
can be calculated to be 10 pA, presenting a relation to Ohm‘s law.
Typical whole-cell recordings show current values between 200 and
1000 pA or even higher, which often are rectifying, i.e., they do not
follow Ohm‘s law; then, the leak remains below 1–5% of the total
current.
4.3.2. Automated patch-clamp
Automated patch-clamp recordings allow probing an increased
cell number under exactly the same conditions and were therefore
used to test for the heterogeneity of naive RBC conductance among
the RBCs of a donor as well as investigating the variability between
different donors. Fig. 3 depicts this comparison for two healthy
donors.
The simultaneous measurements of 4 to 96 RBCs (depending on the
model of the automated patch systems) allow for measurement of a
population of RBCs with exactly the same experimental procedure,
and there is no experimental bias towards choosing a (particular) cell.
In contrast, classical patch-clamp allows for more (visual) control over
the particular experiment/cell and at least an order of magnitude
lower noise level, typically approximately 1 pA.
4.3.3. Comparison of patch-clamp data with other entities
Comparing data from cell suspension experiments (cp. Section (4.2)
“Ion ﬂuxes”) and those issued from patch-clamp studies is a common
but difﬁcult task, which can be exempliﬁed by the entry of Ca2+ ob-
served in sickle cells upon deoxygenation. This entry, designated Psickle,
is best characterised as a poorly selective permeability pathway for
small, inorganic monovalent and divalent cations.77 Experiments in
which the fraction of activated cells was studied as a function of the ex-
ternal Ca2+ concentration showed that sickling is a stochastic event of
random intensity among HbSS RBCs, capable of generating maximal
Gardos channel activation in a small fraction of cells during each
deoxygenation-sickling pulse. Consistent with the stochastic nature of
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Fig. 3. Heterogeneity of RBCs — measurements derived from automated patch-clamp
whole cell recordings (NPC-16 Patchliner, Nanion, Munich, Germany). (A) depicts the
voltage protocol. The bath solution contained 80 mM NaCl, 3 mM KCl, 10 mM MgCl2,
35 mM CaCl2, and 10 mM HEPES/NaOH, pH 7.4, while the pipette solution contained
50 mM CsCl, 10 mM NaCl, 60 mM CsF, 20 mM EGTA, 10 mM HEPES/CsOH, pH 7.2. The
seal resistance was in the range of 1–5 GΩ at a holding potential of−40 mV. (B) exem-
pliﬁes the recordings fromsingle RBCs of 2 healthy subjects, (a) and (b). The current traces
are superpositions of leak currents and channel-mediated currents. The non-Ohmic ap-
pearance of the currents indicates to differences in the cellular properties rather than in
the patch resistance. Panel (C) shows the I/V plots for the whole cell currents (mean±
SD, n=24 cells per subject). Please note that both samples were from freshly drawn
RBCs (experiments within 2 h) and are not attributed to different cell treatments as
outlined in Fig. 2.
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Psickle, repeated pulses led to the progressive accumulation of dense
cells, whereas a single long pulse caused only an early production of a
single small fraction of dense RBCs.78 Lew et al. eventually depicted
this nature clearly by writing: “When electrophysiologists ﬁnally
approach the study of Psickle under patch-clamp, they ought to bear in
mind the probabilistic nature of Psickle in each deoxygenation pulse be-
fore consulting their psychiatrist for the lack of reproducibility!”.77
One has to keep in mind that electrophysiology conclusions are
drawn from results where the membrane potential is changed at
will by the experimenter, meaning that they are rarely obtained at
the resting membrane potential, rendering comparison with cell
suspensions difﬁcult. This is exempliﬁed in a recent study, where it
was shown that increased membrane permeability for sorbitol in
malaria-infected RBCs could not easily be reconciled with data from
whole-cell experiments.79 Indeed, in isosmotic sorbitol haemolysis,
the membrane potential reaches values above+50 mV due to the ab-
sence of charges at the extracellular side of the membrane. Subse-
quent comparison of these data to that obtained with patch-clamp
(at this membrane potential, inwardly rectiﬁed currents induced by
infection are almost totally abolished62,65) seems impossible.
4.4. Flow cytometry
FCM is a technique that uses optical detection methods for
counting and analysing particles in the size range of micrometres. In
comparison to microscopic investigations of single RBCs (see below),
the application of FCM and cell sorting present some advantages as
well as disadvantages.
4.4.1. Advantages of ﬂow cytometry
A major advantage of FCM compared to single-cell imaging is the
inherent analysis of a larger amount of cells within a shorter time (a
minimum of several 10,000 cells vs. a few hundred cells). This reduces
the statistical noise. The gating for cell populations is easy and reduces
the analysed cells to a dedicated population out of a heterogeneous
sample.
The forward scatter mode shows the size distribution of the cells.
Although it is by no means an exact measure of the absolute cell vol-
ume, it can be used as an indicator of the relative size changes of the
RBC samples.
The side scatter mode shows the “granularity” of the cell, which is
related to the complexity of structures in the cell interior. It can pro-
vide information on the presence of different cell types in a single
suspension of cells (e.g., in blood). A useful feature of ﬂow cytometry
is connected with the possibility of measuring the ﬂuorescence emit-
ted by suitable ﬂuorochromes that are used as probes for a given par-
ticular cell property. Fluorescently labelled antibodies and ﬂuorescent
probes sensitive for a particular chemico-physical parameter of the
cell (e.g., pH, Ca2+, PS exposure, mesomorphic state of the lipids)
are the most commonly used ﬂuorescent molecules.
4.4.2. Limitations of ﬂow cytometry
Due to the measurement technique, cells have to pass the cu-
vette in a high-speed ﬂuid stream. This limits measurements to
cells in a suspension and excludes larger aggregates. However,
doublets of RBCs can be easily recognised by the ﬂuorescence
signal forward or side scatter. Although the side scatter is an indi-
cator for the granularity and surface shape, it is not possible to
measure and reliably distinguish the different shapes (echinocytes,
discocytes, stomatocytes) of RBCs. In the forward and the side scat-
ter, RBCs present shapes that are nearly similar and overlapping
signals.
The ﬂuorescence intensities observed by FCM are integrated
values of the entire cell and do not resolve a subcellular distribution
of the ﬂuorescence as in imaging (see below).
In some experiments, the formation of microvesicles can be ob-
served. Due to the small size of the microvesicles, they will be
shown in the forward and side scatter below the threshold together
with the cell debris and dead cells and will normally be discarded.
However, the ﬂuorescence might be used to discriminate the vesicles
from the debris, and this could allow a quantitative analysis.
In contrast to single-cell imaging approaches, it is not possible to
follow the kinetics of any signal in a single cell. After measurement
of the optical parameters, the cell is either discarded or collected in
a tube with RBCs depicting the same properties.
In all ﬂuorescence measurements of RBCs, haemoglobin shows a
strong absorption of UV and visible light (for more details and discus-
sion, see Section (4.5) “Cellular imaging”). This requires dyes with
emission wavelengths above 600 nm or brighter ﬂuorophores (com-
pared to thresholds that are known for haemoglobin-free cells).
4.4.3. Potential artefacts
Before measuring the different parameters, the cells are sucked
under pressure in a ﬂuid stream through a small capillary into the
measurement chamber. While the cell suspension is passing through
a capillary in the FCM to the measurement chamber, the cells can be
exposed to shear stress because of the different speeds of the sample
and the sheath ﬂuid. An applied shear stress can induce different
mechanisms such as the activation or inactivation of physiological
processes in the cells (e.g., Ca2+ increase in RBCs exposed to mechan-
ical stress80) or even damage the membrane. Values for the applied
pressure can reach 500 kPa and higher (manufacturer information),
which exceed the normal systolic arterial blood pressure value of ap-
proximately 15 kPa by a factor of more than 30. It is well known from
other cell types that cell damage can occur because of the applied
pressure,81 and our own observations showed that a population of
fragile RBCs (observed in imaging) can disappear in FCM (unpublished
observations).
4.5. Cellular imaging
Live cell imaging is a popular method to explore cellular signal-
ling.82 However, for the investigation of RBCs, it is rather sparsely ap-
plied. This might be due to three major drawbacks:
(i) The absorption spectrum of the haemoglobin heavily interferes
with the absorption of many commonly used dyes and addi-
tionally quenches their emission, as exempliﬁed by the most
popular Ca2+ ﬂuorophores.83
(ii) Due to the lack of a protein translation mechanism, the appli-
cation of ﬂuorescent proteins and genetically encoded biosen-
sors as an emerging tool in biomedical research is limited to
the generation of transgenic animals (cp. also84).
(iii) In live cell imaging (time lapse), each experiment follows a sub-
stantial number of cells (not just one as, e.g., in patch-clamp re-
cordings), and each cell is followed over an arbitrary time
course (not just one time point as, e.g., in FCM). This leads to a
large amount of data. In light of the increasing awareness that
RBCs can form a highly heterogeneous population (Fig. 3),
there is a requirement for analysis guidelines that are not yet
ﬁled and that would exceed the size of this section.
Although these 3 points are serious and have to be taken into ac-
count, cellular imaging is a powerful tool in RBC research.
4.5.1. Potential artefacts and how to avoid them
A number of points have to be considered to avoid artefacts. In im-
aging approaches, dye molecules and photons are used to probe the
cells. Photons can interact with the cellular constituents and may in-
duce what is commonly referred to as phototoxicity. For RBCs, this is
known for near infrared light85 and for the interaction of UV light
97G. Minetti et al. / Blood Reviews 27 (2013) 91–101
with haemoglobin, resulting in the generation of a highly ﬂuorescent
photoproduct, most likely bilirubin.86
The interaction of the photons with the dye can lead to photo-
bleaching and induce a “loss of signal”. This decreased ﬂuorescence
leads to underestimation of the signal of interest. Furthermore, there
is another almost opposite effect that is often neglected but may occur
with some dyes, e.g., with Fluo-4, the so-called “antibleaching”.87 This
is, in this example, the light-mediated induction of Ca2+ insensitive
but highly ﬂuorescent dye molecules that can occur if illumination of
high intensity is used. Consequently, the signal of interest is prone to
be overestimated.
Additionally, triple interactions between endogenous proteins,
ﬂuorescent dyes and photons may alter the properties of the ﬂuores-
cent read-out. If there is a binding afﬁnity between the endogenous
proteins and the ﬂuorescent dye under certain conditions,88 Förster
Resonance Energy Transfer (FRET) occurs and consequently alters
the ﬂuorescence intensity, spectral properties and ﬂuorescence life-
time. In RBCs, FRET can occur, e.g., between the dye Fura-red and
haemoglobin (unpublished results).
It must be noted that FRET can also be used in a beneﬁcial way, as
nicely shown by Esposito et al.89 for imaging the haemoglobin con-
centrations in malaria-infected RBCs.
Yet another factor that inﬂuences the ﬂuorescence intensity is RBC
volume changes because a change in volume results in a change in the
dye concentration and hence an altered ﬂuorescence signal.
Fortunately, most of the above mentioned sources of artefacts are
rather small and might be neglected when the observed signals are
robust. However, if minute signals are expected or observed, the arte-
facts are likely to become relevant.
An almost unavoidable artiﬁcial situation in live cell imaging is the
fact that the RBCs are attached to a (coated or uncoated) coverslip.
The only way to exclude artiﬁcial conclusions is the comparison/
combination with complementary methods.
Last but not least, live cell imaging is often used to detect hormonal
or pharmacological stimulation of RBCs. To have a proper control
of the solution surrounding the cell, a local perfusion (a micro-
manipulator-associated cannula placed close to the RBCs to apply a lam-
inarﬂow) is preferred over an exchange of the bulk solution of the entire
dish that almost certainlywould lead to slow gradients of the exchanged
solutions and a loss of control concerning the timing of the drug or hor-
monal stimulation. Because RBCs contain a number of mechanically
sensitive proteins,38 one has tomake sure that theﬂowdoes not change
with the application, and therefore, the ﬂow must be kept constant
(also under control conditions) and just the solution composition
needs to be switched from the battery of solutions.
4.6. Adhesion force measurements
Adhesion is traditionally measured by either microscopic investiga-
tion, quantifying a microscopic aggregation index90 or by indirect
methods based on the properties of RBC suspensions. Such techniques
include sedimentation-associated procedures, transmission light or
ultrasound scattering, impedance measurements, determination of vis-
cosity or other rheometricmethods.91 The classicalmethods tomeasure
RBC aggregation have been recently reviewed.92 However, with regard
to adhesion force measurements, a focus was set to rheometric tech-
niques.93,94 These methods are all indirect and suffer from a limited
amount of information on the number of cells involved or the impact
of RBC morphological and deformability changes.
4.6.1. Quantitative force measurements
Recently, two quantitative RBC intercellular adhesion measure-
ments were introduced at the single-cell level and compared to each
other.95,96 The two techniques are holographic optical tweezers (HOT)
and atomic force microscope-based single cell force spectroscopy
(SCFS). To exert forces on cells with optical tweezers, a limited force
regime is available due to cell damage with increasing laser power,
i.e., there exists an upper limit of force at which the adhesion forces be-
tween cells can be measured. In addition to that, a lower limit of mea-
surable adhesion forces exists for the SCFS, which is due to both the
limited force resolution of the systemand the squeezing of the cells dur-
ing themeasurements that can possibly induce adhesion force artefacts
(see below). Both limits could be illustrated by measuring the small
adhesion forces between single RBCs under physiological conditions
(Fig. 4).
The only way to explain the difference in both techniques is the
slightly invasive nature of the SCFS. An inevitable part of the SCFS
measurements is the requirement for a preset force set point that is
used as a marker if both cells have come into close contact (i.e.,
squeezing the two cells together with a certain set point force). This
invasive squeezing of the cells is artiﬁcial, and it most likely induces
a small adhesion by itself.
The abovementioned problems should not arisewhen probing RBCs
for speciﬁc molecules, e.g., for testing receptor binding.97 In this case,
the cantilever is functionalised with the speciﬁc molecules (e.g., ﬁbrin-
ogen), the binding between receptor and agonist is speciﬁc and thus al-
lows measuring the adhesion between a molecule-coated cantilever
and the RBC.
4.6.2. Selection criteria for force measurements
When measuring forces between RBCs, it would be desirable to
combine the complementary methods of SCFS and HOT. Unfortunate-
ly, both methods are complex and laborious, and this advice might
not always be feasible. Therefore, the tool can be chosen according
to the dimension of the expected force. The SCFS is advised for adhe-
sion forces larger than 30 pN and the HOT for adhesion forces smaller
than 30 pN. While the squeezing of the cells in the SCFS measure-
ments is the critical parameter, the laser power is the critical param-
eter in the HOT measurements.
5. Conclusions
We are left with the impression that a signiﬁcant portion of the past
literature on RBCs should be re-read to verify whether it could have
been affected by the problem of cell contamination. Of course, one
will not incur such problems when studying RBCs at a single-cell level.
Recent studies provided ﬁrst indications that RBC populations are
rather heterogeneous,10 Fig. 3, which may result in additional prob-
lems when working with bulk suspensions as well as with single
RBCs. A major reason for the inhomogeneities of circulating RBCs are
differences in the cell age.98 There are indications that the plasma
membrane Ca2+ pump activity decreaseswith RBC age in amonotonic
fashion,99 whichmay lead, at least for some cells, to changes in the so-
dium and potassium content. However, when performing single-cell
experiments, the cells are chosen randomly, i.e., cells can be from
one or the other end of the age scale. Moreover, variable amounts of
circulating reticulocytes also contribute to the variability of measure-
ments performed on bulk RBC suspensions, even after WBCs and
platelets have been carefully removed. Therefore, a ﬂow chart of an
optimised protocol for studying a property/component of mature
RBCs should involve the following: leukodepletion by any suitable
method/ﬁlter; gelatin zymography to ascertain the level of residual
PMNs; the efﬁcient use of anti-proteases; reticulocyte quantiﬁcation
(count and/or Western Blotting of, for instance, CD71, the transferrin
receptor); separation of RBCs into subpopulations of different densi-
ty/age and isolation of a population of “mature” RBCs.98 However,
the availability of a reliable and artefact-free separation technique is
still debated.
Alternatively, to elucidate the inter-cellular variability of responses,
measurements in cell suspensions should be combined with single-
cell techniques such as ﬂuorescent live cell imaging, FCM and/or patch-
clamp approaches. However, even between single-cell techniques,
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there are regularly discrepancies and confusing interpretations be-
cause cell behaviour is highly sensitive, and often the devil is in the ex-
perimental details. Therefore, considerations that will lead to better
harmonisation of experimental conditions are timely and relevant, es-
pecially regarding the accumulation of large amounts of data in the
literature.
6. Research agenda
• Matching RBC protein libraries with functional observations.
• RBC storage conditions for transfusion bear a high potential for im-
provements.
• Potential of comparative studies should be better utilised.
• Single cell investigations should become more prominent.
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6. Discussion NMDA receptor in red blood cells as a novel calcium influx pathway NMDA receptors in bone marrow and erythroid precursor cells (EPCs) We were the first to show the presence of NMDA receptors in the EPCs and in the circulating RBCs of rats and humans. In line with our observations systemic exposure to glutamate was shown to induce a massive accumulation of adipose tissue and reduction of hematopoietic tissue within the bone marrow in mice 291. These processes were earlier on largely attributed to the action of glutamate on NMDA receptors in megakaryocytes.  In these cells expression of the NR1 and NR2D mRNA and NR1 protein was reported by Genever and colleagues 292. Staining for the presence of NR1 subunit (immunohistochemistry) and the receptor activity ([3H]MK 801 binding) revealed high levels of the NMDARs in megakaryocytes 292. However, staining specific for the NR1 subunit in bone marrow sections was not entirely restricted to the megakaryocytes alone (See Fig 1). No attempts were done to identify the localization of the NR2D and NR3 subunits in this study.  
 
Figure 1. Binding of [3H]MK-801 (black dots, silver staining) and staining with the NR1 antibody (brown staining) in rat bone marrow (from the Genever et 
al 292). The highest intensity of staining was attributed to megakaryocytes, however, some staining is seen in the plasma membranes of surrounding cells (red arrows).    
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We showed that the NMDA receptors are present in the cells populating bone marrow, in particular those forming erythroid progeny in rats and humans. In rat bone marrow NR1 subunit was co-expressed with early erythropoetic marker CD36 (Paper 1, Figure 1). The presence of NR1 was later on tracked in CD71+ rat reticulocytes (Paper 1, Figure 1). Using ex vivo erythropoiesis system we have observed expression of the receptor subunits NR1, NR2A, 2C, 2D, 3A and 3B in human CD34+ monocytes-derived proerythroblasts, polychromatic and orthochromatic erythroblasts and reticulocytes (Paper 2, Figure 1, 2). In human erythroid precursor cells NR2D and 3B appeared to be the dominating subunits (Paper 2).  High abundance of the NR3 subunits in EPCs defines specific features of the receptor channel. Channels formed by the NR1 and NR3 subunits expressed in 
Xenopus oocytes were resistant to Mg2+ block and therefore may be activated at the transmembrane potentials as low as -70  mV  293. The ligand sensitivity of NR3-containing receptors differs from that of NR1/NR2 heterotetramers.  Receptors formed by the NR1 and NR3 subunits and expressed in Xenopus oocytes reaches their maximal activation at glycine concentration of 10 µM, higher concentrations have an inhibitory action (plasma glycine concentration is around 200-300 µM). D-serine known as an agonist of the conventional NMDA receptors inhibits the ones formed by NR1 and 3 293. Such “glycine receptors” are activated in response to local decrease of the glycine or D-serine concentrations and do not require glutamate or NMDA for their activation 293. They have low cation selectivity and low affinity to the channel pore blockers MK-801 and memantine. Furthermore, of NR3-containing receptors, unlike NR1/NR2 receptors, are able to respond only by the partial activation (see Chapter 1) 294. Moreover, unlike “neuronal” NR1/NR2 receptors NR1/NR3, are insensitive to MK-801 and memantine (295, see also Table 1 in Chapter 1).  Some of these properties are lacking in the receptors expressed in the EPCs and present in RBCs. Activation of erythroid receptors with NMDA/glutamate (100-300 µM) and glycine (100 µM) in the precursor cells is clearly associated with Ca2+ uptake that can be blocked by memantine or MK-801 (Paper 2 Figure 3A ). In human EPCs glycine administration induces tiny currents whereas co-administration of NMDA causes their pronounced amplification (P. Haenggi 83  
unpublished data). The NMDA receptors in early EPCs (proerythroblasts and basophilic erythroblasts) respond to the stimulation with agonists with high amplitude currents with fast deactivation kinetics whereas cells at the later differentiation stages the EPCs switch from expression of the NR2A (fast-inactivating currents with high amplitude) to NR2C (slow-inactivating currents with small amplitude) resulting in receptor-mediated currents with smaller amplitude and longer decay time (P. Haenggi unpulished data).        To our knowledge, receptors formed by the NR2D and 3B as well as NR2A (early stages)/2C (late stages) similar to those expressed in the EPCs have never been studied in model systems. Their properties remain largely unknown and await further investigation.  Possible physiological role of the erythroid NMDA receptors is one more thrilling and poorly explored area. The nature of signals sensed by these receptors in the EPCs remains unknown. The presence of glutamate/aspartate transporters (GLAST) and GLT-1 and the proteins required for controlled vesicle release in megakaryocytic membranes suggests that these cells may actively release glutamate into the intercellular space in bone marrow 296, 292. These changes in glutamate levels, when occurring, will be sensed by the NMDA receptors in erythroid progenitor cells. EPCs will also respond to the “systemic” changes in glutamate, NMDA and D-serine levels occurring in blood plasma. Furthermore, the receptors are known to respond to the changes in pH, voltage, and the changes in redox state and NO. They are mechanosensitive and thus sensing shear stress in particular when passing through the cellulose column of during separation on Percoll gradient (Paper 3).  Calcium-driven signaling was reported to be a very essential part of differentiation program of the EPCs 297, 298. Calcium was required for the Epo to Epo receptor signaling cascade to function 298, and to support viability of cells at the earlier (CFU and BFU-e) stages of erythropoietic development 299. Among the Ca2+ uptake pathways expressed in the EPCs are transient receptor potential channels (TRPCs 2,3 and 6), Cav2.1 channels, and NMDA receptors (Paper 2, Fig 3A). Importance of the erythroid NMDA receptors for the EPCs is reflected by high sensitivity of the cells in culture to high doses of MK-801 or memantine, channel-pore targeting antagonists of the receptor. Exposure to antagonists 84  
resulted in an increase in mortality which was most prominent at the proerythroblastic stage (Paper 2, Figure 3B, Paper 3, Figure 7). For the unknown reasons sensitivity to antagonists is markedly blunted in proerythroblasts of patients with sickle cell disease (Paper 3 Figure 7B) which are significantly less sensitive to the antagonsits, than those of healthy humans (Paper 3, Figure 7A). Polychromatic and ortochromatic erythroblasts appeared to be less sensitive to the antagonists. Hyperactivation of the NMDA receptors in EPCs by supplementing incubation medium with NMDA showed no adverse effects.  Our preliminary data (Pascal Haenggi, unpublished) indicate that inhibition of the NMDA receptor is associated with activation of caspases, externalisation of phosphatidylserineand induction of apoptosis (Paper 3, Figure 7C, vacuolization).    We observed substantial inter-cellular and inter-individual heterogeneity between the NMDA receptor subunits expression and the receptor abundance in healthy EPCs within one differentiation stage (Paper 2, Figure 1, 2). These findings most probably indicate the existence of several sub-populations of cells with different sets of properties that provide more flexibility in regulation of erythropoiesis.  Heterogeneity of precursor cells is followed by heterogeneity of the functional NMDA receptor levels in mature RBC (Paper 2, Figure 6)  and in NMDA-mediated responses (Paper 2, Figure 4C, 7D). These findings supports current paradigm about RBC heterogeneity 300.    Further characterization of the physiological and pathophysiological role of the NMDA receptor in EPCs and other hematopoietic progenitor cells including megakaryocytes and lymphocytic progenitors is crucial for understanding of pathologies associated with progression of congenital anemias. Pharmacological regulation of NMDA receptor activity  in the EPCs can be beneficial for  upregulation of RBC production in cases of congenital anemia, platelet production in patients with thrombocytopenia  and downregulation of leukocyte production  in patients with leukemia  Differences in NMDA receptor subunit composition we have observed between the EPCs (lack of NR2B subunit) and white blood cells (Paper 2, Table 1) and other lineage-specific properties allow development of specific compounds targeting distinct of bone marrow-driven blood disorders. 85  
Mammalian bone marrow pluripotent cells are capable to differentiate into neurons and express neuronal proteins including NMDA receptors 301. Bone marrow was developed very early in the vertebrate evolution, it already exist cartilaginous fishes (e.g. sharks) 302. Studies of embryogenesis of vertebrates and anatomy of a primitive chordate B. lanceolatum indicate that hematopoiesis generally takes place concomitantly with cardiovascular development. Within the embryo, hematopoietic regions form within the aorta-gonads-mesonephros region.  Later in development part of hematopoetic cells forming this region migrates into the cardiogenic domain. Furthermore, evolutionary hematopoietic cells appear to be precursors of endothelial cells in vertebrates 303. In humans with severe congenital anemia erythropoietic pool can be expanded from the normal location in the bone marrow of axial bones (e.g. vertebra, skull and rib cage) to other bones, spleen, liver and soft tissues adjacent to bone (304, p 293). Thus, it seems that NMDA receptors could be an attribute of pluripotent non-differentiated cells (stem and cancer cells 305). In some cell types (podocytes 306, osteoclasts, thrombocytes etc) NMDA receptor protein is preserved up to the terminal stage of development.  NMDA receptor function in rat and human erythrocytes During the last steps of the maturation human and rat RBCs are losing the majority of their NMDA receptors (Fig 2). From several thousands per cell NMDA receptor copies is reduced to several dozen in young red blood cell population and further to few receptor copies per cell on average in mature and senescent population (Paper 1: 3.5*105 NMDAR per cell in human erytroid progenitor cell line, Paper 2: 18,300 –540,000 copies of NR2D subunit per cell at day 12 of differentiation). In healthy circulating human and rat RBCs these receptors are involved in regulation of RBC volume and density (Paper 2, Figure 7D) as they regulate activity of the Ca2+-sensitive K+ (Gardos) channels (Paper 1, Figures 4 and 5, Paper 2, Table 2). NMDA receptors are active players in control of intracellular Ca2+ levels (Paper 1, Figure 3, Paper 2 Figure 4 and 7) contributing thereby to the regulation of activity of eNOS and NOX in RBCs (Paper 1, Figure 7A and B) by that regulating intracellular redox state (Paper 1, Figure 7C), rheology and vascular tone 307. Very essential, but yet poorly understood finding 86  
of ours study is the involvement of the intracellular Ca2+ in regulation of hemoglobin oxygen affinity (Paper 2 Figure 8). This striking feature seems to be closely related with the adaptive optimization of oxygen supply in athletes as exhaustive exercise is associated with a transient increase in plasma glutamate levels (Makhro unpublished data, 308).  Calpain activity and gradual oxidation are the two Ca2+-dependent factors defining RBC life span that is reduced in endurance athletes 309. Our most fundamental findings on the composition and possible physiological/pathophysiological function of the NMDA receptors in human and rat RBC are summarized in the Table 1:  
Table 1. NMDA receptor properties and function in rat and human erythrocytes.  Human (Papers 2 and 3) Rat (Paper 1) 
Abundance in EPCs and RBC  
GRIN1, 2A, 2C, 2D, 3A, 3B transcripts were found in erythroid progenitors (from day 6 to day 18 in culture). Protein detection:  NR1 (in circulating RBCs) and NR2C, NR2D, NR3A and NR3B subunits (EPCs) were identified ~350 000 of NMDAR copies in UT-7/Epo cells (erythroid progenitor cell line) 
NR1 subunit protein co-localized with CD36 (early erythroid precursors) in bone marrow;  
Function in EPCs 
Agonists-driven Ca2+ influx;  a complete NMDA receptor block at the early stages of erythropoiesis induced apoptotic cell death 
Not accessed 
Abundance in All detected NR subunits NR1 subunit colocalized 
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reticulocytes (transferrin receptor CD71 as a marker) 
were co-expressed with CD71 with CD71. NR1 subunit abundance correlated with high intracellular Ca2+ content in circulating red blood cells Number of NMDA receptor copies in circulating red blood cells 
Young RBC: 34.9±7.5,  mature RBC: 4.1 ± 0.7, senescent RBC: 4.3± 0.6 General RBC population:  8 per cell 
Ca2+ entrance 
Produced by NMDA, HCA. Glu and Gly, high intracellular and intraindividual heterogeneity of response; blocked by NMDA receptor antagonists 
Produced by NMDA, HCA. Glu and Gly, high intracellular heterogeneity of response; blocked by NMDA receptor antagonists 
K+ fluxes NMDA/Gly produced NMDAR antagonist-sensitive flux 
NMDA, HCA and Glu produced concentration-dependent NMDAR-antagonists sensitive fluxes; NMDA-induced flux was completely abolished by clotrimazole or Ca2+ chelators 
RBC volume 
Transient volume reduction in response to NMDA treatment; High inter-individual and inter-cellular variability 
NMDA and HCA treatment produced reversible volume reduction and echinocyte formation;  Reversibility was abolished by Ca2+pump inhibitor Oxidative stress Not accessed in healthy NO-synthase – mediated 
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humans oxidative damage 
Intracellular pH and oxygen saturation 
NMDA treatment produced pH-mediated transient changes in hemoglobin-oxygen binding Not accessed 
Hemolysis  Never observed 
NMDA and HCA treatment induced severe hemolysis; NMDA receptor antagonists had protective effect  
 
Figure 2. NMDA receptors in human and rat red blood cells. A schematic representation of the data published in papers 1 and 2.  NMDA receptors (as well as other membrane proteins) are highly abundant in hematopoietic stem cells. They are required for the Ca2+ signaling and essential for the cell survival.  Orthochromatic erythroblasts and reticulocytes lose most of their NMDA receptors during the maturation. Clearance of the receptors continues in 
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reticulocytes and young RBCs (neocytes) after they are released into the circulation. Enriched with receptors, these young cells are more susceptible to Ca2+ overload and subsequent elimination than mature cells in a process known as neocytolysis 310.  In mature erythrocytes only few copies of the NMDA receptor are present. NMDA receptor is activated by plasma amino acids Glu and Gly followed by the Ca2+ entrance into the erythrocyte. We followed two targets modified by NMDA receptor-mediated Ca2+ influx: Gardos channel and endothelial NO synthase (eNOS). Ca2+ activates Gardos channels and therefore K+ loss leading to the cellular dehydration and volume reduction. The cell shape and volume will recover as soon as Ca2+ and Na+/K+ pumps will re-establish ion gradients. Plasma membrane Ca2+ ATPase inhibition by orthovanadate (VO43-) prevents shape and volume recovery and eventually leads to the cell destruction in the spleen. Ca2+ interacts with hemoglobin molecules and induces oxygen and proton release. Activation of eNOS in the presence of a substrate arginine leads to the NO production and vasodialatation. In the Arg- or tetrahydrobiopterin (BH4) – deprived environment active eNOS produces superoxide anion which is converted to H2O2 by superoxide dismutase. Oxidative stress causes methemoglobin production (Fe2+ oxidation), glutathione depletion, Band3 clustering 311 (Band3 clusters bind to naturally occurring antibodies, Nabs, which facilitates RBC removal 312) and result in premature clearance.    In membranes of erythrocytes of patients with sickle cell disease (SCD)  NMDA receptors are more abundant than in healthy controls (Paper 3, Figure 1B,C) although the receptor expression (mRNA and protein, Paper 3, Figures 5, 6) during the hematopoiesis was not altered. For the “mature” red cell population this  reflects the fact that the lifespan sickle cell erythrocytes is substantially reduced (RBC lifespan being on average 15 days instead of 70 – 140 days in healthy subjects 313, 314) and the circulating cells are about 10 times younger than healthy erythrocytes having more of NMDA receptors retained. However, this does not explain a two to 10-fold increase in the number of active receptors in the young population of SCD-RBCs compared to the young population of healthy human donors which is most susceptible to premature clearance 315. It suggests that the excessive NMDA receptor abundance in SCD RBC results from the incomplete clearance in the course of disturbed maturation process. During the final stage of erythropoiesis RBC precursor cells are losing the nucleus, most of the intracellular organelles including mitochondria, and many of the proteins located within the plasma membrane. The mutated hemoglobin S is known to have higher affinity to the membrane cytoskeleton 316 disturbing thereby 90  
cytoskeletal remodeling occurring during the RBC maturation and resulting in delayed clearance of integral and cytoskeletal proteins and increasing membrane rigidity. Indeed, proteomic studies showed that two main cytoskeletal proteins 4.1 and ankyrin are upregulated in SCD RBC 317.  Similar to that in the EPCs activation of the NMDA receptor by various agonists induces calcium influx into human and rat RBCs (Paper 1, Figure 3, Paper 2, Figures 4 and 7, Paper 3, Figure 3 and 4). Calcium uptake is followed by the activation of Ca2+-sensitive K+ (Gardos)-channels . Net loss of K+ and Cl- and water results in transient shrinkage. The reduction in cell volume was associated with the formation of “91otential91 cells” (echinocytes) and “cup cells” (stomatocytes) (Paper 1, Figure 6A, Paper 3, Figure 4D). Such shape changes are known to affect red cell deformability, mechanical stability and rheology 318. In line with that hemolysis was induced by stimulation of the NMDA receptors in RBC from the anemia patients (SCD and some cases of hereditary spherocytosis, unpublished observations) with abnormally high NMDA receptor abundance.  Long-term up-regulation of intraerythrocytic Ca2+ levels occurring in vivo in the circulation further contributes to the loss of mechanical stability by induction of proteolysis of cytoskeletal proteins by Ca2+-sensitive protease µ-calpain and stimulation of superoxide anion production by NADPH oxidases 201 making cells of patients even more fragile and prone to shear-stress-induced hemolysis.   In SCD patients more factors add to the the in vivo the mechanism of the NMDA receptor-mediated hemolysis which are related to the specific properties of HbS. Deoxygenation, low pH values and increase in shear stress normally occurring in the capillaries of tissues as well as pro-inflammatory cytokines present in blood of this group of patients during the crises activate Psickle conductive pathway (for details see Chapter 3) along with the onset of polymerization of HbS. Psickle is caring both inward Ca2+ and Na+ current and outward  K+ flux. Uptake of Ca2+ triggers further K+ loss via the activated Ca2+ activated K+-channels (Gardos), causing severe dehydration. The hemoglobin S concentration in the sickled cells is increasing favoring irreversible polymerization of deoxyhaemoglobin. Based on our experimental data and striking similarities between known Psickle and NMDA receptor properties, we assume that Psickle is at least partially carried by 91  
NMDA receptors.  The cells undergo sickle cell transformation getting mechanically fragile. Excess of calcium triggers extensive oxidative damage due to the abnormally high abundance and activity of NOXes 319. Gardos channel is further activated upon cleavage by µ-calpain 320 and band 3 protein cleavage by this protease is prominent 321.  As a result premature clearance and hemolysis occur. Patients with SCD are asymptomatic most of the time, but decrease in oxygen availability (hypobaric hypoxia, diving, lung disease), hyperthermia, inflammatory process or dehydration result in development of pain crises associated with an increase in number of terminally dehydrated RBCs with polymerized HbS. The number of NMDA receptors in RBCs during pain crises increases above that in asymptomatic period as does sensitivity to agonist stimulation (Paper 3, Figures 1 and 2).   
Ex vivo we showed that SCD RBC pretreated by NMDA receptor channel blocker memantine exhibit almost no sickling even in 0.5% O2 atmosphere during 15 min (Paper 3 Figure 4B). Furthermore, decrease in the intracellular calcium was followed by rehydration of SCD-RBCs. Long-term effects could not be monitored in our ex vivo experimental settings. The expected ones include lower adherability 322 and decrease in incidence of vaso-occlusive crises are often associated with hemolytic and pain crises in patients with SCD.  Calcium was shown to be ultimately required to promote adherence of SCD-RBCs to the endothelial cells 323, 324, 325). Increased rigidity, poor membrane stability and high adherence give rise to facilitated thrombus formation, stroke, myocardial infarction or multi-organ failure in patients with SCD 326. According to the World Health Organisation (2011), about 5% of the humanity carries abnormal hemoglobin genes, mostly hemoglobin S (HbS). Why these mutations in beta chain of hemoglobin gene, although leading to such devastating diseases, were not eliminated but actually preserved by the natural selection? Reversible polymerization/crystallization of hemogolobin as an adaptive hemoparasite defense strategy is relatively wide-spread in vertebrates. It was described in fishes 327, 328, reptiles and mammals (cervidae deer, 329). In humans the appearance of hemoglobin S in Africa (2000-3000 years ago) and Asia (4000 years ago) followed the development of iron tools and advanced agricultural system that promoted increased human habitation density (304, p 92  
565). Bigger settlements provided better breeding environments for the mosquitos caring the malaria plasmodium parasite. Hemoglobin S allele (as well as thalassemia and other abnormal hemoglobin alleles) geographically coexist with current or historical malaria regions. While HbS homozygotes (who carry two alleles of abnormal hemoglobin) have very short life expectancy, heterozygotes do not suffer from anemia and pain crisis and exhibit high resistance to malaria. One of the proposed mechanisms of such resistance is the increased RBC fragility due to spontaneous irreversible (in contrast to other vertebrats) polymerization of deoxyHbS. The attempt of the plasmodium parasite to invade such red cells results in their facilitated hemolysis and prevention of progression of the disease 330. In addition, excessive amounts of intracellular Ca2+ in hemoglobin S containing RBC can also does not favor the parasite invasion 331. Thus, expression of hemoglobin S is an adaptive tool to confront the malaria via increased NMDA receptor abundance in mature red 
blood cells. The point mutation GAG → GTG creates substitution Glu → Val in 
position 6 on the β chain which attaches to the plasma membrane proteins and affects red blood cell maturation. That substitution was strongly supported by natural selection in at least five geographically separated regions of Africa, India and Arabia (304, p 566) leading to 10-20% prevalence of hemoglobin S genotype.   A role of myocardial NMDA receptor in rhythm formation and ventricular signal transduction (Table and figure references to the manuscript “Cardiac N-methyl D-aspartate receptors as a pharmacological target” are in bold.) Earlier on expression of the NMDA receptor subunits was reported in mouse, rat, sea lion and human myocardium 332, 333, 334, 335, 336.  We were the first to perform extensive screening for the GRIN gene expression patterns and the receptor activity in various areas in the heart. Furthermore we characterized responses of denervated rat heart to agonists and antagonists of NMDA receptors and obtained cardiac receptor pharmacological profile for the rat (see the attached manuscript), as well as for human and horse ventricular and atrial tissue (Makhro, Mitchell and Kosenkov unpublished data).   
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Our knowledge of molecular and pharmacological characterization of cardiac NMDA receptors may be implicated in the pathobiology of some cardiac disease. Epidemiological studies revealed that high plasma concentrations of NMDA receptor agonist homocysteine predict one-year survival in patients with severe systolic heart failure 337, post-infarctional development of the heart failure 338, high plasma homocysteine concentration correlates with the severity of heart failure in patients with chronic myocardial infarction 339. Moreover, plasma homocysteine predicts the risk of recurrence of nonvalvular atrial fibrillation 340, 341. Plasma homocysteine is associated with an alteration in the electrical atrial conduction, possibly contributing, at least in part, to the increased risk of cardiac arrhythmias in the denervated hearts of orthotopic heart transplantation patients 342. Based on our data, we may propose cardiac NMDA receptor as a novel target for pharmacological interventions in patients suffering from arrhythmias and heart failure. Moreover, NMDA receptor antagonists could be beneficial during the surgical interventions or for the post-operational treatment to prevent cardiological complications in patients undergoing heart surgery.   
Site-specific subunit composition of the receptor and its pharmacological 
properties  One of the unexpected findings of our work is a marked diversity of the subunit composition and the receptor density in various regions of rat heart.  As shown in Table 3, in most parts of the rat myocardium NMDA receptors are formed by the NR2D/NR3A subunits similarly to that in human erythroid precursor cells where NR2D and NR3 subunits were dominant. Receptors containing that types of subunits are known to have very slow deactivation kinetics (several seconds 59, 60). But in contrast to erythroid lineage, NR2B subunit is also present in heart chambers and its amount is increasing with the age of animal (Figure 
4E). NR2B forms relatively high amplitude fast inactivating receptors and represents a well–known pharmacological target for ifenprodil-like compounds 343. In atria more of the subunits commonly found in the rat brain are expressed. Those including NR2A subunit forming together with NR1 fast receptors with high current amplitude 59. NR3B subunit transcripts in rat atria 94  
were below the direction limits. What is the actual NMDA receptor composition (NR1/NR2A or NR1/NR3A/NR2B/NR2D etc.) in the myocardial cells remains unknown. However, since  the inhibitory effect of the NMDA receptor channel pore targeting antagonist MK-801 on the heart rate  had no synergetic effect with NR2B specific antagonists, we assume that NMDA receptors of pacemaker cells have an obligatory NR2B subunit in their composition (Figure S2). High abundance of NR2B subunit in rat myocardium was confirmed by autoradiography (Figure 4 C). In presence of eliprodil [3H]MK-801 binding was suppressed in all regions of heart. NR1, NR2A, NR2B and NR2C subunits were detected in the whole heart homogenates by western blot using specific antibodies. However, other groups could not detect some of these subunits, for example, the group of Seeber could detect NR2B subunit only in neonates. This group failed to detect any other NMDA receptor subunits in rat heart. They showed that NR2B subunit in rat cardiomyocytes underwent cardiac-specific post-translational modifications 134.  Group of Leung 131 could not detect any of the NR2 subunits by immunoblotting. The possible reason for these contradictory findings obtained in several groups including the present study most likely are cardiac-specific posttranslational modifications of NMDA receptor subunits making them invisible for many of the brain-specific antibodies.  Expression of the NMDA receptor transcripts is restricted to the cardiomyocytes. Isolated adult ventricular cardiomyocytes expressed the same subunits (NR3A/NR2D/NR2B) as ventricular tissue (Table 3. None of them could be detected in isolated fibroblasts.  A striking feature of the myocardial NMDA receptors making them different from the well-studied neuronal receptors is the lack of NR1 glycine binding subunit in ventricles. Very low expression of this subunit was detected in atria. At present it is believed that NR1 subunit is obligatory for the NMDA receptor trafficking from the endoplasmic reticulum to the surface of sarcolemmal membrane (see Chapter 1). Moreover, each NR1 subunit is associated with NR2 subunit in functional dimer within the NMDA receptor complex (see Fig 3B in Chapter 1).  Thus what we observed in the heart could be: 
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1) a novel type of NMDA receptor composed of NR3A-NR2 subunits with low affinity to NMDA and D-Ser, but high affinity of glutamate and glycine (Figure 2A-D); 2) a chimeric type of glutamate receptor with unusual properties (AMPA-NMDA receptor or kainate-NMDA receptor or in combination with other channels like ryanodine receptors 134); 3) it remains unclear if AMPA or kainate receptors are required to prime the NMDA receptor activation in the heart. Membrane depolarization in prior to the NMDA receptor activation may be triggered by other cardiac channels. Also, cardiac NMDA receptors may not possess voltage-dependent channel block (NR1/NR3 receptors are resistant to Mg block, see Table 1.1 in Chapter 1) and consequently may not require membrane depolarization for the channel activation. Pharmacological properties of the rat cardiac NMDA receptors were assessed in isolated myocardial sarcollemal membranes and in tissue sections by using displacement of [3H]MK-801, NMDA receptor channel pore targeting ligand. In both atrial and ventricular sarcolemmal membrane MK-801 affinity was similar to that in the brain 66 (see also Chapter 1 Table 1), Figure 3. However, affinity of the cardiac NMDA receptors to memantine was 3 orders of magnitude higher in the ventricular tissue than in the brain (IC50 1 nM vs ~1µM). Receptors in the atrial tissue had lower affinity to memantine than ventricular tissue (IC50 ~40 nM) but still much higher than that in the brain tissue. Sensitivity of the cardiac NMDA receptoir to ketamine (racemate) was similar in the myocardium and brain membranes.  Pretreatment of the sarcolemmal membranes or tissue sections with NR2B subunit targeting drug eliprodil decreased [3H]MK-801 binding (Figures 3C and 4C). Electrophysiological studies in neurons revealed that eliprodil analog ifenprodil reduces the frequency of channel opening 344. Therefore, the probability for the radiolabeled channel pore blocker to bind to the receptor was reduced in the presence of ifenprodil-like compounds. Thus, specific pharmacological properties of rat cardiac NMDA receptors resulted from their unusual subunit composition. That feature of cardiac NMDA receptors makes them an attractive target for cardiac-specific drug development.  
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Similar to that in EPCs and circulating RBCs, hyperactivation of the NMDA receptors was not deleterious for the neonatal cardiomyocytes, whereas exposure of them to the channel pore-targeting inhibitor memantine was toxic and caused massive cell death (Figure 3). Adult rat heart on the contrary responded to the intracoronary administration of the NMDA receptor agonists with induction of arrhythmia and impairment of miscroperfusion of ventricular capillaries (Figure 2E).      
 
Figure 3. Cultured neonatal cardiomyocytes with or without memantine. Blue color designates nuclei of intact cells (Hoechst staining), red color (propidium iodide, PI) indicates PI-positive nuclei of dead cells. Memantine treatment for 24 h resulted in massive death of neonatal cardiomyocytes.   We have observed the corresponding changes in heart rhythmicity following the changes in activity of NMDA receptors in isolated rat heat.   Rhythm and ECG To study the role of cardiac NMDA receptors in rat heart we have chosen isolated rat heart model. The main advantage of our setup is that heart is free from the all kinds of neuronal or neurohormonal regulation.  Hearts were perfused either with buffer, or with the blood obtained from the same animal. Hearts perfused with Krebs-Henseleit (KH) buffer instead of blood had about two times lower spontaneous contractility rate. However, in that experimental setup we controlled amino acid concentration acting on myocardial NMDA receptors. Treatment with Glu-Gly mixture showed reversible increase of the heart rate and heart rate variability within the physiological range (EC50 for 97  
tachycardia 149 µM, for heart rate variability 271 µM). Surprisingly, specific NMDA receptor agonist NMDA and co-agonist D-serine affected the heart rate only within the millimolar range. As we know from electrophysiological studies on NMDA receptors expressed in neurons (cultured cells or tissue slices), in model cell cultures (human embryonic kidney cells), Xenopus oocytes, affinity and efficiency of NMDA and D-Ser were similar to Glu and Gly (see Chapter 1). There are two possible reasons explaining the difference between Glu and NMDA-driven effects: specific cardiac NMDA receptor properties (see below) or coupling with other glutamate receptors (similar to the AMPAR-NMDAR coupling in the brain). Unlike neuronal NMDA receptors, myocardial receptors are constantly exposed to the plasma-borne high concentrations of their main agonist glutamate and co-agonist glycine because these amino acids are very abundant components of the blood plasma (~150 µM of Glu 345, 300-500 µM of Gly 346). Hyperactivation of the cardiac NMDA receptors by addition of high doses of agonists to the perfusate (blood or KH buffer – (Glu, NMDA or homocysteic acid) provoked either tachycardic or arrhythmic responses (Figure S2). Administration of pore-targeting antagonists was causing negative chronotropic effect in blood-perfused hearts even in the absence of additional stimulation with agonists.  These findings obtained using isolated blood-perfused rat hearts suggested that the cardiac NMDA receptors are most likely permanently active in the pacemaker cells. Ifenprodil-like compounds eliprodil and Ro25-6981, targets NMDA receptor regulatory site, both induced bradycardia. Glutamate-binding site competitive antagonists APV and PEAQX (or NVP-AAM077) had no effect on the heart rate probably due to the presence of excessive glutamate in the blood plasma (~200 µM of Glu). Glycine binding site competitive antagonist L-701,324 failed to produce any changes in the heart rate as well (plasma Gly concentration is >300 µM).  As a ligand-gated non-selective cation channel NMDA receptor contributes to the electric activity of the heart including autonomous rhythm formation in pacemaker cells and in excitation propagation thought the ventricular walls in cardiomyocytes. Slow depolarization of the pacemaker cells is mediated by the activation of several channels and ion transporters are involved in that process 98  
forming K+-Na+-Ca2+ “funny” current including hyperpolarization-activated, cyclic-nucleotide-gated channels (HCN). These channels share certain structural-functional similarities with NMDA receptors including their chimeric origin (see Figure 1 in Chapter 2).   Both HCN and NMDA receptor channels respond to the same channel blocker ZD7288, used as heart rate-reducing agent (151, p 109) which inhibits hippocampal NMDA receptors in vivo 347. The inhibitory potential of the pore-targeting NMDA receptor antagonists towards the HCN channels has never been tested. We have shown that the NMDA receptor pore-targeting inhibitors were acting as anti-arrhythmic drugs (Table 2). This anti-arrhythmic effect of the channel pore-targeting drugs MK-801, memantine or ketamine may be hence attributed to their non-specific action on HCN channels. However, similar bradycardic and anti-arrhythmic action has been demonstrated for the antagonists targeting alternative binding sites (such as Ro25-6981 and eliprodil which bind to the ifenprodil binding site localized within the NR2B subunit (Chapter 1 Figure 1.3A). In line with these observations bradycardia has been reported in human clinical trials of ifenprodil and eliprodil and anti-arrhythmic action (reduction in dysrhythmia) noted for aptiganel, a competitive NMDA receptor blocker 150.  In experiments on isolated blood-perfused rat hearts we observed that NMDA receptors remain permanently active in the heart pacemaker cells. We can always reduce the pacemaker activity (or hyperactivity in case of tachyarrhythmia) using NMDA receptor antagonists. Unlike neuronal NMDA receptors, myocardial receptors are constantly exposed to high concentrations of their main agonist glutamate and co-agonist glycine because these amino acids are very abundant components of the blood plasma.  NMDA receptor-related effects in the myocardial tissue could be seen on ECG recordings (Figure 1). Channel pore-targeting NMDA receptor antagonists were prolonging QTc interval (QT interval corrected for the heart rhythm), i.e. prolonging ventricular repolarization.  Both channel pore- and ifenprodil-like drugs also prolonged QRS interval, meaning that NMDA receptors somehow contribute to the rapid ventricular depolarization. NMDA receptor agonists had no effect on the ECG intervals.  99  
In blood-perfused rat heart the presence of NMDA receptor agonists and antagonists affected capillary perfusion of the ventricular tissue (Figure 2E). Receptor activation caused tissue edema (swelled cardiomyocytes and restricted capillary perfusion), while treatment with antagonist facilitated capillary perfusion (reduced cardiomyocyte’s volume). We used L-type calcium channels blockers (CCB) verapamil and diltiatazem to compare their action on heart rhythmicity with that of NMDA receptor antagonists. In our model CCB induced second degree AV block and irregular bradycardia. Moreover, similar effects of CCB on atrio-ventricular conductance were observed in human patients 348. In contrast to that, NMDA receptor antagonists produced regular bradycardia (Table 2). Thus, CCB had pro-arrithmogenic effects while NMDA receptor antagonists were increasing rhythm regularity in all experiments. Therefore it’s highly unlikely that both classes of compounds hit the same target. Initially Zn2+ was used in our study as a potential NMDA receptor antagonist (NR2A specific, see Chapter 1). However, treatment with Zn2+ caused tachycardia and premature ventricular contractions (i.e. hyperactivation of ventricular cardiomyocytes), (Figure 1D, Figure S2F). Moreover, those effects were insensitive to MK 801 treatment. In isolated sarcolemmal membranes Zn2+ ions were reducing [3H]MK 801 binding within the channel pore at high concentrations (>1 µM) (Figure 3D).  Low concentrations of Zn2+ ions (1 – 10 nM) facilitated [3H]MK 801 binding kinetics as well as a steady state binding (after 1 hour of incubation). In NMDA receptors composed only from NR1 and NR3 subunits Zn2+ ions are known to be a potent activators 349. Zn2+ most likely binds to regulatory site on the receptor and facilitates channel opening probability. At the same time Zn2+ at high concentrations (10 – 100 µM) was shown to block NMDA receptor channel pore in the voltage-depended manner, in that way Zn2+ acts as inhibitor 350. In our experiments Zn2+ probably interacted with both channel pore and with the regulatory binding site. Acting as an activator by binging to the NTD Zn2+ was interfering with MK 801 binding within the receptor pore. Since Zn2+ ions precipitate in the protein-rich environment such as blood plasma, it is hard to say what was the concentration of free Zn2+ ions in our experiments, and what the amount of Zn2+ ions was reaching for 100  
cardiomyocytes and pacemaker cells. Further studies on Zn2+ binding to cardiac NMDA receptors are needed to clarify the mechanism of Zn2+ -driven effects in the heart.   Comparison with clinical data The data we have obtained were on the rodent heart. Can we use this model to predict the in vivo effects of NMDA receptor antagonists and CCB in humans? There are two examples of acute drug poisoning by verapamil (suicidal ingestion) and ketamine (drug addiction) suggesting that our findings can be translated, at some extent, to human. 
Example 1 In healthy young man (18 years old) verapamil overdose caused depression of the sinus node function and atrioventricular dissociation (Fig 4A) 351. In 24 h ECG completely recovered and expressed no abnormalities.  Similar results we obtained on isolated hearts from the young healthy rats treated with verapamil or diltiatazem. The resulting atrioventricular block is shown on Fig 4B, P wave inversion also occurred in some experiments. Thus, the effect of high acute doses of L-type calcium blockers in humans can be recreated in isolated rat heart model. 
Figure 4. A. Verapamil intoxication in human subject 351. Upper part is 101  
representing ECG of patient on admission to the hospital in two hours after ingestion of 2 g of verapamil. P wave is inverted, activity of sino-atrial node is suppressed (atrio-ventricular node is maintaining the rhythm of ventricular contraction while atria contracting independently). Red arrows show P wave positions. After 11 hours of recovery sinus rhythm was reappeared. B. The acute treatment of isolated rat heart with diltiatazem. Similarly to A, heart rhythm is maintained by atrio-ventricular node activity. Excitation of atria is seen first as a “shoulder” of QRS complex and then as independent peak.   
Example 2 31-years-old man without significant past medical history and family history of syncope or sudden cardiac death used high dose of ketamine for recreational purpose (391 μg/L in blood plasma at the moment of hospital admission) 352. No rhythm abnormalities were observed, however, ST segment prolongation and elevation (on V2 lead) were present (Fig 5A). In 12 hours ST segment normalized and no more pathological changes on the ECG record were seen. On the ECG obtained from the isolated rat heart ST segment prolongation was detected for ketamine as well for other NMDA receptor channel blockers (Fig 5B). We were using only one ECG lead in our experiments (similar to the lead II), thus, we could not detect ST segment shape abnormalities as present on V2 lead (Fig 5A).  
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Figure 5. A. Ketamine overdose in healthy human subject 352. ST segment prolongation in all leads and ST segment elevation in lead V2 were detected. After the recovery period ECG record was normal. B. Ketamine provoking ST segment prolongation in isolated rat heart.   Poisoning by NMDA receptor agonists such as glutamate and domoic acid (sea food) was associated with chest pain (a major symptom of Chinese restaurant 103  
syndrome) and arrhythmias 353, 354, 355. However, neurological symptoms of NMDA receptor agonist poisoning are much more pronounced and taken under consideration by physicians, so no ECG records from intoxicated patients are available. According to these examples, blood perfused isolated rat heart may be a fair model of acute drug effects in the human heart. Although effective drug concentrations could differ between human and rat, the character of ECG changes seems to be the same at least for acute high doses of NMDA receptor agonists and antagonists.                         104  
7. Conclusion NMDA receptors have been traditionally viewed as an integral part of neurotransmission process endemic to the central and peripheral nervous systems. Recent findings including those in the present study clearly indicate that this is not entirely true. Impressive diversity of properties of currents mediated by the tetrameric receptors formed by four out of seven subunits, most of which are presented with several splice isoforms makes these receptors into a multisensory modality responding to the changes in availability of external amino acids, mechanic stress, voltage, pH, redox state. These responses can be further modulated by the intracellular regulators and signals from other receptors. This type of the receptors appeared early in evolution and was successfully used thereafter by the organisms some of which lacked or possessed very primitive nervous system. It is therefore not unexpected that various subsets of NMDA receptor appear to be in multiple organs perform a variety of tissue-specific tasks.  We have unraveled a small number of those focusing on the erythroid and cardiac NMDA receptors. In both tissues these channels appear to be responding to the changes in agonists levels, and mechanical stimuli (shear stress and mechanical overload). NMDA receptors contribute to the changes in volume as their activation results in RBC shrinkage and swelling of adult rat cardiomyocytes. Activation or inhibition of the NMDA receptors impacts transmembrane potential in the EPCs and in cardiomyocytes modulating activity of pacemaker cells.  Changes in plasma glutamate or homocysteine levels and the following activation of the NMDA receptors result in transient reduction in oxygen affinity of hemoglobin and in development of tachycardia and increased incidence of arrhythmia. All these processes have to be taken into account when designing and applying drugs antagonizing the NMDA receptors. Further investigations are needed to gain more insights into the structure and function of non-neuronal NMDA receptors in health and disease.      
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8. Outlook Functionally active erythroid and cardiac NMDA receptors represent a novel target for pharmacological intervention in a disease.  At present in collaboration with our colleagues from the Divisions of Haematology of the University Hospital and Children’s Hospital Zurich we prepare a proof-of-principle trial in which the efficiency of memantine will be tested in a small cohort of patient sickle cell disease. The start of the trial is planned for the coming fall 2014. Our further goals regarding the erythroid NMDA receptors include:  (i) a detailed study on a role of NMDA receptors in control of oxygen delivery and RBC properties in subjects practicing physical exercises (now in progress) and in regulation of red cell mass upon ascent and descent from the high altitude; (ii) screening of the other hereditary forms of hemolytic anemia associated with an increased cytoplasmic Ca2+ concentration (e. g. thalassemia, PFK deficiency, spherocytosis etc.) for the abundance and activity of the NMDA receptors in circulating RBCs.  Together with the Division of Cardiac Surgery of the University Hospital of Verona, Italy, and Prof Colin Schwarzwald and his group from the Equine Clinic, Animal Hospital Zurich, as well as with the Division of Health and Medical Care of the Russian Railways company we follow up on the characterization of the cardiac NMDA receptors. (i) We are currently exploring NMDA receptor subunit composition and pharmacology of human and equine cardiac NMDA receptors and their relation to the pathology. Our preliminary data reveal the presence of NMDA receptors in human and horse heart. However, remarkable differences were observed between human and rodent cardiac NMDA receptor subunit composition and pharmacology. This finding questions the possibility of direct transfer the findings obtained using rat model to human or equine settings directly.  In fact, NMDA receptors in horse heart appear to share similarities in subunit composition and pharmacology with those in human heart making  horses into an expensive, but fair model for studying NMDA receptors in human heart.  (ii) We have demonstrated pro-arrhythmogenic potential of hyperactivation of the NMDA receptors in isolated spontaneously beating rat heart. We now elaborate on characterization of the possible relationship 
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between the activation state of cardiac NMDA receptors and the incidence of arrhythmia in horses and humans. In contrast to rats, horses and humans are known to develop spontaneous arrhythmia and atrial fibrillation which is commonly triggered by physical exercises (races, exhaustive training). Non-trained humans and endurance athletes are also known to produce premature ventricular contraction, AV block, atrial fibrillation, and sudden cardiac death in response to exhaustive exercises.  We are currently following the links between exercise and open-heart surgical intervention, arrhythmia, and the levels of NMDA receptor agonists/activation state of the receptors.  A long-standing goal we pursue involves characterization of the cause-consequence relations between arrhythmia development and NMDA receptors and testing of the anti-arrhythmic potential of specific antagonists of the cardiac NMDA receptors in vivo.                       107  
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